sentances,predictions
To systematically review and assess the efficacy and safety of hydroxychloroquine (HCQ) for treating primary Sjogren's syndrome (pSS).,"[{'To': 'O'}, {'systematically': 'O'}, {'review': 'O'}, {'and': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'(HCQ)': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
BACKGROUND AND Migraine and systemic autoimmune diseases are 2-3-fold more common in women and various studies have reported an association between the two pathologies.,"[{'BACKGROUND': 'O'}, {'AND': 'O'}, {'Migraine': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'2-3-fold': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'women': 'O'}, {'and': 'O'}, {'various': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'reported': 'O'}, {'an': 'O'}, {'association': 'O'}, {'between': 'O'}, {'the': 'O'}, {'two': 'O'}, {'pathologies.': 'O'}]"
"FM seems to contribute to constitutional symptoms more in SLE than in pSS, suggesting a different underlying cause of fatigue and widespread pain in these two different connective tissue diseases.Rome, Italy.","[{'FM': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'constitutional': 'O'}, {'symptoms': 'O'}, {'more': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'than': 'O'}, {'in': 'O'}, {'pSS,': 'O'}, {'suggesting': 'O'}, {'a': 'O'}, {'different': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'widespread': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'these': 'O'}, {'two': 'O'}, {'different': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.Rome,': 'I-Entity'}, {'Italy.': 'O'}]"
"In this case, daily use of hydroxypropyl cellulose ophthalmic inserts effectively treated autoimmune dry eye, providing symptomatic relief, and resulted in improved objective measures of disease severity across several decades.","[{'In': 'O'}, {'this': 'O'}, {'case,': 'O'}, {'daily': 'O'}, {'use': 'O'}, {'of': 'O'}, {'hydroxypropyl': 'B-Entity'}, {'cellulose': 'I-Entity'}, {'ophthalmic': 'O'}, {'inserts': 'O'}, {'effectively': 'O'}, {'treated': 'O'}, {'autoimmune': 'B-Entity'}, {'dry': 'I-Entity'}, {'eye,': 'I-Entity'}, {'providing': 'O'}, {'symptomatic': 'O'}, {'relief,': 'O'}, {'and': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'improved': 'O'}, {'objective': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'severity': 'O'}, {'across': 'O'}, {'several': 'O'}, {'decades.': 'O'}]"
"The Short Form Health Survey (SF-36), Functional Assessment of Chronic Illness Therapy (FACIT) fatigue scale and Hospital Anxiety and Depression Scale (HADS) were also administered.","[{'The': 'O'}, {'Short': 'O'}, {'Form': 'O'}, {'Health': 'O'}, {'Survey': 'O'}, {'(SF-36),': 'O'}, {'Functional': 'O'}, {'Assessment': 'O'}, {'of': 'O'}, {'Chronic': 'B-Entity'}, {'Illness': 'I-Entity'}, {'Therapy': 'O'}, {'(FACIT)': 'O'}, {'fatigue': 'I-Entity'}, {'scale': 'O'}, {'and': 'O'}, {'Hospital': 'O'}, {'Anxiety': 'O'}, {'and': 'O'}, {'Depression': 'O'}, {'Scale': 'O'}, {'(HADS)': 'O'}, {'were': 'O'}, {'also': 'O'}, {'administered.': 'O'}]"
(99m)Tc-ECD brain SPECT abnormalities were significantly more common in patients with pSS (10/10) than controls (2/10; p<0.05).,"[{'(99m)Tc-ECD': 'O'}, {'brain': 'O'}, {'SPECT': 'O'}, {'abnormalities': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'(10/10)': 'O'}, {'than': 'O'}, {'controls': 'O'}, {'(2/10;': 'O'}, {'p<0.05).': 'O'}]"
zengxfpumc@163.com.Sep 14.immunoassay for diagnosing inflammation related to dry eye.,"[{'zengxfpumc@163.com.Sep': 'O'}, {'14.immunoassay': 'O'}, {'for': 'O'}, {'diagnosing': 'O'}, {'inflammation': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"Extraglandular manifestations may also be prevalent in patients with pSS, including cutaneous, musculoskeletal, pulmonary, renal, hematological and neurological involvement.","[{'Extraglandular': 'O'}, {'manifestations': 'O'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'including': 'O'}, {'cutaneous,': 'B-Entity'}, {'musculoskeletal,': 'I-Entity'}, {'pulmonary,': 'I-Entity'}, {'renal,': 'I-Entity'}, {'hematological': 'I-Entity'}, {'and': 'I-Entity'}, {'neurological': 'I-Entity'}, {'involvement.': 'O'}]"
"Aggressive surveillance of thyroid and pulmonary functions should therefore be performed in these patients.General Hospital, National Defense Medical Center, Taipei, Taiwan, Republic of China (C-TC, Y-CT, C-WY, H-HL, P-JC, T-YH, Y-LS, W-KC, T-YH); and Division of Gastroenterology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan, Republic of China (H-CC).clonotypes.","[{'Aggressive': 'O'}, {'surveillance': 'O'}, {'of': 'O'}, {'thyroid': 'O'}, {'and': 'O'}, {'pulmonary': 'O'}, {'functions': 'O'}, {'should': 'O'}, {'therefore': 'O'}, {'be': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients.General': 'O'}, {'Hospital,': 'O'}, {'National': 'O'}, {'Defense': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'Taipei,': 'O'}, {'Taiwan,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'China': 'O'}, {'(C-TC,': 'O'}, {'Y-CT,': 'O'}, {'C-WY,': 'O'}, {'H-HL,': 'O'}, {'P-JC,': 'O'}, {'T-YH,': 'O'}]"
"The patients were interviewed regarding the 5 major KCS symptoms, foreign body sensation, dry eye sensation, photophobia, ocular pain, and blurred vision, with each graded from none (0) to very severe (4).","[{'The': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'interviewed': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'5': 'O'}, {'major': 'O'}, {'KCS': 'I-Entity'}, {'symptoms,': 'O'}, {'foreign': 'B-Entity'}, {'body': 'I-Entity'}, {'sensation,': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'sensation,': 'I-Entity'}, {'photophobia,': 'I-Entity'}, {'ocular': 'B-Entity'}, {'pain,': 'I-Entity'}, {'and': 'O'}, {'blurred': 'B-Entity'}, {'vision,': 'I-Entity'}, {'with': 'O'}, {'each': 'O'}, {'graded': 'O'}, {'from': 'O'}, {'none': 'O'}, {'(0)': 'O'}, {'to': 'O'}, {'very': 'O'}, {'severe': 'O'}, {'(4).': 'O'}]"
The aim of this study was to evaluate a new algorithm considering anti-DFS70 antibodies for routine ANA testing.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'a': 'O'}, {'new': 'O'}, {'algorithm': 'O'}, {'considering': 'O'}, {'anti-DFS70': 'O'}, {'antibodies': 'O'}, {'for': 'O'}, {'routine': 'O'}, {'ANA': 'O'}, {'testing.': 'O'}]"
Parotid and submandibular glands were examined in longitudinal and transverse planes and evaluated bedside using a simplified scoring system (0-3).,"[{'Parotid': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'glands': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'in': 'O'}, {'longitudinal': 'O'}, {'and': 'O'}, {'transverse': 'O'}, {'planes': 'O'}, {'and': 'O'}, {'evaluated': 'O'}, {'bedside': 'O'}, {'using': 'O'}, {'a': 'O'}, {'simplified': 'O'}, {'scoring': 'O'}, {'system': 'O'}, {'(0-3).': 'O'}]"
A total of 51 patients underwent endoscopic-assisted salivary surgery over a 24-month period.,"[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'51': 'O'}, {'patients': 'O'}, {'underwent': 'O'}, {'endoscopic-assisted': 'O'}, {'salivary': 'O'}, {'surgery': 'O'}, {'over': 'O'}, {'a': 'O'}, {'24-month': 'O'}, {'period.': 'O'}]"
"We successfully administered cART with the addition of oral prednisolone, and the patient's condition recovered without side effects related to the metabolic or immunosuppressive effects of these drugs.Organization Kyushu Medical Center, Japan.15.","[{'We': 'O'}, {'successfully': 'O'}, {'administered': 'O'}, {'cART': 'O'}, {'with': 'O'}, {'the': 'O'}, {'addition': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'prednisolone,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'condition': 'O'}, {'recovered': 'O'}, {'without': 'O'}, {'side': 'O'}, {'effects': 'O'}, {'related': 'O'}, {'to': 'O'}, {'the': 'O'}, {'metabolic': 'O'}, {'or': 'O'}, {'immunosuppressive': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'these': 'O'}, {'drugs.Organization': 'O'}, {'Kyushu': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'Japan.15.': 'O'}]"
"All patients with AITD were female, and anticentromere antibody positivity, the complication of Sjogrens syndrome, severe facial skin sclerosis and atrophy of the thyroid gland were significantly prevalent in SSc patients with AITD.","[{'All': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'AITD': 'I-Entity'}, {'were': 'O'}, {'female,': 'O'}, {'and': 'O'}, {'anticentromere': 'O'}, {'antibody': 'O'}, {'positivity,': 'O'}, {'the': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'severe': 'O'}, {'facial': 'O'}, {'skin': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'atrophy': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'thyroid': 'I-Entity'}, {'gland': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'SSc': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'AITD.': 'I-Entity'}]"
"Because it is actively secreted by the salivary glands, radiation damage to these glands can occur.","[{'Because': 'O'}, {'it': 'O'}, {'is': 'O'}, {'actively': 'O'}, {'secreted': 'O'}, {'by': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'radiation': 'O'}, {'damage': 'O'}, {'to': 'O'}, {'these': 'O'}, {'glands': 'O'}, {'can': 'O'}, {'occur.': 'O'}]"
"However, some studies reported an association between headache, migraine and systemic sclerosis, especially where gliotic brain lesions and Raynaud are coexisting.","[{'However,': 'O'}, {'some': 'O'}, {'studies': 'O'}, {'reported': 'O'}, {'an': 'O'}, {'association': 'O'}, {'between': 'O'}, {'headache,': 'I-Entity'}, {'migraine': 'I-Entity'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'especially': 'O'}, {'where': 'O'}, {'gliotic': 'B-Entity'}, {'brain': 'I-Entity'}, {'lesions': 'I-Entity'}, {'and': 'O'}, {'Raynaud': 'I-Entity'}, {'are': 'O'}, {'coexisting.': 'O'}]"
The novel agent CFZ533 improved both disease activity and patient-reported indexes.,"[{'The': 'O'}, {'novel': 'O'}, {'agent': 'O'}, {'CFZ533': 'I-Entity'}, {'improved': 'O'}, {'both': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'patient-reported': 'O'}, {'indexes.': 'O'}]"
"In 6 of 7 patients with initially high SS disease activity (M-protein, cryoglobulins, IgM rheumatoid factor > 100 KIU/l, severe extraglandular manifestations), MALT lymphoma progressed and/or SS disease activity increased after a median followup of 39 months (range 4-98 mo), necessitating retreatment.","[{'In': 'O'}, {'6': 'O'}, {'of': 'O'}, {'7': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'initially': 'O'}, {'high': 'O'}, {'SS': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'(M-protein,': 'O'}, {'cryoglobulins,': 'O'}, {'IgM': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'>': 'O'}, {'100': 'O'}, {'KIU/l,': 'O'}, {'severe': 'O'}, {'extraglandular': 'O'}, {'manifestations),': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'progressed': 'O'}, {'and/or': 'O'}, {'SS': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'increased': 'O'}, {'after': 'O'}]"
This finding suggests that dissemination of DLE was triggered by scratching and a K‚Äö√†√∂‚Äö√†√ábner phenomenon-like effect related to hypohidrotic and xerotic skin.,"[{'This': 'O'}, {'finding': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'dissemination': 'O'}, {'of': 'O'}, {'DLE': 'I-Entity'}, {'was': 'O'}, {'triggered': 'O'}, {'by': 'O'}, {'scratching': 'O'}, {'and': 'O'}, {'a': 'O'}, {'K‚Äö√†√∂‚Äö√†√ábner': 'O'}, {'phenomenon-like': 'O'}, {'effect': 'O'}, {'related': 'O'}, {'to': 'O'}, {'hypohidrotic': 'I-Entity'}, {'and': 'O'}, {'xerotic': 'I-Entity'}, {'skin.': 'O'}]"
Carotid intima-media thickness (CIMT) and arterial stiffness measurements are commonly used to detect subclinical atherosclerosis.,"[{'Carotid': 'O'}, {'intima-media': 'O'}, {'thickness': 'O'}, {'(CIMT)': 'O'}, {'and': 'O'}, {'arterial': 'O'}, {'stiffness': 'O'}, {'measurements': 'O'}, {'are': 'O'}, {'commonly': 'O'}, {'used': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'subclinical': 'O'}, {'atherosclerosis.': 'I-Entity'}]"
Connective tissue diseases in the elderly represent a growing concern for healthcare providers and an increasing burden of global health resources worldwide.,"[{'Connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'elderly': 'O'}, {'represent': 'O'}, {'a': 'O'}, {'growing': 'O'}, {'concern': 'O'}, {'for': 'O'}, {'healthcare': 'O'}, {'providers': 'O'}, {'and': 'O'}, {'an': 'O'}, {'increasing': 'O'}, {'burden': 'O'}, {'of': 'O'}, {'global': 'O'}, {'health': 'O'}, {'resources': 'O'}, {'worldwide.': 'O'}]"
Increased expression of certain T helper or inflammatory cytokines in these tissues was observed in Aec mice.,"[{'Increased': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'certain': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'or': 'O'}, {'inflammatory': 'O'}, {'cytokines': 'O'}, {'in': 'O'}, {'these': 'O'}, {'tissues': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'Aec': 'O'}, {'mice.': 'O'}]"
"We investigated whether systemic lupus erythematosus (SLE) patients could be distinguished based on the time of disease onset and, if so, whether the groups differed in their clinical and laboratory features in ethnically homogeneous Korean patients.","[{'We': 'O'}, {'investigated': 'O'}, {'whether': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'patients': 'O'}, {'could': 'O'}, {'be': 'O'}, {'distinguished': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'onset': 'O'}, {'and,': 'O'}, {'if': 'O'}, {'so,': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'groups': 'O'}, {'differed': 'O'}, {'in': 'O'}, {'their': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'features': 'O'}, {'in': 'O'}, {'ethnically': 'O'}, {'homogeneous': 'O'}, {'Korean': 'O'}, {'patients.': 'O'}]"
"CONCLUSIONS A rare case of chronic hyponatremia due to the SIAD associated with CCA is reported that demonstrates the importance of correct diagnosis, management, and clinical follow-up of the SIAD, including bone densitometry.SP, Brazil.SP, Brazil.SP, Brazil.SP, Brazil.SP, Brazil.SP, Brazil.SP, Brazil.SP, Brazil.","[{'CONCLUSIONS': 'O'}, {'A': 'O'}, {'rare': 'O'}, {'case': 'O'}, {'of': 'O'}, {'chronic': 'B-Entity'}, {'hyponatremia': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'SIAD': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'CCA': 'I-Entity'}, {'is': 'O'}, {'reported': 'O'}, {'that': 'O'}, {'demonstrates': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'correct': 'O'}, {'diagnosis,': 'O'}, {'management,': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'the': 'O'}, {'SIAD,': 'I-Entity'}, {'including': 'O'}, {'bone': 'O'}, {'densitometry.SP,': 'O'}, {'Brazil.SP,': 'O'}]"
"Here we report the successful amelioration of bone lesions through a multidisciplinary approach that improved renal tubular acidosis, with a special focus on treatment of the underlying inflammatory disorder with glucocorticoids.Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan.28.","[{'Here': 'O'}, {'we': 'O'}, {'report': 'O'}, {'the': 'O'}, {'successful': 'O'}, {'amelioration': 'O'}, {'of': 'O'}, {'bone': 'B-Entity'}, {'lesions': 'I-Entity'}, {'through': 'O'}, {'a': 'O'}, {'multidisciplinary': 'O'}, {'approach': 'O'}, {'that': 'O'}, {'improved': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis,': 'I-Entity'}, {'with': 'O'}, {'a': 'O'}, {'special': 'O'}, {'focus': 'O'}, {'on': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'inflammatory': 'B-Entity'}, {'disorder': 'I-Entity'}, {'with': 'O'}, {'glucocorticoids.Occupational': 'O'}, {'and': 'O'}, {'Environmental': 'O'}, {'Health,': 'O'}, {'Japan,': 'O'}, {'1-1': 'O'}, {'Iseigaoka,': 'O'}]"
Salivary glands involvement in Sjogren's syndrome is often associated with viral infection.,"[{'Salivary': 'O'}, {'glands': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'viral': 'B-Entity'}, {'infection.': 'I-Entity'}]"
"Plasma homocysteine, serum and urine methylmalonic acid were also normal.","[{'Plasma': 'O'}, {'homocysteine,': 'I-Entity'}, {'serum': 'O'}, {'and': 'O'}, {'urine': 'O'}, {'methylmalonic': 'B-Entity'}, {'acid': 'I-Entity'}, {'were': 'O'}, {'also': 'O'}, {'normal.': 'O'}]"
"To estimate the incidence and mortality rates, and their evolution over time, of physician-diagnosed primary Sjogren syndrome (pSS) in residents of Olmsted County, Minnesota.","[{'To': 'O'}, {'estimate': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'rates,': 'O'}, {'and': 'O'}, {'their': 'O'}, {'evolution': 'O'}, {'over': 'O'}, {'time,': 'O'}, {'of': 'O'}, {'physician-diagnosed': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'in': 'O'}, {'residents': 'O'}, {'of': 'O'}, {'Olmsted': 'O'}, {'County,': 'O'}, {'Minnesota.': 'O'}]"
The objective of this study was to determine the clinical relevance and the diagnostic significance of positive antinuclear antibodies (ANA) without identified antigenic target by the usual characterization technique.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'relevance': 'O'}, {'and': 'O'}, {'the': 'O'}, {'diagnostic': 'O'}, {'significance': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'(ANA)': 'O'}, {'without': 'O'}, {'identified': 'O'}, {'antigenic': 'O'}, {'target': 'O'}, {'by': 'O'}, {'the': 'O'}, {'usual': 'O'}, {'characterization': 'O'}, {'technique.': 'O'}]"
We undertook this review to assess the efficacy and safety of immunomodulation on primary SS from randomized clinical trials (RCTs).,"[{'We': 'O'}, {'undertook': 'O'}, {'this': 'O'}, {'review': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'immunomodulation': 'O'}, {'on': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'from': 'O'}, {'randomized': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'(RCTs).': 'O'}]"
The prevalence of complete dRTA (urinary acidification defect with acidosis) was 5% (3/57).,"[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'complete': 'O'}, {'dRTA': 'I-Entity'}, {'(urinary': 'O'}, {'acidification': 'O'}, {'defect': 'O'}, {'with': 'O'}, {'acidosis)': 'I-Entity'}, {'was': 'O'}, {'5%': 'O'}, {'(3/57).': 'O'}]"
"Generally, the adult atrioventricular (AV) node is believed to be relatively resistant to the scarring effects of anti-Ro/anti-La autoantibodies.","[{'Generally,': 'O'}, {'the': 'O'}, {'adult': 'O'}, {'atrioventricular': 'B-Entity'}, {'(AV)': 'I-Entity'}, {'node': 'O'}, {'is': 'O'}, {'believed': 'O'}, {'to': 'O'}, {'be': 'O'}, {'relatively': 'O'}, {'resistant': 'O'}, {'to': 'O'}, {'the': 'O'}, {'scarring': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'anti-Ro/anti-La': 'O'}, {'autoantibodies.': 'O'}]"
"Usable data for cerebrospinal fluid anti-NR2A/B antibodies were available in only 4 studies [pooled OR=0.831 (95% CI 0.365-1.888), p=0.658].","[{'Usable': 'O'}, {'data': 'O'}, {'for': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'anti-NR2A/B': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'available': 'O'}, {'in': 'O'}, {'only': 'O'}, {'4': 'O'}, {'studies': 'O'}, {'[pooled': 'O'}, {'OR=0.831': 'O'}, {'(95%': 'O'}, {'CI': 'O'}, {'0.365-1.888),': 'O'}, {'p=0.658].': 'O'}]"
The TIN indicated SS as the underlying cause of osteomalacia.,"[{'The': 'O'}, {'TIN': 'O'}, {'indicated': 'O'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'osteomalacia.': 'I-Entity'}]"
"Amyloidosis accompanied by Sjogrens syndrome (SS) has been reported to occur primarily in the skin, lungs, tongue, and mammary gland.","[{'Amyloidosis': 'I-Entity'}, {'accompanied': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'occur': 'O'}, {'primarily': 'O'}, {'in': 'O'}, {'the': 'O'}, {'skin,': 'O'}, {'lungs,': 'O'}, {'tongue,': 'O'}, {'and': 'O'}, {'mammary': 'O'}, {'gland.': 'O'}]"
There are recent reports using multipotent mesenchymal stromal cells (MSCs) as a therapeutic strategy for autoimmune diseases due to their anti-inflammatory and immunomodulatory capabilities.,"[{'There': 'O'}, {'are': 'O'}, {'recent': 'O'}, {'reports': 'O'}, {'using': 'O'}, {'multipotent': 'O'}, {'mesenchymal': 'O'}, {'stromal': 'O'}, {'cells': 'O'}, {'(MSCs)': 'O'}, {'as': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'strategy': 'O'}, {'for': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'their': 'O'}, {'anti-inflammatory': 'O'}, {'and': 'O'}, {'immunomodulatory': 'O'}, {'capabilities.': 'O'}]"
"Thus, we conducted a retrospective national cohort study to investigate whether Sjogren's syndrome (SS) increases the risk of respiratory failure (RF).","[{'Thus,': 'O'}, {'we': 'O'}, {'conducted': 'O'}, {'a': 'O'}, {'retrospective': 'O'}, {'national': 'O'}, {'cohort': 'O'}, {'study': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'increases': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'respiratory': 'B-Entity'}, {'failure': 'I-Entity'}, {'(RF).': 'O'}]"
"Treatment consists of potassium repletion, alkali therapy, and corticosteroids.","[{'Treatment': 'O'}, {'consists': 'O'}, {'of': 'O'}, {'potassium': 'I-Entity'}, {'repletion,': 'O'}, {'alkali': 'O'}, {'therapy,': 'O'}, {'and': 'O'}, {'corticosteroids.': 'O'}]"
"Systemic rheumatic diseases are characterized by a long natural history with few symptoms, an undifferentiated picture or a remitting course making difficult a timely diagnosis.","[{'Systemic': 'O'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'long': 'O'}, {'natural': 'O'}, {'history': 'O'}, {'with': 'O'}, {'few': 'O'}, {'symptoms,': 'O'}, {'an': 'O'}, {'undifferentiated': 'O'}, {'picture': 'O'}, {'or': 'O'}, {'a': 'O'}, {'remitting': 'O'}, {'course': 'O'}, {'making': 'O'}, {'difficult': 'O'}, {'a': 'O'}, {'timely': 'O'}, {'diagnosis.': 'O'}]"
"Altogether, this study revealed new cellular players in pSS pathogenesis, their transcriptional signatures, and differential dependency on the lymphotoxin/LIGHT signaling axis that help to interpret the negative results of the Baminercept trial and will guide future therapeutic interventions.Oct 7.","[{'Altogether,': 'O'}, {'this': 'O'}, {'study': 'O'}, {'revealed': 'O'}, {'new': 'O'}, {'cellular': 'O'}, {'players': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'pathogenesis,': 'O'}, {'their': 'O'}, {'transcriptional': 'O'}, {'signatures,': 'O'}, {'and': 'O'}, {'differential': 'O'}, {'dependency': 'O'}, {'on': 'O'}, {'the': 'O'}, {'lymphotoxin/LIGHT': 'O'}, {'signaling': 'O'}, {'axis': 'O'}, {'that': 'O'}, {'help': 'O'}, {'to': 'O'}, {'interpret': 'O'}, {'the': 'O'}, {'negative': 'O'}, {'results': 'O'}, {'of': 'O'}, {'the': 'O'}, {'Baminercept': 'I-Entity'}, {'trial': 'O'}, {'and': 'O'}, {'will': 'O'}, {'guide': 'O'}, {'future': 'O'}, {'therapeutic': 'O'}, {'interventions.Oct': 'O'}, {'7.': 'O'}]"
Pulmonary function tests are a sensitive tool detecting interstitial lung disease.,"[{'Pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'are': 'O'}, {'a': 'O'}, {'sensitive': 'O'}, {'tool': 'O'}, {'detecting': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Topical CyA has been proven to be beneficial in the dry eye of Sjogren's syndrome, whereas oral treatment with CyA can be considered for the severe complications of adult onset Still's disease.","[{'Topical': 'O'}, {'CyA': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'proven': 'O'}, {'to': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'in': 'O'}, {'the': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'whereas': 'O'}, {'oral': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'CyA': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'for': 'O'}, {'the': 'O'}, {'severe': 'O'}, {'complications': 'O'}, {'of': 'O'}, {'adult': 'O'}, {'onset': 'O'}, {""Still's"": 'B-Entity'}, {'disease.': 'I-Entity'}]"
Malignant lymphoma involving the salivary glands is a rare entity that accounts for only 1 to 4% of all salivary gland tumors.,"[{'Malignant': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'involving': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'entity': 'O'}, {'that': 'O'}, {'accounts': 'O'}, {'for': 'O'}, {'only': 'O'}, {'1': 'O'}, {'to': 'O'}, {'4%': 'O'}, {'of': 'O'}, {'all': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'tumors.': 'I-Entity'}]"
"Although central nervous system complications are rare in pediatric SS, this condition should be considered in the differential diagnosis when a patient presents with idiopathic autoimmune encephalitis of unknown cause.","[{'Although': 'O'}, {'central': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'complications': 'I-Entity'}, {'are': 'O'}, {'rare': 'O'}, {'in': 'O'}, {'pediatric': 'O'}, {'SS,': 'I-Entity'}, {'this': 'O'}, {'condition': 'O'}, {'should': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'when': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'idiopathic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'encephalitis': 'I-Entity'}, {'of': 'O'}, {'unknown': 'O'}, {'cause.': 'O'}]"
"She was admitted because of fever, weight loss, and paresthesia of the plantae and fingers.","[{'She': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'because': 'O'}, {'of': 'O'}, {'fever,': 'I-Entity'}, {'weight': 'B-Entity'}, {'loss,': 'I-Entity'}, {'and': 'O'}, {'paresthesia': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'plantae': 'O'}, {'and': 'O'}, {'fingers.': 'O'}]"
"After the plasma exchange sessions, we examined the patient to determine the reason for her symptoms upon presentation to the hospital.","[{'After': 'O'}, {'the': 'O'}, {'plasma': 'O'}, {'exchange': 'O'}, {'sessions,': 'O'}, {'we': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'reason': 'O'}, {'for': 'O'}, {'her': 'O'}, {'symptoms': 'O'}, {'upon': 'O'}, {'presentation': 'O'}, {'to': 'O'}, {'the': 'O'}, {'hospital.': 'O'}]"
We aimed to assess the prevalence of patients with either primary Sjogrens syndrome (pSS) and positive anticentromere antibodies (ACA) and secondary Sjogrens syndrome (sSS) and limited cutaneous ACA positive-systemic sclerosis (SSc) in two large cohorts of patients with pSS and SSc¬¨¬®‚Äö√†√® and also to compare the clinical features of these two subsets with those of patients affected by 'ACA-positive SSc without sicca symptoms' and 'pSS'.,"[{'We': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'either': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'anticentromere': 'O'}, {'antibodies': 'O'}, {'(ACA)': 'O'}, {'and': 'O'}, {'secondary': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(sSS)': 'O'}, {'and': 'O'}, {'limited': 'O'}, {'cutaneous': 'O'}, {'ACA': 'O'}, {'positive-systemic': 'O'}, {'sclerosis': 'I-Entity'}, {'(SSc)': 'O'}, {'in': 'O'}, {'two': 'O'}, {'large': 'O'}, {'cohorts': 'O'}]"
A retrospective study among patients seen at the Department of oral medicine for complaints of dry mouth was performed.,"[{'A': 'O'}, {'retrospective': 'O'}, {'study': 'O'}, {'among': 'O'}, {'patients': 'O'}, {'seen': 'O'}, {'at': 'O'}, {'the': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'medicine': 'O'}, {'for': 'O'}, {'complaints': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'was': 'O'}, {'performed.': 'O'}]"
We enrolled 52 eyes of 52 dry eye patients (34 dry eyes with superficial punctate keratopathy [SPK] in the central corneal region [central SPK] and 18 dry eyes without central SPK) and 20 eyes of 20 normal control subjects.,"[{'We': 'O'}, {'enrolled': 'O'}, {'52': 'O'}, {'eyes': 'O'}, {'of': 'O'}, {'52': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'(34': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'with': 'O'}, {'superficial': 'O'}, {'punctate': 'O'}, {'keratopathy': 'I-Entity'}, {'[SPK]': 'O'}, {'in': 'O'}, {'the': 'O'}, {'central': 'O'}, {'corneal': 'O'}, {'region': 'O'}, {'[central': 'O'}, {'SPK]': 'O'}, {'and': 'O'}, {'18': 'O'}, {'dry': 'I-Entity'}, {'eyes': 'I-Entity'}, {'without': 'O'}, {'central': 'O'}, {'SPK)': 'I-Entity'}, {'and': 'O'}, {'20': 'O'}, {'eyes': 'O'}, {'of': 'O'}, {'20': 'O'}, {'normal': 'O'}, {'control': 'O'}, {'subjects.': 'O'}]"
In this article I review studies examining the potential involvement of H. pylori infection in autoimmune systemic rheumatic diseases.,"[{'In': 'O'}, {'this': 'O'}, {'article': 'O'}, {'I': 'O'}, {'review': 'O'}, {'studies': 'O'}, {'examining': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'H.': 'B-Entity'}, {'pylori': 'I-Entity'}, {'infection': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'I-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
The aim of this study was to evaluate the incidence and clinical features of patients who developed collagen vascular disease (CVD) after an initial diagnosis of idiopathic nonspecific interstitial pneumonia (NSIP).,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CVD)': 'O'}, {'after': 'O'}, {'an': 'O'}, {'initial': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'idiopathic': 'B-Entity'}, {'nonspecific': 'I-Entity'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(NSIP).': 'O'}]"
"Having a definitive diagnosis of SS may encourage patients to obtain a better understanding of their disease and have coping mechanisms in place to better manage their symptoms.Francisco, California, USA.Francisco, California, USA.Francisco, California, USA.California, USA.California, San Francisco, California, USA.Francisco, California, USA.2017.","[{'Having': 'O'}, {'a': 'O'}, {'definitive': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'encourage': 'O'}, {'patients': 'O'}, {'to': 'O'}, {'obtain': 'O'}, {'a': 'O'}, {'better': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'their': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'have': 'O'}, {'coping': 'O'}, {'mechanisms': 'O'}, {'in': 'O'}, {'place': 'O'}, {'to': 'O'}, {'better': 'O'}, {'manage': 'O'}, {'their': 'O'}, {'symptoms.Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}, {'California,': 'O'}, {'USA.California,': 'O'}, {'USA.California,': 'O'}, {'San': 'O'}, {'Francisco,': 'O'}, {'California,': 'O'}, {'USA.Francisco,': 'O'}]"
Anti-SS-A antibodies correlate with higher disease activity (ESSDAI ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢ 5) and higher FS.,"[{'Anti-SS-A': 'O'}, {'antibodies': 'O'}, {'correlate': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'(ESSDAI': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢': 'O'}, {'5)': 'O'}, {'and': 'O'}, {'higher': 'O'}, {'FS.': 'O'}]"
"Our findings highlight the roles of chronic antigenic stimulation and disease activity in the development of this severe complication.Blanche and EA 2216, INSERM ESPRI, ERI29, Universit‚Äö√†√∂¬¨¬© de Brest, Brest, France.France.France.France.Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.","[{'Our': 'O'}, {'findings': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'roles': 'O'}, {'of': 'O'}, {'chronic': 'O'}, {'antigenic': 'O'}, {'stimulation': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'this': 'O'}, {'severe': 'O'}, {'complication.Blanche': 'O'}, {'and': 'O'}, {'EA': 'I-Entity'}, {'2216,': 'I-Entity'}, {'INSERM': 'O'}, {'ESPRI,': 'O'}, {'ERI29,': 'O'}, {'Universit‚Äö√†√∂¬¨¬©': 'O'}, {'de': 'O'}, {'Brest,': 'O'}, {'Brest,': 'O'}, {'France.France.France.France.Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre,': 'O'}]"
"Primary Sjogren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue.","[{'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'mouth': 'B-Entity'}, {'and': 'I-Entity'}, {'eye': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'pain,': 'I-Entity'}, {'and': 'O'}, {'fatigue.': 'I-Entity'}]"
The authors report an exceptional case of an anterior horn syndrome associated with Sjogrens syndrome in a 58-year-old patient with a flaccid tetraparesis revealed by asymmetric atrophy and diffuse fasciculations associated with xerostomia and xerophthalmia.,"[{'The': 'O'}, {'authors': 'O'}, {'report': 'O'}, {'an': 'O'}, {'exceptional': 'O'}, {'case': 'O'}, {'of': 'O'}, {'an': 'O'}, {'anterior': 'B-Entity'}, {'horn': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'58-year-old': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'a': 'O'}, {'flaccid': 'B-Entity'}, {'tetraparesis': 'I-Entity'}, {'revealed': 'O'}, {'by': 'O'}, {'asymmetric': 'O'}, {'atrophy': 'I-Entity'}, {'and': 'O'}, {'diffuse': 'O'}, {'fasciculations': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'xerophthalmia.': 'I-Entity'}]"
"An association between celiac disease and autoimmune disorders, such as type 1 diabetes, autoimmune thyroid disease, and Sjogrens syndrome, has been well documented.","[{'An': 'O'}, {'association': 'O'}, {'between': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'type': 'B-Entity'}, {'1': 'I-Entity'}, {'diabetes,': 'I-Entity'}, {'autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'well': 'O'}, {'documented.': 'O'}]"
It may be convenient to look for vit D deficiency and to correct vit D nutritional status in SS patients.Asia Pty Ltd.28.characterisation and outcomes in 1580 patients (GEAS-SS Registry).,"[{'It': 'O'}, {'may': 'O'}, {'be': 'O'}, {'convenient': 'O'}, {'to': 'O'}, {'look': 'O'}, {'for': 'O'}, {'vit': 'B-Entity'}, {'D': 'I-Entity'}, {'deficiency': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'correct': 'O'}, {'vit': 'B-Entity'}, {'D': 'I-Entity'}, {'nutritional': 'O'}, {'status': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients.Asia': 'O'}, {'Pty': 'O'}, {'Ltd.28.characterisation': 'O'}, {'and': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'1580': 'O'}, {'patients': 'O'}, {'(GEAS-SS': 'O'}, {'Registry).': 'O'}]"
"The WT and B(-/-) NOD mice given anti-CD25 developed diabetes much earlier than WT mice given rat IgG, whereas rat IgG-treated B(-/-) mice did not develop diabetes.","[{'The': 'O'}, {'WT': 'O'}, {'and': 'O'}, {'B(-/-)': 'O'}, {'NOD': 'O'}, {'mice': 'O'}, {'given': 'O'}, {'anti-CD25': 'O'}, {'developed': 'O'}, {'diabetes': 'I-Entity'}, {'much': 'O'}, {'earlier': 'O'}, {'than': 'O'}, {'WT': 'O'}, {'mice': 'O'}, {'given': 'O'}, {'rat': 'O'}, {'IgG,': 'O'}, {'whereas': 'O'}, {'rat': 'O'}, {'IgG-treated': 'O'}, {'B(-/-)': 'O'}, {'mice': 'O'}, {'did': 'O'}, {'not': 'O'}, {'develop': 'O'}, {'diabetes.': 'I-Entity'}]"
"Congenital complete heart block (CCHB) occurs in 2-5% of pregnancies with positive anti-Ro/SSA and/or anti-La/SSB antibodies, and has a recurrence rate of 12-25% in a subsequent pregnancy.","[{'Congenital': 'B-Entity'}, {'complete': 'I-Entity'}, {'heart': 'I-Entity'}, {'block': 'I-Entity'}, {'(CCHB)': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'2-5%': 'O'}, {'of': 'O'}, {'pregnancies': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'anti-Ro/SSA': 'O'}, {'and/or': 'O'}, {'anti-La/SSB': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'has': 'O'}, {'a': 'O'}, {'recurrence': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'12-25%': 'O'}, {'in': 'O'}, {'a': 'O'}, {'subsequent': 'O'}, {'pregnancy.': 'O'}]"
"In the current work, we evaluated such automated method, the LIAISON(¬¨¬®‚àö√ú) (DiaSorin, Italy) for the detection of ANA.","[{'In': 'O'}, {'the': 'O'}, {'current': 'O'}, {'work,': 'O'}, {'we': 'O'}, {'evaluated': 'O'}, {'such': 'O'}, {'automated': 'O'}, {'method,': 'O'}, {'the': 'O'}, {'LIAISON(¬¨¬®‚àö√ú)': 'O'}, {'(DiaSorin,': 'O'}, {'Italy)': 'O'}, {'for': 'O'}, {'the': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'ANA.': 'I-Entity'}]"
(18)F-FDG PET/CT distinguish between soft tissue and bone infections and diagnose osteomyelitis complicated by fracture or surgery.,"[{'(18)F-FDG': 'O'}, {'PET/CT': 'O'}, {'distinguish': 'O'}, {'between': 'O'}, {'soft': 'B-Entity'}, {'tissue': 'I-Entity'}, {'and': 'I-Entity'}, {'bone': 'I-Entity'}, {'infections': 'I-Entity'}, {'and': 'O'}, {'diagnose': 'O'}, {'osteomyelitis': 'I-Entity'}, {'complicated': 'O'}, {'by': 'O'}, {'fracture': 'I-Entity'}, {'or': 'O'}, {'surgery.': 'O'}]"
"A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene.","[{'A': 'O'}, {'30-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'AIP': 'I-Entity'}, {'had': 'O'}, {'recurrent': 'O'}, {'acute': 'O'}, {'abdominal': 'B-Entity'}, {'pain,': 'I-Entity'}, {'nausea': 'I-Entity'}, {'and': 'O'}, {'vomiting,': 'I-Entity'}, {'constipation,': 'I-Entity'}, {'persistent': 'O'}, {'chest,': 'B-Entity'}, {'back,': 'I-Entity'}, {'and': 'I-Entity'}, {'waist': 'I-Entity'}, {'pain,': 'I-Entity'}, {'red': 'O'}, {'urine,': 'O'}, {'positivity': 'O'}, {'for': 'O'}, {'porphobilinogen': 'O'}, {'(PBG)': 'O'}, {'in': 'O'}, {'urine': 'O'}, {'and': 'O'}, {'a': 'O'}, {'pathogenic': 'O'}]"
"Direct detection of type I interferon protein in biologic samples has proved challenging, thus indirect methods are often used to infer the presence of type I IFN via quantification of antiviral activity and/or induced expression of IFN-responsive genes.","[{'Direct': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'type': 'O'}, {'I': 'O'}, {'interferon': 'O'}, {'protein': 'O'}, {'in': 'O'}, {'biologic': 'O'}, {'samples': 'O'}, {'has': 'O'}, {'proved': 'O'}, {'challenging,': 'O'}, {'thus': 'O'}, {'indirect': 'O'}, {'methods': 'O'}, {'are': 'O'}, {'often': 'O'}, {'used': 'O'}, {'to': 'O'}, {'infer': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'via': 'O'}, {'quantification': 'O'}, {'of': 'O'}, {'antiviral': 'O'}, {'activity': 'O'}, {'and/or': 'O'}, {'induced': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'IFN-responsive': 'O'}, {'genes.': 'O'}]"
"Hence, diagnosing juvenile Sjogrens syndrome may be challenging to the attending pediatric dentist, and long-term management without proper diagnosis may be jeopardized.","[{'Hence,': 'O'}, {'diagnosing': 'O'}, {'juvenile': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'challenging': 'O'}, {'to': 'O'}, {'the': 'O'}, {'attending': 'O'}, {'pediatric': 'O'}, {'dentist,': 'O'}, {'and': 'O'}, {'long-term': 'O'}, {'management': 'O'}, {'without': 'O'}, {'proper': 'O'}, {'diagnosis': 'O'}, {'may': 'O'}, {'be': 'O'}, {'jeopardized.': 'O'}]"
"There was significant difference in Raman spectra between the pathological and normal lip salivary glands, and the classification model established by SVM could discriminate the pathological glands from the normal ones.Xiamen Fujian 361003, China.of stomatology","[{'There': 'O'}, {'was': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'Raman': 'O'}, {'spectra': 'O'}, {'between': 'O'}, {'the': 'O'}, {'pathological': 'O'}, {'and': 'O'}, {'normal': 'O'}, {'lip': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'classification': 'O'}, {'model': 'O'}, {'established': 'O'}, {'by': 'O'}, {'SVM': 'O'}, {'could': 'O'}, {'discriminate': 'O'}, {'the': 'O'}, {'pathological': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'ones.Xiamen': 'O'}, {'Fujian': 'O'}, {'361003,': 'O'}, {'China.of': 'O'}, {'stomatology': 'O'}]"
"Primary Sjogrens syndrome (pSS) is one of the most frequent autoimmune systemic diseases, mainly characterized by ocular and oral dryness due to the progressive destruction of lachrymal and salivary glands by an inflammatory process.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'O'}, {'diseases,': 'O'}, {'mainly': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'progressive': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'lachrymal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'by': 'O'}, {'an': 'O'}, {'inflammatory': 'O'}, {'process.': 'O'}]"
"Multivariate regression analyses revealed that depression (PHQ-9) and/or fatigue, particularly lack of stamina, but not dryness, were significantly associated with physician visits and working status in pSS patients.","[{'Multivariate': 'O'}, {'regression': 'O'}, {'analyses': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'depression': 'I-Entity'}, {'(PHQ-9)': 'O'}, {'and/or': 'O'}, {'fatigue,': 'I-Entity'}, {'particularly': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'stamina,': 'O'}, {'but': 'O'}, {'not': 'O'}, {'dryness,': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'physician': 'O'}, {'visits': 'O'}, {'and': 'O'}, {'working': 'O'}, {'status': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
A 65-year-old man complaining for easy fatigue and dry cough was evaluated.,"[{'A': 'O'}, {'65-year-old': 'O'}, {'man': 'O'}, {'complaining': 'O'}, {'for': 'O'}, {'easy': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'cough': 'I-Entity'}, {'was': 'O'}, {'evaluated.': 'O'}]"
"Only 13 patients (13.8%) evolved into a defined connective tissue disease (CTD), of which 8.5% (n:8) developed systemic lupus erythematosus (SLE), 4.2% (n:4) Sjogren syndrome (SS) and 1.1% (n:1) rheumatoid arthritis (RA).","[{'Only': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'(13.8%)': 'O'}, {'evolved': 'O'}, {'into': 'O'}, {'a': 'O'}, {'defined': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD),': 'O'}, {'of': 'O'}, {'which': 'O'}, {'8.5%': 'O'}, {'(n:8)': 'O'}, {'developed': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'4.2%': 'O'}, {'(n:4)': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}]"
"From the Registry of Catastrophic Illness database in the National Health Insurance Research Database in Taiwan, we identified 389 female patients with a diagnosis of pSS from 2005 to 2010.","[{'From': 'O'}, {'the': 'O'}, {'Registry': 'O'}, {'of': 'O'}, {'Catastrophic': 'B-Entity'}, {'Illness': 'I-Entity'}, {'database': 'O'}, {'in': 'O'}, {'the': 'O'}, {'National': 'O'}, {'Health': 'O'}, {'Insurance': 'O'}, {'Research': 'O'}, {'Database': 'O'}, {'in': 'O'}, {'Taiwan,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'389': 'O'}, {'female': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'from': 'O'}, {'2005': 'O'}, {'to': 'O'}, {'2010.': 'O'}]"
The purpose of this study was to evaluate efficacy of casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) and casein phosphopeptide-amorphous calcium fluoride phosphate (CPP-ACFP) containing pastes among individuals with Sjogrens syndrome (SS).,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'casein': 'O'}, {'phosphopeptide-amorphous': 'O'}, {'calcium': 'B-Entity'}, {'phosphate': 'I-Entity'}, {'(CPP-ACP)': 'O'}, {'and': 'O'}, {'casein': 'O'}, {'phosphopeptide-amorphous': 'O'}, {'calcium': 'B-Entity'}, {'fluoride': 'I-Entity'}, {'phosphate': 'I-Entity'}, {'(CPP-ACFP)': 'O'}, {'containing': 'O'}, {'pastes': 'O'}, {'among': 'O'}]"
pSS patients with positive anti-MDM2 were characterized by longer disease duration and more lymphocytes focal gathering in labial gland.,"[{'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'anti-MDM2': 'O'}, {'were': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'longer': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'and': 'O'}, {'more': 'O'}, {'lymphocytes': 'O'}, {'focal': 'O'}, {'gathering': 'O'}, {'in': 'O'}, {'labial': 'O'}, {'gland.': 'O'}]"
She had suffered from morning stiffness and dry mouth for 1 year without being medically examined.,"[{'She': 'O'}, {'had': 'O'}, {'suffered': 'O'}, {'from': 'O'}, {'morning': 'B-Entity'}, {'stiffness': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'for': 'O'}, {'1': 'O'}, {'year': 'O'}, {'without': 'O'}, {'being': 'O'}, {'medically': 'O'}, {'examined.': 'O'}]"
Primary Sjogrens syndrome (pSS) sufferers have rated chronic fatigue as the most important symptom needing improvement.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'sufferers': 'O'}, {'have': 'O'}, {'rated': 'O'}, {'chronic': 'B-Entity'}, {'fatigue': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'most': 'O'}, {'important': 'O'}, {'symptom': 'O'}, {'needing': 'O'}, {'improvement.': 'O'}]"
We report the use of tocilizumab in a refractory organising pneumonia associated with Sjogrens disease.,"[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'tocilizumab': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'refractory': 'O'}, {'organising': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'disease.': 'I-Entity'}]"
Neonatal lupus erythematosus (NLE) is an infrequent disease caused by transplacental maternal autoantibodies.,"[{'Neonatal': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(NLE)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'infrequent': 'O'}, {'disease': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'transplacental': 'O'}, {'maternal': 'O'}, {'autoantibodies.': 'O'}]"
Four microarray studies have been published in SS that identified dysregulated genes within type I IFN signaling in either salivary glands or peripheral blood of SS patients.,"[{'Four': 'O'}, {'microarray': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'published': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'that': 'O'}, {'identified': 'O'}, {'dysregulated': 'O'}, {'genes': 'O'}, {'within': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'signaling': 'O'}, {'in': 'O'}, {'either': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'or': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"HO may be secondary to renal tubular acidosis of SS patients, and it might be a diagnostic challenge when the kidney involvement in SS is latent and precede the typical sicca symptoms.bDepartment of Endocrinology and Metabolism, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.syndrome: a duplex Doppler sonographic study.","[{'HO': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'secondary': 'O'}, {'to': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'and': 'O'}, {'it': 'O'}, {'might': 'O'}, {'be': 'O'}, {'a': 'O'}, {'diagnostic': 'O'}, {'challenge': 'O'}, {'when': 'O'}, {'the': 'O'}, {'kidney': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'latent': 'O'}, {'and': 'O'}, {'precede': 'O'}, {'the': 'O'}, {'typical': 'O'}, {'sicca': 'I-Entity'}, {'symptoms.bDepartment': 'O'}, {'of': 'O'}, {'Endocrinology': 'O'}, {'and': 'O'}, {'Metabolism,': 'O'}, {'West': 'O'}, {'China': 'O'}, {'Hospital,': 'O'}, {'Sichuan': 'O'}]"
"Additional features of his illness included a marked peripheral eosinophilia, obstructive pulmonary disease, and lymphoplasmacytic aortitis.","[{'Additional': 'O'}, {'features': 'O'}, {'of': 'O'}, {'his': 'O'}, {'illness': 'O'}, {'included': 'O'}, {'a': 'O'}, {'marked': 'O'}, {'peripheral': 'B-Entity'}, {'eosinophilia,': 'I-Entity'}, {'obstructive': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'disease,': 'I-Entity'}, {'and': 'O'}, {'lymphoplasmacytic': 'B-Entity'}, {'aortitis.': 'I-Entity'}]"
"Among the 307 RA patients, 86 (28%) responded positive to at least one question about sicca symptoms, and 11 patients were positive for both Schirmer I and USWC tests, giving a minimum prevalence of sSS at 3.6%.","[{'Among': 'O'}, {'the': 'O'}, {'307': 'O'}, {'RA': 'I-Entity'}, {'patients,': 'O'}, {'86': 'O'}, {'(28%)': 'O'}, {'responded': 'O'}, {'positive': 'O'}, {'to': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'question': 'O'}, {'about': 'O'}, {'sicca': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'and': 'O'}, {'11': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'both': 'O'}, {'Schirmer': 'O'}, {'I': 'O'}, {'and': 'O'}, {'USWC': 'O'}, {'tests,': 'O'}, {'giving': 'O'}, {'a': 'O'}, {'minimum': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'sSS': 'O'}, {'at': 'O'}, {'3.6%.': 'O'}]"
"The results of this study show the prevalence of SS in the Peruvian population and serve to strengthen the health strategies of rheumatology, ophthalmology, and oral health to improve the diagnosis, treatment, follow-up of the disease, and the quality of life of patients with SS.University, Madrid; and Department of Investigation, Innovaci‚Äö√†√∂‚Äö√¢‚Ä¢n y Desarrollo Per‚Äö√†√∂‚Äö√†¬¥ SAC, Ancash, Per‚Äö√†√∂‚Äö√†¬¥.","[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'show': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'Peruvian': 'O'}, {'population': 'O'}, {'and': 'O'}, {'serve': 'O'}, {'to': 'O'}, {'strengthen': 'O'}, {'the': 'O'}, {'health': 'O'}, {'strategies': 'O'}, {'of': 'O'}, {'rheumatology,': 'O'}, {'ophthalmology,': 'O'}, {'and': 'O'}, {'oral': 'O'}, {'health': 'O'}, {'to': 'O'}, {'improve': 'O'}, {'the': 'O'}, {'diagnosis,': 'O'}, {'treatment,': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.University,': 'I-Entity'}, {'Madrid;': 'O'}]"
"From a total of 329 patients with SS, 35 MALT-SS patients were identified, with a median followup of 76 months (range 16-153 mo).","[{'From': 'O'}, {'a': 'O'}, {'total': 'O'}, {'of': 'O'}, {'329': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'35': 'O'}, {'MALT-SS': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'identified,': 'O'}, {'with': 'O'}, {'a': 'O'}, {'median': 'O'}, {'followup': 'O'}, {'of': 'O'}, {'76': 'O'}, {'months': 'O'}, {'(range': 'O'}, {'16-153': 'O'}, {'mo).': 'O'}]"
EULAR Sjogrens syndrome disease activity index (ESSDAI) score was also evaluated accordingly.,"[{'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI)': 'O'}, {'score': 'O'}, {'was': 'O'}, {'also': 'O'}, {'evaluated': 'O'}, {'accordingly.': 'O'}]"
"In pSS patients, respiratory symptoms and radiographic abnormalities were common, although with a poor association with PFT variables.","[{'In': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'respiratory': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'radiographic': 'O'}, {'abnormalities': 'O'}, {'were': 'O'}, {'common,': 'O'}, {'although': 'O'}, {'with': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'association': 'O'}, {'with': 'O'}, {'PFT': 'O'}, {'variables.': 'O'}]"
We highlight the approach to assessing renal tubular acidosis by discussing a case study with a temporal data set collected over more than 5 weeks.,"[{'We': 'O'}, {'highlight': 'O'}, {'the': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'assessing': 'O'}, {'renal': 'O'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'by': 'O'}, {'discussing': 'O'}, {'a': 'O'}, {'case': 'O'}, {'study': 'O'}, {'with': 'O'}, {'a': 'O'}, {'temporal': 'O'}, {'data': 'O'}, {'set': 'O'}, {'collected': 'O'}, {'over': 'O'}, {'more': 'O'}, {'than': 'O'}, {'5': 'O'}, {'weeks.': 'O'}]"
Cryoglobulinemia and anti-SSA and SSB antibodies at diagnosis were associated with new systemic involvements.,"[{'Cryoglobulinemia': 'I-Entity'}, {'and': 'O'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'SSB': 'O'}, {'antibodies': 'O'}, {'at': 'O'}, {'diagnosis': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'new': 'O'}, {'systemic': 'O'}, {'involvements.': 'O'}]"
The presence of ADDE should trigger further work-up to differentiate between SS-ADDE and non-SS-ADDE.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'ADDE': 'I-Entity'}, {'should': 'O'}, {'trigger': 'O'}, {'further': 'O'}, {'work-up': 'O'}, {'to': 'O'}, {'differentiate': 'O'}, {'between': 'O'}, {'SS-ADDE': 'O'}, {'and': 'O'}, {'non-SS-ADDE.': 'O'}]"
All the patients with sensorimotor (n = 5) or nonataxic sensory neuropathy (n = 4) were improved or stabilized.,"[{'All': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'sensorimotor': 'O'}, {'(n': 'I-Entity'}, {'=': 'O'}, {'5)': 'O'}, {'or': 'O'}, {'nonataxic': 'O'}, {'sensory': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'4)': 'O'}, {'were': 'O'}, {'improved': 'O'}, {'or': 'O'}, {'stabilized.': 'O'}]"
Sjogrens syndrome (SS) is a chronic autoimmune disease characterized by lymphocytic infiltration of salivary and lacrimal glands resulting in diminished production of saliva and tears.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'diminished': 'O'}, {'production': 'O'}, {'of': 'O'}, {'saliva': 'O'}, {'and': 'O'}, {'tears.': 'O'}]"
Xerostomia may predispose patients to periodontal disease (PD) and an association between SS and PD has been reported.,"[{'Xerostomia': 'I-Entity'}, {'may': 'O'}, {'predispose': 'O'}, {'patients': 'O'}, {'to': 'O'}, {'periodontal': 'B-Entity'}, {'disease': 'I-Entity'}, {'(PD)': 'O'}, {'and': 'O'}, {'an': 'O'}, {'association': 'O'}, {'between': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'PD': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported.': 'O'}]"
"We studied the prevalence of immunologic and hematologic laboratory abnormalities, specific rheumatologic examination findings, and physician-confirmed thyroid, liver, and kidney disease, as well as lymphoma among SICCA participants.","[{'We': 'O'}, {'studied': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'immunologic': 'O'}, {'and': 'O'}, {'hematologic': 'O'}, {'laboratory': 'O'}, {'abnormalities,': 'O'}, {'specific': 'O'}, {'rheumatologic': 'O'}, {'examination': 'O'}, {'findings,': 'O'}, {'and': 'O'}, {'physician-confirmed': 'O'}, {'thyroid,': 'B-Entity'}, {'liver,': 'I-Entity'}, {'and': 'I-Entity'}, {'kidney': 'I-Entity'}, {'disease,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'lymphoma': 'I-Entity'}, {'among': 'O'}, {'SICCA': 'O'}, {'participants.': 'O'}]"
"BACKGROUND AND Although brain involvement is common in primary Sjogrens syndrome (pSS), results from cerebral imaging studies are inconsistent.","[{'BACKGROUND': 'O'}, {'AND': 'O'}, {'Although': 'O'}, {'brain': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'common': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'results': 'O'}, {'from': 'O'}, {'cerebral': 'O'}, {'imaging': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'inconsistent.': 'O'}]"
"Smoking is reported to affect the risk of a number of chronic disorders, including rheumatic diseases.","[{'Smoking': 'I-Entity'}, {'is': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'a': 'O'}, {'number': 'O'}, {'of': 'O'}, {'chronic': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'including': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"A 36-year-old woman was admitted due to petechiae, purpura, gingival bleeding, dyspnea on exertion, and a lack of concentration.","[{'A': 'O'}, {'36-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'due': 'O'}, {'to': 'O'}, {'petechiae,': 'I-Entity'}, {'purpura,': 'I-Entity'}, {'gingival': 'B-Entity'}, {'bleeding,': 'I-Entity'}, {'dyspnea': 'I-Entity'}, {'on': 'O'}, {'exertion,': 'O'}, {'and': 'O'}, {'a': 'B-Entity'}, {'lack': 'B-Entity'}, {'of': 'I-Entity'}, {'concentration.': 'I-Entity'}]"
"Therapy with fludarabine, cytoxan, and rituximab (FCR) resulted in a dramatic resolution of her sicca symptoms and periocular xanthogranulomas.","[{'Therapy': 'O'}, {'with': 'O'}, {'fludarabine,': 'I-Entity'}, {'cytoxan,': 'I-Entity'}, {'and': 'O'}, {'rituximab': 'I-Entity'}, {'(FCR)': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'dramatic': 'O'}, {'resolution': 'O'}, {'of': 'O'}, {'her': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'O'}, {'and': 'O'}, {'periocular': 'B-Entity'}, {'xanthogranulomas.': 'I-Entity'}]"
"The mean age of presentation was 43 years (range, 7-74 years), and 61% of patients were male.","[{'The': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'of': 'O'}, {'presentation': 'O'}, {'was': 'O'}, {'43': 'O'}, {'years': 'O'}, {'(range,': 'O'}, {'7-74': 'O'}, {'years),': 'O'}, {'and': 'O'}, {'61%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'male.': 'O'}]"
SGEC demethylation in SS patients was associated with a 7-fold decrease in DNA methyl transferase (DNMT) 1 and a 2-fold increase in Gadd45-alpha expression.,"[{'SGEC': 'I-Entity'}, {'demethylation': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'7-fold': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'DNA': 'O'}, {'methyl': 'O'}, {'transferase': 'O'}, {'(DNMT)': 'O'}, {'1': 'O'}, {'and': 'O'}, {'a': 'O'}, {'2-fold': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'Gadd45-alpha': 'O'}, {'expression.': 'O'}]"
"The present case suggests that symmetry bilateral lesions can occur as a symptom of pSS, which could be induced by an autoimmune mechanism.Province, China.","[{'The': 'O'}, {'present': 'O'}, {'case': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'symmetry': 'O'}, {'bilateral': 'O'}, {'lesions': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'as': 'O'}, {'a': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'pSS,': 'I-Entity'}, {'which': 'O'}, {'could': 'O'}, {'be': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'mechanism.Province,': 'O'}, {'China.': 'O'}]"
"We have seen great advances in the role of inflammation in ocular, oral and extra-glandular manifestations of Sjogrens syndrome.","[{'We': 'O'}, {'have': 'O'}, {'seen': 'O'}, {'great': 'O'}, {'advances': 'O'}, {'in': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'ocular,': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'extra-glandular': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
DESIGN: Consensus panel evaluation of reported treatments for dry eye disease.,"[{'DESIGN:': 'O'}, {'Consensus': 'O'}, {'panel': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'reported': 'O'}, {'treatments': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Passive transfer of Ro52-immune sera induced SG dysfunction in recipient mice, only if the recipients were primed with alum.","[{'Passive': 'O'}, {'transfer': 'O'}, {'of': 'O'}, {'Ro52-immune': 'I-Entity'}, {'sera': 'O'}, {'induced': 'O'}, {'SG': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'recipient': 'O'}, {'mice,': 'O'}, {'only': 'O'}, {'if': 'O'}, {'the': 'O'}, {'recipients': 'O'}, {'were': 'O'}, {'primed': 'O'}, {'with': 'O'}, {'alum.': 'O'}]"
"If this involvement is heavier, as reflected by SG swelling and cryoglobulinaemia, disease activity may be considered higher, and the risk of lymphoma is increased.","[{'If': 'O'}, {'this': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'heavier,': 'O'}, {'as': 'O'}, {'reflected': 'O'}, {'by': 'O'}, {'SG': 'O'}, {'swelling': 'O'}, {'and': 'O'}, {'cryoglobulinaemia,': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'may': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'higher,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'is': 'O'}, {'increased.': 'O'}]"
"Although anti-B cell therapy is promising in primary SS, no treatment has yet been demonstrated to modify the disease course.","[{'Although': 'O'}, {'anti-B': 'O'}, {'cell': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'promising': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'SS,': 'I-Entity'}, {'no': 'O'}, {'treatment': 'O'}, {'has': 'O'}, {'yet': 'O'}, {'been': 'O'}, {'demonstrated': 'O'}, {'to': 'O'}, {'modify': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'course.': 'O'}]"
"Statistically significant differences in staining, subjective questionnaire scores, and contrast sensitivity were measured between the normal and Sjogrens syndrome groups.","[{'Statistically': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'staining,': 'O'}, {'subjective': 'O'}, {'questionnaire': 'O'}, {'scores,': 'O'}, {'and': 'O'}, {'contrast': 'O'}, {'sensitivity': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'between': 'O'}, {'the': 'O'}, {'normal': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'groups.': 'O'}]"
"Complete response was observed in 14 patients, partial response in 1 patient, and stable disease in 20 patients.","[{'Complete': 'O'}, {'response': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'14': 'O'}, {'patients,': 'O'}, {'partial': 'O'}, {'response': 'O'}, {'in': 'O'}, {'1': 'O'}, {'patient,': 'O'}, {'and': 'O'}, {'stable': 'O'}, {'disease': 'O'}, {'in': 'O'}, {'20': 'O'}, {'patients.': 'O'}]"
A retrospective review was performed in pSS patients who were followed up over a 10-year period in our department.,"[{'A': 'O'}, {'retrospective': 'O'}, {'review': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'up': 'O'}, {'over': 'O'}, {'a': 'O'}, {'10-year': 'O'}, {'period': 'O'}, {'in': 'O'}, {'our': 'O'}, {'department.': 'O'}]"
"This case demonstrates that Sjogren's syndrome may be a causative or aggravating factor in mental disorders and that autoimmune diseases should be carefully considered in the differential diagnosis of psychiatric illness especially in cases of concurrent physical symptomatology and severity or treatment resistance of psychiatric disease.Sydney, Sydney, NSW, Australia.Sydney, Sydney, NSW, Australia.2017.","[{'This': 'O'}, {'case': 'O'}, {'demonstrates': 'O'}, {'that': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'causative': 'O'}, {'or': 'O'}, {'aggravating': 'O'}, {'factor': 'O'}, {'in': 'O'}, {'mental': 'B-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'that': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'carefully': 'O'}, {'considered': 'O'}, {'in': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'psychiatric': 'B-Entity'}, {'illness': 'I-Entity'}, {'especially': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'concurrent': 'O'}, {'physical': 'O'}, {'symptomatology': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'or': 'O'}, {'treatment': 'O'}, {'resistance': 'O'}, {'of': 'O'}, {'psychiatric': 'B-Entity'}]"
The objective of this cross-sectional study was to determine characteristics of Sjogrens syndrome as a cause for severe neuropathy with limb weakness.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'cross-sectional': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'cause': 'O'}, {'for': 'O'}, {'severe': 'O'}, {'neuropathy': 'I-Entity'}, {'with': 'O'}, {'limb': 'B-Entity'}, {'weakness.': 'I-Entity'}]"
BACKGROUND AND Sensory neuronopathies (SN) are peripheral nervous system disorders associated with degeneration of dorsal root ganglion neurons.,"[{'BACKGROUND': 'O'}, {'AND': 'O'}, {'Sensory': 'B-Entity'}, {'neuronopathies': 'I-Entity'}, {'(SN)': 'O'}, {'are': 'O'}, {'peripheral': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'disorders': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'degeneration': 'B-Entity'}, {'of': 'O'}, {'dorsal': 'O'}, {'root': 'O'}, {'ganglion': 'O'}, {'neurons.': 'I-Entity'}]"
"Differential conditions should be considered, especially the ones that promote xerostomia, such as diabetes, ectodermal dysplasia, rheumatoid arthritis, scleroderma, systemic lupus erythematosus, sarcoidosis, lymphoma, HIV and HTLV infection.","[{'Differential': 'O'}, {'conditions': 'O'}, {'should': 'O'}, {'be': 'O'}, {'considered,': 'O'}, {'especially': 'O'}, {'the': 'O'}, {'ones': 'O'}, {'that': 'O'}, {'promote': 'O'}, {'xerostomia,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'diabetes,': 'I-Entity'}, {'ectodermal': 'B-Entity'}, {'dysplasia,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'scleroderma,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'lymphoma,': 'I-Entity'}]"
"Whereas, it appears that localized amyloidosis associated to a MALT lymphoma seems to have a better prognosis than a disseminated amyloidosis.mlika.zorgati.mona@hotmail.comJul 4.an association with erosive rheumatoid arthritis and systemic Sjogren syndrome.","[{'Whereas,': 'O'}, {'it': 'O'}, {'appears': 'O'}, {'that': 'O'}, {'localized': 'O'}, {'amyloidosis': 'I-Entity'}, {'associated': 'O'}, {'to': 'O'}, {'a': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'have': 'O'}, {'a': 'O'}, {'better': 'O'}, {'prognosis': 'O'}, {'than': 'O'}, {'a': 'O'}, {'disseminated': 'O'}, {'amyloidosis.mlika.zorgati.mona@hotmail.comJul': 'I-Entity'}, {'4.an': 'O'}, {'association': 'O'}, {'with': 'O'}, {'erosive': 'O'}]"
We examined this possibility using a SS mouse model (thrombospondin-1 deficient (TSP1(-/-))) with well-characterized ocular disease.,"[{'We': 'O'}, {'examined': 'O'}, {'this': 'O'}, {'possibility': 'O'}, {'using': 'O'}, {'a': 'O'}, {'SS': 'I-Entity'}, {'mouse': 'O'}, {'model': 'O'}, {'(thrombospondin-1': 'O'}, {'deficient': 'O'}, {'(TSP1(-/-)))': 'O'}, {'with': 'O'}, {'well-characterized': 'O'}, {'ocular': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"In the past years, better knowledge of the disease has led to improvement in treatment management.Aug 11.Sjogrens syndrome.","[{'In': 'O'}, {'the': 'O'}, {'past': 'O'}, {'years,': 'O'}, {'better': 'O'}, {'knowledge': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'has': 'O'}, {'led': 'O'}, {'to': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'treatment': 'O'}, {'management.Aug': 'O'}, {'11.Sjogrens': 'O'}, {'syndrome.': 'I-Entity'}]"
"The purpose of this review article is to provide an overview of glandular dysfunction in pSS as well as the impact of discrepancy between objective assessment, subjective symptom and extraglandular disease activity on disease management.roberto.gerli@unipg.it.Sjogren Syndrome.","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'review': 'O'}, {'article': 'O'}, {'is': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'an': 'O'}, {'overview': 'O'}, {'of': 'O'}, {'glandular': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'the': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'discrepancy': 'O'}, {'between': 'O'}, {'objective': 'O'}, {'assessment,': 'O'}, {'subjective': 'O'}, {'symptom': 'O'}, {'and': 'O'}, {'extraglandular': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'on': 'O'}, {'disease': 'O'}, {'management.roberto.gerli@unipg.it.Sjogren': 'O'}]"
"These autoimmune mice had interstitial lung disease characterized by lymphocytic aggregates containing Tg T cells with an activated, effector memory phenotype.","[{'These': 'O'}, {'autoimmune': 'I-Entity'}, {'mice': 'O'}, {'had': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphocytic': 'O'}, {'aggregates': 'O'}, {'containing': 'O'}, {'Tg': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'an': 'O'}, {'activated,': 'O'}, {'effector': 'O'}, {'memory': 'O'}, {'phenotype.': 'O'}]"
"pSS activity significantly affected the birthweight percentile, which was lower in pregnancies occurring after the diagnosis of pSS than in those occurring before (32.43¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†21.57 vs. 60.46¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†27.37; p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.008).","[{'pSS': 'O'}, {'activity': 'O'}, {'significantly': 'O'}, {'affected': 'O'}, {'the': 'O'}, {'birthweight': 'O'}, {'percentile,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'lower': 'O'}, {'in': 'O'}, {'pregnancies': 'O'}, {'occurring': 'O'}, {'after': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'than': 'O'}, {'in': 'O'}, {'those': 'O'}, {'occurring': 'O'}, {'before': 'O'}, {'(32.43¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†21.57': 'O'}]"
The presence of anti-T-lymphotropic virus type 1 antibodies was significantly more common in patients with airway diseases.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-T-lymphotropic': 'O'}, {'virus': 'I-Entity'}, {'type': 'I-Entity'}, {'1': 'I-Entity'}, {'antibodies': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'airway': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Systemic lupus erythematosus was the main EGID-associated CTD (35%), followed by rheumatoid arthritis (20%), systemic sclerosis or inflammatory myopathies (15%, each), and Sjogrens syndrome, scleromyositis or other overlapping connective tissue disease (5%, each).","[{'Systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'main': 'O'}, {'EGID-associated': 'O'}, {'CTD': 'I-Entity'}, {'(35%),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(20%),': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'or': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathies': 'I-Entity'}, {'(15%,': 'O'}, {'each),': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}]"
"We detected significant numbers of CD138+, non-proliferating, Bcl-2 expressing plasma cells in the salivary glands of pSS patients with high focus score (FS).","[{'We': 'O'}, {'detected': 'O'}, {'significant': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'CD138+,': 'O'}, {'non-proliferating,': 'O'}, {'Bcl-2': 'O'}, {'expressing': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'high': 'O'}, {'focus': 'O'}, {'score': 'O'}, {'(FS).': 'O'}]"
"In addition, two injection sites were compared in these two strains: the abdominal area and the tailbase.","[{'In': 'O'}, {'addition,': 'O'}, {'two': 'O'}, {'injection': 'O'}, {'sites': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'in': 'O'}, {'these': 'O'}, {'two': 'O'}, {'strains:': 'O'}, {'the': 'O'}, {'abdominal': 'O'}, {'area': 'O'}, {'and': 'O'}, {'the': 'O'}, {'tailbase.': 'O'}]"
The Prof-M is a simple self-report measure which could be useful in screening PSS subjects who may benefit from detailed psychometric evaluation.,"[{'The': 'O'}, {'Prof-M': 'O'}, {'is': 'O'}, {'a': 'O'}, {'simple': 'O'}, {'self-report': 'O'}, {'measure': 'O'}, {'which': 'O'}, {'could': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'in': 'O'}, {'screening': 'O'}, {'PSS': 'I-Entity'}, {'subjects': 'O'}, {'who': 'O'}, {'may': 'O'}, {'benefit': 'O'}, {'from': 'O'}, {'detailed': 'O'}, {'psychometric': 'O'}, {'evaluation.': 'O'}]"
"It is known that rheumatoid factor or ANA characteristic of rheumatic disease are often present in patients with paraneoplastic rheumatic syndromes, which can lead to wrong conclusions about the possible systemic connective tissue diseases and ultimately delay the correct diagnosis.","[{'It': 'O'}, {'is': 'O'}, {'known': 'O'}, {'that': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'or': 'O'}, {'ANA': 'O'}, {'characteristic': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'are': 'O'}, {'often': 'O'}, {'present': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'paraneoplastic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'syndromes,': 'I-Entity'}, {'which': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'wrong': 'O'}, {'conclusions': 'O'}, {'about': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'systemic': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'ultimately': 'O'}, {'delay': 'O'}, {'the': 'O'}, {'correct': 'O'}, {'diagnosis.': 'O'}]"
"The hallmark characteristics of SS are dry eye and dry mouth, but there are a broad range of other possible symptoms such as joint and muscle pain, skin rashes, chronic dry cough, vaginal dryness, extremity numbness or tingling, and disabling fatigue.","[{'The': 'O'}, {'hallmark': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'are': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'but': 'O'}, {'there': 'O'}, {'are': 'O'}, {'a': 'O'}, {'broad': 'O'}, {'range': 'O'}, {'of': 'O'}, {'other': 'O'}, {'possible': 'O'}, {'symptoms': 'O'}, {'such': 'O'}, {'as': 'O'}, {'joint': 'B-Entity'}, {'and': 'I-Entity'}, {'muscle': 'I-Entity'}, {'pain,': 'I-Entity'}, {'skin': 'B-Entity'}, {'rashes,': 'I-Entity'}, {'chronic': 'O'}, {'dry': 'B-Entity'}, {'cough,': 'I-Entity'}, {'vaginal': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'extremity': 'O'}, {'numbness': 'I-Entity'}, {'or': 'I-Entity'}, {'tingling,': 'I-Entity'}, {'and': 'O'}, {'disabling': 'O'}, {'fatigue.': 'I-Entity'}]"
"Seven of the 19 patients had systemic lupus erythematosus (SLE), 3 patients had Sjogrens syndrome, 2 patients had rheumatoid arthritis (RA), 1 patient had connective tissue disease, 1 patient had juvenile idiopathic arthritis (JIA), 1 patient had Guillain-Barre syndrome (GBS), 1 patient had systemic sclerosis, 1 patient had Crohn's disease, 1 patient had relapsing polychondritis (RPC), and 1 patient had autoinflammatory disease (AID).","[{'Seven': 'O'}, {'of': 'O'}, {'the': 'O'}, {'19': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'3': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'2': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'1': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease,': 'I-Entity'}, {'1': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'juvenile': 'B-Entity'}, {'idiopathic': 'I-Entity'}, {'arthritis': 'I-Entity'}]"
"Thoracic endoscopy revealed a fragile, inflammatory, and granulomatous aspect of the bronchi.","[{'Thoracic': 'O'}, {'endoscopy': 'O'}, {'revealed': 'O'}, {'a': 'O'}, {'fragile,': 'O'}, {'inflammatory,': 'O'}, {'and': 'O'}, {'granulomatous': 'I-Entity'}, {'aspect': 'O'}, {'of': 'O'}, {'the': 'O'}, {'bronchi.': 'O'}]"
"The most frequent histopathological features observed in cases of IP were a lymphocytic infiltrate with perivascular (8 cases, 89%) and perieccrine distribution (6 cases, 66%), dermal edema (5 cases, 55%), and necrotic keratinocytes (5 cases, 55%), whereas those found in perniosis associated with an autoimmune disease were lymphocytic infiltrate with perivascular distribution (11 cases, 100%) but without perieccrine distribution (3 cases, 27%), vacuolation of the basal layer (7 cases, 63%), and necrotic keratinocytes (5 cases, 45%).","[{'The': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'histopathological': 'O'}, {'features': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'IP': 'O'}, {'were': 'O'}, {'a': 'O'}, {'lymphocytic': 'O'}, {'infiltrate': 'O'}, {'with': 'O'}, {'perivascular': 'O'}, {'(8': 'O'}, {'cases,': 'O'}, {'89%)': 'O'}, {'and': 'O'}, {'perieccrine': 'O'}, {'distribution': 'O'}, {'(6': 'O'}, {'cases,': 'O'}, {'66%),': 'O'}, {'dermal': 'B-Entity'}, {'edema': 'I-Entity'}, {'(5': 'O'}, {'cases,': 'O'}, {'55%),': 'O'}, {'and': 'O'}]"
"MATERIAL AND Eligible studies were identified through a comprehensive search of two databases, that is, PubMed and EMBASE.","[{'MATERIAL': 'O'}, {'AND': 'O'}, {'Eligible': 'O'}, {'studies': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'through': 'O'}, {'a': 'O'}, {'comprehensive': 'O'}, {'search': 'O'}, {'of': 'O'}, {'two': 'O'}, {'databases,': 'O'}, {'that': 'O'}, {'is,': 'O'}, {'PubMed': 'O'}, {'and': 'O'}, {'EMBASE.': 'O'}]"
Both groups were followed and the risks of SS were calculated by Cox proportional hazards regression.,"[{'Both': 'O'}, {'groups': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'and': 'O'}, {'the': 'O'}, {'risks': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'were': 'O'}, {'calculated': 'O'}, {'by': 'O'}, {'Cox': 'O'}, {'proportional': 'O'}, {'hazards': 'O'}, {'regression.': 'O'}]"
The treatment of red blood cells with 2-mercaptoethanol resulted in the loss of spontaneous agglutination.,"[{'The': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'red': 'O'}, {'blood': 'O'}, {'cells': 'O'}, {'with': 'O'}, {'2-mercaptoethanol': 'I-Entity'}, {'resulted': 'O'}, {'in': 'O'}, {'the': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'spontaneous': 'O'}, {'agglutination.': 'O'}]"
Magnetic resonance imaging (MRI) revealed that the cause of her neurological symptoms was cervical myelitis.,"[{'Magnetic': 'O'}, {'resonance': 'O'}, {'imaging': 'O'}, {'(MRI)': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'her': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'was': 'O'}, {'cervical': 'B-Entity'}, {'myelitis.': 'I-Entity'}]"
"In paraneoplastic cases, the tumor was small cell lung cancer in 1 (with positive anti-Hu antibodies), and epidermoid lung cancer in the other.","[{'In': 'O'}, {'paraneoplastic': 'O'}, {'cases,': 'O'}, {'the': 'O'}, {'tumor': 'I-Entity'}, {'was': 'O'}, {'small': 'B-Entity'}, {'cell': 'I-Entity'}, {'lung': 'I-Entity'}, {'cancer': 'I-Entity'}, {'in': 'O'}, {'1': 'O'}, {'(with': 'O'}, {'positive': 'O'}, {'anti-Hu': 'O'}, {'antibodies),': 'O'}, {'and': 'O'}, {'epidermoid': 'B-Entity'}, {'lung': 'I-Entity'}, {'cancer': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'other.': 'O'}]"
"His sensory ataxia might be attributed to Sjogren syndrome-associated ganglionopathy at the cervical level, and the MRI findings might reflect centripetal Wallerian degeneration in the cuneate fasciculus.","[{'His': 'O'}, {'sensory': 'B-Entity'}, {'ataxia': 'I-Entity'}, {'might': 'O'}, {'be': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome-associated': 'I-Entity'}, {'ganglionopathy': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'cervical': 'O'}, {'level,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'MRI': 'O'}, {'findings': 'O'}, {'might': 'O'}, {'reflect': 'O'}, {'centripetal': 'O'}, {'Wallerian': 'B-Entity'}, {'degeneration': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'cuneate': 'O'}, {'fasciculus.': 'O'}]"
"In this review, we would like to summarize our recent understanding of regulatory mechanism of impaired sweating function in allergic inflammatory skin diseases by introducing clinical presentations of AD/SS overlap cases as the model of hypoidrotic inflammatory skin diseases.B.V.","[{'In': 'O'}, {'this': 'O'}, {'review,': 'O'}, {'we': 'O'}, {'would': 'O'}, {'like': 'O'}, {'to': 'O'}, {'summarize': 'O'}, {'our': 'O'}, {'recent': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'regulatory': 'O'}, {'mechanism': 'O'}, {'of': 'O'}, {'impaired': 'B-Entity'}, {'sweating': 'I-Entity'}, {'function': 'O'}, {'in': 'O'}, {'allergic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'skin': 'I-Entity'}, {'diseases': 'I-Entity'}, {'by': 'O'}, {'introducing': 'O'}, {'clinical': 'O'}, {'presentations': 'O'}, {'of': 'O'}, {'AD/SS': 'I-Entity'}, {'overlap': 'O'}, {'cases': 'O'}, {'as': 'O'}, {'the': 'O'}, {'model': 'O'}, {'of': 'O'}, {'hypoidrotic': 'O'}, {'inflammatory': 'B-Entity'}, {'skin': 'I-Entity'}, {'diseases.B.V.': 'I-Entity'}]"
It has been recently observed that small fibre neuropathy (SFN) may present as distal symmetrical polyneuropathy and with atypical non-length-dependent pattern.,"[{'It': 'O'}, {'has': 'O'}, {'been': 'O'}, {'recently': 'O'}, {'observed': 'O'}, {'that': 'O'}, {'small': 'B-Entity'}, {'fibre': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'(SFN)': 'O'}, {'may': 'O'}, {'present': 'O'}, {'as': 'O'}, {'distal': 'O'}, {'symmetrical': 'O'}, {'polyneuropathy': 'I-Entity'}, {'and': 'O'}, {'with': 'O'}, {'atypical': 'O'}, {'non-length-dependent': 'O'}, {'pattern.': 'O'}]"
"These results reveal a regulatory function of pDC in controlling autoreactivity to RNA-binding nuclear antigens.Center, Oklahoma City.Weatherford, OK, USA.Center, Oklahoma City.Sjogrens syndrome.","[{'These': 'O'}, {'results': 'O'}, {'reveal': 'O'}, {'a': 'O'}, {'regulatory': 'O'}, {'function': 'O'}, {'of': 'O'}, {'pDC': 'O'}, {'in': 'O'}, {'controlling': 'O'}, {'autoreactivity': 'O'}, {'to': 'O'}, {'RNA-binding': 'O'}, {'nuclear': 'O'}, {'antigens.Center,': 'O'}, {'Oklahoma': 'O'}, {'City.Weatherford,': 'O'}, {'OK,': 'O'}, {'USA.Center,': 'O'}, {'Oklahoma': 'O'}, {'City.Sjogrens': 'O'}, {'syndrome.': 'I-Entity'}]"
Pediatric oncology specialists should be aware of the association of MALT lymphoma with Sjogren syndrome and have a high index of suspicion for this malignant complication.,"[{'Pediatric': 'O'}, {'oncology': 'O'}, {'specialists': 'O'}, {'should': 'O'}, {'be': 'O'}, {'aware': 'O'}, {'of': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'have': 'O'}, {'a': 'O'}, {'high': 'O'}, {'index': 'O'}, {'of': 'O'}, {'suspicion': 'O'}, {'for': 'O'}, {'this': 'O'}, {'malignant': 'O'}, {'complication.': 'O'}]"
"Infused MSCs migrated toward the inflammatory regions in a stromal cell-derived factor-1-dependent manner, as neutralization of stromal cell-derived factor-1 ligand CXCR4 abolished the effectiveness of bone marrow mesenchymal stem cell treatment.","[{'Infused': 'O'}, {'MSCs': 'O'}, {'migrated': 'O'}, {'toward': 'O'}, {'the': 'O'}, {'inflammatory': 'O'}, {'regions': 'O'}, {'in': 'O'}, {'a': 'O'}, {'stromal': 'O'}, {'cell-derived': 'O'}, {'factor-1-dependent': 'O'}, {'manner,': 'O'}, {'as': 'O'}, {'neutralization': 'O'}, {'of': 'O'}, {'stromal': 'O'}, {'cell-derived': 'O'}, {'factor-1': 'O'}, {'ligand': 'O'}, {'CXCR4': 'O'}, {'abolished': 'O'}, {'the': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'bone': 'O'}, {'marrow': 'O'}, {'mesenchymal': 'O'}, {'stem': 'O'}, {'cell': 'O'}, {'treatment.': 'O'}]"
"Common rheumatologic manifestations of HCV-associated CGEV were skin lesions (90%), arthralgia (85%), frequent peripheral nervous system involvement (52%) and glomerulonephritis (38%).","[{'Common': 'O'}, {'rheumatologic': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'HCV-associated': 'I-Entity'}, {'CGEV': 'I-Entity'}, {'were': 'O'}, {'skin': 'O'}, {'lesions': 'O'}, {'(90%),': 'O'}, {'arthralgia': 'I-Entity'}, {'(85%),': 'O'}, {'frequent': 'O'}, {'peripheral': 'B-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement': 'O'}, {'(52%)': 'O'}, {'and': 'O'}, {'glomerulonephritis': 'I-Entity'}, {'(38%).': 'O'}]"
The studies showed no significant difference from placebo in primary or secondary clinical outcome measures but did demonstrate B cell-specific immunologic activity.,"[{'The': 'O'}, {'studies': 'O'}, {'showed': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'from': 'O'}, {'placebo': 'O'}, {'in': 'O'}, {'primary': 'O'}, {'or': 'O'}, {'secondary': 'O'}, {'clinical': 'O'}, {'outcome': 'O'}, {'measures': 'O'}, {'but': 'O'}, {'did': 'O'}, {'demonstrate': 'O'}, {'B': 'O'}, {'cell-specific': 'O'}, {'immunologic': 'O'}, {'activity.': 'O'}]"
"The clinical diagnosis of such involvement in early stages is difficult, since a mild cognitive impairment can be the only symptom.","[{'The': 'O'}, {'clinical': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'such': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'early': 'O'}, {'stages': 'O'}, {'is': 'O'}, {'difficult,': 'O'}, {'since': 'O'}, {'a': 'O'}, {'mild': 'O'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'the': 'O'}, {'only': 'O'}, {'symptom.': 'O'}]"
Survival was significantly reduced in patients with peripheral neuropathy (especially in those with mononeuropathy multiplex and axonal polyneuropathy) in comparison with the control group (log rank =0.001).,"[{'Survival': 'O'}, {'was': 'O'}, {'significantly': 'O'}, {'reduced': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'(especially': 'O'}, {'in': 'O'}, {'those': 'O'}, {'with': 'O'}, {'mononeuropathy': 'B-Entity'}, {'multiplex': 'I-Entity'}, {'and': 'O'}, {'axonal': 'O'}, {'polyneuropathy)': 'I-Entity'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'the': 'O'}, {'control': 'O'}, {'group': 'O'}, {'(log': 'O'}, {'rank': 'O'}, {'=0.001).': 'O'}]"
The degree and pattern of staining and inflammation was then evaluated.,"[{'The': 'O'}, {'degree': 'O'}, {'and': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'staining': 'O'}, {'and': 'O'}, {'inflammation': 'I-Entity'}, {'was': 'O'}, {'then': 'O'}, {'evaluated.': 'O'}]"
The patient returned to independent oral feeding after 46 sessions of NMES.,"[{'The': 'O'}, {'patient': 'O'}, {'returned': 'O'}, {'to': 'O'}, {'independent': 'O'}, {'oral': 'O'}, {'feeding': 'O'}, {'after': 'O'}, {'46': 'O'}, {'sessions': 'O'}, {'of': 'O'}, {'NMES.': 'O'}]"
"Only CRP level is independently associated with functional impairment (‚âà√≠‚Äö√¢¬ß = 0.38, P = 0.025).","[{'Only': 'O'}, {'CRP': 'O'}, {'level': 'O'}, {'is': 'O'}, {'independently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'functional': 'B-Entity'}, {'impairment': 'I-Entity'}, {'(‚âà√≠‚Äö√¢¬ß': 'O'}, {'=': 'O'}, {'0.38,': 'O'}, {'P': 'O'}, {'=': 'O'}, {'0.025).': 'O'}]"
"It is an autoimmune disease characterized by features of systemic autoimmunity, dysfunction, and inflammation in the exocrine glands (mainly salivary and lacrimal glands) and lymphocytic infiltration of exocrine glands.","[{'It': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'features': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'autoimmunity,': 'I-Entity'}, {'dysfunction,': 'I-Entity'}, {'and': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'(mainly': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands)': 'O'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
"Similar patterns were observed in the pancreas, even though these mice do not develop diabetes.","[{'Similar': 'O'}, {'patterns': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pancreas,': 'O'}, {'even': 'O'}, {'though': 'O'}, {'these': 'O'}, {'mice': 'O'}, {'do': 'O'}, {'not': 'O'}, {'develop': 'O'}, {'diabetes.': 'I-Entity'}]"
"In particular, the issue of whether the presence of these cardiovascular risk factors is associated with an increased risk of cardiovascular events needs to be further explored.","[{'In': 'O'}, {'particular,': 'O'}, {'the': 'O'}, {'issue': 'O'}, {'of': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'these': 'O'}, {'cardiovascular': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'cardiovascular': 'O'}, {'events': 'O'}, {'needs': 'O'}, {'to': 'O'}, {'be': 'O'}, {'further': 'O'}, {'explored.': 'O'}]"
"The main ocular manifestation of rheumatoid arthritis is dry eyes (secondary Sjogrens syndrome), followed by scleritis, peripheral ulcerative keratitis and uveitis.","[{'The': 'O'}, {'main': 'O'}, {'ocular': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'is': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'(secondary': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome),': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'scleritis,': 'I-Entity'}, {'peripheral': 'O'}, {'ulcerative': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'and': 'O'}, {'uveitis.': 'I-Entity'}]"
"Primary Sjogrens syndrome (pSS) is a complex, heterogenous autoimmune disease; no immunomodulatory drug has demonstrated efficacy, and no current treatments target the underlying cause.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'complex,': 'O'}, {'heterogenous': 'O'}, {'autoimmune': 'B-Entity'}, {'disease;': 'I-Entity'}, {'no': 'O'}, {'immunomodulatory': 'O'}, {'drug': 'O'}, {'has': 'O'}, {'demonstrated': 'O'}, {'efficacy,': 'O'}, {'and': 'O'}, {'no': 'O'}, {'current': 'O'}, {'treatments': 'O'}, {'target': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'cause.': 'O'}]"
"The corticosteroid treatment induced a reduction of both molecules, although higher in SS than in MGD, because of its direct inhibitory effect on inflammation.rights reserved.for Ocular Surface Diseases, University of Messina, Messina, Italy.","[{'The': 'O'}, {'corticosteroid': 'O'}, {'treatment': 'O'}, {'induced': 'O'}, {'a': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'both': 'O'}, {'molecules,': 'O'}, {'although': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'than': 'O'}, {'in': 'O'}, {'MGD,': 'I-Entity'}, {'because': 'O'}, {'of': 'O'}, {'its': 'O'}, {'direct': 'O'}, {'inhibitory': 'O'}, {'effect': 'O'}, {'on': 'O'}, {'inflammation.rights': 'O'}, {'reserved.for': 'O'}, {'Ocular': 'B-Entity'}, {'Surface': 'I-Entity'}, {'Diseases,': 'I-Entity'}, {'University': 'O'}, {'of': 'O'}, {'Messina,': 'O'}, {'Messina,': 'O'}, {'Italy.': 'O'}]"
The results will need to be replicated.,"[{'The': 'O'}, {'results': 'O'}, {'will': 'O'}, {'need': 'O'}, {'to': 'O'}, {'be': 'O'}, {'replicated.': 'O'}]"
Rankin and European Sjogrens Syndrome Disease Activity Index scales decreased significantly in group 1.,"[{'Rankin': 'O'}, {'and': 'O'}, {'European': 'O'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'scales': 'O'}, {'decreased': 'O'}, {'significantly': 'O'}, {'in': 'O'}, {'group': 'O'}, {'1.': 'O'}]"
The associations of biomarkers with disease activity were examined.,"[{'The': 'O'}, {'associations': 'O'}, {'of': 'O'}, {'biomarkers': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'were': 'O'}, {'examined.': 'O'}]"
"On the seventh day of hospitalization, the patient's serum Cr level was 5.7¬¨¬®‚Äö√Ñ‚Ä†mg/dL, indicating rapidly progressive glomerulonephritis.","[{'On': 'O'}, {'the': 'O'}, {'seventh': 'O'}, {'day': 'O'}, {'of': 'O'}, {'hospitalization,': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'serum': 'O'}, {'Cr': 'I-Entity'}, {'level': 'O'}, {'was': 'O'}, {'5.7¬¨¬®‚Äö√Ñ‚Ä†mg/dL,': 'O'}, {'indicating': 'O'}, {'rapidly': 'O'}, {'progressive': 'O'}, {'glomerulonephritis.': 'I-Entity'}]"
To determine the clinical and pathological characteristics of eosinophilic gastrointestinal disease (EGID) associated with autoimmune connective tissue disease (CTD).,"[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'eosinophilic': 'B-Entity'}, {'gastrointestinal': 'I-Entity'}, {'disease': 'I-Entity'}, {'(EGID)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD).': 'O'}]"
"She was treated with potassium, bicarbonate, steroids, ramipril and warfarin.","[{'She': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'potassium,': 'I-Entity'}, {'bicarbonate,': 'I-Entity'}, {'steroids,': 'I-Entity'}, {'ramipril': 'I-Entity'}, {'and': 'O'}, {'warfarin.': 'I-Entity'}]"
The primary objective is to assess the extent to which rituximab improves symptoms of fatigue and oral dryness.,"[{'The': 'O'}, {'primary': 'O'}, {'objective': 'O'}, {'is': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'extent': 'O'}, {'to': 'O'}, {'which': 'O'}, {'rituximab': 'I-Entity'}, {'improves': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'oral': 'B-Entity'}, {'dryness.': 'I-Entity'}]"
"In the absence of previous studies, our objective was to assess whether gout was associated with an increase or decrease in the risk of Sjogren's Syndrome (SS) in older adults, 65 years or older.","[{'In': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'previous': 'O'}, {'studies,': 'O'}, {'our': 'O'}, {'objective': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'whether': 'O'}, {'gout': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'or': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'in': 'O'}, {'older': 'O'}, {'adults,': 'O'}, {'65': 'O'}, {'years': 'O'}, {'or': 'O'}, {'older.': 'O'}]"
"PI is known to be associated with several clinical conditions, such as pulmonary diseases, gastrointestinal diseases, and traumatic injury, as well as autoimmune disorders.","[{'PI': 'I-Entity'}, {'is': 'O'}, {'known': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'several': 'O'}, {'clinical': 'O'}, {'conditions,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'pulmonary': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'gastrointestinal': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'and': 'O'}, {'traumatic': 'B-Entity'}, {'injury,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'autoimmune': 'B-Entity'}, {'disorders.': 'I-Entity'}]"
"Common HE and Giemsa slices are histopathologically examined and graduated for lymphocyte infiltration (focus): grade 0: absent, grade 1: slight, grade 2: moderate non-focal infiltration, grade 3: 1 focus (> or =50 lymphocytes) per 4 mm2, grade 4: >1 focus.","[{'Common': 'O'}, {'HE': 'O'}, {'and': 'O'}, {'Giemsa': 'O'}, {'slices': 'O'}, {'are': 'O'}, {'histopathologically': 'O'}, {'examined': 'O'}, {'and': 'O'}, {'graduated': 'O'}, {'for': 'O'}, {'lymphocyte': 'O'}, {'infiltration': 'O'}, {'(focus):': 'O'}, {'grade': 'O'}, {'0:': 'O'}, {'absent,': 'O'}, {'grade': 'O'}, {'1:': 'O'}, {'slight,': 'O'}, {'grade': 'O'}, {'2:': 'O'}, {'moderate': 'O'}, {'non-focal': 'O'}, {'infiltration,': 'O'}, {'grade': 'O'}, {'3:': 'O'}, {'1': 'O'}, {'focus': 'O'}, {'(>': 'O'}, {'or': 'O'}, {'=50': 'O'}]"
"Also, a significantly different immune response to virus infection (protein IFI16, interferons gamma and beta, dendritic cells, and receptor for natural killers) was revealed in the minor salivary glands of the study groups.","[{'Also,': 'O'}, {'a': 'O'}, {'significantly': 'O'}, {'different': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'to': 'O'}, {'virus': 'B-Entity'}, {'infection': 'I-Entity'}, {'(protein': 'O'}, {'IFI16,': 'O'}, {'interferons': 'O'}, {'gamma': 'O'}, {'and': 'O'}, {'beta,': 'O'}, {'dendritic': 'O'}, {'cells,': 'O'}, {'and': 'O'}, {'receptor': 'O'}, {'for': 'O'}, {'natural': 'O'}, {'killers)': 'O'}, {'was': 'O'}, {'revealed': 'O'}, {'in': 'O'}, {'the': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'groups.': 'O'}]"
"Autoimmune workup for refractory TTP revealed positive antinuclear antibodies, Anti-SSA, and Anti-SSB.","[{'Autoimmune': 'O'}, {'workup': 'O'}, {'for': 'O'}, {'refractory': 'O'}, {'TTP': 'I-Entity'}, {'revealed': 'O'}, {'positive': 'O'}, {'antinuclear': 'O'}, {'antibodies,': 'O'}, {'Anti-SSA,': 'O'}, {'and': 'O'}, {'Anti-SSB.': 'O'}]"
"Type III IFN expression was examined in minor salivary gland tissues (MSG), peripheral blood mononuclear cells (PBMCs), sera and resting or Toll-like receptor (TLR)-stimulated salivary gland epithelial cells (SGEC) from SS patients and sicca-complaining controls.","[{'Type': 'O'}, {'III': 'O'}, {'IFN': 'O'}, {'expression': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'in': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'tissues': 'O'}, {'(MSG),': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'(PBMCs),': 'O'}, {'sera': 'O'}, {'and': 'O'}, {'resting': 'O'}, {'or': 'O'}, {'Toll-like': 'O'}, {'receptor': 'O'}, {'(TLR)-stimulated': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'(SGEC)': 'O'}]"
IL-1‚âà√≠‚Äö√¢¬ß and IL-6 levels in blood plasma and supernatant after ATP stimulation were measured by ELISA.,"[{'IL-1‚âà√≠‚Äö√¢¬ß': 'O'}, {'and': 'O'}, {'IL-6': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'blood': 'O'}, {'plasma': 'O'}, {'and': 'O'}, {'supernatant': 'O'}, {'after': 'O'}, {'ATP': 'I-Entity'}, {'stimulation': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'by': 'O'}, {'ELISA.': 'O'}]"
"Pathologic and microscopic studies, as well as a review of medications, allergies, and habits, may further highlight possible etiologies.","[{'Pathologic': 'O'}, {'and': 'O'}, {'microscopic': 'O'}, {'studies,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'a': 'O'}, {'review': 'O'}, {'of': 'O'}, {'medications,': 'O'}, {'allergies,': 'I-Entity'}, {'and': 'O'}, {'habits,': 'O'}, {'may': 'O'}, {'further': 'O'}, {'highlight': 'O'}, {'possible': 'O'}, {'etiologies.': 'O'}]"
"Furthermore, HCQ-treated patients were stratified based on IFN activation and differences in disease activity and clinical parameters were studied.","[{'Furthermore,': 'O'}, {'HCQ-treated': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'stratified': 'O'}, {'based': 'O'}, {'on': 'O'}, {'IFN': 'O'}, {'activation': 'O'}, {'and': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'parameters': 'O'}, {'were': 'O'}, {'studied.': 'O'}]"
"Of these 4 cases, 2 had underlying autoimmunity.","[{'Of': 'O'}, {'these': 'O'}, {'4': 'O'}, {'cases,': 'O'}, {'2': 'O'}, {'had': 'O'}, {'underlying': 'O'}, {'autoimmunity.': 'I-Entity'}]"
She also revealed severe dry eye in both eyes.,"[{'She': 'O'}, {'also': 'O'}, {'revealed': 'O'}, {'severe': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'I-Entity'}, {'both': 'O'}, {'eyes.': 'I-Entity'}]"
A preliminary evaluation of the parotid secretion cellular composition in patients with Sjogren's Syndrome (SS) and a diagnostic accuracy assessment of salivary lymphocyte detection and immunophenotyping in Sjogren's Syndrome diagnosis and prognosis were performed.,"[{'A': 'O'}, {'preliminary': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'secretion': 'O'}, {'cellular': 'O'}, {'composition': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'a': 'O'}, {'diagnostic': 'O'}, {'accuracy': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'lymphocyte': 'O'}, {'detection': 'O'}, {'and': 'O'}, {'immunophenotyping': 'O'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'diagnosis': 'O'}, {'and': 'O'}, {'prognosis': 'O'}]"
Pulmonary function tests were normal in four cases.,"[{'Pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'were': 'O'}, {'normal': 'O'}, {'in': 'O'}, {'four': 'O'}, {'cases.': 'O'}]"
To examine the role of CD40-CD154 costimulation and effects of therapeutic pathway blockade in the non-obese diabetic (NOD/ShiLtJ) model of Sjogrens syndrome (SS).,"[{'To': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'role': 'O'}, {'of': 'O'}, {'CD40-CD154': 'O'}, {'costimulation': 'O'}, {'and': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'therapeutic': 'O'}, {'pathway': 'O'}, {'blockade': 'O'}, {'in': 'O'}, {'the': 'O'}, {'non-obese': 'O'}, {'diabetic': 'I-Entity'}, {'(NOD/ShiLtJ)': 'O'}, {'model': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"The recent finding that IL-7 and IL-7R‚âà√≠¬¨¬±+ T cells were both found to be increased in exocrine glands of pSS patients indicates that IL-7 could contribute to glandular inflammation by activation of IL-7R‚âà√≠¬¨¬±+ responder T cells despite the increased numbers of Tregs.Utrecht, P.O.","[{'The': 'O'}, {'recent': 'O'}, {'finding': 'O'}, {'that': 'O'}, {'IL-7': 'O'}, {'and': 'O'}, {'IL-7R‚âà√≠¬¨¬±+': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'were': 'O'}, {'both': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'indicates': 'O'}, {'that': 'O'}, {'IL-7': 'O'}, {'could': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'glandular': 'O'}, {'inflammation': 'I-Entity'}, {'by': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'IL-7R‚âà√≠¬¨¬±+': 'O'}]"
The aim of this study was to assess the incidence of PMs in pSS and to determine the factors predisposing to the occurrence of this complication.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'PMs': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'factors': 'O'}, {'predisposing': 'O'}, {'to': 'O'}, {'the': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'this': 'O'}, {'complication.': 'O'}]"
"An evidence-based screening algorithm for determining which patients with dry eye should be tested for underlying SS may be particularly helpful in preventing delays in diagnosis.in Health, Brown University School of Public Health, Providence, RI.Syndrome Foundation, Bethesda, MD.","[{'An': 'O'}, {'evidence-based': 'O'}, {'screening': 'O'}, {'algorithm': 'O'}, {'for': 'O'}, {'determining': 'O'}, {'which': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'tested': 'O'}, {'for': 'O'}, {'underlying': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'particularly': 'O'}, {'helpful': 'O'}, {'in': 'O'}, {'preventing': 'O'}, {'delays': 'O'}, {'in': 'O'}, {'diagnosis.in': 'O'}, {'Health,': 'O'}, {'Brown': 'O'}, {'University': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Public': 'O'}, {'Health,': 'O'}, {'Providence,': 'O'}, {'RI.Syndrome': 'O'}, {'Foundation,': 'O'}, {'Bethesda,': 'O'}, {'MD.': 'O'}]"
"Ten patients demonstrated both clinical and radiologic evidence of near, if not complete, abolishment of disease activity, in conjunction with impressive reconstitution of neurologic function in the 6-month period following HDMTX-LR.","[{'Ten': 'O'}, {'patients': 'O'}, {'demonstrated': 'O'}, {'both': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'radiologic': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'near,': 'O'}, {'if': 'O'}, {'not': 'O'}, {'complete,': 'O'}, {'abolishment': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'in': 'O'}, {'conjunction': 'O'}, {'with': 'O'}, {'impressive': 'O'}, {'reconstitution': 'O'}, {'of': 'O'}, {'neurologic': 'O'}, {'function': 'O'}, {'in': 'O'}, {'the': 'O'}, {'6-month': 'O'}, {'period': 'O'}, {'following': 'O'}, {'HDMTX-LR.': 'I-Entity'}]"
The occurrence of spontaneous bacterial peritonitis was significantly different in PBC-SS patients than in PBC-only patients (P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.002).,"[{'The': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'spontaneous': 'O'}, {'bacterial': 'O'}, {'peritonitis': 'I-Entity'}, {'was': 'O'}, {'significantly': 'O'}, {'different': 'O'}, {'in': 'O'}, {'PBC-SS': 'I-Entity'}, {'patients': 'O'}, {'than': 'O'}, {'in': 'O'}, {'PBC-only': 'I-Entity'}, {'patients': 'O'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬ß=‚Äö√Ñ√∂‚àö√ë‚àö¬ß0.002).': 'O'}]"
There were abnormal aspects on the sylvian artery and hyperintense lesions of periventricular predominance.,"[{'There': 'O'}, {'were': 'O'}, {'abnormal': 'O'}, {'aspects': 'O'}, {'on': 'O'}, {'the': 'O'}, {'sylvian': 'O'}, {'artery': 'O'}, {'and': 'O'}, {'hyperintense': 'O'}, {'lesions': 'O'}, {'of': 'O'}, {'periventricular': 'O'}, {'predominance.': 'O'}]"
"The goal of this study was to use quantitative proteomics to investigate changes in tear proteins in a rabbit model of SS-associated dry eye, induced autoimmune dacryoadenitis (IAD).","[{'The': 'O'}, {'goal': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'use': 'O'}, {'quantitative': 'O'}, {'proteomics': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'tear': 'O'}, {'proteins': 'O'}, {'in': 'O'}, {'a': 'O'}, {'rabbit': 'O'}, {'model': 'O'}, {'of': 'O'}, {'SS-associated': 'I-Entity'}, {'dry': 'B-Entity'}, {'eye,': 'I-Entity'}, {'induced': 'O'}, {'autoimmune': 'B-Entity'}, {'dacryoadenitis': 'I-Entity'}, {'(IAD).': 'O'}]"
"Pulmonary manifestations (PMs) in primary Sjogrens syndrome (pSS) are among the most frequent extraglandular complications, with reported prevalence varying widely (9-75%), depending on the methods of detection.","[{'Pulmonary': 'O'}, {'manifestations': 'O'}, {'(PMs)': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'are': 'O'}, {'among': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequent': 'O'}, {'extraglandular': 'O'}, {'complications,': 'O'}, {'with': 'O'}, {'reported': 'O'}, {'prevalence': 'O'}, {'varying': 'O'}, {'widely': 'O'}, {'(9-75%),': 'O'}, {'depending': 'O'}, {'on': 'O'}, {'the': 'O'}, {'methods': 'O'}, {'of': 'O'}, {'detection.': 'O'}]"
There is an increased risk of fetal loss in pregnant patients with pSS.,"[{'There': 'O'}, {'is': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'fetal': 'B-Entity'}, {'loss': 'I-Entity'}, {'in': 'O'}, {'pregnant': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
There are no clinical trials evaluating the efficacy of systemic immune suppressive therapy for peripheral or central nervous system involvement.,"[{'There': 'O'}, {'are': 'O'}, {'no': 'O'}, {'clinical': 'O'}, {'trials': 'O'}, {'evaluating': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'immune': 'O'}, {'suppressive': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'peripheral': 'O'}, {'or': 'O'}, {'central': 'O'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'involvement.': 'O'}]"
"A decrease in the extended, fucosylated core 2 disialylated structure on MUC7, residual mucosal wetness, and whole mouth saliva flow rate appeared to have a negative and cumulative effect on the perception of oral dryness.","[{'A': 'O'}, {'decrease': 'O'}, {'in': 'O'}, {'the': 'O'}, {'extended,': 'O'}, {'fucosylated': 'I-Entity'}, {'core': 'O'}, {'2': 'O'}, {'disialylated': 'O'}, {'structure': 'O'}, {'on': 'O'}, {'MUC7,': 'O'}, {'residual': 'O'}, {'mucosal': 'O'}, {'wetness,': 'O'}, {'and': 'O'}, {'whole': 'O'}, {'mouth': 'O'}, {'saliva': 'O'}, {'flow': 'O'}, {'rate': 'O'}, {'appeared': 'O'}, {'to': 'O'}, {'have': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'and': 'O'}, {'cumulative': 'O'}, {'effect': 'O'}, {'on': 'O'}, {'the': 'O'}, {'perception': 'O'}, {'of': 'O'}, {'oral': 'B-Entity'}, {'dryness.': 'I-Entity'}]"
"BLAST analysis identified several mimicry peptides, originating from human oral, intestinal, skin and vaginal bacteria, as well as environmental bacteria.","[{'BLAST': 'O'}, {'analysis': 'O'}, {'identified': 'O'}, {'several': 'O'}, {'mimicry': 'O'}, {'peptides,': 'O'}, {'originating': 'O'}, {'from': 'O'}, {'human': 'O'}, {'oral,': 'O'}, {'intestinal,': 'O'}, {'skin': 'O'}, {'and': 'I-Entity'}, {'vaginal': 'O'}, {'bacteria,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'environmental': 'O'}, {'bacteria.': 'O'}]"
"Patients with SS treated with HCQ had a significantly lower cumulative incidence of new-onset DM than those not treated with HCQ (adjusted hazard ratio: 0.51, 95% confidence interval: 0.28-0.96, P < 0.05).","[{'Patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'treated': 'O'}, {'with': 'O'}, {'HCQ': 'I-Entity'}, {'had': 'O'}, {'a': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'cumulative': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'new-onset': 'O'}, {'DM': 'I-Entity'}, {'than': 'O'}, {'those': 'O'}, {'not': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'HCQ': 'I-Entity'}, {'(adjusted': 'O'}, {'hazard': 'O'}, {'ratio:': 'O'}, {'0.51,': 'O'}, {'95%': 'O'}, {'confidence': 'O'}, {'interval:': 'O'}, {'0.28-0.96,': 'O'}, {'P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
Rituximab infusions without corticosteroid therapy produced meaningful improvements in HRQoL.,"[{'Rituximab': 'I-Entity'}, {'infusions': 'O'}, {'without': 'O'}, {'corticosteroid': 'O'}, {'therapy': 'O'}, {'produced': 'O'}, {'meaningful': 'O'}, {'improvements': 'O'}, {'in': 'O'}, {'HRQoL.': 'O'}]"
Lung auscultation showed decreased breath sounds with bibasilar inspiratory crackles.,"[{'Lung': 'O'}, {'auscultation': 'O'}, {'showed': 'O'}, {'decreased': 'B-Entity'}, {'breath': 'I-Entity'}, {'sounds': 'I-Entity'}, {'with': 'O'}, {'bibasilar': 'O'}, {'inspiratory': 'O'}, {'crackles.': 'I-Entity'}]"
Genetic ablation of P2Y(2) Rs in IL-14‚âà√≠¬¨¬±TG mice significantly reduced B and T lymphocyte infiltration of SMGs.,"[{'Genetic': 'O'}, {'ablation': 'O'}, {'of': 'O'}, {'P2Y(2)': 'O'}, {'Rs': 'O'}, {'in': 'O'}, {'IL-14‚âà√≠¬¨¬±TG': 'O'}, {'mice': 'O'}, {'significantly': 'O'}, {'reduced': 'O'}, {'B': 'O'}, {'and': 'O'}, {'T': 'O'}, {'lymphocyte': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'SMGs.': 'O'}]"
"Our study showed a better efficacy of CLHA compared with HA in maintaining the stability of the tear film in a patient suffering from SSDE.University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy .University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy .University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy .University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy .University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy ., Messina, Italy .University of Perugia , S. Maria della Misericordia Hospital, Perugia, Italy .Association for Ocular Pharmacology and TherapeuticsMay 30.","[{'Our': 'O'}, {'study': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'better': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'CLHA': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'HA': 'I-Entity'}, {'in': 'O'}, {'maintaining': 'O'}, {'the': 'O'}, {'stability': 'O'}, {'of': 'O'}, {'the': 'O'}, {'tear': 'O'}, {'film': 'O'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'SSDE.University': 'I-Entity'}, {'of': 'O'}, {'Perugia': 'O'}, {',': 'O'}, {'S.': 'O'}, {'Maria': 'O'}, {'della': 'O'}, {'Misericordia': 'O'}, {'Hospital,': 'O'}, {'Perugia,': 'O'}, {'Italy': 'O'}, {'.University': 'O'}, {'of': 'O'}, {'Perugia': 'O'}, {',': 'O'}, {'S.': 'O'}, {'Maria': 'O'}, {'della': 'O'}, {'Misericordia': 'O'}]"
mauricio.arcos-burgos@anu.edu.au.peg-interferon-alpha treatment for chronic hepatitis C.,"[{'mauricio.arcos-burgos@anu.edu.au.peg-interferon-alpha': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'chronic': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'C.': 'I-Entity'}]"
The glandular and extraglandular dysfunction of SS is associated with lymphocytic infiltrates that invade the epithelial structures of affected organs.,"[{'The': 'O'}, {'glandular': 'B-Entity'}, {'and': 'I-Entity'}, {'extraglandular': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'that': 'O'}, {'invade': 'O'}, {'the': 'O'}, {'epithelial': 'O'}, {'structures': 'O'}, {'of': 'O'}, {'affected': 'O'}, {'organs.': 'O'}]"
"Symptoms were described as highly unpredictable and variable, with fatigue rated as the most severe and burdensome.","[{'Symptoms': 'O'}, {'were': 'O'}, {'described': 'O'}, {'as': 'O'}, {'highly': 'O'}, {'unpredictable': 'O'}, {'and': 'O'}, {'variable,': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'rated': 'O'}, {'as': 'O'}, {'the': 'O'}, {'most': 'O'}, {'severe': 'O'}, {'and': 'O'}, {'burdensome.': 'O'}]"
"The orbital biopsy revealed ductular destruction, periductular plasma cells, and fibrosis, mimicking Sjogren's syndrome and Castleman's disease.","[{'The': 'O'}, {'orbital': 'O'}, {'biopsy': 'O'}, {'revealed': 'O'}, {'ductular': 'B-Entity'}, {'destruction,': 'I-Entity'}, {'periductular': 'O'}, {'plasma': 'O'}, {'cells,': 'O'}, {'and': 'O'}, {'fibrosis,': 'I-Entity'}, {'mimicking': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {""Castleman's"": 'B-Entity'}, {'disease.': 'I-Entity'}]"
Primary Sjogrens syndrome (pSS) is an autoimmune disease affecting the exocrine glands and internal organs including the central nervous system (CNS).,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'affecting': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'and': 'O'}, {'internal': 'O'}, {'organs': 'O'}, {'including': 'O'}, {'the': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(CNS).': 'O'}]"
"Studying additional antigens, the platelet-selectin and vasoactive intestinal peptides, in patients with pSS can help to elucidate the origin and process of autoimmunity, or even lead to potential biomarkers.","[{'Studying': 'O'}, {'additional': 'O'}, {'antigens,': 'O'}, {'the': 'O'}, {'platelet-selectin': 'O'}, {'and': 'O'}, {'vasoactive': 'O'}, {'intestinal': 'O'}, {'peptides,': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'can': 'O'}, {'help': 'O'}, {'to': 'O'}, {'elucidate': 'O'}, {'the': 'O'}, {'origin': 'O'}, {'and': 'O'}, {'process': 'O'}, {'of': 'O'}, {'autoimmunity,': 'I-Entity'}, {'or': 'O'}, {'even': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'potential': 'O'}, {'biomarkers.': 'O'}]"
Mean Expanded Disability Status Score (EDSS) before rituximab was 4 (3-5.5).,"[{'Mean': 'O'}, {'Expanded': 'O'}, {'Disability': 'O'}, {'Status': 'O'}, {'Score': 'O'}, {'(EDSS)': 'O'}, {'before': 'O'}, {'rituximab': 'I-Entity'}, {'was': 'O'}, {'4': 'O'}, {'(3-5.5).': 'O'}]"
"On the other hand, SjS is characterized by the complication of various lung manifestations, including lung cysts.","[{'On': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand,': 'O'}, {'SjS': 'I-Entity'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'the': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'various': 'O'}, {'lung': 'O'}, {'manifestations,': 'O'}, {'including': 'O'}, {'lung': 'B-Entity'}, {'cysts.': 'I-Entity'}]"
"The aim of this study was to report a case of sterile corneal ulcer leading to perforation, which was treated effectively with autologous serum eye drops, topical regenerative agent (poly-carboxymethylglucose sulfate), steroids, and systemic immunosuppression in a patient with undiagnosed primary Sjogrens syndrome.","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'sterile': 'O'}, {'corneal': 'B-Entity'}, {'ulcer': 'I-Entity'}, {'leading': 'O'}, {'to': 'O'}, {'perforation,': 'I-Entity'}, {'which': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'effectively': 'O'}, {'with': 'O'}, {'autologous': 'O'}, {'serum': 'O'}, {'eye': 'O'}, {'drops,': 'O'}, {'topical': 'O'}, {'regenerative': 'O'}, {'agent': 'O'}, {'(poly-carboxymethylglucose': 'O'}, {'sulfate),': 'I-Entity'}, {'steroids,': 'I-Entity'}]"
Salivary duct obstructions due to sialolithiasis or stenosis can cause salivary gland enlargement.,"[{'Salivary': 'B-Entity'}, {'duct': 'I-Entity'}, {'obstructions': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'sialolithiasis': 'I-Entity'}, {'or': 'O'}, {'stenosis': 'I-Entity'}, {'can': 'O'}, {'cause': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'enlargement.': 'I-Entity'}]"
The systemic form of the disease is characterized by immune complex mediated manifestations and is complicated by lymphoma as a result of a polyclonal B cell hyperactivity that is evolving into B cell malignancy.,"[{'The': 'O'}, {'systemic': 'O'}, {'form': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'is': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'immune': 'O'}, {'complex': 'O'}, {'mediated': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'is': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'lymphoma': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'a': 'O'}, {'polyclonal': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'hyperactivity': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'evolving': 'O'}, {'into': 'O'}, {'B': 'B-Entity'}, {'cell': 'I-Entity'}, {'malignancy.': 'I-Entity'}]"
"Mixed cryoglobulinaemic syndrome is diagnosed when a patient has typical organ involvement (mainly skin, kidney, or peripheral nerve) and circulating cryoglobulins.","[{'Mixed': 'B-Entity'}, {'cryoglobulinaemic': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'diagnosed': 'O'}, {'when': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'has': 'O'}, {'typical': 'O'}, {'organ': 'O'}, {'involvement': 'O'}, {'(mainly': 'O'}, {'skin,': 'O'}, {'kidney,': 'O'}, {'or': 'O'}, {'peripheral': 'O'}, {'nerve)': 'O'}, {'and': 'O'}, {'circulating': 'O'}, {'cryoglobulins.': 'O'}]"
Sjogrens syndrome is an autoimmune disease characterised by exocrinopathy mainly involving the salivary and lacrimal glands.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'exocrinopathy': 'I-Entity'}, {'mainly': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'I-Entity'}, {'lacrimal': 'I-Entity'}, {'glands.': 'O'}]"
"The patient was treated with half-dose glucocorticoid (prednisone, 25 mg oral qd maintained up to 12 months).","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'half-dose': 'O'}, {'glucocorticoid': 'O'}, {'(prednisone,': 'O'}, {'25': 'O'}, {'mg': 'O'}, {'oral': 'O'}, {'qd': 'O'}, {'maintained': 'O'}, {'up': 'O'}, {'to': 'O'}, {'12': 'O'}, {'months).': 'O'}]"
"Recognition of the defining features of each condition will lead to reduced time to diagnosis and improved patient management for these poorly understood conditions.Buffalo, NY, USA.USA.Buffalo, NY, USA; Oral Biology, State University of New York at Buffalo, Buffalo, NY, USA.","[{'Recognition': 'O'}, {'of': 'O'}, {'the': 'O'}, {'defining': 'O'}, {'features': 'O'}, {'of': 'O'}, {'each': 'O'}, {'condition': 'O'}, {'will': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'reduced': 'O'}, {'time': 'O'}, {'to': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'improved': 'O'}, {'patient': 'O'}, {'management': 'O'}, {'for': 'O'}, {'these': 'O'}, {'poorly': 'O'}, {'understood': 'O'}, {'conditions.Buffalo,': 'O'}, {'NY,': 'O'}, {'USA.USA.Buffalo,': 'O'}, {'NY,': 'O'}, {'USA;': 'O'}, {'Oral': 'O'}, {'Biology,': 'O'}, {'State': 'O'}, {'University': 'O'}, {'of': 'O'}, {'New': 'O'}, {'York': 'O'}, {'at': 'O'}, {'Buffalo,': 'O'}, {'Buffalo,': 'O'}, {'NY,': 'O'}, {'USA.': 'O'}]"
One common complication of minor salivary gland biopsy is lip paraesthesia from iatrogenic sensory nerve injury.,"[{'One': 'O'}, {'common': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'is': 'O'}, {'lip': 'O'}, {'paraesthesia': 'I-Entity'}, {'from': 'O'}, {'iatrogenic': 'O'}, {'sensory': 'B-Entity'}, {'nerve': 'I-Entity'}, {'injury.': 'I-Entity'}]"
Nearly 7% of the general population have chronic neuropathic pain responsible for severe quality-of-life impairments.,"[{'Nearly': 'O'}, {'7%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'general': 'O'}, {'population': 'O'}, {'have': 'O'}, {'chronic': 'B-Entity'}, {'neuropathic': 'I-Entity'}, {'pain': 'I-Entity'}, {'responsible': 'O'}, {'for': 'O'}, {'severe': 'O'}, {'quality-of-life': 'O'}, {'impairments.': 'O'}]"
"Juvenile systemic lupus erythematosus with or without associated antiphospholipid syndrome; juvenile dermatomyositis; sclerodermiform syndromes, including systemic and localized sclerodermas and eosinophilic fasciitis; mixed connective tissue disease; and Sjogren syndrome are the disorders that affect children most frequently.","[{'Juvenile': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'associated': 'O'}, {'antiphospholipid': 'B-Entity'}, {'syndrome;': 'I-Entity'}, {'juvenile': 'B-Entity'}, {'dermatomyositis;': 'I-Entity'}, {'sclerodermiform': 'B-Entity'}, {'syndromes,': 'I-Entity'}, {'including': 'O'}, {'systemic': 'O'}, {'and': 'O'}, {'localized': 'O'}, {'sclerodermas': 'I-Entity'}, {'and': 'O'}, {'eosinophilic': 'B-Entity'}, {'fasciitis;': 'I-Entity'}, {'mixed': 'O'}, {'connective': 'I-Entity'}]"
FLC levels can be used as a biomarker for systemic disease activity and monitoring treatment responses.,"[{'FLC': 'O'}, {'levels': 'O'}, {'can': 'O'}, {'be': 'O'}, {'used': 'O'}, {'as': 'O'}, {'a': 'O'}, {'biomarker': 'O'}, {'for': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'monitoring': 'O'}, {'treatment': 'O'}, {'responses.': 'O'}]"
"He was diagnosed with autoimmune hepatitis, polymyositis and Sjogrens syndrome and received combined antiretroviral therapy (cART); however, the laboratory abnormalities persisted.","[{'He': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'hepatitis,': 'I-Entity'}, {'polymyositis': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'received': 'O'}, {'combined': 'O'}, {'antiretroviral': 'O'}, {'therapy': 'O'}, {'(cART);': 'O'}, {'however,': 'O'}, {'the': 'O'}, {'laboratory': 'O'}, {'abnormalities': 'O'}, {'persisted.': 'O'}]"
"To investigate by laser scanning confocal microscopy (LSCM) the density of presumed epithelial, presumed goblet, and presumed inflammatory cells in the tarsal conjunctiva of healthy young and older subjects and in patients with Sjogrens syndrome (SS).","[{'To': 'O'}, {'investigate': 'O'}, {'by': 'O'}, {'laser': 'O'}, {'scanning': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'(LSCM)': 'O'}, {'the': 'O'}, {'density': 'O'}, {'of': 'O'}, {'presumed': 'O'}, {'epithelial,': 'O'}, {'presumed': 'O'}, {'goblet,': 'O'}, {'and': 'O'}, {'presumed': 'O'}, {'inflammatory': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'tarsal': 'O'}, {'conjunctiva': 'O'}, {'of': 'O'}, {'healthy': 'O'}, {'young': 'O'}, {'and': 'O'}, {'older': 'O'}, {'subjects': 'O'}, {'and': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
The morphometric analysis of confocal images demonstrated at month 1 an improvement of nerve tortuosity in group 2; after 3 months both groups showed a significant improvement versus baseline.,"[{'The': 'O'}, {'morphometric': 'O'}, {'analysis': 'O'}, {'of': 'O'}, {'confocal': 'O'}, {'images': 'O'}, {'demonstrated': 'O'}, {'at': 'O'}, {'month': 'O'}, {'1': 'O'}, {'an': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'nerve': 'O'}, {'tortuosity': 'I-Entity'}, {'in': 'O'}, {'group': 'O'}, {'2;': 'O'}, {'after': 'O'}, {'3': 'O'}, {'months': 'O'}, {'both': 'O'}, {'groups': 'O'}, {'showed': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'versus': 'O'}, {'baseline.': 'O'}]"
Potential precursors of pathological infiltrates form in the lacrimal glands by the time of sexual maturity.,"[{'Potential': 'O'}, {'precursors': 'O'}, {'of': 'O'}, {'pathological': 'O'}, {'infiltrates': 'O'}, {'form': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'glands': 'O'}, {'by': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'sexual': 'O'}, {'maturity.': 'O'}]"
"The presence of multi-system involvement, evidence of inflammation and lack of any obvious cause should alert a clinician to the possibility of CTD.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'multi-system': 'O'}, {'involvement,': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'any': 'O'}, {'obvious': 'O'}, {'cause': 'O'}, {'should': 'O'}, {'alert': 'O'}, {'a': 'O'}, {'clinician': 'O'}, {'to': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'CTD.': 'I-Entity'}]"
Keratoconjunctivitis sicca represents a progressive deterioration of ocular surface produced by a deficient secretion of lachrymal film (quantitative disorder) or excessive tear evaporation (qualitative disorder).,"[{'Keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'represents': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'deterioration': 'B-Entity'}, {'of': 'O'}, {'ocular': 'I-Entity'}, {'surface': 'I-Entity'}, {'produced': 'O'}, {'by': 'O'}, {'a': 'O'}, {'deficient': 'O'}, {'secretion': 'O'}, {'of': 'O'}, {'lachrymal': 'O'}, {'film': 'O'}, {'(quantitative': 'O'}, {'disorder)': 'O'}, {'or': 'O'}, {'excessive': 'O'}, {'tear': 'O'}, {'evaporation': 'O'}, {'(qualitative': 'O'}, {'disorder).': 'O'}]"
"Physical examination showed malar rash, V-sign, periungual erythema, and mechanic hands.","[{'Physical': 'O'}, {'examination': 'O'}, {'showed': 'O'}, {'malar': 'B-Entity'}, {'rash,': 'I-Entity'}, {'V-sign,': 'O'}, {'periungual': 'B-Entity'}, {'erythema,': 'I-Entity'}, {'and': 'O'}, {'mechanic': 'B-Entity'}, {'hands.': 'I-Entity'}]"
"Many participants perceived a poor understanding of pSS amongst physicians, leading to emotional distress and difficulties obtaining a diagnosis.","[{'Many': 'O'}, {'participants': 'O'}, {'perceived': 'O'}, {'a': 'O'}, {'poor': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'amongst': 'O'}, {'physicians,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'emotional': 'O'}, {'distress': 'I-Entity'}, {'and': 'O'}, {'difficulties': 'O'}, {'obtaining': 'O'}, {'a': 'O'}, {'diagnosis.': 'O'}]"
The aim of this study was to evaluate the relationship between arterial stiffness and pSS.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'arterial': 'O'}, {'stiffness': 'O'}, {'and': 'O'}, {'pSS.': 'O'}]"
This is an independent study of the subjective use and efficacy of topical treatments used by members of the British Sjogrens Syndrome Association (BSSA) related to product viscosity.,"[{'This': 'O'}, {'is': 'O'}, {'an': 'O'}, {'independent': 'O'}, {'study': 'O'}, {'of': 'O'}, {'the': 'O'}, {'subjective': 'O'}, {'use': 'O'}, {'and': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'topical': 'O'}, {'treatments': 'O'}, {'used': 'O'}, {'by': 'O'}, {'members': 'O'}, {'of': 'O'}, {'the': 'O'}, {'British': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Association': 'O'}, {'(BSSA)': 'O'}, {'related': 'O'}, {'to': 'O'}, {'product': 'O'}, {'viscosity.': 'O'}]"
"For Permissions, please email: journals.permissions@oup.com.2015 May 3.during monoclonal antibody therapy of Crohn's disease].","[{'For': 'O'}, {'Permissions,': 'O'}, {'please': 'O'}, {'email:': 'O'}, {'journals.permissions@oup.com.2015': 'O'}, {'May': 'O'}, {'3.during': 'O'}, {'monoclonal': 'O'}, {'antibody': 'O'}, {'therapy': 'O'}, {'of': 'O'}, {""Crohn's"": 'B-Entity'}, {'disease].': 'I-Entity'}]"
"Other causes of HBI were as follows: secondary liver diseases (n = 11, 0.7%), SSc-related HBI (n = 7, 0.4%), nodular regenerative hyperplasia (n = 3, 0.2%), liver cirrhosis (n = 3, 0.2%), and HBI of unknown origin (n = 2, 0.1%).","[{'Other': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'HBI': 'I-Entity'}, {'were': 'O'}, {'as': 'O'}, {'follows:': 'O'}, {'secondary': 'O'}, {'liver': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'11,': 'O'}, {'0.7%),': 'O'}, {'SSc-related': 'I-Entity'}, {'HBI': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'7,': 'O'}, {'0.4%),': 'O'}, {'nodular': 'B-Entity'}, {'regenerative': 'I-Entity'}, {'hyperplasia': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'3,': 'O'}, {'0.2%),': 'O'}, {'liver': 'B-Entity'}, {'cirrhosis': 'I-Entity'}]"
"For 15 patients undergoing ultrasound examination only, 11 (73%) had SS findings, but all 15 had SS findings on MRSIAL.","[{'For': 'O'}, {'15': 'O'}, {'patients': 'O'}, {'undergoing': 'O'}, {'ultrasound': 'O'}, {'examination': 'O'}, {'only,': 'O'}, {'11': 'O'}, {'(73%)': 'O'}, {'had': 'O'}, {'SS': 'I-Entity'}, {'findings,': 'O'}, {'but': 'O'}, {'all': 'O'}, {'15': 'O'}, {'had': 'O'}, {'SS': 'I-Entity'}, {'findings': 'O'}, {'on': 'O'}, {'MRSIAL.': 'O'}]"
"Frequently involved domains at diagnosis were the biological (96%) followed by the constitutional (68%), glandular (44%), articular (44%), cutaneous domains (28%), renal (16%), and central nervous system (12%).","[{'Frequently': 'O'}, {'involved': 'O'}, {'domains': 'O'}, {'at': 'O'}, {'diagnosis': 'O'}, {'were': 'O'}, {'the': 'O'}, {'biological': 'O'}, {'(96%)': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'constitutional': 'O'}, {'(68%),': 'O'}, {'glandular': 'O'}, {'(44%),': 'O'}, {'articular': 'O'}, {'(44%),': 'O'}, {'cutaneous': 'O'}, {'domains': 'O'}, {'(28%),': 'O'}, {'renal': 'O'}, {'(16%),': 'O'}, {'and': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'(12%).': 'O'}]"
"There were also statistically significant differences of positive anti-Smith antibodies in renal damage, arthritis, photosensitization, oral ulcers, hematological abnormalities and serositis (p<0.05) and of positive anti-Rib antibodies in renal damage, arthritis, photosensitization, malar rash, hematological abnormalities and serositis (p<0.05).","[{'There': 'O'}, {'were': 'O'}, {'also': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-Smith': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'damage,': 'I-Entity'}, {'arthritis,': 'I-Entity'}, {'photosensitization,': 'I-Entity'}, {'oral': 'B-Entity'}, {'ulcers,': 'I-Entity'}, {'hematological': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'and': 'O'}, {'serositis': 'I-Entity'}, {'(p<0.05)': 'O'}, {'and': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-Rib': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'damage,': 'I-Entity'}, {'arthritis,': 'I-Entity'}]"
"Additionally, some of the studies identified splenomegaly, low C3 serum levels, lymphopenia and neutropenia as significant prognostic factors.","[{'Additionally,': 'O'}, {'some': 'O'}, {'of': 'O'}, {'the': 'O'}, {'studies': 'O'}, {'identified': 'O'}, {'splenomegaly,': 'I-Entity'}, {'low': 'O'}, {'C3': 'O'}, {'serum': 'O'}, {'levels,': 'O'}, {'lymphopenia': 'I-Entity'}, {'and': 'O'}, {'neutropenia': 'I-Entity'}, {'as': 'O'}, {'significant': 'O'}, {'prognostic': 'O'}, {'factors.': 'O'}]"
"This review provides details on the main epidemiological features regarding NHL incidence in AD, the pathogenetic factors that favour lymphoma onset and some recent advances in therapeutic approaches that are effective in both autoimmune and malignant lymphoproliferative disorders.corrado.tarella@unito.itDec 4.susceptibility to rheumatoid arthritis.","[{'This': 'O'}, {'review': 'O'}, {'provides': 'O'}, {'details': 'O'}, {'on': 'O'}, {'the': 'O'}, {'main': 'O'}, {'epidemiological': 'O'}, {'features': 'O'}, {'regarding': 'O'}, {'NHL': 'I-Entity'}, {'incidence': 'O'}, {'in': 'O'}, {'AD,': 'I-Entity'}, {'the': 'O'}, {'pathogenetic': 'O'}, {'factors': 'O'}, {'that': 'O'}, {'favour': 'O'}, {'lymphoma': 'I-Entity'}, {'onset': 'O'}, {'and': 'O'}, {'some': 'O'}, {'recent': 'O'}, {'advances': 'O'}, {'in': 'O'}, {'therapeutic': 'O'}, {'approaches': 'O'}, {'that': 'O'}, {'are': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'both': 'O'}, {'autoimmune': 'B-Entity'}, {'and': 'I-Entity'}, {'malignant': 'I-Entity'}, {'lymphoproliferative': 'I-Entity'}, {'disorders.corrado.tarella@unito.itDec': 'I-Entity'}]"
"To the best of our knowledge, this is the first report of fluocinolone acetonide intravitreal therapy in a patient with corneal disease.","[{'To': 'O'}, {'the': 'O'}, {'best': 'O'}, {'of': 'O'}, {'our': 'O'}, {'knowledge,': 'O'}, {'this': 'O'}, {'is': 'O'}, {'the': 'O'}, {'first': 'O'}, {'report': 'O'}, {'of': 'O'}, {'fluocinolone': 'B-Entity'}, {'acetonide': 'I-Entity'}, {'intravitreal': 'O'}, {'therapy': 'O'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'corneal': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Other features - Arthralgias (91%), arthritis (42%), mucositis (38%), Neuropathy (30%), skin rash (20%) cytopenias (19%), Erosive arthritis (10%), interstitial lung disease (10%) and Raynaud Phenomenon (10%).","[{'Other': 'O'}, {'features': 'O'}, {'-': 'O'}, {'Arthralgias': 'I-Entity'}, {'(91%),': 'O'}, {'arthritis': 'I-Entity'}, {'(42%),': 'O'}, {'mucositis': 'I-Entity'}, {'(38%),': 'O'}, {'Neuropathy': 'I-Entity'}, {'(30%),': 'O'}, {'skin': 'B-Entity'}, {'rash': 'I-Entity'}, {'(20%)': 'O'}, {'cytopenias': 'I-Entity'}, {'(19%),': 'O'}, {'Erosive': 'B-Entity'}, {'arthritis': 'I-Entity'}]"
"Primary Sjogrens syndrome (PSS) is a systemic autoimmune disorder characterized by chronic inflammation of exocrine glands such as the lachrymal and salivary glands, leading to xerophthalmia and xerostomia.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'lachrymal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'xerophthalmia': 'I-Entity'}, {'and': 'O'}, {'xerostomia.': 'I-Entity'}]"
The inter-observer agreement was satisfactory when the samples were stratified as consistent and non-consistent with the final diagnosis of pSS (median ‚âà√≠‚Äö√†¬¥ =0.75; mean ‚âà√≠‚Äö√†¬¥ =0.70).,"[{'The': 'O'}, {'inter-observer': 'O'}, {'agreement': 'O'}, {'was': 'O'}, {'satisfactory': 'O'}, {'when': 'O'}, {'the': 'O'}, {'samples': 'O'}, {'were': 'O'}, {'stratified': 'O'}, {'as': 'O'}, {'consistent': 'O'}, {'and': 'O'}, {'non-consistent': 'O'}, {'with': 'O'}, {'the': 'O'}, {'final': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'(median': 'O'}, {'‚âà√≠‚Äö√†¬¥': 'O'}, {'=0.75;': 'O'}, {'mean': 'O'}, {'‚âà√≠‚Äö√†¬¥': 'O'}, {'=0.70).': 'O'}]"
Sjogren's syndrome(SS) is defined as a slowly processing autoimmune inflammatory exocrinopathy affecting the salivary and lachrymal glands.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome(SS)': 'I-Entity'}, {'is': 'O'}, {'defined': 'O'}, {'as': 'O'}, {'a': 'O'}, {'slowly': 'O'}, {'processing': 'O'}, {'autoimmune': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'exocrinopathy': 'I-Entity'}, {'affecting': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lachrymal': 'O'}, {'glands.': 'O'}]"
"Biopsy is a necessary examination to decrease or avoid misdiagnosis.China.China.Beijing 100044, China.","[{'Biopsy': 'O'}, {'is': 'O'}, {'a': 'O'}, {'necessary': 'O'}, {'examination': 'O'}, {'to': 'O'}, {'decrease': 'O'}, {'or': 'O'}, {'avoid': 'O'}, {'misdiagnosis.China.China.Beijing': 'O'}, {'100044,': 'I-Entity'}, {'China.': 'O'}]"
"Elevated levels of ‚âà√≠‚Äö√¢‚Ä¢-globulins contain autoantibodies directed against nonspecific antigens such as rheumatoid factor, antinuclear antibodies, and cellular antigens SS-A/Ro and SS-B/La.","[{'Elevated': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'‚âà√≠‚Äö√¢‚Ä¢-globulins': 'O'}, {'contain': 'O'}, {'autoantibodies': 'O'}, {'directed': 'O'}, {'against': 'O'}, {'nonspecific': 'O'}, {'antigens': 'O'}, {'such': 'O'}, {'as': 'O'}, {'rheumatoid': 'O'}, {'factor,': 'O'}, {'antinuclear': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'cellular': 'O'}, {'antigens': 'O'}, {'SS-A/Ro': 'O'}, {'and': 'O'}]"
Her symptoms responded well to intravenous methylprednisolone.,"[{'Her': 'O'}, {'symptoms': 'O'}, {'responded': 'O'}, {'well': 'O'}, {'to': 'O'}, {'intravenous': 'O'}, {'methylprednisolone.': 'I-Entity'}]"
Treatment by subcutaneous tocilizumab (TCZ) 162‚Äö√Ñ√∂‚àö√ë‚àö¬ßmg every two weeks was introduced.,"[{'Treatment': 'O'}, {'by': 'O'}, {'subcutaneous': 'O'}, {'tocilizumab': 'I-Entity'}, {'(TCZ)': 'O'}, {'162‚Äö√Ñ√∂‚àö√ë‚àö¬ßmg': 'O'}, {'every': 'O'}, {'two': 'O'}, {'weeks': 'O'}, {'was': 'O'}, {'introduced.': 'O'}]"
"Our data suggest a possible pathogenic/prognostic significance of ASCA in pSS.School of Medicine, University of L'Aquila; and Department of Medicine, ASL1 Avezzano-Sulmona-L'Aquila, Italy.School of Medicine, University of L'Aquila, Italy.roberto.gerli@unipg.it.","[{'Our': 'O'}, {'data': 'O'}, {'suggest': 'O'}, {'a': 'O'}, {'possible': 'O'}, {'pathogenic/prognostic': 'O'}, {'significance': 'O'}, {'of': 'O'}, {'ASCA': 'O'}, {'in': 'O'}, {'pSS.School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'University': 'O'}, {'of': 'O'}, {""L'Aquila;"": 'O'}, {'and': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'ASL1': 'O'}, {""Avezzano-Sulmona-L'Aquila,"": 'O'}, {'Italy.School': 'O'}, {'of': 'O'}, {'Medicine,': 'O'}, {'University': 'O'}, {'of': 'O'}, {""L'Aquila,"": 'O'}]"
"Demographics, clinical/laboratory features, classical risk factors for atherosclerosis and osteoporosis (OP) were recorded.","[{'Demographics,': 'O'}, {'clinical/laboratory': 'O'}, {'features,': 'O'}, {'classical': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'atherosclerosis': 'I-Entity'}, {'and': 'O'}, {'osteoporosis': 'I-Entity'}, {'(OP)': 'O'}, {'were': 'O'}, {'recorded.': 'O'}]"
"Diagnosis was rheumatoid arthritis (RA) in 71/81, psoriatic arthritis in 5, juvenile idiopathic arthritis (JIA) in 2, Sjogren syndrome in 1, undifferentiated polyarthritis in 1, and spondyloarthritis in 1.","[{'Diagnosis': 'O'}, {'was': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'in': 'O'}, {'71/81,': 'O'}, {'psoriatic': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'in': 'O'}, {'5,': 'O'}, {'juvenile': 'B-Entity'}, {'idiopathic': 'I-Entity'}, {'arthritis': 'I-Entity'}, {'(JIA)': 'O'}, {'in': 'O'}, {'2,': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'1,': 'O'}, {'undifferentiated': 'O'}, {'polyarthritis': 'I-Entity'}, {'in': 'O'}, {'1,': 'O'}]"
"Novel treatment strategies are available for NMO, but other causes need to be excluded in NMO-IgG-seronegative patients.USA.inflammatory responses in mice.","[{'Novel': 'O'}, {'treatment': 'O'}, {'strategies': 'O'}, {'are': 'O'}, {'available': 'O'}, {'for': 'O'}, {'NMO,': 'I-Entity'}, {'but': 'O'}, {'other': 'O'}, {'causes': 'O'}, {'need': 'O'}, {'to': 'O'}, {'be': 'O'}, {'excluded': 'O'}, {'in': 'O'}, {'NMO-IgG-seronegative': 'I-Entity'}, {'patients.USA.inflammatory': 'O'}, {'responses': 'O'}, {'in': 'O'}, {'mice.': 'O'}]"
"Finally, we will conclude with an update of the clinical manifestations of the disease and with an overview of the future therapies.University of Athens, Greece.Pisa, Italy.Pisa, Italy.with Sjogren's syndrome: a case report.","[{'Finally,': 'O'}, {'we': 'O'}, {'will': 'O'}, {'conclude': 'O'}, {'with': 'O'}, {'an': 'O'}, {'update': 'O'}, {'of': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'and': 'O'}, {'with': 'O'}, {'an': 'O'}, {'overview': 'O'}, {'of': 'O'}, {'the': 'O'}, {'future': 'O'}, {'therapies.University': 'O'}, {'of': 'O'}, {'Athens,': 'O'}, {'Greece.Pisa,': 'O'}, {'Italy.Pisa,': 'O'}, {'Italy.with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome:': 'I-Entity'}, {'a': 'O'}, {'case': 'O'}, {'report.': 'O'}]"
"In this particular case report, we must underline the clinical presentation of a sicca syndrome as a manifestation of the HIV infection, bearing in mind that, frequently, the differential diagnosis from other diseases, namely the Sjogrens syndrome, is a real challenge.with recurrent abdominal distension.","[{'In': 'O'}, {'this': 'O'}, {'particular': 'O'}, {'case': 'O'}, {'report,': 'O'}, {'we': 'O'}, {'must': 'O'}, {'underline': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'a': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'HIV': 'B-Entity'}, {'infection,': 'I-Entity'}, {'bearing': 'O'}, {'in': 'O'}, {'mind': 'O'}, {'that,': 'O'}, {'frequently,': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'from': 'O'}, {'other': 'O'}, {'diseases,': 'O'}, {'namely': 'O'}, {'the': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'real': 'O'}, {'challenge.with': 'O'}, {'recurrent': 'O'}, {'abdominal': 'B-Entity'}, {'distension.': 'I-Entity'}]"
The presence of ectopic GC-like structures in MSG biopsy tissue is associated with the risk of lymphoma in patients with primary SS.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'ectopic': 'O'}, {'GC-like': 'O'}, {'structures': 'O'}, {'in': 'O'}, {'MSG': 'O'}, {'biopsy': 'O'}, {'tissue': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'O'}, {'SS.': 'I-Entity'}]"
"Our findings indicate that ARFI imaging may provide a non-invasive, simple¬¨¬®‚Äö√Ñ‚Ä†and fast means of assessment of glandular impairment as an alternative test when other salivary gland tests are inconclusive or¬¨¬®‚Äö√Ñ‚Ä†cannot be performed.","[{'Our': 'O'}, {'findings': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'ARFI': 'O'}, {'imaging': 'O'}, {'may': 'O'}, {'provide': 'O'}, {'a': 'O'}, {'non-invasive,': 'O'}, {'simple¬¨¬®‚Äö√Ñ‚Ä†and': 'O'}, {'fast': 'O'}, {'means': 'O'}, {'of': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'glandular': 'B-Entity'}, {'impairment': 'I-Entity'}, {'as': 'O'}, {'an': 'O'}, {'alternative': 'O'}, {'test': 'O'}, {'when': 'O'}, {'other': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'tests': 'O'}, {'are': 'O'}, {'inconclusive': 'O'}, {'or¬¨¬®‚Äö√Ñ‚Ä†cannot': 'O'}]"
Order ANA assays only when clinical features suggest a connective tissue disorder.,"[{'Order': 'O'}, {'ANA': 'O'}, {'assays': 'O'}, {'only': 'O'}, {'when': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'suggest': 'O'}, {'a': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disorder.': 'I-Entity'}]"
"Focus scores as well as dry mouth may reflect lymphoproliferative activity in the lungs in patients with primary Sjogrens syndrome.University Graduate School of Biomedical Sciences, Nagasaki, Japan.","[{'Focus': 'O'}, {'scores': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'may': 'O'}, {'reflect': 'O'}, {'lymphoproliferative': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'the': 'O'}, {'lungs': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.University': 'I-Entity'}, {'Graduate': 'O'}, {'School': 'O'}, {'of': 'O'}, {'Biomedical': 'O'}, {'Sciences,': 'O'}, {'Nagasaki,': 'O'}, {'Japan.': 'O'}]"
A diagnosis of type 1 RTA likely secondary to Sjogrens Syndrome was made.,"[{'A': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'type': 'O'}, {'1': 'O'}, {'RTA': 'I-Entity'}, {'likely': 'O'}, {'secondary': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'was': 'O'}, {'made.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a chronic autoimmune systemic disease, characterized by a lymphoplasmocytic infiltration and a progressive destruction of salivary and lachrymal glands, leading to ocular and mouth dryness.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'I-Entity'}, {'disease,': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'lymphoplasmocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lachrymal': 'O'}, {'glands,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
"In this cohort of the pSS patients, female is predominant and the incidence of extro-glandular manifestations, such as leukopenia, lung and liver involvements is high, and pSS has inheritance intention.Beijing 100044, China.","[{'In': 'O'}, {'this': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'female': 'O'}, {'is': 'O'}, {'predominant': 'O'}, {'and': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'extro-glandular': 'O'}, {'manifestations,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'leukopenia,': 'I-Entity'}, {'lung': 'B-Entity'}, {'and': 'I-Entity'}, {'liver': 'I-Entity'}, {'involvements': 'I-Entity'}, {'is': 'O'}, {'high,': 'O'}, {'and': 'O'}, {'pSS': 'I-Entity'}, {'has': 'O'}, {'inheritance': 'O'}, {'intention.Beijing': 'O'}, {'100044,': 'O'}, {'China.': 'O'}]"
Diffuse infiltrative lymphocytic syndrome is a clinical identity that can be part of the spectrum of Human Immunodeficiency Virus infection.,"[{'Diffuse': 'O'}, {'infiltrative': 'B-Entity'}, {'lymphocytic': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'identity': 'O'}, {'that': 'O'}, {'can': 'O'}, {'be': 'O'}, {'part': 'O'}, {'of': 'O'}, {'the': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'Human': 'B-Entity'}, {'Immunodeficiency': 'I-Entity'}, {'Virus': 'I-Entity'}, {'infection.': 'I-Entity'}]"
"InflammaDry showed sensitivity of 85% (in 121 of 143 patients), specificity of 94% (59 of 63), negative predictive value of 73% (59 of 81), and positive predictive value of 97% (121 of 125).","[{'InflammaDry': 'O'}, {'showed': 'O'}, {'sensitivity': 'O'}, {'of': 'O'}, {'85%': 'O'}, {'(in': 'O'}, {'121': 'O'}, {'of': 'O'}, {'143': 'O'}, {'patients),': 'O'}, {'specificity': 'O'}, {'of': 'O'}, {'94%': 'O'}, {'(59': 'O'}, {'of': 'O'}, {'63),': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'73%': 'O'}, {'(59': 'O'}, {'of': 'O'}, {'81),': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'97%': 'O'}, {'(121': 'O'}, {'of': 'O'}, {'125).': 'O'}]"
The diagnosis was suspected on the basis of the presence of a facial rash.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'suspected': 'O'}, {'on': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'facial': 'B-Entity'}, {'rash.': 'I-Entity'}]"
"ANA were detected in all cases, anti-Ro antibodies - 60%, a positive rheumatoid factor - 56.7% of patients.","[{'ANA': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'all': 'O'}, {'cases,': 'O'}, {'anti-Ro': 'O'}, {'antibodies': 'O'}, {'-': 'O'}, {'60%,': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'-': 'O'}, {'56.7%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
Genetic predisposition to increased type I IFN signaling is supported by candidate gene studies showing evidence for association of variants within IFN-related genes.,"[{'Genetic': 'O'}, {'predisposition': 'O'}, {'to': 'O'}, {'increased': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'I-Entity'}, {'signaling': 'O'}, {'is': 'O'}, {'supported': 'O'}, {'by': 'O'}, {'candidate': 'O'}, {'gene': 'O'}, {'studies': 'O'}, {'showing': 'O'}, {'evidence': 'O'}, {'for': 'O'}, {'association': 'O'}, {'of': 'O'}, {'variants': 'O'}, {'within': 'O'}, {'IFN-related': 'O'}, {'genes.': 'O'}]"
"CNS manifestations associated with primary Sjogren syndrome include focal central lesions, conditions that mimic multiple sclerosis, encephalitis, aseptic meningitis, cerebellar syndromes, movement disorders, and problems with memory, cognition, and depression.","[{'CNS': 'O'}, {'manifestations': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'include': 'O'}, {'focal': 'O'}, {'central': 'O'}, {'lesions,': 'O'}, {'conditions': 'O'}, {'that': 'O'}, {'mimic': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'encephalitis,': 'I-Entity'}, {'aseptic': 'B-Entity'}, {'meningitis,': 'I-Entity'}, {'cerebellar': 'B-Entity'}, {'syndromes,': 'I-Entity'}, {'movement': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'and': 'O'}, {'problems': 'B-Entity'}, {'with': 'I-Entity'}, {'memory,': 'I-Entity'}, {'cognition,': 'I-Entity'}, {'and': 'O'}, {'depression.': 'I-Entity'}]"
"Dementia risk was analyzed using a Cox proportional hazards regression model stratified by sex, age, and comorbidities.","[{'Dementia': 'I-Entity'}, {'risk': 'O'}, {'was': 'O'}, {'analyzed': 'O'}, {'using': 'O'}, {'a': 'O'}, {'Cox': 'O'}, {'proportional': 'O'}, {'hazards': 'O'}, {'regression': 'O'}, {'model': 'O'}, {'stratified': 'O'}, {'by': 'O'}, {'sex,': 'O'}, {'age,': 'O'}, {'and': 'O'}, {'comorbidities.': 'O'}]"
"The innate immune system has been demonstrated to have an important role at the early stage of the disease, notably through activation of the type I interferon (IFN) system.","[{'The': 'O'}, {'innate': 'O'}, {'immune': 'O'}, {'system': 'O'}, {'has': 'O'}, {'been': 'O'}, {'demonstrated': 'O'}, {'to': 'O'}, {'have': 'O'}, {'an': 'O'}, {'important': 'O'}, {'role': 'O'}, {'at': 'O'}, {'the': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease,': 'O'}, {'notably': 'O'}, {'through': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'type': 'O'}, {'I': 'O'}, {'interferon': 'O'}, {'(IFN)': 'O'}, {'system.': 'O'}]"
"Solid cancers, such as lymphomas, increase serum calcium primarily through parathyroid hormone-related protein or ectopic production of 1alpha-hydroxylase.","[{'Solid': 'O'}, {'cancers,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'lymphomas,': 'I-Entity'}, {'increase': 'O'}, {'serum': 'O'}, {'calcium': 'I-Entity'}, {'primarily': 'O'}, {'through': 'O'}, {'parathyroid': 'O'}, {'hormone-related': 'O'}, {'protein': 'O'}, {'or': 'O'}, {'ectopic': 'O'}, {'production': 'O'}, {'of': 'O'}, {'1alpha-hydroxylase.': 'O'}]"
"In addition to these oral manifestations, this review will discuss the systemic manifestations of Sjogrens syndrome as well as the current understanding of factors that have a role in its aetiology and pathogenesis.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'these': 'O'}, {'oral': 'O'}, {'manifestations,': 'O'}, {'this': 'O'}, {'review': 'O'}, {'will': 'O'}, {'discuss': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'the': 'O'}, {'current': 'O'}, {'understanding': 'O'}, {'of': 'O'}, {'factors': 'O'}, {'that': 'O'}, {'have': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'its': 'O'}, {'aetiology': 'O'}, {'and': 'O'}, {'pathogenesis.': 'O'}]"
"After six year, massive proteinuria and serological findings developed and systemic lupus erythematosus nephritis was diagnosed by kidney biopsy.","[{'After': 'O'}, {'six': 'O'}, {'year,': 'O'}, {'massive': 'O'}, {'proteinuria': 'I-Entity'}, {'and': 'O'}, {'serological': 'O'}, {'findings': 'O'}, {'developed': 'O'}, {'and': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'nephritis': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'by': 'O'}, {'kidney': 'O'}, {'biopsy.': 'O'}]"
"These conditions were associated with significant negative effects on the outcome of pregnancy.Matteo Foundation, Pavia, Italy.2012 Jan 30.","[{'These': 'O'}, {'conditions': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'significant': 'O'}, {'negative': 'O'}, {'effects': 'O'}, {'on': 'O'}, {'the': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'pregnancy.Matteo': 'O'}, {'Foundation,': 'O'}, {'Pavia,': 'O'}, {'Italy.2012': 'O'}, {'Jan': 'O'}, {'30.': 'O'}]"
Testing for antinuclear antibodies is useful for the diagnosis of systemic rheumatic diseases.,"[{'Testing': 'O'}, {'for': 'O'}, {'antinuclear': 'O'}, {'antibodies': 'O'}, {'is': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"The homogeneous collection of clinical data, disease activity, patient-related outcome, and biological samples, including DNA, RNA and serum, is definitively mandatory to determine new biological prognostic factors and identify disease activity markers.","[{'The': 'O'}, {'homogeneous': 'O'}, {'collection': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'data,': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'patient-related': 'O'}, {'outcome,': 'O'}, {'and': 'O'}, {'biological': 'O'}, {'samples,': 'O'}, {'including': 'O'}, {'DNA,': 'O'}, {'RNA': 'O'}, {'and': 'O'}, {'serum,': 'O'}, {'is': 'O'}, {'definitively': 'O'}, {'mandatory': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'new': 'O'}, {'biological': 'O'}, {'prognostic': 'O'}, {'factors': 'O'}, {'and': 'O'}, {'identify': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'markers.': 'O'}]"
"After multiple biological, immunological, histological, neurological, psychiatric, ophthalmological, digestive investigations, it was reached the conclusion that the patient presents a rare autoimmune disease (primary Sjogrens syndrome) involving mainly peripheral neuromuscular and psychological (small frequency) and the patient was given specific immunomodulatory, anti-inflammatory and anti-depressive treatment, to which he responded well.","[{'After': 'O'}, {'multiple': 'O'}, {'biological,': 'O'}, {'immunological,': 'O'}, {'histological,': 'O'}, {'neurological,': 'O'}, {'psychiatric,': 'O'}, {'ophthalmological,': 'O'}, {'digestive': 'O'}, {'investigations,': 'O'}, {'it': 'O'}, {'was': 'O'}, {'reached': 'O'}, {'the': 'O'}, {'conclusion': 'O'}, {'that': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'presents': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'(primary': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome)': 'I-Entity'}, {'involving': 'O'}, {'mainly': 'O'}, {'peripheral': 'B-Entity'}, {'neuromuscular': 'I-Entity'}, {'and': 'I-Entity'}, {'psychological': 'I-Entity'}, {'(small': 'I-Entity'}]"
Twenty-three SS patients (14 primary SS and 9 secondary SS) and 14 controls were followed up for three years.,"[{'Twenty-three': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'(14': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'9': 'O'}, {'secondary': 'O'}, {'SS)': 'I-Entity'}, {'and': 'O'}, {'14': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'followed': 'O'}, {'up': 'O'}, {'for': 'O'}, {'three': 'O'}, {'years.': 'O'}]"
"Significant elevation of synovial fluid CTGF concentration was found in RA patients, demonstrating excellent diagnostic ability to predict RA (area under the curve (AUC)‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.97).","[{'Significant': 'O'}, {'elevation': 'O'}, {'of': 'O'}, {'synovial': 'O'}, {'fluid': 'O'}, {'CTGF': 'O'}, {'concentration': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'patients,': 'O'}, {'demonstrating': 'O'}, {'excellent': 'O'}, {'diagnostic': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'predict': 'O'}, {'RA': 'I-Entity'}, {'(area': 'O'}, {'under': 'O'}, {'the': 'O'}, {'curve': 'O'}, {'(AUC)‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.97).': 'O'}]"
Primary Sjogrens syndrome (pSS) is a common autoimmune disease involving abnormal Th17 activation.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'involving': 'O'}, {'abnormal': 'O'}, {'Th17': 'O'}, {'activation.': 'O'}]"
"Attempts at T cell-targeted therapy of PSS have been limited, although therapy targeted at other arms of the immune response may also affect T cells.","[{'Attempts': 'O'}, {'at': 'O'}, {'T': 'O'}, {'cell-targeted': 'O'}, {'therapy': 'O'}, {'of': 'O'}, {'PSS': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'limited,': 'O'}, {'although': 'O'}, {'therapy': 'O'}, {'targeted': 'O'}, {'at': 'O'}, {'other': 'O'}, {'arms': 'O'}, {'of': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'response': 'O'}, {'may': 'O'}, {'also': 'O'}, {'affect': 'O'}, {'T': 'O'}, {'cells.': 'O'}]"
We describe the case of a nonsmoker 62-year-old woman with Sjogren syndrome who presented concomitantly a Pulmonary Langerhans Histiocytosis mimicking a pulmonary complication of its Sjogren.,"[{'We': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'nonsmoker': 'O'}, {'62-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'concomitantly': 'O'}, {'a': 'O'}, {'Pulmonary': 'O'}, {'Langerhans': 'I-Entity'}, {'Histiocytosis': 'I-Entity'}, {'mimicking': 'O'}, {'a': 'O'}, {'pulmonary': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'its': 'O'}, {'Sjogren.': 'I-Entity'}]"
"Capable of multi-organ involvement in Sjogren's syndrome (SS), cardiac findings of pulmonary effusion, left ventricular diastolic dysfunction and pulmonary hypertension are seen in patients with SS.","[{'Capable': 'O'}, {'of': 'O'}, {'multi-organ': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'cardiac': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'effusion,': 'I-Entity'}, {'left': 'B-Entity'}, {'ventricular': 'I-Entity'}, {'diastolic': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'hypertension': 'I-Entity'}, {'are': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS.': 'I-Entity'}]"
"In both women with and without SS, the presence of symptoms of dry eyes and/or dry mouth rather than SS itself resulted in higher odds of depression.","[{'In': 'O'}, {'both': 'O'}, {'women': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'SS,': 'I-Entity'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and/or': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'rather': 'O'}, {'than': 'O'}, {'SS': 'I-Entity'}, {'itself': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'higher': 'O'}, {'odds': 'O'}, {'of': 'O'}, {'depression.': 'I-Entity'}]"
A random-effects model was used to evaluate pregnancy complications in patients with pSS and healthy controls.,"[{'A': 'O'}, {'random-effects': 'O'}, {'model': 'O'}, {'was': 'O'}, {'used': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'pregnancy': 'B-Entity'}, {'complications': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
"In light of the increased risk of further progression of cerebral infarction, we decided to perform surgical revascularization in spite of her active inflammatory condition.","[{'In': 'O'}, {'light': 'O'}, {'of': 'O'}, {'the': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'further': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'cerebral': 'B-Entity'}, {'infarction,': 'I-Entity'}, {'we': 'O'}, {'decided': 'O'}, {'to': 'O'}, {'perform': 'O'}, {'surgical': 'O'}, {'revascularization': 'O'}, {'in': 'O'}, {'spite': 'O'}, {'of': 'O'}, {'her': 'O'}, {'active': 'O'}, {'inflammatory': 'O'}, {'condition.': 'O'}]"
"Upon relapse of SSM, serum amyloid A protein (SAA) level was markedly elevated.","[{'Upon': 'O'}, {'relapse': 'O'}, {'of': 'O'}, {'SSM,': 'I-Entity'}, {'serum': 'B-Entity'}, {'amyloid': 'B-Entity'}, {'A': 'I-Entity'}, {'protein': 'O'}, {'(SAA)': 'O'}, {'level': 'O'}, {'was': 'O'}, {'markedly': 'O'}, {'elevated.': 'O'}]"
The objective of this systematic review was to evaluate Rituximab effectiveness and safety for treating pSS.,"[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'systematic': 'O'}, {'review': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'Rituximab': 'I-Entity'}, {'effectiveness': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'pSS.': 'I-Entity'}]"
The 3-year follow-up showed that the incidences of renal injury and pulmonary interstitial lesion in patients with low miR-146a and miR-4484 expressions were significantly lower than those with high expressions (p<0.05).,"[{'The': 'O'}, {'3-year': 'O'}, {'follow-up': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'the': 'O'}, {'incidences': 'O'}, {'of': 'O'}, {'renal': 'B-Entity'}, {'injury': 'I-Entity'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'interstitial': 'I-Entity'}, {'lesion': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'low': 'O'}, {'miR-146a': 'O'}, {'and': 'O'}, {'miR-4484': 'O'}, {'expressions': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'than': 'O'}, {'those': 'O'}, {'with': 'O'}, {'high': 'O'}, {'expressions': 'O'}, {'(p<0.05).': 'O'}]"
"A multiple linear regression analysis revealed that arterial stiffness was associated with age, MAP and LDL levels in pSS patients.","[{'A': 'O'}, {'multiple': 'O'}, {'linear': 'O'}, {'regression': 'O'}, {'analysis': 'O'}, {'revealed': 'O'}, {'that': 'O'}, {'arterial': 'B-Entity'}, {'stiffness': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'age,': 'O'}, {'MAP': 'O'}, {'and': 'O'}, {'LDL': 'O'}, {'levels': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"For patients with acute acquired cerebellar ataxia, immune-mediated cerebellar ataxia should be an important differential diagnosis aside from the more common causes like stroke or drugs.a previous Sjogrens syndrome diagnosis.","[{'For': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'acquired': 'O'}, {'cerebellar': 'B-Entity'}, {'ataxia,': 'I-Entity'}, {'immune-mediated': 'O'}, {'cerebellar': 'B-Entity'}, {'ataxia': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'an': 'O'}, {'important': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'aside': 'O'}, {'from': 'O'}, {'the': 'O'}, {'more': 'O'}, {'common': 'O'}, {'causes': 'O'}, {'like': 'O'}, {'stroke': 'I-Entity'}, {'or': 'O'}, {'drugs.a': 'O'}, {'previous': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'diagnosis.': 'O'}]"
Eye dryness was severest in SS compared to DES and controls (P < 0.001).,"[{'Eye': 'B-Entity'}, {'dryness': 'I-Entity'}, {'was': 'O'}, {'severest': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'compared': 'O'}, {'to': 'O'}, {'DES': 'I-Entity'}, {'and': 'O'}, {'controls': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.001).': 'O'}]"
"Histological examination of the thigh revealed diameter variation, degeneration of muscle fibers and inflammatory cell infiltration in the perivascular area, corresponding to the inflammatory myopathy of pSS.","[{'Histological': 'O'}, {'examination': 'O'}, {'of': 'O'}, {'the': 'O'}, {'thigh': 'O'}, {'revealed': 'O'}, {'diameter': 'O'}, {'variation,': 'O'}, {'degeneration': 'O'}, {'of': 'O'}, {'muscle': 'O'}, {'fibers': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'the': 'O'}, {'perivascular': 'O'}, {'area,': 'O'}, {'corresponding': 'O'}, {'to': 'O'}, {'the': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathy': 'I-Entity'}, {'of': 'O'}, {'pSS.': 'I-Entity'}]"
"We report the successful additive effect of a matrix regenerating agent (RGTA, Cacicol) in SS patients with severe superficial ulcerative keratitis resistant to conventional therapy.","[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'successful': 'O'}, {'additive': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'a': 'O'}, {'matrix': 'O'}, {'regenerating': 'O'}, {'agent': 'O'}, {'(RGTA,': 'O'}, {'Cacicol)': 'I-Entity'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'superficial': 'O'}, {'ulcerative': 'B-Entity'}, {'keratitis': 'I-Entity'}, {'resistant': 'O'}, {'to': 'O'}, {'conventional': 'O'}, {'therapy.': 'O'}]"
"The autoimmune exocrinopathy, Sjogrens syndrome (SS), is associated with secretory defects in patients, including individuals with mild lymphocytic infiltration and minimal glandular damage.","[{'The': 'O'}, {'autoimmune': 'B-Entity'}, {'exocrinopathy,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'secretory': 'O'}, {'defects': 'O'}, {'in': 'O'}, {'patients,': 'O'}, {'including': 'O'}, {'individuals': 'O'}, {'with': 'O'}, {'mild': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'minimal': 'O'}, {'glandular': 'B-Entity'}, {'damage.': 'I-Entity'}]"
We report a 31-year-old woman hospitalised for a 1 year history of muscle weakness and joint and chest wall pains.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'31-year-old': 'O'}, {'woman': 'O'}, {'hospitalised': 'O'}, {'for': 'O'}, {'a': 'O'}, {'1': 'O'}, {'year': 'O'}, {'history': 'O'}, {'of': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'and': 'O'}, {'joint': 'B-Entity'}, {'and': 'I-Entity'}, {'chest': 'I-Entity'}, {'wall': 'I-Entity'}, {'pains.': 'I-Entity'}]"
"These results suggest that autoantibodies to Ro60 might play a pathogenic role in lymphopenia in both SLE and pSS, but the pathogenic mechanisms might differ.Medical University, Hefei, China shuaizongwen@medmail.com.cn.Medical University, Hefei, China.Medical University, Hefei, China.Medical University, Hefei, China.Medical University, Hefei, China.","[{'These': 'O'}, {'results': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'autoantibodies': 'O'}, {'to': 'O'}, {'Ro60': 'I-Entity'}, {'might': 'O'}, {'play': 'O'}, {'a': 'O'}, {'pathogenic': 'O'}, {'role': 'O'}, {'in': 'O'}, {'lymphopenia': 'I-Entity'}, {'in': 'O'}, {'both': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'pSS,': 'I-Entity'}, {'but': 'O'}, {'the': 'O'}, {'pathogenic': 'O'}, {'mechanisms': 'O'}, {'might': 'O'}, {'differ.Medical': 'O'}, {'University,': 'O'}, {'Hefei,': 'O'}, {'China': 'O'}, {'shuaizongwen@medmail.com.cn.Medical': 'O'}]"
"However, there are several diseases, which could manifest as salivary gland swelling, mimicking Mikulicz's disease, such as Sjogren's syndrome, mumps virus infection, obstruction of parotid duct, non-Hodgkin's lymphoma (NHL), and so on.","[{'However,': 'O'}, {'there': 'O'}, {'are': 'O'}, {'several': 'O'}, {'diseases,': 'O'}, {'which': 'O'}, {'could': 'O'}, {'manifest': 'O'}, {'as': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling,': 'I-Entity'}, {'mimicking': 'O'}, {""Mikulicz's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'mumps': 'B-Entity'}, {'virus': 'I-Entity'}, {'infection,': 'I-Entity'}, {'obstruction': 'B-Entity'}, {'of': 'I-Entity'}, {'parotid': 'I-Entity'}, {'duct,': 'I-Entity'}, {""non-Hodgkin's"": 'B-Entity'}, {'lymphoma': 'I-Entity'}]"
"Checking for the presence antiaquaporin-4 antibodies provides important prognostic information and may help to guide treatment decisions.Ann Arbor, MI 48109-5358, USA.","[{'Checking': 'O'}, {'for': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'antiaquaporin-4': 'O'}, {'antibodies': 'O'}, {'provides': 'O'}, {'important': 'O'}, {'prognostic': 'O'}, {'information': 'O'}, {'and': 'O'}, {'may': 'O'}, {'help': 'O'}, {'to': 'O'}, {'guide': 'O'}, {'treatment': 'O'}, {'decisions.Ann': 'O'}, {'Arbor,': 'O'}, {'MI': 'O'}, {'48109-5358,': 'O'}, {'USA.': 'O'}]"
Inflammatory cytokines and other related indicators were measured.,"[{'Inflammatory': 'O'}, {'cytokines': 'O'}, {'and': 'O'}, {'other': 'O'}, {'related': 'O'}, {'indicators': 'O'}, {'were': 'O'}, {'measured.': 'O'}]"
"Sjogrens syndrome (SS) is a common, progressive autoimmune exocrinopathy distinguished by dry eyes and mouth and affects ‚Äö√Ñ√∂‚àö‚Ä†¬¨‚à´0.7% of the European population.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'common,': 'O'}, {'progressive': 'O'}, {'autoimmune': 'B-Entity'}, {'exocrinopathy': 'I-Entity'}, {'distinguished': 'O'}, {'by': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'affects': 'O'}, {'‚Äö√Ñ√∂‚àö‚Ä†¬¨‚à´0.7%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'European': 'O'}, {'population.': 'O'}]"
"Various pathologies may mimic LVV either by causing systemic inflammation and constitutional symptoms, or by causing lumen narrowing with or without aneurysm formation in the aorta and its branches.","[{'Various': 'O'}, {'pathologies': 'O'}, {'may': 'O'}, {'mimic': 'O'}, {'LVV': 'I-Entity'}, {'either': 'O'}, {'by': 'O'}, {'causing': 'O'}, {'systemic': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'constitutional': 'O'}, {'symptoms,': 'O'}, {'or': 'O'}, {'by': 'O'}, {'causing': 'O'}, {'lumen': 'O'}, {'narrowing': 'O'}, {'with': 'O'}, {'or': 'O'}, {'without': 'O'}, {'aneurysm': 'I-Entity'}, {'formation': 'O'}, {'in': 'O'}, {'the': 'O'}, {'aorta': 'O'}, {'and': 'O'}, {'its': 'O'}, {'branches.': 'O'}]"
CCL25 protein and mRNA levels were elevated in the LSGs of patients with primary SS as compared to non-SS sicca controls.,"[{'CCL25': 'O'}, {'protein': 'O'}, {'and': 'O'}, {'mRNA': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'elevated': 'O'}, {'in': 'O'}, {'the': 'O'}, {'LSGs': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'non-SS': 'O'}, {'sicca': 'I-Entity'}, {'controls.': 'O'}]"
"The patient had resolution of decreased visual acuity, visual hallucinations, encephalopathy, and contrast-enhancing brain lesions in response to plasma exchange therapy.","[{'The': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'resolution': 'O'}, {'of': 'O'}, {'decreased': 'B-Entity'}, {'visual': 'I-Entity'}, {'acuity,': 'I-Entity'}, {'visual': 'B-Entity'}, {'hallucinations,': 'I-Entity'}, {'encephalopathy,': 'I-Entity'}, {'and': 'O'}, {'contrast-enhancing': 'O'}, {'brain': 'B-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'response': 'O'}, {'to': 'O'}, {'plasma': 'O'}, {'exchange': 'O'}, {'therapy.': 'O'}]"
"Salivary analysis may be useful for diagnosing systemic oral disorders, as well as for monitoring hormone and therapeutic levels of drug.Velappanchavadi, Chennai, India.","[{'Salivary': 'O'}, {'analysis': 'O'}, {'may': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'diagnosing': 'O'}, {'systemic': 'O'}, {'oral': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'for': 'O'}, {'monitoring': 'O'}, {'hormone': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'drug.Velappanchavadi,': 'O'}, {'Chennai,': 'O'}, {'India.': 'O'}]"
"In general, patients will have evidence of both airway and interstitial lung disease by radiographs and pathology.","[{'In': 'O'}, {'general,': 'O'}, {'patients': 'O'}, {'will': 'O'}, {'have': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'both': 'O'}, {'airway': 'B-Entity'}, {'and': 'I-Entity'}, {'interstitial': 'I-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'by': 'O'}, {'radiographs': 'O'}, {'and': 'O'}, {'pathology.': 'O'}]"
"369 well defined sera from: 44 rheumatoid arthritis, 50 systemic lupus erythematosus, 35 scleroderma, 19 Sjogrens syndrome, and 10 polymyositis patients as well as 99 healthy controls were examined.","[{'369': 'O'}, {'well': 'O'}, {'defined': 'O'}, {'sera': 'O'}, {'from:': 'O'}, {'44': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis,': 'I-Entity'}, {'50': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'35': 'O'}, {'scleroderma,': 'I-Entity'}, {'19': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'10': 'O'}, {'polymyositis': 'I-Entity'}, {'patients': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'99': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'examined.': 'O'}]"
"Furthermore, it is important to measure ADAMTS13 activity and anti-ADAMTS13 antibodies, because TTP with SS seems to be a concurrent overlapping autoimmune disorder.","[{'Furthermore,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'important': 'O'}, {'to': 'O'}, {'measure': 'O'}, {'ADAMTS13': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'anti-ADAMTS13': 'O'}, {'antibodies,': 'O'}, {'because': 'O'}, {'TTP': 'I-Entity'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'concurrent': 'O'}, {'overlapping': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder.': 'I-Entity'}]"
"The aim of this study was to evaluate the cumulative incidence and the predictive factors for collagen vascular disease (CVD) in patients initially diagnosed with idiopathic pulmonary fibrosis (IPF), and to examine the features of patients who then developed CVD.","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'cumulative': 'O'}, {'incidence': 'O'}, {'and': 'O'}, {'the': 'O'}, {'predictive': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'collagen': 'B-Entity'}, {'vascular': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CVD)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'initially': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'idiopathic': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'fibrosis': 'I-Entity'}, {'(IPF),': 'O'}, {'and': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'features': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'then': 'O'}, {'developed': 'O'}, {'CVD.': 'I-Entity'}]"
"However, while the objective assessment and grading of glandular dysfunction can be easily performed, the spectrum of clinical symptoms encompassed by the terms 'dry eye' and 'dry mouth' is wide and heterogeneous.","[{'However,': 'O'}, {'while': 'O'}, {'the': 'O'}, {'objective': 'O'}, {'assessment': 'O'}, {'and': 'O'}, {'grading': 'O'}, {'of': 'O'}, {'glandular': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'easily': 'O'}, {'performed,': 'O'}, {'the': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'encompassed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'terms': 'O'}, {""'dry"": 'O'}, {""eye'"": 'I-Entity'}, {'and': 'O'}, {""'dry"": 'O'}, {""mouth'"": 'I-Entity'}, {'is': 'O'}, {'wide': 'O'}, {'and': 'O'}, {'heterogeneous.': 'O'}]"
"Among these patients, 11 had primary and six had secondary Sjogren syndrome associated with systemic lupus erythematosus.","[{'Among': 'O'}, {'these': 'O'}, {'patients,': 'O'}, {'11': 'O'}, {'had': 'O'}, {'primary': 'O'}, {'and': 'O'}, {'six': 'O'}, {'had': 'O'}, {'secondary': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus.': 'I-Entity'}]"
"Interestingly, in most cases, each antibody is associated with a specific phenotype in CTDs and therefore help in better defining either the disease subtypes or diseases activity and outcome.","[{'Interestingly,': 'O'}, {'in': 'O'}, {'most': 'O'}, {'cases,': 'O'}, {'each': 'O'}, {'antibody': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'specific': 'O'}, {'phenotype': 'O'}, {'in': 'O'}, {'CTDs': 'I-Entity'}, {'and': 'O'}, {'therefore': 'O'}, {'help': 'O'}, {'in': 'O'}, {'better': 'O'}, {'defining': 'O'}, {'either': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'subtypes': 'O'}, {'or': 'O'}, {'diseases': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'outcome.': 'O'}]"
"She was diagnosed to have chronic IC, based upon the cystoscopic biopsy finding of chronic inflammation in the bladder wall.","[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'to': 'O'}, {'have': 'O'}, {'chronic': 'O'}, {'IC,': 'I-Entity'}, {'based': 'O'}, {'upon': 'O'}, {'the': 'O'}, {'cystoscopic': 'O'}, {'biopsy': 'O'}, {'finding': 'O'}, {'of': 'O'}, {'chronic': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'bladder': 'O'}, {'wall.': 'O'}]"
"Benign lymphoepithelial lesions (BLLs) usually affect the parotid glands, resulting in their asymmetrical enlargement.","[{'Benign': 'O'}, {'lymphoepithelial': 'B-Entity'}, {'lesions': 'I-Entity'}, {'(BLLs)': 'O'}, {'usually': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'their': 'O'}, {'asymmetrical': 'O'}, {'enlargement.': 'O'}]"
"Also, her brain MRI revealed cerebellar degeneration.","[{'Also,': 'O'}, {'her': 'O'}, {'brain': 'O'}, {'MRI': 'O'}, {'revealed': 'O'}, {'cerebellar': 'B-Entity'}, {'degeneration.': 'I-Entity'}]"
"Polymyositis was suspected at initial diagnosis due to her clinical course, physical examination, and autoimmune disease.","[{'Polymyositis': 'I-Entity'}, {'was': 'O'}, {'suspected': 'O'}, {'at': 'O'}, {'initial': 'O'}, {'diagnosis': 'O'}, {'due': 'O'}, {'to': 'O'}, {'her': 'O'}, {'clinical': 'O'}, {'course,': 'O'}, {'physical': 'O'}, {'examination,': 'O'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Although the pathogenesis of the disorder is incompletely understood, but some studies have reported that anti-moesin antibodies have been detected in autoimmune diseases with which SS is closely associated.","[{'Although': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disorder': 'O'}, {'is': 'O'}, {'incompletely': 'O'}, {'understood,': 'O'}, {'but': 'O'}, {'some': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'reported': 'O'}, {'that': 'O'}, {'anti-moesin': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'with': 'O'}, {'which': 'O'}, {'SS': 'I-Entity'}, {'is': 'O'}, {'closely': 'O'}, {'associated.': 'O'}]"
Various mechanisms have been proposed in an attempt to explain the extra-intestinal manifestations of H. pylori infections.,"[{'Various': 'O'}, {'mechanisms': 'O'}, {'have': 'O'}, {'been': 'O'}, {'proposed': 'O'}, {'in': 'O'}, {'an': 'O'}, {'attempt': 'O'}, {'to': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'extra-intestinal': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'H.': 'B-Entity'}, {'pylori': 'I-Entity'}, {'infections.': 'I-Entity'}]"
Our analysis suggested that findings from physical examination and CT and MRI scans in the absence of neoplastic cells on fine needle aspiration biopsy could be used to make the diagnosis of lymphoepithelial lesion preoperatively.,"[{'Our': 'O'}, {'analysis': 'O'}, {'suggested': 'O'}, {'that': 'O'}, {'findings': 'O'}, {'from': 'O'}, {'physical': 'O'}, {'examination': 'O'}, {'and': 'O'}, {'CT': 'O'}, {'and': 'O'}, {'MRI': 'O'}, {'scans': 'O'}, {'in': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'neoplastic': 'O'}, {'cells': 'O'}, {'on': 'O'}, {'fine': 'O'}, {'needle': 'O'}, {'aspiration': 'O'}, {'biopsy': 'O'}, {'could': 'O'}, {'be': 'O'}, {'used': 'O'}, {'to': 'O'}, {'make': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'lymphoepithelial': 'B-Entity'}, {'lesion': 'I-Entity'}, {'preoperatively.': 'O'}]"
HCQ-treated mice showed similar results except SMG index was not different from the untreated mice.,"[{'HCQ-treated': 'I-Entity'}, {'mice': 'O'}, {'showed': 'O'}, {'similar': 'O'}, {'results': 'O'}, {'except': 'O'}, {'SMG': 'O'}, {'index': 'O'}, {'was': 'O'}, {'not': 'O'}, {'different': 'O'}, {'from': 'O'}, {'the': 'O'}, {'untreated': 'O'}, {'mice.': 'O'}]"
Patients with primary Sjogrens syndrome (pSS) have also been described to suffer from IBS-like symptoms.,"[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'have': 'O'}, {'also': 'O'}, {'been': 'O'}, {'described': 'O'}, {'to': 'O'}, {'suffer': 'O'}, {'from': 'O'}, {'IBS-like': 'I-Entity'}, {'symptoms.': 'O'}]"
"Early recognition of HP due to the underlying SS-related FS with prompt therapy not only could terminate potentially life-threatening hypokalemia, but also improve renal outcome.General Hospital, Kaohsiung, Taiwan, Republic of China.diseasesby the 2002 criteria.","[{'Early': 'O'}, {'recognition': 'O'}, {'of': 'O'}, {'HP': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'underlying': 'O'}, {'SS-related': 'I-Entity'}, {'FS': 'I-Entity'}, {'with': 'O'}, {'prompt': 'O'}, {'therapy': 'O'}, {'not': 'O'}, {'only': 'O'}, {'could': 'O'}, {'terminate': 'O'}, {'potentially': 'O'}, {'life-threatening': 'O'}, {'hypokalemia,': 'I-Entity'}, {'but': 'O'}, {'also': 'O'}, {'improve': 'O'}, {'renal': 'O'}, {'outcome.General': 'O'}, {'Hospital,': 'O'}, {'Kaohsiung,': 'O'}, {'Taiwan,': 'O'}, {'Republic': 'O'}, {'of': 'O'}, {'China.diseasesby': 'O'}, {'the': 'O'}, {'2002': 'O'}, {'criteria.': 'O'}]"
A 77-year-old woman with Sjogrens syndrome has been followed for mild interstitial pneumonia.,"[{'A': 'O'}, {'77-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'followed': 'O'}, {'for': 'O'}, {'mild': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia.': 'I-Entity'}]"
The predicted biologic targets of microRNA associated with inflammation or salivary gland dysfunction identified both overlapping and distinct biologic pathways and processes.,"[{'The': 'O'}, {'predicted': 'O'}, {'biologic': 'O'}, {'targets': 'O'}, {'of': 'O'}, {'microRNA': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'inflammation': 'I-Entity'}, {'or': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'identified': 'O'}, {'both': 'O'}, {'overlapping': 'O'}, {'and': 'O'}, {'distinct': 'O'}, {'biologic': 'O'}, {'pathways': 'O'}, {'and': 'O'}, {'processes.': 'O'}]"
We contrast two classifications of parotid calcifications: 1) intraductal stones that cause recurrent duct obstruction and are often located within the main parotid duct along or anterior to the masseter and 2) punctate intraparenchymal parotid gland calcifications that are not visualized on sialendoscopy and may represent underlying inflammatory disease.,"[{'We': 'O'}, {'contrast': 'O'}, {'two': 'O'}, {'classifications': 'O'}, {'of': 'O'}, {'parotid': 'B-Entity'}, {'calcifications:': 'I-Entity'}, {'1)': 'O'}, {'intraductal': 'O'}, {'stones': 'I-Entity'}, {'that': 'O'}, {'cause': 'O'}, {'recurrent': 'O'}, {'duct': 'B-Entity'}, {'obstruction': 'I-Entity'}, {'and': 'O'}, {'are': 'O'}, {'often': 'O'}, {'located': 'O'}, {'within': 'O'}, {'the': 'O'}, {'main': 'O'}, {'parotid': 'O'}, {'duct': 'O'}, {'along': 'O'}, {'or': 'O'}, {'anterior': 'O'}, {'to': 'O'}, {'the': 'O'}, {'masseter': 'O'}, {'and': 'O'}, {'2)': 'O'}, {'punctate': 'O'}, {'intraparenchymal': 'O'}, {'parotid': 'O'}]"
(i) To analyze the in vivo corneal structure and sub-basal plexus nerves in patients with primary Sjogrens syndrome (pSS) and no-SS dry eye by confocal scanning laser microscopy (CSLM) and (ii) to correlate CSLM findings with tear function tests and with patients' subjective dryness.,"[{'(i)': 'O'}, {'To': 'O'}, {'analyze': 'O'}, {'the': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'corneal': 'O'}, {'structure': 'O'}, {'and': 'O'}, {'sub-basal': 'O'}, {'plexus': 'O'}, {'nerves': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'and': 'O'}, {'no-SS': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'by': 'O'}, {'confocal': 'O'}, {'scanning': 'O'}, {'laser': 'O'}, {'microscopy': 'O'}, {'(CSLM)': 'O'}, {'and': 'O'}, {'(ii)': 'O'}, {'to': 'O'}, {'correlate': 'O'}, {'CSLM': 'O'}]"
"The diagnosis of pSS is complex and requires a stepwise approach to evaluate symptoms of ocular and oral dryness, objective measures of lacrimal and salivary gland dysfunction, and evidence of autoimmunity with Ro/La autoantibodies and labial salivary gland biopsy.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'is': 'O'}, {'complex': 'O'}, {'and': 'O'}, {'requires': 'O'}, {'a': 'O'}, {'stepwise': 'O'}, {'approach': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness,': 'I-Entity'}, {'objective': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'lacrimal': 'B-Entity'}, {'and': 'I-Entity'}, {'salivary': 'I-Entity'}, {'gland': 'I-Entity'}, {'dysfunction,': 'I-Entity'}, {'and': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'autoimmunity': 'I-Entity'}, {'with': 'O'}, {'Ro/La': 'B-Entity'}, {'autoantibodies': 'O'}, {'and': 'O'}, {'labial': 'O'}, {'salivary': 'O'}]"
We speculated that the coincidence of proximal tubular dysfunction and distal RTA cause a severe manifestation of osteomalacia.vutakim@hotmail.com.15.,"[{'We': 'O'}, {'speculated': 'O'}, {'that': 'O'}, {'the': 'O'}, {'coincidence': 'O'}, {'of': 'O'}, {'proximal': 'O'}, {'tubular': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'distal': 'O'}, {'RTA': 'I-Entity'}, {'cause': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'osteomalacia.vutakim@hotmail.com.15.': 'I-Entity'}]"
"Since then, numerous promising new drugs, mostly affecting B and T lymphocytes, have been studied in clinical trials.","[{'Since': 'O'}, {'then,': 'O'}, {'numerous': 'O'}, {'promising': 'O'}, {'new': 'O'}, {'drugs,': 'O'}, {'mostly': 'O'}, {'affecting': 'O'}, {'B': 'O'}, {'and': 'O'}, {'T': 'O'}, {'lymphocytes,': 'O'}, {'have': 'O'}, {'been': 'O'}, {'studied': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'trials.': 'O'}]"
No laboratory parameters to monitor the activation of this disease have been identified.,"[{'No': 'O'}, {'laboratory': 'O'}, {'parameters': 'O'}, {'to': 'O'}, {'monitor': 'O'}, {'the': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'this': 'O'}, {'disease': 'O'}, {'have': 'O'}, {'been': 'O'}, {'identified.': 'O'}]"
"It can be associated with autoimmune diseases, such as Sjogren's syndrome and autoimmune thyroiditis.","[{'It': 'O'}, {'can': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroiditis.': 'I-Entity'}]"
"A paediatric female patient was referred to our clinic for dental treatment complaining about dry mouth, oral discomfort, and dysphagia.","[{'A': 'O'}, {'paediatric': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'referred': 'O'}, {'to': 'O'}, {'our': 'O'}, {'clinic': 'O'}, {'for': 'O'}, {'dental': 'O'}, {'treatment': 'O'}, {'complaining': 'O'}, {'about': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'oral': 'B-Entity'}, {'discomfort,': 'I-Entity'}, {'and': 'O'}, {'dysphagia.': 'I-Entity'}]"
Only one of the included pregnancies was complicated by intrauterine AV block.,"[{'Only': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'included': 'O'}, {'pregnancies': 'O'}, {'was': 'O'}, {'complicated': 'O'}, {'by': 'O'}, {'intrauterine': 'B-Entity'}, {'AV': 'I-Entity'}, {'block.': 'I-Entity'}]"
"The main reason for ICU admission was autoimmune disease flare-up in 20 (54.0%) patients, followed by infections in 12 (32.4%).","[{'The': 'O'}, {'main': 'O'}, {'reason': 'O'}, {'for': 'O'}, {'ICU': 'O'}, {'admission': 'O'}, {'was': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'flare-up': 'O'}, {'in': 'O'}, {'20': 'O'}, {'(54.0%)': 'O'}, {'patients,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'infections': 'I-Entity'}, {'in': 'O'}, {'12': 'O'}, {'(32.4%).': 'O'}]"
"Conjunctival tissue specimens from patients with cGVHD or Sjogrens syndrome (SS) or from healthy individuals were examined by light microscopy and EM, impression cytology, and immunohistochemistry.","[{'Conjunctival': 'O'}, {'tissue': 'O'}, {'specimens': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'cGVHD': 'I-Entity'}, {'or': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'or': 'O'}, {'from': 'O'}, {'healthy': 'O'}, {'individuals': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'light': 'O'}, {'microscopy': 'O'}, {'and': 'O'}, {'EM,': 'O'}, {'impression': 'O'}, {'cytology,': 'O'}, {'and': 'O'}, {'immunohistochemistry.': 'O'}]"
Female hormone levels appeared to play a role in disease pathogenesis in this case.,"[{'Female': 'O'}, {'hormone': 'O'}, {'levels': 'O'}, {'appeared': 'O'}, {'to': 'O'}, {'play': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'pathogenesis': 'O'}, {'in': 'O'}, {'this': 'O'}, {'case.': 'O'}]"
The aim of this study was to evaluate subclinical atherosclerosis in 49 patients with Sjogren syndrome using noninvasive methods.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'subclinical': 'O'}, {'atherosclerosis': 'I-Entity'}, {'in': 'O'}, {'49': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'using': 'O'}, {'noninvasive': 'O'}, {'methods.': 'O'}]"
These findings indicate a potentially important role for IL-13 in gland regulation and disease pathology.Sep 14.Sjogren's Syndrome: An Elusive Cause.,"[{'These': 'O'}, {'findings': 'O'}, {'indicate': 'O'}, {'a': 'O'}, {'potentially': 'O'}, {'important': 'O'}, {'role': 'O'}, {'for': 'O'}, {'IL-13': 'O'}, {'in': 'O'}, {'gland': 'O'}, {'regulation': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'pathology.Sep': 'O'}, {""14.Sjogren's"": 'O'}, {'Syndrome:': 'I-Entity'}, {'An': 'O'}, {'Elusive': 'O'}, {'Cause.': 'O'}]"
"In line with this notion, several biomarkers of B cell activity are significantly affected by treatment, both in the target organs and periphery.","[{'In': 'O'}, {'line': 'O'}, {'with': 'O'}, {'this': 'O'}, {'notion,': 'O'}, {'several': 'O'}, {'biomarkers': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activity': 'O'}, {'are': 'O'}, {'significantly': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'treatment,': 'O'}, {'both': 'O'}, {'in': 'O'}, {'the': 'O'}, {'target': 'O'}, {'organs': 'O'}, {'and': 'O'}, {'periphery.': 'O'}]"
"Notably, off-target B cells were also triggered resulting in increased anti-EBV and autoantibody titres.","[{'Notably,': 'O'}, {'off-target': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'were': 'O'}, {'also': 'O'}, {'triggered': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'increased': 'O'}, {'anti-EBV': 'O'}, {'and': 'O'}, {'autoantibody': 'O'}, {'titres.': 'O'}]"
There was statistically significant difference of positive anti-U1RNP antibodies in renal damage (p<0.05).,"[{'There': 'O'}, {'was': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-U1RNP': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'damage': 'I-Entity'}, {'(p<0.05).': 'O'}]"
"The delay in diagnosis allows the establishment of a chronic inflammatory state, which makes primary Sjogren syndrome an interesting model for the study of atherosclerosis.","[{'The': 'O'}, {'delay': 'O'}, {'in': 'O'}, {'diagnosis': 'O'}, {'allows': 'O'}, {'the': 'O'}, {'establishment': 'O'}, {'of': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'inflammatory': 'O'}, {'state,': 'O'}, {'which': 'O'}, {'makes': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'an': 'O'}, {'interesting': 'O'}, {'model': 'O'}, {'for': 'O'}, {'the': 'O'}, {'study': 'O'}, {'of': 'O'}, {'atherosclerosis.': 'I-Entity'}]"
"They presented with a significantly lower incidence of interstitial lung disease (ILD), leukocytopenia and elevated immunoglobulin G levels (P < 0.05).","[{'They': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'a': 'O'}, {'significantly': 'O'}, {'lower': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD),': 'O'}, {'leukocytopenia': 'I-Entity'}, {'and': 'O'}, {'elevated': 'O'}, {'immunoglobulin': 'O'}, {'G': 'O'}, {'levels': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.05).': 'O'}]"
"From our prospective institutional PAH database, 40 consecutive patients without any obvious cause of PAH at the time of PAH diagnosis were identified.","[{'From': 'O'}, {'our': 'O'}, {'prospective': 'O'}, {'institutional': 'O'}, {'PAH': 'I-Entity'}, {'database,': 'O'}, {'40': 'O'}, {'consecutive': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'any': 'O'}, {'obvious': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'PAH': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'PAH': 'I-Entity'}, {'diagnosis': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
"Whereas aberrant regeneration of the 7th cranial nerve occurring after a Bell palsy may lead to a variety of clinical findings, hemifacial spasm only rarely occurs.","[{'Whereas': 'O'}, {'aberrant': 'O'}, {'regeneration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'7th': 'O'}, {'cranial': 'O'}, {'nerve': 'O'}, {'occurring': 'O'}, {'after': 'O'}, {'a': 'O'}, {'Bell': 'B-Entity'}, {'palsy': 'I-Entity'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'clinical': 'O'}, {'findings,': 'O'}, {'hemifacial': 'B-Entity'}, {'spasm': 'I-Entity'}, {'only': 'O'}, {'rarely': 'O'}, {'occurs.': 'O'}]"
The prevalence of incomplete dRTA (urinary acidification defect without acidosis) was 25% (14/57).,"[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'incomplete': 'O'}, {'dRTA': 'I-Entity'}, {'(urinary': 'O'}, {'acidification': 'O'}, {'defect': 'O'}, {'without': 'O'}, {'acidosis)': 'I-Entity'}, {'was': 'O'}, {'25%': 'O'}, {'(14/57).': 'O'}]"
In the follow up the patient developed a mucosa-associated lymphoid tissue pulmonary neoplasm.,"[{'In': 'O'}, {'the': 'O'}, {'follow': 'O'}, {'up': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'developed': 'O'}, {'a': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'B-Entity'}, {'tissue': 'I-Entity'}, {'pulmonary': 'I-Entity'}, {'neoplasm.': 'I-Entity'}]"
"In the present study, clinical observations and laboratory assessments are not correlated with persistent fatigue and reduced functioning.","[{'In': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study,': 'O'}, {'clinical': 'O'}, {'observations': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'assessments': 'O'}, {'are': 'O'}, {'not': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'persistent': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'reduced': 'O'}, {'functioning.': 'O'}]"
The present study was aimed to clinically evaluate transitional treatment of pulpitis during pregnancy.,"[{'The': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'clinically': 'O'}, {'evaluate': 'O'}, {'transitional': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'pulpitis': 'I-Entity'}, {'during': 'O'}, {'pregnancy.': 'O'}]"
"Based on the patient's medical history, laboratory and imaging examination, and treatment, we speculate that the disorders of the nervous system were caused by the Sjogren syndrome.","[{'Based': 'O'}, {'on': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'medical': 'O'}, {'history,': 'O'}, {'laboratory': 'O'}, {'and': 'O'}, {'imaging': 'O'}, {'examination,': 'O'}, {'and': 'O'}, {'treatment,': 'O'}, {'we': 'O'}, {'speculate': 'O'}, {'that': 'O'}, {'the': 'O'}, {'disorders': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'were': 'O'}, {'caused': 'O'}, {'by': 'O'}, {'the': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"The diagnosis was established based on the clinical symptoms of xerostomia and xerophthalmia along with serologic detection of antinuclear antibodies, rheumatoid factor, anti-Sjogrens syndrome-related antigen A (SSA)/Ro antibodies, and anti-Sjogrens syndrome-related antigen B (SSB)/La antibodies.","[{'The': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'established': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'xerophthalmia': 'I-Entity'}, {'along': 'O'}, {'with': 'O'}, {'serologic': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'antinuclear': 'O'}, {'antibodies,': 'O'}, {'rheumatoid': 'O'}, {'factor,': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome-related': 'I-Entity'}, {'antigen': 'O'}, {'A': 'O'}, {'(SSA)/Ro': 'O'}, {'antibodies,': 'O'}]"
"Herein, we describe the cases of two women with pSS whose presenting symptoms involve the kidneys.","[{'Herein,': 'O'}, {'we': 'O'}, {'describe': 'O'}, {'the': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'two': 'O'}, {'women': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'whose': 'O'}, {'presenting': 'O'}, {'symptoms': 'O'}, {'involve': 'O'}, {'the': 'O'}, {'kidneys.': 'O'}]"
"The most important thoracic manifestations of CTDs are interstitial lung disease and pulmonary arterial hypertension, with nonspecific interstitial pneumonia being the most common pattern of interstitial lung disease.","[{'The': 'O'}, {'most': 'O'}, {'important': 'O'}, {'thoracic': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'CTDs': 'I-Entity'}, {'are': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension,': 'I-Entity'}, {'with': 'O'}, {'nonspecific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'being': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease.': 'I-Entity'}]"
To analyse the worldwide occurrence of sicca/Sjogrens (SS) syndrome associated with the use of immune checkpoint inhibitors (ICI) in patients with cancer.,"[{'To': 'O'}, {'analyse': 'O'}, {'the': 'O'}, {'worldwide': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'sicca/Sjogrens': 'B-Entity'}, {'(SS)': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'checkpoint': 'O'}, {'inhibitors': 'O'}, {'(ICI)': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'cancer.': 'I-Entity'}]"
IgG4-related disease is a novel lymphoproliferative disorder that shows hyper-IgG4-‚âà√≠‚Äö√¢‚Ä¢-globulinemia and IgG4-producing plasma cell expansion in affected organs with fibrotic or sclerotic changes.,"[{'IgG4-related': 'O'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'novel': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'disorder': 'I-Entity'}, {'that': 'O'}, {'shows': 'O'}, {'hyper-IgG4-‚âà√≠‚Äö√¢‚Ä¢-globulinemia': 'O'}, {'and': 'O'}, {'IgG4-producing': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'expansion': 'O'}, {'in': 'O'}, {'affected': 'O'}, {'organs': 'O'}, {'with': 'O'}, {'fibrotic': 'I-Entity'}]"
"We found that 844 Nova Scotia residents had a diagnosis of one of the rheumatic diseases of interest, based on administrative data, and had had ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢ 1 rheumatology assessment at a provincial arthritis center.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'844': 'O'}, {'Nova': 'O'}, {'Scotia': 'O'}, {'residents': 'O'}, {'had': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'of': 'O'}, {'interest,': 'O'}, {'based': 'O'}, {'on': 'O'}, {'administrative': 'O'}, {'data,': 'O'}, {'and': 'O'}, {'had': 'O'}, {'had': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢': 'O'}, {'1': 'O'}, {'rheumatology': 'O'}, {'assessment': 'O'}, {'at': 'O'}, {'a': 'O'}, {'provincial': 'O'}, {'arthritis': 'I-Entity'}, {'center.': 'O'}]"
There is no data to support any definitive therapeutic intervention for SS-related pulmonary amyloidosis.,"[{'There': 'O'}, {'is': 'O'}, {'no': 'O'}, {'data': 'O'}, {'to': 'O'}, {'support': 'O'}, {'any': 'O'}, {'definitive': 'O'}, {'therapeutic': 'O'}, {'intervention': 'O'}, {'for': 'O'}, {'SS-related': 'I-Entity'}, {'pulmonary': 'B-Entity'}, {'amyloidosis.': 'I-Entity'}]"
"Furthermore, we estimated the general intrathecal B-cell activation (IgG index), measured anti-NR2 antibodies in cerebrospinal fluid, and explored whether these variables were associated with neuropsychiatric manifestations.","[{'Furthermore,': 'O'}, {'we': 'O'}, {'estimated': 'O'}, {'the': 'O'}, {'general': 'O'}, {'intrathecal': 'O'}, {'B-cell': 'O'}, {'activation': 'O'}, {'(IgG': 'O'}, {'index),': 'O'}, {'measured': 'O'}, {'anti-NR2': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'cerebrospinal': 'O'}, {'fluid,': 'O'}, {'and': 'O'}, {'explored': 'O'}, {'whether': 'O'}, {'these': 'O'}, {'variables': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'neuropsychiatric': 'O'}, {'manifestations.': 'O'}]"
Electronic address: weirongfang@163.com.6.with primary biliary cholangitis and Sjogren syndrome with subsequent autoimmune hemolytic anemia: A case report.,"[{'Electronic': 'O'}, {'address:': 'O'}, {'weirongfang@163.com.6.with': 'O'}, {'primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cholangitis': 'I-Entity'}, {'and': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'subsequent': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia:': 'I-Entity'}, {'A': 'O'}, {'case': 'O'}, {'report.': 'O'}]"
"The clinical presentation is variable and can be vague, as this disease affects many organs and new presentations are continuing to be described.","[{'The': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'is': 'O'}, {'variable': 'O'}, {'and': 'O'}, {'can': 'O'}, {'be': 'O'}, {'vague,': 'O'}, {'as': 'O'}, {'this': 'O'}, {'disease': 'O'}, {'affects': 'O'}, {'many': 'O'}, {'organs': 'O'}, {'and': 'O'}, {'new': 'O'}, {'presentations': 'O'}, {'are': 'O'}, {'continuing': 'O'}, {'to': 'O'}, {'be': 'O'}, {'described.': 'O'}]"
"This paper will not, however, discuss burning mouth syndrome (oral dysesthesia), which is a diagnosis of exclusion, whereby the oral mucosa is clinically normal and there are no identifiable medical or dental causes to account for the patient's symptoms.Leeds Teaching Hospitals NHS Trust/University of Leeds, Leeds, UK.","[{'This': 'O'}, {'paper': 'O'}, {'will': 'O'}, {'not,': 'O'}, {'however,': 'O'}, {'discuss': 'O'}, {'burning': 'B-Entity'}, {'mouth': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(oral': 'O'}, {'dysesthesia),': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'exclusion,': 'O'}, {'whereby': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'mucosa': 'O'}, {'is': 'O'}, {'clinically': 'O'}, {'normal': 'O'}, {'and': 'O'}, {'there': 'O'}, {'are': 'O'}, {'no': 'O'}, {'identifiable': 'O'}, {'medical': 'O'}, {'or': 'O'}, {'dental': 'O'}, {'causes': 'O'}, {'to': 'O'}, {'account': 'O'}, {'for': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'symptoms.Leeds': 'O'}, {'Teaching': 'O'}, {'Hospitals': 'O'}, {'NHS': 'O'}, {'Trust/University': 'O'}]"
Forty-one percent of all patients with pSS and 30% of the never-smoking patients with pSS fulfilled the Global Initiative for Chronic Obstructive Lung Disease criteria for COPD.,"[{'Forty-one': 'O'}, {'percent': 'O'}, {'of': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'30%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'never-smoking': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}, {'Global': 'O'}, {'Initiative': 'O'}, {'for': 'O'}, {'Chronic': 'B-Entity'}, {'Obstructive': 'I-Entity'}, {'Lung': 'I-Entity'}, {'Disease': 'I-Entity'}, {'criteria': 'O'}, {'for': 'O'}, {'COPD.': 'I-Entity'}]"
"The mechanism underlying the development of SjS is the destruction of the epithelium of the exocrine glands, as a consequence of abnormal B cell and T cell responses to the autoantigens Ro/SSA and La/SSB, among others.","[{'The': 'O'}, {'mechanism': 'O'}, {'underlying': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'SjS': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'epithelium': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'as': 'O'}, {'a': 'O'}, {'consequence': 'O'}, {'of': 'O'}, {'abnormal': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'and': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'responses': 'O'}, {'to': 'O'}, {'the': 'O'}, {'autoantigens': 'O'}, {'Ro/SSA': 'I-Entity'}, {'and': 'O'}, {'La/SSB,': 'I-Entity'}, {'among': 'O'}, {'others.': 'O'}]"
"Significant research effort has been made to reveal the major underlying biological events in this subgroup and identify biomarkers for early diagnosis, prognosis and response to treatment.","[{'Significant': 'O'}, {'research': 'O'}, {'effort': 'O'}, {'has': 'O'}, {'been': 'O'}, {'made': 'O'}, {'to': 'O'}, {'reveal': 'O'}, {'the': 'O'}, {'major': 'O'}, {'underlying': 'O'}, {'biological': 'O'}, {'events': 'O'}, {'in': 'O'}, {'this': 'O'}, {'subgroup': 'O'}, {'and': 'O'}, {'identify': 'O'}, {'biomarkers': 'O'}, {'for': 'O'}, {'early': 'O'}, {'diagnosis,': 'O'}, {'prognosis': 'O'}, {'and': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment.': 'O'}]"
"Significant research effort has been made to reveal the major underlying biological events in this subgroup and identify biomarkers for early diagnosis, prognosis and response to treatment.","[{'Significant': 'O'}, {'research': 'O'}, {'effort': 'O'}, {'has': 'O'}, {'been': 'O'}, {'made': 'O'}, {'to': 'O'}, {'reveal': 'O'}, {'the': 'O'}, {'major': 'O'}, {'underlying': 'O'}, {'biological': 'O'}, {'events': 'O'}, {'in': 'O'}, {'this': 'O'}, {'subgroup': 'O'}, {'and': 'O'}, {'identify': 'O'}, {'biomarkers': 'O'}, {'for': 'O'}, {'early': 'O'}, {'diagnosis,': 'O'}, {'prognosis': 'O'}, {'and': 'O'}, {'response': 'O'}, {'to': 'O'}, {'treatment.': 'O'}]"
"A significant reduction in corneal axon density and mechanical sensitivity were observed, which negatively correlate with epithelial cell proliferation.","[{'A': 'O'}, {'significant': 'O'}, {'reduction': 'O'}, {'in': 'O'}, {'corneal': 'O'}, {'axon': 'O'}, {'density': 'O'}, {'and': 'O'}, {'mechanical': 'O'}, {'sensitivity': 'O'}, {'were': 'O'}, {'observed,': 'O'}, {'which': 'O'}, {'negatively': 'O'}, {'correlate': 'O'}, {'with': 'O'}, {'epithelial': 'O'}, {'cell': 'O'}, {'proliferation.': 'O'}]"
A 48-year-old man was referred because of right hip pain due to a hematoma.,"[{'A': 'O'}, {'48-year-old': 'O'}, {'man': 'O'}, {'was': 'O'}, {'referred': 'O'}, {'because': 'O'}, {'of': 'O'}, {'right': 'O'}, {'hip': 'B-Entity'}, {'pain': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'hematoma.': 'I-Entity'}]"
"Thirty-nine experts assessed 5 profiles for whether disease activity had improved, worsened, or remained stable at visits 2 and 3.","[{'Thirty-nine': 'O'}, {'experts': 'O'}, {'assessed': 'O'}, {'5': 'O'}, {'profiles': 'O'}, {'for': 'O'}, {'whether': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'had': 'O'}, {'improved,': 'O'}, {'worsened,': 'O'}, {'or': 'O'}, {'remained': 'O'}, {'stable': 'O'}, {'at': 'O'}, {'visits': 'O'}, {'2': 'O'}, {'and': 'O'}, {'3.': 'O'}]"
The immunological processes leading to a Sjogrens-like illness after Ro-peptide immunization were interrupted in a stepwise fashion in these differing mice strains.,"[{'The': 'O'}, {'immunological': 'O'}, {'processes': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'a': 'O'}, {'Sjogrens-like': 'B-Entity'}, {'illness': 'I-Entity'}, {'after': 'O'}, {'Ro-peptide': 'I-Entity'}, {'immunization': 'O'}, {'were': 'O'}, {'interrupted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'stepwise': 'O'}, {'fashion': 'O'}, {'in': 'O'}, {'these': 'O'}, {'differing': 'O'}, {'mice': 'O'}, {'strains.': 'O'}]"
"Serum IgG4 levels were measured at 51 of our 800 patients followed up because of Sjogrens syndrome (SS) if one or more clinical signs during the disease course raised the possibility of IgG4-RD (persisting salivary gland swelling, absence of anti-Ro/SSA and anti-La/SSB antibodies in the serum, and positive salivary gland biopsy, coexistence of autoimmune pancreatitis, autoimmune hepatitis, or primary sclerosing cholangitis, persisting lymphadenopathy).","[{'Serum': 'O'}, {'IgG4': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'at': 'O'}, {'51': 'O'}, {'of': 'O'}, {'our': 'O'}, {'800': 'O'}, {'patients': 'O'}, {'followed': 'O'}, {'up': 'O'}, {'because': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'if': 'O'}, {'one': 'O'}, {'or': 'O'}, {'more': 'O'}, {'clinical': 'O'}, {'signs': 'O'}, {'during': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'course': 'O'}, {'raised': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'IgG4-RD': 'O'}, {'(persisting': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'swelling,': 'I-Entity'}, {'absence': 'O'}, {'of': 'O'}, {'anti-Ro/SSA': 'O'}]"
"Pathologically, in the UIP/pSS group, interstitial inflammation, plasma cell infiltration, lymphoid follicles with germinal centers, cysts, bronchiolitis, and pleuritis were significantly more prominent, whereas smooth muscle hyperplasia and fibroblastic foci were milder (all P<0.05).","[{'Pathologically,': 'O'}, {'in': 'O'}, {'the': 'O'}, {'UIP/pSS': 'I-Entity'}, {'group,': 'O'}, {'interstitial': 'B-Entity'}, {'inflammation,': 'I-Entity'}, {'plasma': 'O'}, {'cell': 'O'}, {'infiltration,': 'O'}, {'lymphoid': 'O'}, {'follicles': 'O'}, {'with': 'O'}, {'germinal': 'O'}, {'centers,': 'O'}, {'cysts,': 'O'}, {'bronchiolitis,': 'I-Entity'}, {'and': 'O'}, {'pleuritis': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'more': 'O'}, {'prominent,': 'O'}, {'whereas': 'O'}, {'smooth': 'O'}, {'muscle': 'O'}, {'hyperplasia': 'O'}]"
Absence of parotitis was associated with greater degree of organ damage based on SS disease damage index.,"[{'Absence': 'O'}, {'of': 'O'}, {'parotitis': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'greater': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'organ': 'B-Entity'}, {'damage': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'SS': 'B-Entity'}, {'disease': 'O'}, {'damage': 'O'}, {'index.': 'O'}]"
"We observed, both at gene and protein levels, higher expression of SMAD2, 3, and 4 and Snail in the SGEC exposed by TGF-‚âà√≠‚Äö√¢¬ß1 compared to untreated healthy SGEC.","[{'We': 'O'}, {'observed,': 'O'}, {'both': 'O'}, {'at': 'O'}, {'gene': 'O'}, {'and': 'O'}, {'protein': 'O'}, {'levels,': 'O'}, {'higher': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'SMAD2,': 'O'}, {'3,': 'O'}, {'and': 'O'}, {'4': 'O'}, {'and': 'O'}, {'Snail': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SGEC': 'O'}, {'exposed': 'O'}, {'by': 'O'}, {'TGF-‚âà√≠‚Äö√¢¬ß1': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'untreated': 'O'}, {'healthy': 'O'}, {'SGEC.': 'O'}]"
The slope1st can be used as a discriminator to diagnose SS patients (p = 0.015; odds ratio = 4.234; area under the curve = 0.726).,"[{'The': 'O'}, {'slope1st': 'O'}, {'can': 'O'}, {'be': 'O'}, {'used': 'O'}, {'as': 'O'}, {'a': 'O'}, {'discriminator': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.015;': 'O'}, {'odds': 'O'}, {'ratio': 'O'}, {'=': 'O'}, {'4.234;': 'O'}, {'area': 'O'}, {'under': 'O'}, {'the': 'O'}, {'curve': 'O'}, {'=': 'O'}, {'0.726).': 'O'}]"
"Recently, it has been shown that IL-15 could be up-regulated in T cell-mediated inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel diseases.","[{'Recently,': 'O'}, {'it': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'that': 'O'}, {'IL-15': 'O'}, {'could': 'O'}, {'be': 'O'}, {'up-regulated': 'O'}, {'in': 'O'}, {'T': 'O'}, {'cell-mediated': 'O'}, {'inflammatory': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'inflammatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
They had hypokalemia and normal anion gap metabolic acidosis due to distal renal tubular acidosis and positive anti-SS-A and anti-SS-B autoantibodies.,"[{'They': 'O'}, {'had': 'O'}, {'hypokalemia': 'I-Entity'}, {'and': 'O'}, {'normal': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'metabolic': 'O'}, {'acidosis': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'distal': 'O'}, {'renal': 'O'}, {'tubular': 'O'}, {'acidosis': 'I-Entity'}, {'and': 'O'}, {'positive': 'O'}, {'anti-SS-A': 'O'}, {'and': 'O'}, {'anti-SS-B': 'O'}, {'autoantibodies.': 'O'}]"
"Salivary gland MALT lymphoma has an excellent prognosis regardless of initial treatment, and patients with Sjogren disease have improved survival.","[{'Salivary': 'O'}, {'gland': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'has': 'O'}, {'an': 'O'}, {'excellent': 'O'}, {'prognosis': 'O'}, {'regardless': 'O'}, {'of': 'O'}, {'initial': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'disease': 'I-Entity'}, {'have': 'O'}, {'improved': 'O'}, {'survival.': 'O'}]"
"Although lymphatic neovascularization may be a key feature of chronic inflammation, it is almost unexplored in primary Sjogrens syndrome (pSS).","[{'Although': 'O'}, {'lymphatic': 'O'}, {'neovascularization': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'key': 'O'}, {'feature': 'O'}, {'of': 'O'}, {'chronic': 'O'}, {'inflammation,': 'I-Entity'}, {'it': 'O'}, {'is': 'O'}, {'almost': 'O'}, {'unexplored': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"The diagnosis of neonatal lupus erythematosus is made when the mother has autoantibodies to Sjogrens syndrome autoantigens, and the fetus or newborn develops atrioventricular heart block, or the newborn develops the typical rash or hepatic or hematologic manifestations in the absence of other explanation.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'neonatal': 'O'}, {'lupus': 'B-Entity'}, {'erythematosus': 'I-Entity'}, {'is': 'O'}, {'made': 'O'}, {'when': 'O'}, {'the': 'O'}, {'mother': 'O'}, {'has': 'O'}, {'autoantibodies': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'autoantigens,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'fetus': 'O'}, {'or': 'O'}, {'newborn': 'O'}, {'develops': 'O'}, {'atrioventricular': 'B-Entity'}, {'heart': 'I-Entity'}, {'block,': 'I-Entity'}, {'or': 'O'}, {'the': 'O'}, {'newborn': 'O'}, {'develops': 'O'}, {'the': 'O'}, {'typical': 'O'}, {'rash': 'I-Entity'}, {'or': 'O'}, {'hepatic': 'B-Entity'}, {'or': 'I-Entity'}]"
"On the other hand, the number of significant reports and open-label studies of B-cell depletion therapy showing clinical efficacy in sjogren's syndrome has continued to accumulate, which provides a promising future for the patients.","[{'On': 'O'}, {'the': 'O'}, {'other': 'O'}, {'hand,': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'significant': 'O'}, {'reports': 'O'}, {'and': 'O'}, {'open-label': 'O'}, {'studies': 'O'}, {'of': 'O'}, {'B-cell': 'O'}, {'depletion': 'O'}, {'therapy': 'O'}, {'showing': 'O'}, {'clinical': 'O'}, {'efficacy': 'O'}, {'in': 'O'}, {""sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'has': 'O'}, {'continued': 'O'}, {'to': 'O'}, {'accumulate,': 'O'}, {'which': 'O'}, {'provides': 'O'}, {'a': 'O'}, {'promising': 'O'}, {'future': 'O'}, {'for': 'O'}, {'the': 'O'}, {'patients.': 'O'}]"
We evaluated the yield of a panel for systemic vasculitis as a screening test in young patients with ischemic stroke.,"[{'We': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'yield': 'O'}, {'of': 'O'}, {'a': 'O'}, {'panel': 'O'}, {'for': 'O'}, {'systemic': 'B-Entity'}, {'vasculitis': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'screening': 'O'}, {'test': 'O'}, {'in': 'O'}, {'young': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'ischemic': 'B-Entity'}, {'stroke.': 'I-Entity'}]"
"The background of this study is to assess the accuracy of lung ultrasound (LUS) to diagnose interstitial lung disease (ILD) in Sjogrens syndrome (Sjs), in patients who have any alterations in pulmonary function tests (PFT) or respiratory symptoms.","[{'The': 'O'}, {'background': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'accuracy': 'O'}, {'of': 'O'}, {'lung': 'O'}, {'ultrasound': 'O'}, {'(LUS)': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(Sjs),': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'have': 'O'}, {'any': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'pulmonary': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'(PFT)': 'O'}, {'or': 'O'}, {'respiratory': 'O'}, {'symptoms.': 'O'}]"
"The diagnosis of primary SS based on ocular dryness, lacrimal hyposecretion, secretory and excretory dysfunction from sialocintigraphy, and positive anti-SS-A antibodies.","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'ocular': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'lacrimal': 'O'}, {'hyposecretion,': 'O'}, {'secretory': 'O'}, {'and': 'O'}, {'excretory': 'O'}, {'dysfunction': 'I-Entity'}, {'from': 'O'}, {'sialocintigraphy,': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'anti-SS-A': 'O'}, {'antibodies.': 'O'}]"
"In this study, the salivary glands were also observed during thyroid ultrasonography to determine the degree of salivary gland abnormalities detected by ultrasonography.","[{'In': 'O'}, {'this': 'O'}, {'study,': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'were': 'O'}, {'also': 'O'}, {'observed': 'O'}, {'during': 'O'}, {'thyroid': 'O'}, {'ultrasonography': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'abnormalities': 'I-Entity'}, {'detected': 'O'}, {'by': 'O'}, {'ultrasonography.': 'O'}]"
"The patients were asked a standardized series of questions concerning dry mouth, and their whole salivary flow rates were measured.","[{'The': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'asked': 'O'}, {'a': 'O'}, {'standardized': 'O'}, {'series': 'O'}, {'of': 'O'}, {'questions': 'O'}, {'concerning': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'and': 'O'}, {'their': 'O'}, {'whole': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rates': 'O'}, {'were': 'O'}, {'measured.': 'O'}]"
"FLC levels correlated significantly with systemic disease activity, assessed by EULAR SS Disease Activity Index (ESSDAI) and clinical ESSDAI, both cross-sectionally and longitudinally following treatment.","[{'FLC': 'O'}, {'levels': 'O'}, {'correlated': 'O'}, {'significantly': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'assessed': 'O'}, {'by': 'O'}, {'EULAR': 'O'}, {'SS': 'O'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI)': 'O'}, {'and': 'O'}, {'clinical': 'O'}, {'ESSDAI,': 'O'}, {'both': 'O'}, {'cross-sectionally': 'O'}, {'and': 'O'}, {'longitudinally': 'O'}, {'following': 'O'}, {'treatment.': 'O'}]"
Factors associated with an increased number of physician visits and inability to work were determined by multivariate logistic regression analysis.,"[{'Factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'number': 'O'}, {'of': 'O'}, {'physician': 'O'}, {'visits': 'O'}, {'and': 'O'}, {'inability': 'B-Entity'}, {'to': 'I-Entity'}, {'work': 'I-Entity'}, {'were': 'O'}, {'determined': 'O'}, {'by': 'O'}, {'multivariate': 'O'}, {'logistic': 'O'}, {'regression': 'O'}, {'analysis.': 'O'}]"
The frequency of depression and anxiety symptoms in Spanish-speaking patients suffering from rheumatic conditions is unknown when using self-administered detection tools.,"[{'The': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'depression': 'I-Entity'}, {'and': 'O'}, {'anxiety': 'I-Entity'}, {'symptoms': 'O'}, {'in': 'O'}, {'Spanish-speaking': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'rheumatic': 'B-Entity'}, {'conditions': 'I-Entity'}, {'is': 'O'}, {'unknown': 'O'}, {'when': 'O'}, {'using': 'O'}, {'self-administered': 'O'}, {'detection': 'O'}, {'tools.': 'O'}]"
"Analysis of a blood sample obtained before her cardiopulmonary arrest yielded surprising laboratory investigations showed profound hypokalemia (1.1‚Äö√Ñ√∂‚àö√ë‚àö¬¢mEq/L) with renal K wasting, hyperchloremic metabolic acidosis with normal anion gap, hypophosphatemia with hypouricemia, glucosuria, and proteinuria.","[{'Analysis': 'O'}, {'of': 'O'}, {'a': 'O'}, {'blood': 'O'}, {'sample': 'O'}, {'obtained': 'O'}, {'before': 'O'}, {'her': 'O'}, {'cardiopulmonary': 'B-Entity'}, {'arrest': 'I-Entity'}, {'yielded': 'O'}, {'surprising': 'O'}, {'laboratory': 'O'}, {'investigations': 'O'}, {'showed': 'O'}, {'profound': 'O'}, {'hypokalemia': 'I-Entity'}, {'(1.1‚Äö√Ñ√∂‚àö√ë‚àö¬¢mEq/L)': 'O'}, {'with': 'O'}, {'renal': 'B-Entity'}, {'K': 'I-Entity'}, {'wasting,': 'I-Entity'}, {'hyperchloremic': 'I-Entity'}]"
Neuronopathy seems to be the most specific neurological complication of primary Sjogrens syndrome.,"[{'Neuronopathy': 'I-Entity'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'most': 'O'}, {'specific': 'O'}, {'neurological': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Coexisting autoimmune diseases like diabetes mellitus type 1, Sjogren's syndrome, and dermatitis herpetiformis are more common in adults than in children (42 % vs. 5 %).","[{'Coexisting': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'like': 'O'}, {'diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'type': 'I-Entity'}, {'1,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'dermatitis': 'B-Entity'}, {'herpetiformis': 'I-Entity'}, {'are': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'adults': 'O'}, {'than': 'O'}, {'in': 'O'}, {'children': 'O'}, {'(42': 'O'}, {'%': 'O'}, {'vs.': 'O'}, {'5': 'O'}, {'%).': 'O'}]"
"SS patients with certain forms of neurologic involvement, such as small fiber neuropathy and sensory ataxic ganglionopathy, frequently lack anti-SSA and anti-SSB antibodies and other serologic abnormalities.","[{'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'certain': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'neurologic': 'O'}, {'involvement,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'small': 'O'}, {'fiber': 'O'}, {'neuropathy': 'I-Entity'}, {'and': 'O'}, {'sensory': 'O'}, {'ataxic': 'B-Entity'}, {'ganglionopathy,': 'I-Entity'}, {'frequently': 'O'}, {'lack': 'O'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'anti-SSB': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'other': 'O'}, {'serologic': 'O'}, {'abnormalities.': 'O'}]"
In vivo dynamic assessment of central corneal inflammatory cell density may serve as an indicator of dry eye severity and provide new insight for dry eye treatment.2009 Jul 23.Syndrome.,"[{'In': 'O'}, {'vivo': 'O'}, {'dynamic': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'central': 'O'}, {'corneal': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'density': 'O'}, {'may': 'O'}, {'serve': 'O'}, {'as': 'O'}, {'an': 'O'}, {'indicator': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'severity': 'O'}, {'and': 'O'}, {'provide': 'O'}, {'new': 'O'}, {'insight': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'treatment.2009': 'O'}, {'Jul': 'O'}, {'23.Syndrome.': 'O'}]"
To evaluate quantitative and qualitative changes in sub-basal corneal nerves (SBN) via in vivo confocal microscopy in patients with Sjogren syndrome dry eye (SSDE) treated with topical cyclosporine A (CsA).,"[{'To': 'O'}, {'evaluate': 'O'}, {'quantitative': 'O'}, {'and': 'O'}, {'qualitative': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'sub-basal': 'O'}, {'corneal': 'O'}, {'nerves': 'O'}, {'(SBN)': 'O'}, {'via': 'O'}, {'in': 'O'}, {'vivo': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'dry': 'I-Entity'}, {'eye': 'I-Entity'}, {'(SSDE)': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'topical': 'O'}, {'cyclosporine': 'B-Entity'}, {'A': 'I-Entity'}, {'(CsA).': 'O'}]"
Extrahepatic manifestations (EHMs) of hepatitis C virus (HCV) infection can affect a variety of organ systems with significant morbidity and mortality.,"[{'Extrahepatic': 'O'}, {'manifestations': 'O'}, {'(EHMs)': 'O'}, {'of': 'O'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HCV)': 'I-Entity'}, {'infection': 'I-Entity'}, {'can': 'O'}, {'affect': 'O'}, {'a': 'O'}, {'variety': 'O'}, {'of': 'O'}, {'organ': 'O'}, {'systems': 'O'}, {'with': 'O'}, {'significant': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality.': 'O'}]"
The aim of this study was to assess fatigue aspects in Moroccan patients with rheumatoid arthritis (RA) and its relationships with disease-specific variables especially parameters of functional and structural severity.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'fatigue': 'I-Entity'}, {'aspects': 'O'}, {'in': 'O'}, {'Moroccan': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'and': 'O'}, {'its': 'O'}, {'relationships': 'O'}, {'with': 'O'}, {'disease-specific': 'O'}, {'variables': 'O'}, {'especially': 'O'}, {'parameters': 'O'}, {'of': 'O'}, {'functional': 'O'}, {'and': 'O'}, {'structural': 'O'}, {'severity.': 'O'}]"
The present patient was an atypical case of lymphoproliferative pulmonary involvement in a patient with Sjogrens syndrome.,"[{'The': 'O'}, {'present': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'an': 'O'}, {'atypical': 'O'}, {'case': 'O'}, {'of': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'pulmonary': 'I-Entity'}, {'involvement': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Based on this striking case, we here review the characteristic nail and hair manifestations associated with systemic amyloidosis.","[{'Based': 'O'}, {'on': 'O'}, {'this': 'O'}, {'striking': 'O'}, {'case,': 'O'}, {'we': 'O'}, {'here': 'O'}, {'review': 'O'}, {'the': 'O'}, {'characteristic': 'O'}, {'nail': 'O'}, {'and': 'O'}, {'hair': 'O'}, {'manifestations': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'amyloidosis.': 'I-Entity'}]"
"To date, there is limited data on thyroid disorders and autoimmune thyroid disease in Malaysia.","[{'To': 'O'}, {'date,': 'O'}, {'there': 'O'}, {'is': 'O'}, {'limited': 'O'}, {'data': 'O'}, {'on': 'O'}, {'thyroid': 'B-Entity'}, {'disorders': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'Malaysia.': 'O'}]"
A part of the lesions was enhanced by the administration of gadolinium contrast medium.,"[{'A': 'O'}, {'part': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lesions': 'O'}, {'was': 'O'}, {'enhanced': 'O'}, {'by': 'O'}, {'the': 'O'}, {'administration': 'O'}, {'of': 'O'}, {'gadolinium': 'B-Entity'}, {'contrast': 'I-Entity'}, {'medium.': 'I-Entity'}]"
The 2 symptom types are predicted by different variables.,"[{'The': 'O'}, {'2': 'O'}, {'symptom': 'O'}, {'types': 'O'}, {'are': 'O'}, {'predicted': 'O'}, {'by': 'O'}, {'different': 'O'}, {'variables.': 'O'}]"
"Workup includes a diagnosis of exclusion with specific antibodies or titers such as anti-Sjogrens syndrome type A (anti-SSA) antibodies, anti-Sjogrens syndrome type B (anti-SSB) antibodies, angiotensin-converting enzyme (ACE) levels, alpha-1-antitrypsin levels, and vascular endothelial growth factor (VEGF) antibodies with definitive diagnosis limited to tissue confirmation.","[{'Workup': 'O'}, {'includes': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'exclusion': 'O'}, {'with': 'O'}, {'specific': 'O'}, {'antibodies': 'O'}, {'or': 'O'}, {'titers': 'O'}, {'such': 'O'}, {'as': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'type': 'I-Entity'}, {'A': 'I-Entity'}, {'(anti-SSA)': 'O'}, {'antibodies,': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'type': 'I-Entity'}, {'B': 'I-Entity'}, {'(anti-SSB)': 'O'}, {'antibodies,': 'O'}, {'angiotensin-converting': 'I-Entity'}, {'enzyme': 'O'}, {'(ACE)': 'O'}, {'levels,': 'O'}]"
"The autoantibody biomarkers may be used to help diagnose pSS and predict its progression to MALT lymphoma.Dalian, 116024 China.Sjogren syndrome: Case report and review of the literature.","[{'The': 'O'}, {'autoantibody': 'O'}, {'biomarkers': 'O'}, {'may': 'O'}, {'be': 'O'}, {'used': 'O'}, {'to': 'O'}, {'help': 'O'}, {'diagnose': 'O'}, {'pSS': 'O'}, {'and': 'O'}, {'predict': 'O'}, {'its': 'O'}, {'progression': 'O'}, {'to': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma.Dalian,': 'I-Entity'}, {'116024': 'O'}, {'China.Sjogren': 'O'}, {'syndrome:': 'I-Entity'}, {'Case': 'O'}, {'report': 'O'}, {'and': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature.': 'O'}]"
"Given the rapid increase of genetic knowledge about other autoimmune diseases and the potential of finding and testing new biological agents to treat SS, selection of patients who have as uniform a disease process as possible becomes an important goal to better understand and treat this prevalent autoimmune disease.","[{'Given': 'O'}, {'the': 'O'}, {'rapid': 'O'}, {'increase': 'O'}, {'of': 'O'}, {'genetic': 'O'}, {'knowledge': 'O'}, {'about': 'O'}, {'other': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'of': 'O'}, {'finding': 'O'}, {'and': 'O'}, {'testing': 'O'}, {'new': 'O'}, {'biological': 'O'}, {'agents': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'SS,': 'I-Entity'}, {'selection': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'have': 'O'}, {'as': 'O'}, {'uniform': 'O'}, {'a': 'O'}, {'disease': 'O'}, {'process': 'O'}, {'as': 'O'}, {'possible': 'O'}, {'becomes': 'O'}, {'an': 'O'}, {'important': 'O'}, {'goal': 'O'}, {'to': 'O'}, {'better': 'O'}, {'understand': 'O'}, {'and': 'O'}, {'treat': 'O'}, {'this': 'O'}, {'prevalent': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
However the possibility that NLM may appear after recovery from lymphoma should be carefully considered because it could be cause of the patient's death.,"[{'However': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'that': 'O'}, {'NLM': 'I-Entity'}, {'may': 'O'}, {'appear': 'O'}, {'after': 'O'}, {'recovery': 'O'}, {'from': 'O'}, {'lymphoma': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'carefully': 'O'}, {'considered': 'O'}, {'because': 'O'}, {'it': 'O'}, {'could': 'O'}, {'be': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'death.': 'I-Entity'}]"
"The most important non-autoimmune cause of rare ANA patterns was carcinoma, particularly in patients with rare cell-cycle related ANAs.University of Leuven, Belgium.2013 Apr 11.","[{'The': 'O'}, {'most': 'O'}, {'important': 'O'}, {'non-autoimmune': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'rare': 'O'}, {'ANA': 'O'}, {'patterns': 'O'}, {'was': 'O'}, {'carcinoma,': 'I-Entity'}, {'particularly': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rare': 'O'}, {'cell-cycle': 'O'}, {'related': 'O'}, {'ANAs.University': 'O'}, {'of': 'O'}, {'Leuven,': 'O'}, {'Belgium.2013': 'O'}, {'Apr': 'O'}, {'11.': 'O'}]"
"The mean concentrations of Ap(4)A and Ap(5)A in the Sjogren syndrome group were 2.54 ¬¨¬®¬¨¬± 1.02 and 26.13 ¬¨¬®¬¨¬± 6.95 ‚âà√≠¬¨‚à´M, respectively.","[{'The': 'O'}, {'mean': 'O'}, {'concentrations': 'O'}, {'of': 'O'}, {'Ap(4)A': 'B-Entity'}, {'and': 'O'}, {'Ap(5)A': 'B-Entity'}, {'in': 'O'}, {'the': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'group': 'O'}, {'were': 'O'}, {'2.54': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'1.02': 'O'}, {'and': 'O'}, {'26.13': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'6.95': 'O'}, {'‚âà√≠¬¨‚à´M,': 'O'}]"
"Despite similarities in the organs involved in IgG4-related Mikulicz's disease and Sjogrens syndrome, there are marked clinical and pathological differences between these conditions.","[{'Despite': 'O'}, {'similarities': 'O'}, {'in': 'O'}, {'the': 'O'}, {'organs': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'IgG4-related': 'O'}, {""Mikulicz's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'there': 'O'}, {'are': 'O'}, {'marked': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'differences': 'O'}, {'between': 'O'}, {'these': 'O'}, {'conditions.': 'O'}]"
"IBM usually occurs as an isolated condition, but in some cases, it may be associated with another autoimmune disorder, Sjogrens syndrome.","[{'IBM': 'I-Entity'}, {'usually': 'O'}, {'occurs': 'O'}, {'as': 'O'}, {'an': 'O'}, {'isolated': 'O'}, {'condition,': 'O'}, {'but': 'O'}, {'in': 'O'}, {'some': 'O'}, {'cases,': 'O'}, {'it': 'O'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'another': 'O'}, {'autoimmune': 'B-Entity'}, {'disorder,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Lacrimal scintigrams were evaluated for the presence and severity of delayed tear clearance.,"[{'Lacrimal': 'O'}, {'scintigrams': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'and': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'delayed': 'O'}, {'tear': 'O'}, {'clearance.': 'O'}]"
"Targeting both IFN-‚âà√≠‚Äö√¢‚Ä¢ and IL-17 may be beneficial for treating the LG inflammation in SS.College of Medicine, 6565 Fannin Street, NC505G, Houston, TX 77030, Texas, USA.","[{'Targeting': 'O'}, {'both': 'O'}, {'IFN-‚âà√≠‚Äö√¢‚Ä¢': 'O'}, {'and': 'O'}, {'IL-17': 'O'}, {'may': 'O'}, {'be': 'O'}, {'beneficial': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'the': 'O'}, {'LG': 'O'}, {'inflammation': 'I-Entity'}, {'in': 'O'}, {'SS.College': 'I-Entity'}, {'of': 'O'}, {'Medicine,': 'O'}, {'6565': 'O'}, {'Fannin': 'O'}, {'Street,': 'O'}, {'NC505G,': 'O'}, {'Houston,': 'O'}, {'TX': 'O'}, {'77030,': 'O'}, {'Texas,': 'O'}, {'USA.': 'O'}]"
"Sjogrens syndrome is a systemic autoimmune disease that, apart from exocrine glands, may affect every organ or system.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that,': 'O'}, {'apart': 'O'}, {'from': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'may': 'O'}, {'affect': 'O'}, {'every': 'O'}, {'organ': 'O'}, {'or': 'O'}, {'system.': 'O'}]"
"Here, we describe a case of extensive atrophic pityriasis versicolor occurring in a woman affected by Sjogrens syndrome which completely resolved after topical antifungal treatment.Dry Eye Patients Unresponsive to Artificial Tear.","[{'Here,': 'O'}, {'we': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'extensive': 'O'}, {'atrophic': 'O'}, {'pityriasis': 'B-Entity'}, {'versicolor': 'I-Entity'}, {'occurring': 'O'}, {'in': 'O'}, {'a': 'O'}, {'woman': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'which': 'O'}, {'completely': 'O'}, {'resolved': 'O'}, {'after': 'O'}, {'topical': 'O'}, {'antifungal': 'O'}, {'treatment.Dry': 'O'}, {'Eye': 'I-Entity'}, {'Patients': 'O'}, {'Unresponsive': 'O'}, {'to': 'O'}, {'Artificial': 'O'}, {'Tear.': 'O'}]"
"These idiopathic or primary cases are divided into pure autonomic neuropathy, autonomic neuropathy with sensory impairment, and autonomic neuropathy with sensory and motor impairment based on the concomitance or absence of sensory or motor dysfunctions.","[{'These': 'O'}, {'idiopathic': 'O'}, {'or': 'O'}, {'primary': 'O'}, {'cases': 'O'}, {'are': 'O'}, {'divided': 'O'}, {'into': 'O'}, {'pure': 'O'}, {'autonomic': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'autonomic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'with': 'O'}, {'sensory': 'B-Entity'}, {'impairment,': 'I-Entity'}, {'and': 'O'}, {'autonomic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'with': 'O'}, {'sensory': 'B-Entity'}, {'and': 'I-Entity'}, {'motor': 'I-Entity'}, {'impairment': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'concomitance': 'O'}, {'or': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'sensory': 'B-Entity'}, {'or': 'I-Entity'}, {'motor': 'I-Entity'}, {'dysfunctions.': 'I-Entity'}]"
The contrast sensitivity (CS) function in patients with primary Sjogrens syndrome (pSS) may be impaired either frequently as a result of dry eye diseases or rarely as a result of optic neuropathy.,"[{'The': 'O'}, {'contrast': 'O'}, {'sensitivity': 'O'}, {'(CS)': 'O'}, {'function': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'may': 'O'}, {'be': 'O'}, {'impaired': 'O'}, {'either': 'O'}, {'frequently': 'O'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'diseases': 'I-Entity'}, {'or': 'O'}, {'rarely': 'O'}, {'as': 'O'}, {'a': 'O'}, {'result': 'O'}, {'of': 'O'}, {'optic': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
Indirect immunofluorescence analysis showed that NA-14 was strongly expressed in mitotic-phase cells.,"[{'Indirect': 'O'}, {'immunofluorescence': 'O'}, {'analysis': 'O'}, {'showed': 'O'}, {'that': 'O'}, {'NA-14': 'O'}, {'was': 'O'}, {'strongly': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'mitotic-phase': 'O'}, {'cells.': 'O'}]"
Neuromyelitis optica (NMO) is an immune-mediated neurological disorder characterised by recurrent episodes of optic neuritis and longitudinally extensive transverse myelitis.,"[{'Neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'immune-mediated': 'O'}, {'neurological': 'B-Entity'}, {'disorder': 'I-Entity'}, {'characterised': 'O'}, {'by': 'O'}, {'recurrent': 'O'}, {'episodes': 'O'}, {'of': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'and': 'O'}, {'longitudinally': 'O'}, {'extensive': 'O'}, {'transverse': 'B-Entity'}, {'myelitis.': 'I-Entity'}]"
"Anti-N-methyl-(d)-aspartate receptor subunits NR2A/B (anti-NR2A/B) antibodies have been demonstrated in the sera of SLE and SS patients and have been associated with collective or specific NP syndromes, though not consistently.","[{'Anti-N-methyl-(d)-aspartate': 'O'}, {'receptor': 'O'}, {'subunits': 'O'}, {'NR2A/B': 'O'}, {'(anti-NR2A/B)': 'O'}, {'antibodies': 'O'}, {'have': 'O'}, {'been': 'O'}, {'demonstrated': 'O'}, {'in': 'O'}, {'the': 'O'}, {'sera': 'O'}, {'of': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'have': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'collective': 'O'}, {'or': 'O'}, {'specific': 'O'}, {'NP': 'B-Entity'}, {'syndromes,': 'I-Entity'}, {'though': 'O'}, {'not': 'O'}]"
"The aim of this longitudinal prospective study was to evaluate the effects of periodontal treatment on the clinical, microbiological and immunological periodontal parameters, and on the systemic activity (ESSDAI) and subjective (ESSPRI) indexes in patients with primary Sjogrens Syndrome (pSS).","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'longitudinal': 'O'}, {'prospective': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'periodontal': 'O'}, {'treatment': 'O'}, {'on': 'O'}, {'the': 'O'}, {'clinical,': 'O'}, {'microbiological': 'O'}, {'and': 'O'}, {'immunological': 'O'}, {'periodontal': 'O'}, {'parameters,': 'O'}, {'and': 'O'}, {'on': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'activity': 'O'}, {'(ESSDAI)': 'O'}, {'and': 'O'}, {'subjective': 'O'}, {'(ESSPRI)': 'O'}, {'indexes': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}]"
"Amyloidosis is rare but important because it carries a risk for underlying MALT lymphoma or plasmacytoma, and it may lead to hemoptysis during biopsy.","[{'Amyloidosis': 'I-Entity'}, {'is': 'O'}, {'rare': 'O'}, {'but': 'O'}, {'important': 'O'}, {'because': 'O'}, {'it': 'O'}, {'carries': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'for': 'O'}, {'underlying': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'or': 'O'}, {'plasmacytoma,': 'I-Entity'}, {'and': 'O'}, {'it': 'O'}, {'may': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'hemoptysis': 'I-Entity'}, {'during': 'O'}, {'biopsy.': 'O'}]"
An attempt at explaining the possible link between these disorders and migraine is discussed at the end of the review.,"[{'An': 'O'}, {'attempt': 'O'}, {'at': 'O'}, {'explaining': 'O'}, {'the': 'O'}, {'possible': 'O'}, {'link': 'O'}, {'between': 'O'}, {'these': 'O'}, {'disorders': 'O'}, {'and': 'O'}, {'migraine': 'I-Entity'}, {'is': 'O'}, {'discussed': 'O'}, {'at': 'O'}, {'the': 'O'}, {'end': 'O'}, {'of': 'O'}, {'the': 'O'}, {'review.': 'O'}]"
The aim of this study was to examine whether circulating levels of the pro-inflammatory glycoprotein tenascin-C (TNC) are elevated in musculoskeletal disorders including rheumatoid arthritis (RA) and to assess in RA whether levels are related to clinical disease status and/or patient response to treatment.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'whether': 'O'}, {'circulating': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pro-inflammatory': 'O'}, {'glycoprotein': 'O'}, {'tenascin-C': 'O'}, {'(TNC)': 'O'}, {'are': 'O'}, {'elevated': 'O'}, {'in': 'O'}, {'musculoskeletal': 'B-Entity'}, {'disorders': 'I-Entity'}, {'including': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'whether': 'O'}, {'levels': 'O'}, {'are': 'O'}, {'related': 'O'}]"
There has been one case report of a patient with SS presenting with acute motor neuropathy similar to Guillain-Barr‚Äö√†√∂¬¨¬© syndrome (GBS).,"[{'There': 'O'}, {'has': 'O'}, {'been': 'O'}, {'one': 'O'}, {'case': 'O'}, {'report': 'O'}, {'of': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'presenting': 'O'}, {'with': 'O'}, {'acute': 'O'}, {'motor': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'similar': 'O'}, {'to': 'O'}, {'Guillain-Barr‚Äö√†√∂¬¨¬©': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(GBS).': 'O'}]"
"The peak of calcium influx in lymphocytes isolated from pSS patients is reached later, indicating that they respond more slowly to stimulation compared to controls.","[{'The': 'O'}, {'peak': 'O'}, {'of': 'O'}, {'calcium': 'I-Entity'}, {'influx': 'O'}, {'in': 'O'}, {'lymphocytes': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'is': 'O'}, {'reached': 'O'}, {'later,': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'they': 'O'}, {'respond': 'O'}, {'more': 'O'}, {'slowly': 'O'}, {'to': 'O'}, {'stimulation': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'controls.': 'O'}]"
Drug-induced subacute cutaneous lupus erythematosus is an uncommon disorder associated with the use of pharmacological agents including systemic chemotherapy.,"[{'Drug-induced': 'O'}, {'subacute': 'O'}, {'cutaneous': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'uncommon': 'O'}, {'disorder': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'pharmacological': 'O'}, {'agents': 'O'}, {'including': 'O'}, {'systemic': 'O'}, {'chemotherapy.': 'O'}]"
"Patients with primary Sjogrens Syndrome (pSS) have diminished health quality and fatigue, arthralgia along with dryness of the mouth and eyes have major impact on their psychological and social aspects of life.","[{'Patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'have': 'O'}, {'diminished': 'O'}, {'health': 'O'}, {'quality': 'O'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'arthralgia': 'I-Entity'}, {'along': 'O'}, {'with': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'eyes': 'I-Entity'}, {'have': 'O'}, {'major': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'their': 'O'}, {'psychological': 'O'}, {'and': 'O'}, {'social': 'O'}, {'aspects': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
A quarter of the cohort did not display underlying psychiatric disorders before hospitalization.,"[{'A': 'O'}, {'quarter': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cohort': 'O'}, {'did': 'O'}, {'not': 'O'}, {'display': 'O'}, {'underlying': 'O'}, {'psychiatric': 'B-Entity'}, {'disorders': 'I-Entity'}, {'before': 'O'}, {'hospitalization.': 'O'}]"
"The aim of the present study was to assess the prevalence of FM syndrome, fatigue and widespread pain in SLE and pSS patients and to evaluate the contribution of inflammatory disease and FM on those constitutional symptoms.","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'FM': 'B-Entity'}, {'syndrome,': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'widespread': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'contribution': 'O'}, {'of': 'O'}, {'inflammatory': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'FM': 'I-Entity'}, {'on': 'O'}, {'those': 'O'}, {'constitutional': 'O'}, {'symptoms.': 'O'}]"
"In addition, methotrexate may be helpful in vasculitis, haematological manifestations, and perhaps kidney disease.","[{'In': 'O'}, {'addition,': 'O'}, {'methotrexate': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'helpful': 'O'}, {'in': 'O'}, {'vasculitis,': 'I-Entity'}, {'haematological': 'O'}, {'manifestations,': 'O'}, {'and': 'O'}, {'perhaps': 'O'}, {'kidney': 'B-Entity'}, {'disease.': 'I-Entity'}]"
The sensory neuronopathies are sensory-predominant polyneuropathies that result from damage to the dorsal root and trigeminal sensory ganglia.,"[{'The': 'O'}, {'sensory': 'B-Entity'}, {'neuronopathies': 'I-Entity'}, {'are': 'O'}, {'sensory-predominant': 'O'}, {'polyneuropathies': 'I-Entity'}, {'that': 'O'}, {'result': 'O'}, {'from': 'O'}, {'damage': 'I-Entity'}, {'to': 'I-Entity'}, {'the': 'O'}, {'dorsal': 'O'}, {'root': 'I-Entity'}, {'and': 'I-Entity'}, {'trigeminal': 'O'}, {'sensory': 'I-Entity'}, {'ganglia.': 'I-Entity'}]"
"In the present study, we focused on the site of the inflammation and determined the composition of lymphocyte infiltration in labial salivary gland (LSG) biopsies with special emphasis on T(FH) and germinal center B cells.","[{'In': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'the': 'O'}, {'site': 'O'}, {'of': 'O'}, {'the': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'determined': 'O'}, {'the': 'O'}, {'composition': 'O'}, {'of': 'O'}, {'lymphocyte': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'labial': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'(LSG)': 'O'}, {'biopsies': 'O'}, {'with': 'O'}, {'special': 'O'}, {'emphasis': 'O'}, {'on': 'O'}, {'T(FH)': 'O'}, {'and': 'O'}, {'germinal': 'O'}, {'center': 'O'}, {'B': 'O'}, {'cells.': 'O'}]"
Optic neuritis (ON) is often the first symptom of multiple sclerosis (MS) and neuromyelitis optica (NMO) while there has been very little research reported on ON combined with Sjogrens syndrome (SS).,"[{'Optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'(ON)': 'O'}, {'is': 'O'}, {'often': 'O'}, {'the': 'O'}, {'first': 'O'}, {'symptom': 'O'}, {'of': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(MS)': 'O'}, {'and': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO)': 'O'}, {'while': 'O'}, {'there': 'O'}, {'has': 'O'}, {'been': 'O'}, {'very': 'O'}, {'little': 'O'}, {'research': 'O'}, {'reported': 'O'}, {'on': 'O'}, {'ON': 'I-Entity'}, {'combined': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"Further, the visits to the clinic provided opportunities to see the ultrasound picture of the expected infant.","[{'Further,': 'O'}, {'the': 'O'}, {'visits': 'O'}, {'to': 'O'}, {'the': 'O'}, {'clinic': 'O'}, {'provided': 'O'}, {'opportunities': 'O'}, {'to': 'O'}, {'see': 'O'}, {'the': 'O'}, {'ultrasound': 'O'}, {'picture': 'O'}, {'of': 'O'}, {'the': 'O'}, {'expected': 'O'}, {'infant.': 'O'}]"
"Based on the predominant neuropathic symptoms, patients can be considered to have several forms of neuropathies, including sensory ataxic neuropathy, painful sensory neuropathy without sensory ataxia, multiple mononeuropathy, multiple cranial neuropathy, trigeminal neuropathy, autonomic neuropathy, and radiculoneuropathy.","[{'Based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'predominant': 'O'}, {'neuropathic': 'I-Entity'}, {'symptoms,': 'O'}, {'patients': 'O'}, {'can': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'to': 'O'}, {'have': 'O'}, {'several': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'neuropathies,': 'I-Entity'}, {'including': 'O'}, {'sensory': 'O'}, {'ataxic': 'B-Entity'}, {'neuropathy,': 'I-Entity'}, {'painful': 'B-Entity'}, {'sensory': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'without': 'O'}, {'sensory': 'B-Entity'}, {'ataxia,': 'I-Entity'}, {'multiple': 'B-Entity'}, {'mononeuropathy,': 'I-Entity'}, {'multiple': 'B-Entity'}, {'cranial': 'I-Entity'}, {'neuropathy,': 'I-Entity'}, {'trigeminal': 'B-Entity'}, {'neuropathy,': 'I-Entity'}]"
"In the other case with Hashimoto's thyroiditis and Sjogrens syndrome, continuation of insulin therapy was necessary because blood glucose levels were unstably controlled.","[{'In': 'O'}, {'the': 'O'}, {'other': 'O'}, {'case': 'O'}, {'with': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'continuation': 'O'}, {'of': 'O'}, {'insulin': 'O'}, {'therapy': 'O'}, {'was': 'O'}, {'necessary': 'O'}, {'because': 'O'}, {'blood': 'O'}, {'glucose': 'I-Entity'}, {'levels': 'O'}, {'were': 'O'}, {'unstably': 'O'}, {'controlled.': 'O'}]"
"By excluding other possible causes of PH during further examinations, she was diagnosed with severe PH associated with primary Sjogrens syndrome.","[{'By': 'O'}, {'excluding': 'O'}, {'other': 'O'}, {'possible': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'PH': 'I-Entity'}, {'during': 'O'}, {'further': 'O'}, {'examinations,': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'PH': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"Clinically, the disease in most patients is manifested by two severe symptoms: dryness of the mouth (xerostomia) and the eyes (keratoconjunctivitis sicca).","[{'Clinically,': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'in': 'O'}, {'most': 'O'}, {'patients': 'O'}, {'is': 'O'}, {'manifested': 'O'}, {'by': 'O'}, {'two': 'O'}, {'severe': 'O'}, {'symptoms:': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'mouth': 'I-Entity'}, {'(xerostomia)': 'O'}, {'and': 'O'}, {'the': 'I-Entity'}, {'eyes': 'I-Entity'}, {'(keratoconjunctivitis': 'O'}, {'sicca).': 'I-Entity'}]"
There was a trend to higher prevalence of pulmonary arterial hypertension (PAH) in ssSSc patients (29%/19%) but not reach significant difference.,"[{'There': 'O'}, {'was': 'O'}, {'a': 'O'}, {'trend': 'O'}, {'to': 'O'}, {'higher': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'(PAH)': 'O'}, {'in': 'O'}, {'ssSSc': 'I-Entity'}, {'patients': 'O'}, {'(29%/19%)': 'O'}, {'but': 'O'}, {'not': 'O'}, {'reach': 'O'}, {'significant': 'O'}, {'difference.': 'O'}]"
"Interstitial lung disease (ILD) is a frequent manifestation of Sjogrens syndrome (SS), an autoimmune disease of salivary and lacrimal glands, and affects approximately 20% of patients.","[{'Interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'(ILD)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'frequent': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'of': 'O'}, {'salivary': 'I-Entity'}, {'and': 'I-Entity'}, {'lacrimal': 'I-Entity'}, {'glands,': 'I-Entity'}, {'and': 'O'}, {'affects': 'O'}, {'approximately': 'O'}, {'20%': 'O'}, {'of': 'O'}, {'patients.': 'O'}]"
"Compared with controls, patients with xerostomia exhibited significantly decreased whole salivary flow rate, increased rate of oral mucosal symptoms, and higher numbers of Candida.","[{'Compared': 'O'}, {'with': 'O'}, {'controls,': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'xerostomia': 'I-Entity'}, {'exhibited': 'O'}, {'significantly': 'O'}, {'decreased': 'O'}, {'whole': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rate,': 'O'}, {'increased': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'oral': 'O'}, {'mucosal': 'O'}, {'symptoms,': 'O'}, {'and': 'O'}, {'higher': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'Candida.': 'O'}]"
The use of musculoskeletal ultrasound in rheumatology clinical practice has rapidly increased over the past decade.,"[{'The': 'O'}, {'use': 'O'}, {'of': 'O'}, {'musculoskeletal': 'O'}, {'ultrasound': 'O'}, {'in': 'O'}, {'rheumatology': 'O'}, {'clinical': 'O'}, {'practice': 'O'}, {'has': 'O'}, {'rapidly': 'O'}, {'increased': 'O'}, {'over': 'O'}, {'the': 'O'}, {'past': 'O'}, {'decade.': 'O'}]"
"The comorbid diseases of head and neck region including rhinosinusitis, allergic rhinitis, and lymphadenopathy were commonly seen, which could occur more early than enlargement of major salivary glands.","[{'The': 'O'}, {'comorbid': 'O'}, {'diseases': 'O'}, {'of': 'O'}, {'head': 'O'}, {'and': 'O'}, {'neck': 'O'}, {'region': 'O'}, {'including': 'O'}, {'rhinosinusitis,': 'I-Entity'}, {'allergic': 'B-Entity'}, {'rhinitis,': 'I-Entity'}, {'and': 'O'}, {'lymphadenopathy': 'I-Entity'}, {'were': 'O'}, {'commonly': 'O'}, {'seen,': 'O'}, {'which': 'O'}, {'could': 'O'}, {'occur': 'O'}, {'more': 'O'}, {'early': 'O'}, {'than': 'O'}, {'enlargement': 'O'}, {'of': 'O'}, {'major': 'O'}, {'salivary': 'O'}, {'glands.': 'O'}]"
Fifty-one percent of pSS-ILD patients presented with non-sicca onset.,"[{'Fifty-one': 'O'}, {'percent': 'O'}, {'of': 'O'}, {'pSS-ILD': 'O'}, {'patients': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'non-sicca': 'O'}, {'onset.': 'O'}]"
Psychosis is more common in autoimmune disease than previously known.,"[{'Psychosis': 'I-Entity'}, {'is': 'O'}, {'more': 'O'}, {'common': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'than': 'O'}, {'previously': 'O'}, {'known.': 'O'}]"
Saccharomyces cerevisiae is a common yeast used in the food industry.,"[{'Saccharomyces': 'B-Entity'}, {'cerevisiae': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'common': 'O'}, {'yeast': 'O'}, {'used': 'O'}, {'in': 'O'}, {'the': 'O'}, {'food': 'O'}, {'industry.': 'O'}]"
"Female patients, low educational attainment, manual professions, non-workers and diabetes were associated with NP (p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.05).","[{'Female': 'O'}, {'patients,': 'O'}, {'low': 'O'}, {'educational': 'O'}, {'attainment,': 'O'}, {'manual': 'O'}, {'professions,': 'O'}, {'non-workers': 'O'}, {'and': 'O'}, {'diabetes': 'I-Entity'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'NP': 'I-Entity'}, {'(p‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.05).': 'O'}]"
Biopsies of major salivary glands from both cases demonstrated salivary gland tumors and existence of inflammation consistent with Sjogren's syndrome.,"[{'Biopsies': 'O'}, {'of': 'O'}, {'major': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'both': 'O'}, {'cases': 'O'}, {'demonstrated': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'tumors': 'I-Entity'}, {'and': 'O'}, {'existence': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'consistent': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"SGUS may be a useful imaging modality for the selection of patients with more severe disease status or who may require a tight follow-up schedule.inanc.nevsun@gmail.com.Istanbul, Turkey.","[{'SGUS': 'O'}, {'may': 'O'}, {'be': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'imaging': 'O'}, {'modality': 'O'}, {'for': 'O'}, {'the': 'O'}, {'selection': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'disease': 'O'}, {'status': 'O'}, {'or': 'O'}, {'who': 'O'}, {'may': 'O'}, {'require': 'O'}, {'a': 'O'}, {'tight': 'O'}, {'follow-up': 'O'}, {'schedule.inanc.nevsun@gmail.com.Istanbul,': 'O'}, {'Turkey.': 'O'}]"
Resilience in patients with autoimmune rheumatic diseases is a continuum process influenced by age and socioeconomic status.,"[{'Resilience': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'continuum': 'O'}, {'process': 'O'}, {'influenced': 'O'}, {'by': 'O'}, {'age': 'O'}, {'and': 'O'}, {'socioeconomic': 'O'}, {'status.': 'O'}]"
The latter when combined with widespread dysfunctional symptoms is defined fibromyalgia.,"[{'The': 'O'}, {'latter': 'O'}, {'when': 'O'}, {'combined': 'O'}, {'with': 'O'}, {'widespread': 'O'}, {'dysfunctional': 'O'}, {'symptoms': 'O'}, {'is': 'O'}, {'defined': 'O'}, {'fibromyalgia.': 'I-Entity'}]"
Pneumatosis cystoides intestinalis (PCI) is a rare life-threatening gastrointestinal complication in the course of connective tissue disease (CTD).,"[{'Pneumatosis': 'B-Entity'}, {'cystoides': 'I-Entity'}, {'intestinalis': 'I-Entity'}, {'(PCI)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'life-threatening': 'O'}, {'gastrointestinal': 'B-Entity'}, {'complication': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'(CTD).': 'O'}]"
"It is important to recognize the different specific cutaneous lesions in SLE (e.g., ""butterfly"" rash in acute, annular or psoriasiform photosensitive lesions in the subacute form, and discoid lesions in the chronic form) for an early diagnosis and to estimate the associated risks of internal disease, whereas nonspecific lesions (exanthema, vasculitis, and alopecia) can be part of SLE flares.","[{'It': 'O'}, {'is': 'O'}, {'important': 'O'}, {'to': 'O'}, {'recognize': 'O'}, {'the': 'O'}, {'different': 'O'}, {'specific': 'O'}, {'cutaneous': 'O'}, {'lesions': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'(e.g.,': 'O'}, {'""butterfly""': 'O'}, {'rash': 'I-Entity'}, {'in': 'O'}, {'acute,': 'O'}, {'annular': 'O'}, {'or': 'O'}, {'psoriasiform': 'I-Entity'}, {'photosensitive': 'O'}, {'lesions': 'O'}, {'in': 'O'}, {'the': 'O'}, {'subacute': 'O'}, {'form,': 'O'}, {'and': 'O'}, {'discoid': 'B-Entity'}, {'lesions': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'chronic': 'O'}, {'form)': 'O'}, {'for': 'O'}, {'an': 'O'}, {'early': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'to': 'O'}]"
This study was set to investigate whether serum markers of lymphocytic activity are associated with patient-reported outcomes in Sjogrens syndrome (SS).,"[{'This': 'O'}, {'study': 'O'}, {'was': 'O'}, {'set': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'serum': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'lymphocytic': 'O'}, {'activity': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'patient-reported': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"Several factors, including clinical manifestations and laboratory data, have been used to evaluate the disease activity of Sjogrens syndrome (SS).","[{'Several': 'O'}, {'factors,': 'O'}, {'including': 'O'}, {'clinical': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'data,': 'O'}, {'have': 'O'}, {'been': 'O'}, {'used': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
Sixteen patients (64%) had present or past history of hypokalemic paralysis.,"[{'Sixteen': 'O'}, {'patients': 'O'}, {'(64%)': 'O'}, {'had': 'O'}, {'present': 'O'}, {'or': 'O'}, {'past': 'O'}, {'history': 'O'}, {'of': 'O'}, {'hypokalemic': 'I-Entity'}, {'paralysis.': 'I-Entity'}]"
There was increased variability attributable to error in repeated measurements in patients with SS and patients with blepharitis compared with control participants.,"[{'There': 'O'}, {'was': 'O'}, {'increased': 'O'}, {'variability': 'O'}, {'attributable': 'O'}, {'to': 'O'}, {'error': 'O'}, {'in': 'O'}, {'repeated': 'O'}, {'measurements': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'and': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'blepharitis': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'control': 'O'}, {'participants.': 'O'}]"
"A total of 160 cases were included, and 141 cases (88.1%) fulfilled the criterion of disease duration of >6 months, 157 cases (98.1%) the criterion of the clinical symptoms of abdominal pain and/or bloating and 154 cases (96.2%) fulfilled the criterion of imaging findings.","[{'A': 'O'}, {'total': 'O'}, {'of': 'O'}, {'160': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'included,': 'O'}, {'and': 'O'}, {'141': 'O'}, {'cases': 'O'}, {'(88.1%)': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}, {'criterion': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'>6': 'O'}, {'months,': 'O'}, {'157': 'O'}, {'cases': 'O'}, {'(98.1%)': 'O'}, {'the': 'O'}, {'criterion': 'O'}, {'of': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'abdominal': 'B-Entity'}, {'pain': 'I-Entity'}, {'and/or': 'O'}, {'bloating': 'I-Entity'}, {'and': 'O'}, {'154': 'O'}, {'cases': 'O'}, {'(96.2%)': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}]"
On further evaluation she was diagnosed to have type 1 renal tubular acidosis secondary to Sjogren's syndrome.,"[{'On': 'O'}, {'further': 'O'}, {'evaluation': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'to': 'O'}, {'have': 'O'}, {'type': 'O'}, {'1': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"We concluded that OD may be associated with infiltration by IgG4-positive cells.Sapporo, Japan.","[{'We': 'O'}, {'concluded': 'O'}, {'that': 'O'}, {'OD': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'infiltration': 'O'}, {'by': 'O'}, {'IgG4-positive': 'O'}, {'cells.Sapporo,': 'O'}, {'Japan.': 'O'}]"
"She eventually reported dry eyes and dry mouth, and she was diagnosed with Sjogren's syndrome.","[{'She': 'O'}, {'eventually': 'O'}, {'reported': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'and': 'O'}, {'she': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"In the migraine group, the mean for the ocular surface disease index scoring was 36.27¬¨¬®¬¨¬±17.54.","[{'In': 'O'}, {'the': 'O'}, {'migraine': 'I-Entity'}, {'group,': 'O'}, {'the': 'O'}, {'mean': 'O'}, {'for': 'O'}, {'the': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'disease': 'I-Entity'}, {'index': 'O'}, {'scoring': 'O'}, {'was': 'O'}, {'36.27¬¨¬®¬¨¬±17.54.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a chronic autoimmune disease mainly characterised by the inflammation of exocrine glands; however, a broad spectrum of systemic manifestations may characterise the disease.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'mainly': 'O'}, {'characterised': 'O'}, {'by': 'O'}, {'the': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'exocrine': 'O'}, {'glands;': 'O'}, {'however,': 'O'}, {'a': 'O'}, {'broad': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'manifestations': 'O'}, {'may': 'O'}, {'characterise': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
One of the 2 patients with a negative C1q assay experienced persistent cholestasis and early and recurrent acute rejection; the other had an unremarkable outcome.,"[{'One': 'O'}, {'of': 'O'}, {'the': 'O'}, {'2': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'negative': 'O'}, {'C1q': 'O'}, {'assay': 'O'}, {'experienced': 'O'}, {'persistent': 'O'}, {'cholestasis': 'I-Entity'}, {'and': 'O'}, {'early': 'O'}, {'and': 'O'}, {'recurrent': 'O'}, {'acute': 'O'}, {'rejection;': 'O'}, {'the': 'O'}, {'other': 'O'}, {'had': 'O'}, {'an': 'O'}, {'unremarkable': 'O'}, {'outcome.': 'O'}]"
"Besides ocular adnexal lymphomas, C psittaci infection is associated with nongastrointestinal MALT lymphomas and autoimmune precursor lesions, suggesting possible involvement of C psittaci-induced antigenic-driven MALT lymphomagenesis.promotes autoantibody production.","[{'Besides': 'O'}, {'ocular': 'B-Entity'}, {'adnexal': 'I-Entity'}, {'lymphomas,': 'I-Entity'}, {'C': 'B-Entity'}, {'psittaci': 'I-Entity'}, {'infection': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'nongastrointestinal': 'O'}, {'MALT': 'B-Entity'}, {'lymphomas': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'precursor': 'O'}, {'lesions,': 'O'}, {'suggesting': 'O'}, {'possible': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'C': 'B-Entity'}, {'psittaci-induced': 'I-Entity'}, {'antigenic-driven': 'O'}, {'MALT': 'O'}, {'lymphomagenesis.promotes': 'I-Entity'}]"
HIGHLIGHTS: ‚Äö√Ñ√∂‚àö√ë¬¨¬¢Anti-Ro/SS-A and anti-La/SS-B are clinically very relevant during pregnancy mainly because of their association to congenital heart block and neonatal lupus.,"[{'HIGHLIGHTS:': 'O'}, {'‚Äö√Ñ√∂‚àö√ë¬¨¬¢Anti-Ro/SS-A': 'O'}, {'and': 'O'}, {'anti-La/SS-B': 'O'}, {'are': 'O'}, {'clinically': 'O'}, {'very': 'O'}, {'relevant': 'O'}, {'during': 'O'}, {'pregnancy': 'O'}, {'mainly': 'O'}, {'because': 'O'}, {'of': 'O'}, {'their': 'O'}, {'association': 'O'}, {'to': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block': 'I-Entity'}, {'and': 'O'}, {'neonatal': 'O'}]"
A single rheumatologist attributed the indication and cause of withdrawal of glucocorticoids and immunosuppressors.,"[{'A': 'O'}, {'single': 'O'}, {'rheumatologist': 'O'}, {'attributed': 'O'}, {'the': 'O'}, {'indication': 'O'}, {'and': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'withdrawal': 'O'}, {'of': 'O'}, {'glucocorticoids': 'O'}, {'and': 'O'}, {'immunosuppressors.': 'O'}]"
"SLE was finally diagnosed based on bilateral lower limb skin rash, gonarthritis and omarthritis, low level of complement, antinuclear antibody 1:640 and positive antibodies to double-stranded DNA.","[{'SLE': 'I-Entity'}, {'was': 'O'}, {'finally': 'O'}, {'diagnosed': 'O'}, {'based': 'O'}, {'on': 'O'}, {'bilateral': 'O'}, {'lower': 'O'}, {'limb': 'O'}, {'skin': 'B-Entity'}, {'rash,': 'I-Entity'}, {'gonarthritis': 'I-Entity'}, {'and': 'O'}, {'omarthritis,': 'I-Entity'}, {'low': 'O'}, {'level': 'O'}, {'of': 'O'}, {'complement,': 'O'}, {'antinuclear': 'O'}, {'antibody': 'O'}, {'1:640': 'O'}, {'and': 'O'}, {'positive': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'double-stranded': 'O'}, {'DNA.': 'O'}]"
"A recent study of pSS-associated MALT lymphomas identified potential functional abnormalities in the TNFAIP3 gene, which encodes protein A20.","[{'A': 'O'}, {'recent': 'O'}, {'study': 'O'}, {'of': 'O'}, {'pSS-associated': 'O'}, {'MALT': 'B-Entity'}, {'lymphomas': 'I-Entity'}, {'identified': 'O'}, {'potential': 'O'}, {'functional': 'O'}, {'abnormalities': 'O'}, {'in': 'O'}, {'the': 'O'}, {'TNFAIP3': 'O'}, {'gene,': 'O'}, {'which': 'O'}, {'encodes': 'O'}, {'protein': 'O'}, {'A20.': 'O'}]"
"Finally, large propensity cohort population based studies suggested that systemic autoimmune diseases are more frequent in patients suffering from migraine.","[{'Finally,': 'O'}, {'large': 'O'}, {'propensity': 'O'}, {'cohort': 'O'}, {'population': 'O'}, {'based': 'O'}, {'studies': 'O'}, {'suggested': 'O'}, {'that': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'migraine.': 'I-Entity'}]"
"Risk factors, treatment, and long-term outcomes were evaluated.","[{'Risk': 'O'}, {'factors,': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'long-term': 'O'}, {'outcomes': 'O'}, {'were': 'O'}, {'evaluated.': 'O'}]"
"Health care has become increasingly fragmented, partly due to advancing medical technology.","[{'Health': 'O'}, {'care': 'O'}, {'has': 'O'}, {'become': 'O'}, {'increasingly': 'O'}, {'fragmented,': 'O'}, {'partly': 'O'}, {'due': 'O'}, {'to': 'O'}, {'advancing': 'O'}, {'medical': 'O'}, {'technology.': 'O'}]"
The pathogenesis of many of these disorders affects the microvasculature in these organs.,"[{'The': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'many': 'O'}, {'of': 'O'}, {'these': 'O'}, {'disorders': 'O'}, {'affects': 'O'}, {'the': 'O'}, {'microvasculature': 'O'}, {'in': 'O'}, {'these': 'O'}, {'organs.': 'O'}]"
"After treatment of glucocorticoids and hydroxychloroquine for ten months, her dyspnea symptoms were obviously improved in the patient, and the rheumatoid factor had become negative while her erythrocyte sedimentation rate normal.","[{'After': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'glucocorticoids': 'O'}, {'and': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'for': 'O'}, {'ten': 'O'}, {'months,': 'O'}, {'her': 'O'}, {'dyspnea': 'I-Entity'}, {'symptoms': 'O'}, {'were': 'O'}, {'obviously': 'O'}, {'improved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'patient,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'had': 'O'}, {'become': 'O'}, {'negative': 'O'}, {'while': 'O'}, {'her': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate': 'O'}, {'normal.': 'O'}]"
"Visual prognosis of the patients with secondary Sjogren syndrome depends on the early diagnosis, applied therapy follow-up controls along with an effective collaboration between ophthalmologist and rheumatologist.","[{'Visual': 'O'}, {'prognosis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'secondary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'depends': 'O'}, {'on': 'O'}, {'the': 'O'}, {'early': 'O'}, {'diagnosis,': 'O'}, {'applied': 'O'}, {'therapy': 'O'}, {'follow-up': 'O'}, {'controls': 'O'}, {'along': 'O'}, {'with': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'collaboration': 'O'}, {'between': 'O'}, {'ophthalmologist': 'O'}, {'and': 'O'}, {'rheumatologist.': 'O'}]"
"A review of systems was positive for dry mouth and transient arthralgia, while laboratory and instrumental tests enabled us to make the diagnosis of primary Sjogrens syndrome (pSS).","[{'A': 'O'}, {'review': 'O'}, {'of': 'O'}, {'systems': 'O'}, {'was': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'transient': 'B-Entity'}, {'arthralgia,': 'I-Entity'}, {'while': 'O'}, {'laboratory': 'O'}, {'and': 'O'}, {'instrumental': 'O'}, {'tests': 'O'}, {'enabled': 'O'}, {'us': 'O'}, {'to': 'O'}, {'make': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
The MBL pathway of complement activation was potentially involved in pSS-related MN.,"[{'The': 'O'}, {'MBL': 'O'}, {'pathway': 'O'}, {'of': 'O'}, {'complement': 'O'}, {'activation': 'O'}, {'was': 'O'}, {'potentially': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'pSS-related': 'I-Entity'}, {'MN.': 'I-Entity'}]"
"According to the literature, the use of biologic agents in patients with oral diseases is limited mainly to patients suffering from refractory forms of immune-mediated diseases of the oral cavity.","[{'According': 'O'}, {'to': 'O'}, {'the': 'O'}, {'literature,': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'biologic': 'O'}, {'agents': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'oral': 'B-Entity'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'limited': 'O'}, {'mainly': 'O'}, {'to': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'refractory': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'immune-mediated': 'B-Entity'}, {'diseases': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'oral': 'I-Entity'}, {'cavity.': 'I-Entity'}]"
Primary SS may have variable manifestations in the central nervous system which may precede the classic sicca symptoms.,"[{'Primary': 'O'}, {'SS': 'I-Entity'}, {'may': 'O'}, {'have': 'O'}, {'variable': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'the': 'O'}, {'central': 'O'}, {'nervous': 'O'}, {'system': 'O'}, {'which': 'O'}, {'may': 'O'}, {'precede': 'O'}, {'the': 'O'}, {'classic': 'O'}, {'sicca': 'B-Entity'}, {'symptoms.': 'O'}]"
"Patients with moderate and high ESSDAI and SSDAI scores had significantly higher US activity in comparison to that of pSS patients with low disease activity (p = 0.006; p = 0.01, respectively).","[{'Patients': 'O'}, {'with': 'O'}, {'moderate': 'O'}, {'and': 'O'}, {'high': 'O'}, {'ESSDAI': 'O'}, {'and': 'O'}, {'SSDAI': 'O'}, {'scores': 'O'}, {'had': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'US': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'to': 'O'}, {'that': 'O'}, {'of': 'O'}, {'pSS': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'low': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'(p': 'O'}, {'=': 'O'}, {'0.006;': 'O'}, {'p': 'O'}, {'=': 'O'}, {'0.01,': 'O'}, {'respectively).': 'O'}]"
The purpose of the study is to investigate the effect of CQ on the development of dry eye in NOD-LtJ mice.,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'is': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'CQ': 'I-Entity'}, {'on': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'in': 'O'}, {'NOD-LtJ': 'O'}, {'mice.': 'O'}]"
Anti-Ro52 antibodies were detected by a semiquantitative ELISA.,"[{'Anti-Ro52': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'by': 'O'}, {'a': 'O'}, {'semiquantitative': 'O'}, {'ELISA.': 'O'}]"
"In an effort to identify novel potential epigenetic markers that could prove useful in diagnosis and disease monitoring, we explored whether DNA methylation differences can also be detected in saliva from SS patients compared to sicca controls.","[{'In': 'O'}, {'an': 'O'}, {'effort': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'novel': 'O'}, {'potential': 'O'}, {'epigenetic': 'O'}, {'markers': 'O'}, {'that': 'O'}, {'could': 'O'}, {'prove': 'O'}, {'useful': 'O'}, {'in': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'monitoring,': 'O'}, {'we': 'O'}, {'explored': 'O'}, {'whether': 'O'}, {'DNA': 'O'}, {'methylation': 'O'}, {'differences': 'O'}, {'can': 'O'}, {'also': 'O'}, {'be': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'sicca': 'I-Entity'}, {'controls.': 'O'}]"
"Interleukin 12 receptor beta 1 (IL12R‚âà√≠‚Äö√¢¬ß1) deficiency is a primary immunodeficiency resulting mainly in susceptibility to opportunistic infection by non-tuberculous, environmental mycobacteria and severe infection caused by Salmonella spp.","[{'Interleukin': 'O'}, {'12': 'O'}, {'receptor': 'O'}, {'beta': 'O'}, {'1': 'O'}, {'(IL12R‚âà√≠‚Äö√¢¬ß1)': 'O'}, {'deficiency': 'O'}, {'is': 'O'}, {'a': 'O'}, {'primary': 'B-Entity'}, {'immunodeficiency': 'I-Entity'}, {'resulting': 'O'}, {'mainly': 'O'}, {'in': 'O'}, {'susceptibility': 'O'}, {'to': 'O'}, {'opportunistic': 'B-Entity'}, {'infection': 'I-Entity'}, {'by': 'O'}, {'non-tuberculous,': 'O'}, {'environmental': 'O'}, {'mycobacteria': 'I-Entity'}]"
"Disseminated MAC with skin lesions may occur, and several presentations have been reported, including panniculitis, cutaneous granulomas, pustules, ulcerations, and erythematous skin lesions.","[{'Disseminated': 'O'}, {'MAC': 'I-Entity'}, {'with': 'O'}, {'skin': 'O'}, {'lesions': 'O'}, {'may': 'O'}, {'occur,': 'O'}, {'and': 'O'}, {'several': 'O'}, {'presentations': 'O'}, {'have': 'O'}, {'been': 'O'}, {'reported,': 'O'}, {'including': 'O'}, {'panniculitis,': 'I-Entity'}, {'cutaneous': 'O'}, {'granulomas,': 'I-Entity'}, {'pustules,': 'I-Entity'}, {'ulcerations,': 'O'}, {'and': 'O'}, {'erythematous': 'O'}, {'skin': 'O'}, {'lesions.': 'O'}]"
To investigate the association between visual function and ocular surface regularity in dry eye.,"[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'visual': 'O'}, {'function': 'O'}, {'and': 'O'}, {'ocular': 'O'}, {'surface': 'O'}, {'regularity': 'O'}, {'in': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"The serum levels of 25-hydroxyvitamin D and 1,25-dihydroxy vitamin D were low and borderline low, respectively, and the parathyroid hormone level was 70 pg/L.","[{'The': 'O'}, {'serum': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'25-hydroxyvitamin': 'B-Entity'}, {'D': 'I-Entity'}, {'and': 'O'}, {'1,25-dihydroxy': 'B-Entity'}, {'vitamin': 'I-Entity'}, {'D': 'I-Entity'}, {'were': 'O'}, {'low': 'O'}, {'and': 'O'}, {'borderline': 'O'}, {'low,': 'O'}, {'respectively,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'parathyroid': 'O'}, {'hormone': 'O'}, {'level': 'O'}, {'was': 'O'}, {'70': 'O'}, {'pg/L.': 'O'}]"
"No significant differences by smoking status were found regarding ESSDAI total score, activity in the ESSDAI domains or type I IFN signature.","[{'No': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'by': 'O'}, {'smoking': 'I-Entity'}, {'status': 'O'}, {'were': 'O'}, {'found': 'O'}, {'regarding': 'O'}, {'ESSDAI': 'O'}, {'total': 'O'}, {'score,': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'the': 'O'}, {'ESSDAI': 'O'}, {'domains': 'O'}, {'or': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'signature.': 'O'}]"
"In idiopathic inflammatory myopathies, the presence of anti-Jo-1 antibody defines a distinct clinical phenotype (myositis, arthritis, interstitial lung disease, Raynaud's phenomenon fever, mechanic's hands), called antisynthetase syndrome.","[{'In': 'O'}, {'idiopathic': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'myopathies,': 'I-Entity'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-Jo-1': 'O'}, {'antibody': 'O'}, {'defines': 'O'}, {'a': 'O'}, {'distinct': 'O'}, {'clinical': 'O'}, {'phenotype': 'O'}, {'(myositis,': 'O'}, {'arthritis,': 'I-Entity'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease,': 'I-Entity'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'fever,': 'I-Entity'}, {""mechanic's"": 'B-Entity'}, {'hands),': 'I-Entity'}, {'called': 'O'}, {'antisynthetase': 'O'}]"
"It can remain asymptomatic or manifest with metabolic abnormalities including hypokalemia paralysis, hypocalcaemia and hyperchloremic metabolic acidosis.","[{'It': 'O'}, {'can': 'O'}, {'remain': 'O'}, {'asymptomatic': 'O'}, {'or': 'O'}, {'manifest': 'O'}, {'with': 'O'}, {'metabolic': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'including': 'O'}, {'hypokalemia': 'I-Entity'}, {'paralysis,': 'I-Entity'}, {'hypocalcaemia': 'I-Entity'}, {'and': 'O'}, {'hyperchloremic': 'I-Entity'}, {'metabolic': 'B-Entity'}, {'acidosis.': 'I-Entity'}]"
Pregnancy occurs later in life in pSS women.,"[{'Pregnancy': 'O'}, {'occurs': 'O'}, {'later': 'O'}, {'in': 'O'}, {'life': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'women.': 'O'}]"
"In addition, the expansion of ‚âà√≠¬¨¬±‚âà√≠‚Äö√¢¬ß-TCR(+) DN T cells was associated with disease activity.","[{'In': 'O'}, {'addition,': 'O'}, {'the': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'‚âà√≠¬¨¬±‚âà√≠‚Äö√¢¬ß-TCR(+)': 'O'}, {'DN': 'I-Entity'}, {'T': 'O'}, {'cells': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
In these patients 2 (4%) fulfilled AECG criteria without anti-Ro52/60 antibodies vs 4 (8%) patients if anti-Ro52/60 antibodies were included.,"[{'In': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'2': 'O'}, {'(4%)': 'O'}, {'fulfilled': 'O'}, {'AECG': 'O'}, {'criteria': 'O'}, {'without': 'O'}, {'anti-Ro52/60': 'O'}, {'antibodies': 'O'}, {'vs': 'O'}, {'4': 'O'}, {'(8%)': 'O'}, {'patients': 'O'}, {'if': 'O'}, {'anti-Ro52/60': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'included.': 'O'}]"
"Swollen eyelids are commonly ascribed to allergic conjunctivitis, contact dermatitis, eczema, angioedema, or acute sinusitis.","[{'Swollen': 'O'}, {'eyelids': 'O'}, {'are': 'O'}, {'commonly': 'O'}, {'ascribed': 'O'}, {'to': 'O'}, {'allergic': 'B-Entity'}, {'conjunctivitis,': 'I-Entity'}, {'contact': 'B-Entity'}, {'dermatitis,': 'I-Entity'}, {'eczema,': 'I-Entity'}, {'angioedema,': 'I-Entity'}, {'or': 'O'}, {'acute': 'B-Entity'}, {'sinusitis.': 'I-Entity'}]"
"Hypophosphatemic osteomalacia (HO) is a metabolic bone disease, exhibiting different etiologies such as genetic mutation, tumor induction, dysimmunity, or renal disease.","[{'Hypophosphatemic': 'B-Entity'}, {'osteomalacia': 'I-Entity'}, {'(HO)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'metabolic': 'B-Entity'}, {'bone': 'B-Entity'}, {'disease,': 'I-Entity'}, {'exhibiting': 'O'}, {'different': 'O'}, {'etiologies': 'O'}, {'such': 'O'}, {'as': 'O'}, {'genetic': 'O'}, {'mutation,': 'O'}, {'tumor': 'I-Entity'}, {'induction,': 'O'}, {'dysimmunity,': 'I-Entity'}, {'or': 'O'}, {'renal': 'B-Entity'}, {'disease.': 'I-Entity'}]"
She was treated with intravenous methylprednisolone and discharged on oral steroid therapy of prednisolone acetate.,"[{'She': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'intravenous': 'O'}, {'methylprednisolone': 'I-Entity'}, {'and': 'O'}, {'discharged': 'O'}, {'on': 'O'}, {'oral': 'O'}, {'steroid': 'I-Entity'}, {'therapy': 'O'}, {'of': 'O'}, {'prednisolone': 'B-Entity'}, {'acetate.': 'I-Entity'}]"
"The presence of anti-MDM2 autoantibody in pSS patients was 21.0%, significantly higher than normal controls (5.40%).","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-MDM2': 'O'}, {'autoantibody': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'was': 'O'}, {'21.0%,': 'O'}, {'significantly': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'normal': 'O'}, {'controls': 'O'}, {'(5.40%).': 'O'}]"
"An attempt to separate patients with and without pSS without using MSGB findings or via clinical re-evaluation was made in only two studies, in 73 and 120 patients, respectively, with sicca syndrome in the first study and suspected pSS in the other.","[{'An': 'O'}, {'attempt': 'O'}, {'to': 'O'}, {'separate': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'pSS': 'I-Entity'}, {'without': 'O'}, {'using': 'O'}, {'MSGB': 'O'}, {'findings': 'O'}, {'or': 'O'}, {'via': 'O'}, {'clinical': 'O'}, {'re-evaluation': 'O'}, {'was': 'O'}, {'made': 'O'}, {'in': 'O'}, {'only': 'O'}, {'two': 'O'}, {'studies,': 'O'}, {'in': 'O'}, {'73': 'O'}, {'and': 'O'}, {'120': 'O'}, {'patients,': 'O'}, {'respectively,': 'O'}, {'with': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'first': 'O'}, {'study': 'O'}, {'and': 'O'}, {'suspected': 'O'}, {'pSS': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'other.': 'O'}]"
"As fat deposition seems to be more recurrent in SGs affected by SS, we propose the assessment of adipose tissue replacement as a helpful tool for diagnostic evaluation in SS.","[{'As': 'O'}, {'fat': 'O'}, {'deposition': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'more': 'O'}, {'recurrent': 'O'}, {'in': 'O'}, {'SGs': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'SS,': 'I-Entity'}, {'we': 'O'}, {'propose': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'adipose': 'O'}, {'tissue': 'O'}, {'replacement': 'O'}, {'as': 'O'}, {'a': 'O'}, {'helpful': 'O'}, {'tool': 'O'}, {'for': 'O'}, {'diagnostic': 'O'}, {'evaluation': 'O'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
To assess the association between salivary ultrasonography (sUS) findings and disease activity and damage in patients with primary Sjogren's syndrome (pSS).,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'association': 'O'}, {'between': 'O'}, {'salivary': 'O'}, {'ultrasonography': 'O'}, {'(sUS)': 'O'}, {'findings': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'damage': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Two chemokines involved in immune cell trafficking to secondary lymphoid tissue, CCR7 and CCL21, showed markedly increased expression and may contribute to the recruitment of diverse immune cells to the salivary glands, causing inflammation and loss of secretory function.Dental and Craniofacial Research, Bethesda, MD; Dept.of Microbiology & Immunology, Jefferson College of Biomedical Sciences, T.Jefferson University, Philadelphia, PA, USA.Health, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA.Research, Bethesda, MD, USA.Thomas Jefferson University, Philadelphia, PA, USA.Health, National Institute of Dental and Craniofacial Research, Bethesda, MD, USA.","[{'Two': 'O'}, {'chemokines': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'immune': 'O'}, {'cell': 'O'}, {'trafficking': 'O'}, {'to': 'O'}, {'secondary': 'O'}, {'lymphoid': 'O'}, {'tissue,': 'O'}, {'CCR7': 'O'}, {'and': 'O'}, {'CCL21,': 'O'}, {'showed': 'O'}, {'markedly': 'O'}, {'increased': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'the': 'O'}, {'recruitment': 'O'}, {'of': 'O'}, {'diverse': 'O'}, {'immune': 'O'}, {'cells': 'O'}, {'to': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'causing': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'secretory': 'I-Entity'}, {'function.Dental': 'I-Entity'}, {'and': 'O'}, {'Craniofacial': 'O'}]"
This is of great importance in identifying and understanding the causes of immune mediated polyneuropathy.Germany.Germany.Revealing a Rare Association With Primary Gastric Adenocarcinoma.,"[{'This': 'O'}, {'is': 'O'}, {'of': 'O'}, {'great': 'O'}, {'importance': 'O'}, {'in': 'O'}, {'identifying': 'O'}, {'and': 'O'}, {'understanding': 'O'}, {'the': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'immune': 'O'}, {'mediated': 'O'}, {'polyneuropathy.Germany.Germany.Revealing': 'I-Entity'}, {'a': 'O'}, {'Rare': 'O'}, {'Association': 'O'}, {'With': 'O'}, {'Primary': 'B-Entity'}, {'Gastric': 'B-Entity'}, {'Adenocarcinoma.': 'I-Entity'}]"
We report the case of a 35-year-old woman presented to us with persistent unexplained bicytopenia (anemia and thrombocytopenia).,"[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'35-year-old': 'O'}, {'woman': 'O'}, {'presented': 'O'}, {'to': 'O'}, {'us': 'O'}, {'with': 'O'}, {'persistent': 'O'}, {'unexplained': 'O'}, {'bicytopenia': 'I-Entity'}, {'(anemia': 'O'}, {'and': 'O'}, {'thrombocytopenia).': 'I-Entity'}]"
"Higher age, dry mouth, and higher labial gland biopsy focus scores (‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢4) were risk factors for airway diseases (odds ratio [OR] 1.064 confidence interval [CI] 1.026-1.102, OR 8.795 CI 2.317-33.378 and OR 3.261 CI 1.100-9.675, respectively) in the multivariable analysis.","[{'Higher': 'O'}, {'age,': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'and': 'O'}, {'higher': 'O'}, {'labial': 'O'}, {'gland': 'O'}, {'biopsy': 'O'}, {'focus': 'O'}, {'scores': 'O'}, {'(‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢4)': 'O'}, {'were': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'airway': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(odds': 'O'}, {'ratio': 'O'}, {'[OR]': 'O'}, {'1.064': 'O'}, {'confidence': 'O'}, {'interval': 'O'}, {'[CI]': 'O'}, {'1.026-1.102,': 'O'}]"
"Intravenous GC boluses followed by oral GCs and/or, in case of recurrence, intravenous cyclophosphamide and/or rituximab are commonly employed.","[{'Intravenous': 'O'}, {'GC': 'I-Entity'}, {'boluses': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'GCs': 'I-Entity'}, {'and/or,': 'O'}, {'in': 'O'}, {'case': 'O'}, {'of': 'O'}, {'recurrence,': 'O'}, {'intravenous': 'O'}, {'cyclophosphamide': 'I-Entity'}, {'and/or': 'O'}, {'rituximab': 'I-Entity'}, {'are': 'O'}, {'commonly': 'O'}, {'employed.': 'O'}]"
"Distinguishing between DRG versus axonal injury is significant, especially given that mechanisms targeting the DRG may result in irreversible neuronal cell death.","[{'Distinguishing': 'O'}, {'between': 'O'}, {'DRG': 'O'}, {'versus': 'O'}, {'axonal': 'B-Entity'}, {'injury': 'I-Entity'}, {'is': 'O'}, {'significant,': 'O'}, {'especially': 'O'}, {'given': 'O'}, {'that': 'O'}, {'mechanisms': 'O'}, {'targeting': 'O'}, {'the': 'O'}, {'DRG': 'O'}, {'may': 'O'}, {'result': 'O'}, {'in': 'O'}, {'irreversible': 'O'}, {'neuronal': 'O'}, {'cell': 'I-Entity'}, {'death.': 'I-Entity'}]"
"CASE: A thirty two-year-old woman was hospitalized for abnormal abdominal symptoms, and was diagnosed as having paralytic ileus.","[{'CASE:': 'O'}, {'A': 'O'}, {'thirty': 'O'}, {'two-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'hospitalized': 'O'}, {'for': 'O'}, {'abnormal': 'O'}, {'abdominal': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'having': 'O'}, {'paralytic': 'B-Entity'}, {'ileus.': 'I-Entity'}]"
Dependence on invasive procedures for classification of patients with Sjogrens syndrome (SS) hampers timely diagnosis and suitable patient followup.,"[{'Dependence': 'O'}, {'on': 'O'}, {'invasive': 'O'}, {'procedures': 'O'}, {'for': 'O'}, {'classification': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'hampers': 'O'}, {'timely': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'suitable': 'O'}, {'patient': 'O'}, {'followup.': 'O'}]"
To report on fatigue in patients from the United Kingdom primary Sjogrens syndrome (pSS) registry identifying factors associated with fatigue and robust to assignable causes such as comorbidities and medications associated with drowsiness.,"[{'To': 'O'}, {'report': 'O'}, {'on': 'O'}, {'fatigue': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'from': 'O'}, {'the': 'O'}, {'United': 'O'}, {'Kingdom': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'registry': 'O'}, {'identifying': 'O'}, {'factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'robust': 'O'}, {'to': 'O'}, {'assignable': 'O'}, {'causes': 'O'}, {'such': 'O'}, {'as': 'O'}, {'comorbidities': 'O'}, {'and': 'O'}, {'medications': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'drowsiness.': 'O'}]"
For implant-prosthetic rehabilitation of patients with Pe and sLE no conclusions can be drawn due to lack of sufficient clinical data.,"[{'For': 'O'}, {'implant-prosthetic': 'O'}, {'rehabilitation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Pe': 'I-Entity'}, {'and': 'O'}, {'sLE': 'I-Entity'}, {'no': 'O'}, {'conclusions': 'O'}, {'can': 'O'}, {'be': 'O'}, {'drawn': 'O'}, {'due': 'O'}, {'to': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'sufficient': 'O'}, {'clinical': 'O'}, {'data.': 'O'}]"
"Among the 307 RA patients, 28% had at least one sicca symptom.","[{'Among': 'O'}, {'the': 'O'}, {'307': 'O'}, {'RA': 'I-Entity'}, {'patients,': 'O'}, {'28%': 'O'}, {'had': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'sicca': 'I-Entity'}, {'symptom.': 'O'}]"
"The loss of salivary function can have far-reaching consequences, as observed with dry mouth, which is associated with increased orodental disease, speech impairment, dysphagia, and a significant negative effect on quality of life.","[{'The': 'O'}, {'loss': 'B-Entity'}, {'of': 'I-Entity'}, {'salivary': 'I-Entity'}, {'function': 'I-Entity'}, {'can': 'O'}, {'have': 'O'}, {'far-reaching': 'O'}, {'consequences,': 'O'}, {'as': 'O'}, {'observed': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'mouth,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'orodental': 'B-Entity'}, {'disease,': 'I-Entity'}, {'speech': 'B-Entity'}, {'impairment,': 'I-Entity'}, {'dysphagia,': 'I-Entity'}, {'and': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'negative': 'O'}, {'effect': 'O'}, {'on': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"Regarding the Th17/Tr1 ratios, a similar tendency was observed moreover Th17/Tr1 could distinguish between UCTD patients with, or without subsequent SAID progression in a very early UCTD stage.","[{'Regarding': 'O'}, {'the': 'O'}, {'Th17/Tr1': 'O'}, {'ratios,': 'O'}, {'a': 'O'}, {'similar': 'O'}, {'tendency': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'moreover': 'O'}, {'Th17/Tr1': 'O'}, {'could': 'O'}, {'distinguish': 'O'}, {'between': 'O'}, {'UCTD': 'I-Entity'}, {'patients': 'O'}, {'with,': 'O'}, {'or': 'O'}, {'without': 'O'}, {'subsequent': 'O'}, {'SAID': 'I-Entity'}, {'progression': 'O'}, {'in': 'O'}, {'a': 'O'}, {'very': 'O'}, {'early': 'O'}, {'UCTD': 'I-Entity'}, {'stage.': 'O'}]"
"Thus, this study underscores the poor outcome of ILD during pSS; thus, systematic screening of pulmonary involvement is required in pSS patients, resulting in both diagnosis and management at early stage of ILD.","[{'Thus,': 'O'}, {'this': 'O'}, {'study': 'O'}, {'underscores': 'O'}, {'the': 'O'}, {'poor': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'ILD': 'I-Entity'}, {'during': 'O'}, {'pSS;': 'O'}, {'thus,': 'O'}, {'systematic': 'O'}, {'screening': 'O'}, {'of': 'O'}, {'pulmonary': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'required': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'patients,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'both': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'management': 'O'}, {'at': 'O'}, {'early': 'O'}, {'stage': 'O'}, {'of': 'O'}, {'ILD.': 'I-Entity'}]"
Ten patients with negative PET results included 3 additional patients with mucosa-associated lymphoid tissue lymphoma.,"[{'Ten': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'negative': 'O'}, {'PET': 'O'}, {'results': 'O'}, {'included': 'O'}, {'3': 'O'}, {'additional': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'B-Entity'}, {'tissue': 'I-Entity'}, {'lymphoma.': 'I-Entity'}]"
"68 patients (84%) shown non-focal CNS symptoms and 64 (79%) focal CNS deficits with headache as the most common feature (46.9%), followed by cognitive (44.4%) and mood disorders (38.3%).","[{'68': 'O'}, {'patients': 'O'}, {'(84%)': 'O'}, {'shown': 'O'}, {'non-focal': 'O'}, {'CNS': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'64': 'O'}, {'(79%)': 'O'}, {'focal': 'O'}, {'CNS': 'B-Entity'}, {'deficits': 'I-Entity'}, {'with': 'O'}, {'headache': 'I-Entity'}, {'as': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'feature': 'O'}, {'(46.9%),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'cognitive': 'B-Entity'}, {'(44.4%)': 'I-Entity'}, {'and': 'I-Entity'}, {'mood': 'B-Entity'}, {'disorders': 'I-Entity'}, {'(38.3%).': 'O'}]"
"Patient-reported symptoms were recorded by visual analogue scales (VAS) of pain, fatigue, and dryness, as compiled in the EULAR SS patient-reported index (ESSPRI).","[{'Patient-reported': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'recorded': 'O'}, {'by': 'O'}, {'visual': 'O'}, {'analogue': 'O'}, {'scales': 'O'}, {'(VAS)': 'O'}, {'of': 'O'}, {'pain,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'dryness,': 'I-Entity'}, {'as': 'O'}, {'compiled': 'O'}, {'in': 'O'}, {'the': 'O'}, {'EULAR': 'O'}, {'SS': 'I-Entity'}, {'patient-reported': 'O'}, {'index': 'O'}, {'(ESSPRI).': 'O'}]"
"The article concerns a short review of the literature regarding etiology, symptoms, treatment and survival prognosis in that rare disease as well.","[{'The': 'O'}, {'article': 'O'}, {'concerns': 'O'}, {'a': 'O'}, {'short': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'regarding': 'O'}, {'etiology,': 'O'}, {'symptoms,': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'survival': 'O'}, {'prognosis': 'O'}, {'in': 'O'}, {'that': 'O'}, {'rare': 'O'}, {'disease': 'O'}, {'as': 'O'}, {'well.': 'O'}]"
"Primary Sjogrens syndrome (pSS) is a frequent autoimmune systemic disease, clinically characterized by eyes and mouth dryness in all patients, salivary gland swelling or extraglandular systemic manifestations in half of the patients, and development of lymphoma in 5 to 10 % of the patients.","[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'frequent': 'O'}, {'autoimmune': 'B-Entity'}, {'systemic': 'I-Entity'}, {'disease,': 'O'}, {'clinically': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'eyes': 'B-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'dryness': 'I-Entity'}, {'in': 'O'}, {'all': 'O'}, {'patients,': 'O'}, {'salivary': 'O'}, {'gland': 'I-Entity'}, {'swelling': 'I-Entity'}, {'or': 'O'}, {'extraglandular': 'O'}, {'systemic': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'half': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'development': 'O'}, {'of': 'O'}, {'lymphoma': 'I-Entity'}, {'in': 'O'}, {'5': 'O'}, {'to': 'O'}]"
The aim of this study was to investigate if co-morbid conditions as hepatitis C virus infection and celiac disease may be associated to undifferentiated connective tissue disease.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'if': 'O'}, {'co-morbid': 'O'}, {'conditions': 'O'}, {'as': 'O'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'virus': 'I-Entity'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'undifferentiated': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Eight of 14 patients with IN received systemic immunosuppression (IS) during renal disease course and in 6 patients no beneficial effect was observed on renal function, hypokalaemia and RTA.","[{'Eight': 'O'}, {'of': 'O'}, {'14': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IN': 'I-Entity'}, {'received': 'O'}, {'systemic': 'O'}, {'immunosuppression': 'O'}, {'(IS)': 'O'}, {'during': 'O'}, {'renal': 'B-Entity'}, {'disease': 'I-Entity'}, {'course': 'O'}, {'and': 'O'}, {'in': 'O'}, {'6': 'O'}, {'patients': 'O'}, {'no': 'O'}, {'beneficial': 'O'}, {'effect': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'on': 'O'}, {'renal': 'O'}, {'function,': 'O'}, {'hypokalaemia': 'I-Entity'}, {'and': 'O'}, {'RTA.': 'O'}]"
A positive crossmatch has been associated with increased risk in liver transplantation.,"[{'A': 'O'}, {'positive': 'O'}, {'crossmatch': 'O'}, {'has': 'O'}, {'been': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'in': 'O'}, {'liver': 'O'}, {'transplantation.': 'O'}]"
"The aim of the present study was to investigate the prevalence and pattern of cognitive dysfunction observed in primary Sjogrens syndrome (PSS) and to examine the relationships between cognitive abilities, depression, fatigue, and quality of life.","[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'and': 'O'}, {'pattern': 'O'}, {'of': 'O'}, {'cognitive': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'observed': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'relationships': 'O'}, {'between': 'O'}, {'cognitive': 'O'}, {'abilities,': 'O'}, {'depression,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'and': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"A 79-year-old woman presented with rapidly progressive renal failure and complaints of asthenia, anorexia and generalized oedema.","[{'A': 'O'}, {'79-year-old': 'O'}, {'woman': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'rapidly': 'O'}, {'progressive': 'O'}, {'renal': 'B-Entity'}, {'failure': 'I-Entity'}, {'and': 'O'}, {'complaints': 'O'}, {'of': 'O'}, {'asthenia,': 'I-Entity'}, {'anorexia': 'I-Entity'}, {'and': 'O'}, {'generalized': 'O'}, {'oedema.': 'I-Entity'}]"
"In scleroderma, positive Scl70 and capillary loss were observed more frequently in patients without mechanic hands.","[{'In': 'O'}, {'scleroderma,': 'I-Entity'}, {'positive': 'O'}, {'Scl70': 'O'}, {'and': 'O'}, {'capillary': 'O'}, {'loss': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'mechanic': 'O'}, {'hands.': 'O'}]"
"We report a unique case of Sjogrens syndrome complicated with Fanconi syndrome and Hashimoto's thyroiditis in a 53-year-old Chinese woman, initially found to have proteinuria, fatigue and multiple old costal fractures.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'unique': 'O'}, {'case': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'complicated': 'O'}, {'with': 'O'}, {'Fanconi': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'53-year-old': 'O'}, {'Chinese': 'O'}, {'woman,': 'O'}, {'initially': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'proteinuria,': 'I-Entity'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'multiple': 'O'}, {'old': 'O'}, {'costal': 'B-Entity'}, {'fractures.': 'I-Entity'}]"
SS is often overlooked when the symptoms are mild.,"[{'SS': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'overlooked': 'O'}, {'when': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'are': 'O'}, {'mild.': 'O'}]"
"A 66-year-old female patient who was complaining of ocular pain, tearing and decreased vision in her right eye for the previous two days was admitted to our hospital.","[{'A': 'O'}, {'66-year-old': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'who': 'O'}, {'was': 'O'}, {'complaining': 'O'}, {'of': 'O'}, {'ocular': 'B-Entity'}, {'pain,': 'I-Entity'}, {'tearing': 'I-Entity'}, {'and': 'O'}, {'decreased': 'B-Entity'}, {'vision': 'I-Entity'}, {'in': 'O'}, {'her': 'O'}, {'right': 'O'}, {'eye': 'O'}, {'for': 'O'}, {'the': 'O'}, {'previous': 'O'}, {'two': 'O'}, {'days': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital.': 'O'}]"
"Immunosuppression is indicated only in select cases of pulmonary arterial hypertension related to CTD; more commonly, selective pulmonary vasodilators are used.","[{'Immunosuppression': 'O'}, {'is': 'O'}, {'indicated': 'O'}, {'only': 'O'}, {'in': 'O'}, {'select': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'pulmonary': 'B-Entity'}, {'arterial': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'related': 'O'}, {'to': 'O'}, {'CTD;': 'I-Entity'}, {'more': 'O'}, {'commonly,': 'O'}, {'selective': 'O'}, {'pulmonary': 'O'}, {'vasodilators': 'O'}, {'are': 'O'}, {'used.': 'O'}]"
We sought to provide insight for the timely recognition and diagnosis of MAS and efficacious disease management in adults with rheumatic diseases.,"[{'We': 'O'}, {'sought': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'insight': 'O'}, {'for': 'O'}, {'the': 'O'}, {'timely': 'O'}, {'recognition': 'O'}, {'and': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'MAS': 'I-Entity'}, {'and': 'O'}, {'efficacious': 'O'}, {'disease': 'O'}, {'management': 'O'}, {'in': 'O'}, {'adults': 'O'}, {'with': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
Labor was induced in 21 cases (52.5%) and cesarean section rate was 45%.,"[{'Labor': 'O'}, {'was': 'O'}, {'induced': 'O'}, {'in': 'O'}, {'21': 'O'}, {'cases': 'O'}, {'(52.5%)': 'O'}, {'and': 'O'}, {'cesarean': 'O'}, {'section': 'O'}, {'rate': 'O'}, {'was': 'O'}, {'45%.': 'O'}]"
The aim of this study was to compare the rate of maternal and fetal complications between a series of anti-Ro/SS-A positive pregnant women prospectively followed.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'rate': 'O'}, {'of': 'O'}, {'maternal': 'O'}, {'and': 'I-Entity'}, {'fetal': 'I-Entity'}, {'complications': 'I-Entity'}, {'between': 'O'}, {'a': 'O'}, {'series': 'O'}, {'of': 'O'}, {'anti-Ro/SS-A': 'O'}, {'positive': 'O'}, {'pregnant': 'O'}, {'women': 'O'}, {'prospectively': 'O'}, {'followed.': 'O'}]"
"Based on this highly reliable assay, 50% of the pSS patients had antibodies which inhibited carbachol-induced activation of mAchR3; none of the SSc patients, 6% of the patients with MG and 12% of the blood donors had antibodies which reacted with the mAchR3.","[{'Based': 'O'}, {'on': 'O'}, {'this': 'O'}, {'highly': 'O'}, {'reliable': 'O'}, {'assay,': 'O'}, {'50%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'antibodies': 'O'}, {'which': 'O'}, {'inhibited': 'O'}, {'carbachol-induced': 'I-Entity'}, {'activation': 'O'}, {'of': 'O'}, {'mAchR3;': 'O'}, {'none': 'O'}, {'of': 'O'}, {'the': 'O'}, {'SSc': 'I-Entity'}, {'patients,': 'O'}, {'6%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'MG': 'I-Entity'}, {'and': 'O'}, {'12%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'blood': 'O'}, {'donors': 'O'}, {'had': 'O'}, {'antibodies': 'O'}, {'which': 'O'}, {'reacted': 'O'}, {'with': 'O'}, {'the': 'O'}, {'mAchR3.': 'O'}]"
New findings indicate that mRNAs for several chemokines and cytokines are expressed primarily in epithelial cells; certain others are expressed in both epithelial cells and immune cells.,"[{'New': 'O'}, {'findings': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'mRNAs': 'O'}, {'for': 'O'}, {'several': 'O'}, {'chemokines': 'O'}, {'and': 'O'}, {'cytokines': 'O'}, {'are': 'O'}, {'expressed': 'O'}, {'primarily': 'O'}, {'in': 'O'}, {'epithelial': 'O'}, {'cells;': 'O'}, {'certain': 'O'}, {'others': 'O'}, {'are': 'O'}, {'expressed': 'O'}, {'in': 'O'}, {'both': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'immune': 'O'}, {'cells.': 'O'}]"
ACPA present: group I - 13% (associated with higher arthritis incidence; p = 0.003); group II - 8%.,"[{'ACPA': 'I-Entity'}, {'present:': 'O'}, {'group': 'O'}, {'I': 'O'}, {'-': 'O'}, {'13%': 'O'}, {'(associated': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'arthritis': 'I-Entity'}, {'incidence;': 'O'}, {'p': 'O'}, {'=': 'O'}, {'0.003);': 'O'}, {'group': 'O'}, {'II': 'O'}, {'-': 'O'}, {'8%.': 'O'}]"
"We also report an index case of MRH associated with Sjogrens syndrome and pulmonary embolism.Medicine, Istanbul, Turkey.Medicine, Istanbul, Turkey.","[{'We': 'O'}, {'also': 'O'}, {'report': 'O'}, {'an': 'O'}, {'index': 'O'}, {'case': 'O'}, {'of': 'O'}, {'MRH': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'embolism.Medicine,': 'I-Entity'}, {'Istanbul,': 'O'}, {'Turkey.Medicine,': 'O'}, {'Istanbul,': 'O'}, {'Turkey.': 'O'}]"
These included: (1) the journey to diagnosis; (2) disease impact spectrum (of dry mouth amid other symptoms); (3) interactions with healthcare professionals; and (4) the positive coping process.,"[{'These': 'O'}, {'included:': 'O'}, {'(1)': 'O'}, {'the': 'O'}, {'journey': 'O'}, {'to': 'O'}, {'diagnosis;': 'O'}, {'(2)': 'O'}, {'disease': 'O'}, {'impact': 'O'}, {'spectrum': 'O'}, {'(of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'amid': 'O'}, {'other': 'O'}, {'symptoms);': 'O'}, {'(3)': 'O'}, {'interactions': 'O'}, {'with': 'O'}, {'healthcare': 'O'}, {'professionals;': 'O'}, {'and': 'O'}, {'(4)': 'O'}, {'the': 'O'}, {'positive': 'O'}, {'coping': 'O'}, {'process.': 'O'}]"
To evaluate the response of the lacrimal function unit in Sjogren syndrome (SS)-associated dry eye patients exposed to 2 simulated daily life environmental conditions.,"[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'response': 'O'}, {'of': 'O'}, {'the': 'O'}, {'lacrimal': 'O'}, {'function': 'O'}, {'unit': 'O'}, {'in': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)-associated': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'patients': 'O'}, {'exposed': 'O'}, {'to': 'O'}, {'2': 'O'}, {'simulated': 'O'}, {'daily': 'O'}, {'life': 'O'}, {'environmental': 'O'}, {'conditions.': 'O'}]"
The majority of patients (93%) were diagnosed with Sjogrens syndrome after neurological symptoms appeared.,"[{'The': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'(93%)': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'after': 'O'}, {'neurological': 'O'}, {'symptoms': 'O'}, {'appeared.': 'O'}]"
The mean follow-up time was 11 years.,"[{'The': 'O'}, {'mean': 'O'}, {'follow-up': 'O'}, {'time': 'O'}, {'was': 'O'}, {'11': 'O'}, {'years.': 'O'}]"
A 49-year-old woman with primary Sjogren syndrome initially developed pulmonary venous hypertension (PVH) due to heart failure with preserved ejection fraction.,"[{'A': 'O'}, {'49-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'initially': 'O'}, {'developed': 'O'}, {'pulmonary': 'B-Entity'}, {'venous': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'(PVH)': 'O'}, {'due': 'O'}, {'to': 'O'}, {'heart': 'B-Entity'}, {'failure': 'I-Entity'}, {'with': 'O'}, {'preserved': 'O'}, {'ejection': 'O'}, {'fraction.': 'O'}]"
"The sensitivity associated with a specificity of ~95% was 79%, 82% and 78% for NV, FEIA, and CIA, respectively.","[{'The': 'O'}, {'sensitivity': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'specificity': 'O'}, {'of': 'O'}, {'~95%': 'O'}, {'was': 'O'}, {'79%,': 'O'}, {'82%': 'O'}, {'and': 'O'}, {'78%': 'O'}, {'for': 'O'}, {'NV,': 'I-Entity'}, {'FEIA,': 'O'}, {'and': 'O'}, {'CIA,': 'I-Entity'}, {'respectively.': 'O'}]"
"Both artificial tears and punctal plugs relieved dry eye symptoms, repaired corneal lesions, enhanced tear film stability, and improved contrast sensitivity.","[{'Both': 'O'}, {'artificial': 'O'}, {'tears': 'O'}, {'and': 'O'}, {'punctal': 'O'}, {'plugs': 'O'}, {'relieved': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms,': 'I-Entity'}, {'repaired': 'O'}, {'corneal': 'B-Entity'}, {'lesions,': 'I-Entity'}, {'enhanced': 'O'}, {'tear': 'O'}, {'film': 'O'}, {'stability,': 'O'}, {'and': 'O'}, {'improved': 'O'}, {'contrast': 'O'}, {'sensitivity.': 'O'}]"
Peripheral (PNS) and central nervous system (CNS)-related symptoms may occur in the course of the disease.,"[{'Peripheral': 'O'}, {'(PNS)': 'O'}, {'and': 'O'}, {'central': 'I-Entity'}, {'nervous': 'I-Entity'}, {'system': 'I-Entity'}, {'(CNS)-related': 'I-Entity'}, {'symptoms': 'O'}, {'may': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
We investigated the potential prognostic role of sUS as a tool in the assessment of disease activity.,"[{'We': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'prognostic': 'O'}, {'role': 'O'}, {'of': 'O'}, {'sUS': 'O'}, {'as': 'O'}, {'a': 'O'}, {'tool': 'O'}, {'in': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
Interim analysis at 24 weeks included assessment of efficacy (n = 31) and safety (n = 32).,"[{'Interim': 'O'}, {'analysis': 'O'}, {'at': 'O'}, {'24': 'O'}, {'weeks': 'O'}, {'included': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'efficacy': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'31)': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'32).': 'O'}]"
"Forty patients met the inclusion criteria (97% female, mean age 58 years, mean disease duration 10 years).","[{'Forty': 'O'}, {'patients': 'O'}, {'met': 'O'}, {'the': 'O'}, {'inclusion': 'O'}, {'criteria': 'O'}, {'(97%': 'O'}, {'female,': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'58': 'O'}, {'years,': 'O'}, {'mean': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'10': 'O'}, {'years).': 'O'}]"
Non-infectious aortitis often presents with non-specific symptoms leading to inappropriate diagnostic delay.,"[{'Non-infectious': 'O'}, {'aortitis': 'I-Entity'}, {'often': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'non-specific': 'O'}, {'symptoms': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'inappropriate': 'O'}, {'diagnostic': 'O'}, {'delay.': 'O'}]"
"Using the 0-10 physician global assessment (PhGA) scale, each expert scored the disease activity of five patient profiles and 20 realistic vignettes.","[{'Using': 'O'}, {'the': 'O'}, {'0-10': 'O'}, {'physician': 'O'}, {'global': 'O'}, {'assessment': 'O'}, {'(PhGA)': 'O'}, {'scale,': 'O'}, {'each': 'O'}, {'expert': 'O'}, {'scored': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'five': 'O'}, {'patient': 'O'}, {'profiles': 'O'}, {'and': 'O'}, {'20': 'O'}, {'realistic': 'O'}, {'vignettes.': 'O'}]"
"Selection of treatment depends on the patient's clinical condition, as well as on the clinical form and type of disease.","[{'Selection': 'O'}, {'of': 'O'}, {'treatment': 'O'}, {'depends': 'O'}, {'on': 'O'}, {'the': 'O'}, {""patient's"": 'O'}, {'clinical': 'O'}, {'condition,': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'on': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'form': 'O'}, {'and': 'O'}, {'type': 'O'}, {'of': 'O'}, {'disease.': 'O'}]"
"Screening for pSS should be systematically performed in cases of acute or chronic myelopathy and/or cranial nerve involvement, mainly because these patients have a severe outcome.","[{'Screening': 'O'}, {'for': 'O'}, {'pSS': 'O'}, {'should': 'O'}, {'be': 'O'}, {'systematically': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'acute': 'O'}, {'or': 'O'}, {'chronic': 'O'}, {'myelopathy': 'I-Entity'}, {'and/or': 'O'}, {'cranial': 'O'}, {'nerve': 'I-Entity'}, {'involvement,': 'I-Entity'}, {'mainly': 'O'}, {'because': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'have': 'O'}, {'a': 'O'}, {'severe': 'O'}, {'outcome.': 'O'}]"
Various tests were performed to find out the cause of RTA.,"[{'Various': 'O'}, {'tests': 'O'}, {'were': 'O'}, {'performed': 'O'}, {'to': 'O'}, {'find': 'O'}, {'out': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'RTA.': 'I-Entity'}]"
"The association of inflammatory involvement of the distal airways or bronchiolitis and systemic diseases is essentially observed in Sjogrens syndrome, rheumatoid arthritis and chronic inflammatory bowel disease.","[{'The': 'O'}, {'association': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'distal': 'O'}, {'airways': 'O'}, {'or': 'O'}, {'bronchiolitis': 'I-Entity'}, {'and': 'O'}, {'systemic': 'O'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'essentially': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'and': 'O'}, {'chronic': 'B-Entity'}, {'inflammatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"In contrast, the direct sweat volume of lesional or non-lesional AD skin induced by direct stimulation with acetylcholine was only slightly reduced compared to that in normal controls, but not in SS and lesional skin of AD/SS patients.","[{'In': 'O'}, {'contrast,': 'O'}, {'the': 'O'}, {'direct': 'O'}, {'sweat': 'O'}, {'volume': 'O'}, {'of': 'O'}, {'lesional': 'O'}, {'or': 'O'}, {'non-lesional': 'O'}, {'AD': 'I-Entity'}, {'skin': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'direct': 'O'}, {'stimulation': 'O'}, {'with': 'O'}, {'acetylcholine': 'I-Entity'}, {'was': 'O'}, {'only': 'O'}, {'slightly': 'O'}, {'reduced': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'that': 'O'}, {'in': 'O'}, {'normal': 'O'}, {'controls,': 'O'}, {'but': 'O'}, {'not': 'O'}, {'in': 'O'}, {'SS': 'O'}, {'and': 'O'}, {'lesional': 'O'}, {'skin': 'O'}, {'of': 'O'}, {'AD/SS': 'I-Entity'}, {'patients.': 'O'}]"
Primary Sjogrens syndrome is an autoimmune disease that presents with xerostomia and keratoconjunctivitis sicca (due to chronic lymphocytic inflammation of the salivary and lacrimal glands) and in some cases extraglandular features.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'presents': 'O'}, {'with': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'(due': 'O'}, {'to': 'O'}, {'chronic': 'O'}, {'lymphocytic': 'O'}, {'inflammation': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'some': 'O'}, {'cases': 'O'}, {'extraglandular': 'O'}, {'features.': 'O'}]"
Epidemiological data suggest that some viruses may be linked to the development of autoimmunity.,"[{'Epidemiological': 'O'}, {'data': 'O'}, {'suggest': 'O'}, {'that': 'O'}, {'some': 'O'}, {'viruses': 'O'}, {'may': 'O'}, {'be': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'autoimmunity.': 'I-Entity'}]"
pSS leads to destruction and loss of secretory function due to intense lymphoplasmacytic infiltration.,"[{'pSS': 'I-Entity'}, {'leads': 'O'}, {'to': 'O'}, {'destruction': 'O'}, {'and': 'O'}, {'loss': 'O'}, {'of': 'O'}, {'secretory': 'O'}, {'function': 'O'}, {'due': 'O'}, {'to': 'O'}, {'intense': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltration.': 'O'}]"
"Systemic lupus eryethematosus (SLE) is the most common CTD, the others being Juvenile dermatomyositis, systemic sclerosis, mixed connective disease and Sjogren syndrome.","[{'Systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'eryethematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'CTD,': 'O'}, {'the': 'O'}, {'others': 'O'}, {'being': 'O'}, {'Juvenile': 'O'}, {'dermatomyositis,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Occasionally, reactivity levels were increased in a few assays, indicating that false-positive results can be obtained when applying assays of reduced specificity.","[{'Occasionally,': 'O'}, {'reactivity': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'a': 'O'}, {'few': 'O'}, {'assays,': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'false-positive': 'O'}, {'results': 'O'}, {'can': 'O'}, {'be': 'O'}, {'obtained': 'O'}, {'when': 'O'}, {'applying': 'O'}, {'assays': 'O'}, {'of': 'O'}, {'reduced': 'O'}, {'specificity.': 'O'}]"
SS has characteristic microscopic findings involving lymphocytic infiltration surrounding the excretory ducts in combination with destruction of acinar tissue.,"[{'SS': 'I-Entity'}, {'has': 'O'}, {'characteristic': 'O'}, {'microscopic': 'O'}, {'findings': 'O'}, {'involving': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'O'}, {'surrounding': 'O'}, {'the': 'O'}, {'excretory': 'O'}, {'ducts': 'O'}, {'in': 'O'}, {'combination': 'O'}, {'with': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'acinar': 'O'}, {'tissue.': 'O'}]"
"In this manuscript, we present the case of a patient with primary Sjogrens syndrome who developed HLH after an acute infection by Cytomegalovirus.","[{'In': 'O'}, {'this': 'O'}, {'manuscript,': 'O'}, {'we': 'O'}, {'present': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'developed': 'O'}, {'HLH': 'I-Entity'}, {'after': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'infection': 'I-Entity'}, {'by': 'O'}, {'Cytomegalovirus.': 'B-Entity'}]"
"By definition, the disease must be mediated by specific immune reactions against endogenous tissues to qualify as an autoimmune disease.","[{'By': 'O'}, {'definition,': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'must': 'O'}, {'be': 'O'}, {'mediated': 'O'}, {'by': 'O'}, {'specific': 'O'}, {'immune': 'O'}, {'reactions': 'O'}, {'against': 'O'}, {'endogenous': 'O'}, {'tissues': 'O'}, {'to': 'O'}, {'qualify': 'O'}, {'as': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Although bronchial involvement is very common, most patients only complain of cough and this involvement rarely results in severe symptoms or chronic respiratory failure are rarely observed.","[{'Although': 'O'}, {'bronchial': 'O'}, {'involvement': 'O'}, {'is': 'O'}, {'very': 'O'}, {'common,': 'O'}, {'most': 'O'}, {'patients': 'O'}, {'only': 'O'}, {'complain': 'O'}, {'of': 'O'}, {'cough': 'I-Entity'}, {'and': 'O'}, {'this': 'O'}, {'involvement': 'O'}, {'rarely': 'O'}, {'results': 'O'}, {'in': 'O'}, {'severe': 'O'}, {'symptoms': 'O'}, {'or': 'O'}, {'chronic': 'O'}, {'respiratory': 'B-Entity'}, {'failure': 'I-Entity'}, {'are': 'O'}, {'rarely': 'O'}, {'observed.': 'O'}]"
"IL-6-stimulation of PBMC from SS cases revealed prolonged activation of STAT-3 with reduced negative regulation by SOCS3, and enhanced expression of IL-17.","[{'IL-6-stimulation': 'O'}, {'of': 'O'}, {'PBMC': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'cases': 'O'}, {'revealed': 'O'}, {'prolonged': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'STAT-3': 'O'}, {'with': 'O'}, {'reduced': 'O'}, {'negative': 'O'}, {'regulation': 'O'}, {'by': 'O'}, {'SOCS3,': 'O'}, {'and': 'O'}, {'enhanced': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'IL-17.': 'O'}]"
Fatigue VAS correlated with oral sicca symptoms but was inversely correlated with age.,"[{'Fatigue': 'I-Entity'}, {'VAS': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'oral': 'O'}, {'sicca': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'but': 'O'}, {'was': 'O'}, {'inversely': 'O'}, {'correlated': 'O'}, {'with': 'O'}, {'age.': 'O'}]"
"Review of systems questionnaire, medical history, dry eye questionnaire and laboratory work-up (Sjogren-specific antibody A (SSA), Sjogren-specific antibody B (SSB), rheumatoid factor (RF) and antinuclear antibody (ANA)) were obtained.","[{'Review': 'O'}, {'of': 'O'}, {'systems': 'O'}, {'questionnaire,': 'O'}, {'medical': 'O'}, {'history,': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'questionnaire': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'work-up': 'O'}, {'(Sjogren-specific': 'O'}, {'antibody': 'O'}, {'A': 'O'}, {'(SSA),': 'O'}, {'Sjogren-specific': 'B-Entity'}, {'antibody': 'O'}, {'B': 'O'}, {'(SSB),': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'I-Entity'}, {'(RF)': 'O'}, {'and': 'O'}, {'antinuclear': 'O'}, {'antibody': 'I-Entity'}, {'(ANA))': 'O'}]"
"There is currently no cure; therapy is tailored for each patient to reduce symptoms, avoid complications, and improve quality of life.","[{'There': 'O'}, {'is': 'O'}, {'currently': 'O'}, {'no': 'O'}, {'cure;': 'O'}, {'therapy': 'O'}, {'is': 'O'}, {'tailored': 'O'}, {'for': 'O'}, {'each': 'O'}, {'patient': 'O'}, {'to': 'O'}, {'reduce': 'O'}, {'symptoms,': 'O'}, {'avoid': 'O'}, {'complications,': 'O'}, {'and': 'O'}, {'improve': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"In patients with 1-SS and in the SS group as a whole, we observed independent and significant associations between cysts and anti-SSB/La seropositivity or cLPD.","[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'1-SS': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SS': 'I-Entity'}, {'group': 'O'}, {'as': 'O'}, {'a': 'O'}, {'whole,': 'O'}, {'we': 'O'}, {'observed': 'O'}, {'independent': 'O'}, {'and': 'O'}, {'significant': 'O'}, {'associations': 'O'}, {'between': 'O'}, {'cysts': 'O'}, {'and': 'O'}, {'anti-SSB/La': 'O'}, {'seropositivity': 'O'}, {'or': 'O'}, {'cLPD.': 'O'}]"
"In this case-report we describe clinical features, radiographic findings, and treatment of a SS NMOSD patient presenting with severely decreased visual acuity, visual hallucinations, and encephalopathy.","[{'In': 'O'}, {'this': 'O'}, {'case-report': 'O'}, {'we': 'O'}, {'describe': 'O'}, {'clinical': 'O'}, {'features,': 'O'}, {'radiographic': 'O'}, {'findings,': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'a': 'O'}, {'SS': 'O'}, {'NMOSD': 'I-Entity'}, {'patient': 'O'}, {'presenting': 'O'}, {'with': 'O'}, {'severely': 'O'}, {'decreased': 'I-Entity'}, {'visual': 'I-Entity'}, {'acuity,': 'I-Entity'}, {'visual': 'B-Entity'}, {'hallucinations,': 'I-Entity'}, {'and': 'O'}, {'encephalopathy.': 'I-Entity'}]"
Early recognition and prompt treatment results in excellent outcome.Oct 6.patient with Sjogren syndrome.,"[{'Early': 'O'}, {'recognition': 'O'}, {'and': 'O'}, {'prompt': 'O'}, {'treatment': 'O'}, {'results': 'O'}, {'in': 'O'}, {'excellent': 'O'}, {'outcome.Oct': 'O'}, {'6.patient': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Twenty-four eyes from 13 patients with previously diagnosed Sjogren disease who presented to our institution with dry eye symptoms and had thermal pulsation treatment were prospectively followed up.,"[{'Twenty-four': 'O'}, {'eyes': 'O'}, {'from': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'previously': 'O'}, {'diagnosed': 'O'}, {'Sjogren': 'B-Entity'}, {'disease': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'to': 'O'}, {'our': 'O'}, {'institution': 'O'}, {'with': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms': 'O'}, {'and': 'O'}, {'had': 'O'}, {'thermal': 'O'}, {'pulsation': 'O'}, {'treatment': 'O'}, {'were': 'O'}, {'prospectively': 'O'}, {'followed': 'O'}, {'up.': 'O'}]"
Deletion of CCX-CKR results in accelerated experimental autoimmunity induced by immunization.,"[{'Deletion': 'O'}, {'of': 'O'}, {'CCX-CKR': 'O'}, {'results': 'O'}, {'in': 'O'}, {'accelerated': 'O'}, {'experimental': 'O'}, {'autoimmunity': 'I-Entity'}, {'induced': 'O'}, {'by': 'O'}, {'immunization.': 'O'}]"
"A 57-year-old Caucasian woman with a background of mild connective tissue disease presented to our rheumatologist with intermittent left-sided facial pain and swelling, accompanied by hearing loss in her left ear.","[{'A': 'O'}, {'57-year-old': 'O'}, {'Caucasian': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'a': 'O'}, {'background': 'O'}, {'of': 'O'}, {'mild': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease': 'I-Entity'}, {'presented': 'O'}, {'to': 'O'}, {'our': 'O'}, {'rheumatologist': 'O'}, {'with': 'O'}, {'intermittent': 'O'}, {'left-sided': 'O'}, {'facial': 'O'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'swelling,': 'I-Entity'}, {'accompanied': 'O'}, {'by': 'O'}, {'hearing': 'B-Entity'}, {'loss': 'I-Entity'}, {'in': 'O'}, {'her': 'O'}, {'left': 'O'}, {'ear.': 'O'}]"
Initially with IV methylprednisone and Cyclophosphamide therapy followed by Mycophenolate mofetil (MMF) maintenance therapy with good response.,"[{'Initially': 'O'}, {'with': 'O'}, {'IV': 'O'}, {'methylprednisone': 'I-Entity'}, {'and': 'O'}, {'Cyclophosphamide': 'I-Entity'}, {'therapy': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'Mycophenolate': 'B-Entity'}, {'mofetil': 'I-Entity'}, {'(MMF)': 'O'}, {'maintenance': 'O'}, {'therapy': 'O'}, {'with': 'O'}, {'good': 'O'}, {'response.': 'O'}]"
Morphological characteristics of corneal epithelial layers and cellular densities were evaluated by four trained graders from the Doheny Eye Institute.,"[{'Morphological': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'corneal': 'O'}, {'epithelial': 'O'}, {'layers': 'O'}, {'and': 'O'}, {'cellular': 'O'}, {'densities': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'four': 'O'}, {'trained': 'O'}, {'graders': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Doheny': 'O'}, {'Eye': 'O'}, {'Institute.': 'O'}]"
There is still work going on to find effective and equivocal detection methods.,"[{'There': 'O'}, {'is': 'O'}, {'still': 'O'}, {'work': 'O'}, {'going': 'O'}, {'on': 'O'}, {'to': 'O'}, {'find': 'O'}, {'effective': 'O'}, {'and': 'O'}, {'equivocal': 'O'}, {'detection': 'O'}, {'methods.': 'O'}]"
Primary SS (pSS) is the most commonly associated disease to lung interstitial pneumonia (LIP) (25%).,"[{'Primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'associated': 'O'}, {'disease': 'O'}, {'to': 'O'}, {'lung': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(LIP)': 'O'}, {'(25%).': 'O'}]"
Tear osmolarity may also be a useful test for the diagnosis of dry eye disease.,"[{'Tear': 'O'}, {'osmolarity': 'O'}, {'may': 'O'}, {'also': 'O'}, {'be': 'O'}, {'a': 'O'}, {'useful': 'O'}, {'test': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Among them, lymphocytic interstitial pneumonia (LIP) is mainly associated with primary Sjogrens syndrome (pSS).","[{'Among': 'O'}, {'them,': 'O'}, {'lymphocytic': 'B-Entity'}, {'interstitial': 'I-Entity'}, {'pneumonia': 'I-Entity'}, {'(LIP)': 'O'}, {'is': 'O'}, {'mainly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"LPR was diagnosed with positive scores on the Reflux Symptom Index and Reflux and Reflux Finding Score, corroborated by esophagogastroduodenoscopy and/or 24-hour pH-metry.","[{'LPR': 'I-Entity'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'positive': 'O'}, {'scores': 'O'}, {'on': 'O'}, {'the': 'O'}, {'Reflux': 'B-Entity'}, {'Symptom': 'O'}, {'Index': 'O'}, {'and': 'O'}, {'Reflux': 'I-Entity'}, {'and': 'O'}, {'Reflux': 'O'}, {'Finding': 'O'}, {'Score,': 'O'}, {'corroborated': 'O'}, {'by': 'O'}, {'esophagogastroduodenoscopy': 'O'}, {'and/or': 'O'}, {'24-hour': 'O'}, {'pH-metry.': 'O'}]"
"In this paper, we discuss the cholestatic liver diseases (primary biliary cirrhosis, primary sclerosing cholangitis and immunoglobulin G4 associated cholangitis) and associated autoimmune diseases.10.1586/17474124.2016.1095088.","[{'In': 'O'}, {'this': 'O'}, {'paper,': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'the': 'O'}, {'cholestatic': 'B-Entity'}, {'liver': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(primary': 'O'}, {'biliary': 'I-Entity'}, {'cirrhosis,': 'I-Entity'}, {'primary': 'B-Entity'}, {'sclerosing': 'I-Entity'}, {'cholangitis': 'I-Entity'}, {'and': 'O'}, {'immunoglobulin': 'O'}, {'G4': 'O'}, {'associated': 'O'}, {'cholangitis)': 'I-Entity'}, {'and': 'O'}, {'associated': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.10.1586/17474124.2016.1095088.': 'I-Entity'}]"
"Based on the aforementioned evaluations, four patients (17%) had polyuria with normal bladder function, nine patients (39%) had detrusor overactivity (DO), seven patients (32%) had bladder hypersensitivity (including two patients (9%) diagnosed with IC), and three patients (13%) had negative findings.","[{'Based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'aforementioned': 'O'}, {'evaluations,': 'O'}, {'four': 'O'}, {'patients': 'O'}, {'(17%)': 'O'}, {'had': 'O'}, {'polyuria': 'I-Entity'}, {'with': 'O'}, {'normal': 'O'}, {'bladder': 'O'}, {'function,': 'O'}, {'nine': 'O'}, {'patients': 'O'}, {'(39%)': 'O'}, {'had': 'O'}, {'detrusor': 'B-Entity'}, {'overactivity': 'I-Entity'}, {'(DO),': 'O'}, {'seven': 'O'}, {'patients': 'O'}, {'(32%)': 'O'}, {'had': 'O'}, {'bladder': 'B-Entity'}, {'hypersensitivity': 'I-Entity'}, {'(including': 'O'}, {'two': 'O'}, {'patients': 'O'}, {'(9%)': 'O'}]"
About 18.7% (n = 3) of our parasympathetic dysfunction patients had autonomic symptoms.,"[{'About': 'O'}, {'18.7%': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'3)': 'O'}, {'of': 'O'}, {'our': 'O'}, {'parasympathetic': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'patients': 'O'}, {'had': 'O'}, {'autonomic': 'O'}, {'symptoms.': 'O'}]"
Chemotaxis assays were performed to study migration induced by CXCL10 and CCL25.,"[{'Chemotaxis': 'O'}, {'assays': 'O'}, {'were': 'O'}, {'performed': 'O'}, {'to': 'O'}, {'study': 'O'}, {'migration': 'O'}, {'induced': 'O'}, {'by': 'O'}, {'CXCL10': 'I-Entity'}, {'and': 'O'}, {'CCL25.': 'I-Entity'}]"
"Subjects who had been seen by an arthritis center rheumatologist were identified, and the medical records reviewed.","[{'Subjects': 'O'}, {'who': 'O'}, {'had': 'O'}, {'been': 'O'}, {'seen': 'O'}, {'by': 'O'}, {'an': 'O'}, {'arthritis': 'I-Entity'}, {'center': 'O'}, {'rheumatologist': 'O'}, {'were': 'O'}, {'identified,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'medical': 'O'}, {'records': 'O'}, {'reviewed.': 'O'}]"
It comprises an etiologically heterogenous group of inflammatory renal disorders which primarily affect the renal interstitium and tubuli.,"[{'It': 'O'}, {'comprises': 'O'}, {'an': 'O'}, {'etiologically': 'O'}, {'heterogenous': 'O'}, {'group': 'O'}, {'of': 'O'}, {'inflammatory': 'B-Entity'}, {'renal': 'I-Entity'}, {'disorders': 'I-Entity'}, {'which': 'O'}, {'primarily': 'O'}, {'affect': 'O'}, {'the': 'O'}, {'renal': 'O'}, {'interstitium': 'O'}, {'and': 'O'}, {'tubuli.': 'O'}]"
Initial manifestation of SS as an acute fulminant peripheral neuropathy is extremely rare.,"[{'Initial': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'fulminant': 'B-Entity'}, {'peripheral': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'is': 'O'}, {'extremely': 'O'}, {'rare.': 'O'}]"
As for the composition of comprehensive effect for dry eyes and dry mouth improvement: The score for dry eyes and dry mouth decreased in the two groups more after treatment than before treatment.,"[{'As': 'O'}, {'for': 'O'}, {'the': 'O'}, {'composition': 'O'}, {'of': 'O'}, {'comprehensive': 'O'}, {'effect': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'improvement:': 'O'}, {'The': 'O'}, {'score': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'decreased': 'O'}, {'in': 'O'}, {'the': 'O'}, {'two': 'O'}, {'groups': 'O'}, {'more': 'O'}, {'after': 'O'}, {'treatment': 'O'}, {'than': 'O'}, {'before': 'O'}, {'treatment.': 'O'}]"
Panx1 and proinflammatory factors were upregulated during acute inflammation at days 1 to 3 after the IL1‚âà√≠¬¨¬± injection.,"[{'Panx1': 'O'}, {'and': 'O'}, {'proinflammatory': 'O'}, {'factors': 'O'}, {'were': 'O'}, {'upregulated': 'O'}, {'during': 'O'}, {'acute': 'O'}, {'inflammation': 'I-Entity'}, {'at': 'O'}, {'days': 'O'}, {'1': 'O'}, {'to': 'O'}, {'3': 'O'}, {'after': 'O'}, {'the': 'O'}, {'IL1‚âà√≠¬¨¬±': 'O'}, {'injection.': 'O'}]"
Thirty-six patients (72%) fulfilled the criteria for the diagnosis of neuropathy.,"[{'Thirty-six': 'O'}, {'patients': 'O'}, {'(72%)': 'O'}, {'fulfilled': 'O'}, {'the': 'O'}, {'criteria': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'neuropathy.': 'I-Entity'}]"
"The two groups were compared for fatigue, sleepiness, anxiety, and depression scores, and for the frequency of obstructive apneas and hypopneas during sleep.","[{'The': 'O'}, {'two': 'O'}, {'groups': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'for': 'O'}, {'fatigue,': 'I-Entity'}, {'sleepiness,': 'I-Entity'}, {'anxiety,': 'I-Entity'}, {'and': 'O'}, {'depression': 'I-Entity'}, {'scores,': 'O'}, {'and': 'O'}, {'for': 'O'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'obstructive': 'B-Entity'}, {'apneas': 'I-Entity'}, {'and': 'O'}, {'hypopneas': 'I-Entity'}, {'during': 'O'}, {'sleep.': 'O'}]"
"In addition to sicca syndrome and swollen salivary glands, systemic features manifest in the majority of patients, and are severe in 15%, particularly affecting the joints, skin, lungs, and peripheral nervous system.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'sicca': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'swollen': 'B-Entity'}, {'salivary': 'I-Entity'}, {'glands,': 'I-Entity'}, {'systemic': 'O'}, {'features': 'O'}, {'manifest': 'O'}, {'in': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'are': 'O'}, {'severe': 'O'}, {'in': 'O'}, {'15%,': 'O'}, {'particularly': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'joints,': 'O'}, {'skin,': 'O'}, {'lungs,': 'I-Entity'}, {'and': 'O'}, {'peripheral': 'O'}, {'nervous': 'O'}, {'system.': 'O'}]"
Sjogren's syndrome (SS) is an autoimmune disease characterized by dryness of the mouth and the eyes.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'dryness': 'B-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'mouth': 'I-Entity'}, {'and': 'I-Entity'}, {'the': 'I-Entity'}, {'eyes.': 'I-Entity'}]"
"The pulmonary manifestations of primary Sjogren syndrome may be categorized as airway abnormalities, interstitial pneumonias, and lymphoproliferative disorders; in each category, bronchiectasis or centrilobular nodules, nonspecific interstitial pneumonia, and lymphoid interstitial pneumonia are common.","[{'The': 'O'}, {'pulmonary': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'categorized': 'O'}, {'as': 'O'}, {'airway': 'B-Entity'}, {'abnormalities,': 'I-Entity'}, {'interstitial': 'B-Entity'}, {'pneumonias,': 'I-Entity'}, {'and': 'O'}, {'lymphoproliferative': 'B-Entity'}, {'disorders;': 'I-Entity'}, {'in': 'O'}, {'each': 'O'}, {'category,': 'O'}, {'bronchiectasis': 'I-Entity'}, {'or': 'O'}, {'centrilobular': 'O'}, {'nodules,': 'O'}, {'nonspecific': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia,': 'I-Entity'}]"
Acute pericarditis may be the heralding manifestation of various systemic inflammatory diseases (SIDs).,"[{'Acute': 'O'}, {'pericarditis': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'heralding': 'O'}, {'manifestation': 'O'}, {'of': 'O'}, {'various': 'O'}, {'systemic': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(SIDs).': 'O'}]"
"Our data show that higher salivary T‚âà√≠‚Äö√¢¬ß expression characterizes patients with pSS, while T‚âà√≠‚Äö√¢¬ß(4) sulfoxide and T‚âà√≠‚Äö√¢¬ß(10) salivary expression was selectively present in patients with sicca symptoms.","[{'Our': 'O'}, {'data': 'O'}, {'show': 'O'}, {'that': 'O'}, {'higher': 'O'}, {'salivary': 'O'}, {'T‚âà√≠‚Äö√¢¬ß': 'O'}, {'expression': 'O'}, {'characterizes': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS,': 'I-Entity'}, {'while': 'O'}, {'T‚âà√≠‚Äö√¢¬ß(4)': 'O'}, {'sulfoxide': 'I-Entity'}, {'and': 'O'}, {'T‚âà√≠‚Äö√¢¬ß(10)': 'O'}]"
"The patient was suffering from typical clinical PBC and SS, and developed decompensated liver cirrhosis after 32 months of ursodeoxycholic acid (UDCA) therapy.","[{'The': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'typical': 'O'}, {'clinical': 'O'}, {'PBC': 'I-Entity'}, {'and': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'developed': 'O'}, {'decompensated': 'O'}, {'liver': 'B-Entity'}, {'cirrhosis': 'I-Entity'}, {'after': 'O'}, {'32': 'O'}, {'months': 'O'}, {'of': 'O'}, {'ursodeoxycholic': 'B-Entity'}, {'acid': 'I-Entity'}, {'(UDCA)': 'O'}, {'therapy.': 'O'}]"
The silent presentation of the splenic artery aneurysm should previse the clinicians that such an occurrence may cause a significant diagnostic dilemma.University.,"[{'The': 'O'}, {'silent': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'splenic': 'B-Entity'}, {'artery': 'I-Entity'}, {'aneurysm': 'I-Entity'}, {'should': 'O'}, {'previse': 'O'}, {'the': 'O'}, {'clinicians': 'O'}, {'that': 'O'}, {'such': 'O'}, {'an': 'O'}, {'occurrence': 'O'}, {'may': 'O'}, {'cause': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'diagnostic': 'O'}, {'dilemma.University.': 'O'}]"
Sixteen patients with SS suffered from deficient secretion of saliva due to an autoimmune destruction of salivary glands leading to dry mouth symptoms (xerostomia).,"[{'Sixteen': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SS': 'I-Entity'}, {'suffered': 'O'}, {'from': 'O'}, {'deficient': 'O'}, {'secretion': 'O'}, {'of': 'O'}, {'saliva': 'O'}, {'due': 'O'}, {'to': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'destruction': 'I-Entity'}, {'of': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'symptoms': 'O'}, {'(xerostomia).': 'O'}]"
"Extraglandular organ involvement, often involving the retroperitoneum, pancreas, kidney and lung, was often discovered at the time of IgG4-related MD diagnosis.","[{'Extraglandular': 'O'}, {'organ': 'O'}, {'involvement,': 'O'}, {'often': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'retroperitoneum,': 'O'}, {'pancreas,': 'O'}, {'kidney': 'O'}, {'and': 'O'}, {'lung,': 'O'}, {'was': 'O'}, {'often': 'O'}, {'discovered': 'O'}, {'at': 'O'}, {'the': 'O'}, {'time': 'O'}, {'of': 'O'}, {'IgG4-related': 'O'}, {'MD': 'I-Entity'}, {'diagnosis.': 'O'}]"
DNA was extracted from the affected inflammatory lesions.,"[{'DNA': 'O'}, {'was': 'O'}, {'extracted': 'O'}, {'from': 'O'}, {'the': 'O'}, {'affected': 'O'}, {'inflammatory': 'O'}, {'lesions.': 'O'}]"
"Two months before admission, the patient had a blood potassium level of 1.7 mmol/L.","[{'Two': 'O'}, {'months': 'O'}, {'before': 'O'}, {'admission,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'had': 'O'}, {'a': 'O'}, {'blood': 'O'}, {'potassium': 'I-Entity'}, {'level': 'O'}, {'of': 'O'}, {'1.7': 'O'}, {'mmol/L.': 'O'}]"
"Increased serum levels of CX3CL1 protein were observed in SS patients compared with controls (P < 0.0001) and in RA patients compared with controls (P < 0.0001), but no difference was found between Sicca patients and controls (P = 0.22).","[{'Increased': 'O'}, {'serum': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'CX3CL1': 'O'}, {'protein': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'controls': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.0001)': 'O'}, {'and': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'controls': 'O'}, {'(P': 'O'}, {'<': 'O'}, {'0.0001),': 'O'}, {'but': 'O'}, {'no': 'O'}, {'difference': 'O'}, {'was': 'O'}, {'found': 'O'}, {'between': 'O'}, {'Sicca': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'controls': 'O'}, {'(P': 'O'}, {'=': 'O'}, {'0.22).': 'O'}]"
"The purpose of this study was to answer the following question: in all patients referred for MSGB, did strict application of focus scoring criteria alter the sensitivity of and predictive value of the MSGB in the diagnosis of SS compared with the initial interpretation?","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'answer': 'O'}, {'the': 'O'}, {'following': 'O'}, {'question:': 'O'}, {'in': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'referred': 'O'}, {'for': 'O'}, {'MSGB,': 'O'}, {'did': 'O'}, {'strict': 'O'}, {'application': 'O'}, {'of': 'O'}, {'focus': 'O'}, {'scoring': 'O'}, {'criteria': 'O'}, {'alter': 'O'}, {'the': 'O'}, {'sensitivity': 'O'}, {'of': 'O'}, {'and': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'of': 'O'}, {'the': 'O'}, {'MSGB': 'O'}, {'in': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'compared': 'O'}, {'with': 'O'}, {'the': 'O'}, {'initial': 'O'}, {'interpretation?': 'O'}]"
"Tissues were examined by an indirect immunoperoxidase technique (goat polyclonal anti-human IL-19, goat polyclonal anti-human IL-22 or mouse monoclonal anti-human IL-24).","[{'Tissues': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'an': 'O'}, {'indirect': 'O'}, {'immunoperoxidase': 'O'}, {'technique': 'O'}, {'(goat': 'O'}, {'polyclonal': 'O'}, {'anti-human': 'O'}, {'IL-19,': 'O'}, {'goat': 'O'}, {'polyclonal': 'O'}, {'anti-human': 'O'}, {'IL-22': 'O'}, {'or': 'O'}, {'mouse': 'O'}, {'monoclonal': 'O'}, {'anti-human': 'O'}, {'IL-24).': 'O'}]"
"ESSDAI, ESSPRI, rheumatoid factor and IgG levels decreased significantly during abatacept treatment and increased post-treatment.","[{'ESSDAI,': 'O'}, {'ESSPRI,': 'O'}, {'rheumatoid': 'O'}, {'factor': 'O'}, {'and': 'O'}, {'IgG': 'O'}, {'levels': 'O'}, {'decreased': 'O'}, {'significantly': 'O'}, {'during': 'O'}, {'abatacept': 'I-Entity'}, {'treatment': 'O'}, {'and': 'O'}, {'increased': 'O'}, {'post-treatment.': 'O'}]"
Anti-alpha-fodrin IgG and IgA antibodies were associated with pSS after adjustment for anti-SSA and anti-SSB.,"[{'Anti-alpha-fodrin': 'O'}, {'IgG': 'O'}, {'and': 'O'}, {'IgA': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'after': 'O'}, {'adjustment': 'O'}, {'for': 'O'}, {'anti-SSA': 'O'}, {'and': 'O'}, {'anti-SSB.': 'O'}]"
"Moreover, patients with lung involvement had reduced QoL represented by the subscale Physical Functioning, and mortality was increased.Oslo University Hospital Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway.","[{'Moreover,': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'lung': 'B-Entity'}, {'involvement': 'I-Entity'}, {'had': 'O'}, {'reduced': 'O'}, {'QoL': 'O'}, {'represented': 'O'}, {'by': 'O'}, {'the': 'O'}, {'subscale': 'O'}, {'Physical': 'O'}, {'Functioning,': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'was': 'O'}, {'increased.Oslo': 'O'}, {'University': 'O'}, {'Hospital': 'O'}, {'Rikshospitalet,': 'O'}, {'PO': 'O'}, {'Box': 'O'}, {'4950': 'O'}, {'Nydalen,': 'O'}, {'0424': 'O'}, {'Oslo,': 'O'}, {'Norway.': 'O'}]"
Solid phase assays are increasingly replacing indirect immunofluorescence for detection of antinuclear antibodies.,"[{'Solid': 'O'}, {'phase': 'O'}, {'assays': 'O'}, {'are': 'O'}, {'increasingly': 'O'}, {'replacing': 'O'}, {'indirect': 'O'}, {'immunofluorescence': 'O'}, {'for': 'O'}, {'detection': 'O'}, {'of': 'O'}, {'antinuclear': 'O'}, {'antibodies.': 'O'}]"
Keratolysis is a rare severe complication following systemic autoimmunologic diseases.,"[{'Keratolysis': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'severe': 'O'}, {'complication': 'O'}, {'following': 'O'}, {'systemic': 'O'}, {'autoimmunologic': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Among them were 16 patients (69.6%) found as having at least one abnormal autoimmune index, namely, antibodies to antinuclear factor in 8 patients, SSA/La in 6 patients, rheumatoid factor in 4 patients, SSB/Ro in 2 patients, and ds-DNA in 1 patient.","[{'Among': 'O'}, {'them': 'O'}, {'were': 'O'}, {'16': 'O'}, {'patients': 'O'}, {'(69.6%)': 'O'}, {'found': 'O'}, {'as': 'O'}, {'having': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'abnormal': 'O'}, {'autoimmune': 'O'}, {'index,': 'O'}, {'namely,': 'O'}, {'antibodies': 'O'}, {'to': 'O'}, {'antinuclear': 'O'}, {'factor': 'O'}, {'in': 'O'}, {'8': 'O'}, {'patients,': 'O'}, {'SSA/La': 'I-Entity'}, {'in': 'O'}, {'6': 'O'}, {'patients,': 'O'}, {'rheumatoid': 'B-Entity'}, {'factor': 'I-Entity'}, {'in': 'O'}, {'4': 'O'}, {'patients,': 'O'}, {'SSB/Ro': 'I-Entity'}, {'in': 'O'}, {'2': 'O'}]"
We present 3 cases with involvement of the peripheral nervous system as a dominant feature in the clinical picture of systemic connective tissue diseases.,"[{'We': 'O'}, {'present': 'O'}, {'3': 'O'}, {'cases': 'O'}, {'with': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'the': 'O'}, {'peripheral': 'O'}, {'nervous': 'I-Entity'}, {'system': 'O'}, {'as': 'O'}, {'a': 'O'}, {'dominant': 'O'}, {'feature': 'O'}, {'in': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'picture': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"The diagnosis of an autoimmune disease was suspected in 49 patients (54.5%) and confirmed in 30 (33.3%) including 20 cases of connective tissue disease: myositis (n=6), scleroderma (n=5), Sjogrens syndrome (n=3), SLE (n=4), rheumatoid arthritis (n=6) and antiphospholipid syndrome (n=4).","[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'suspected': 'O'}, {'in': 'O'}, {'49': 'O'}, {'patients': 'O'}, {'(54.5%)': 'O'}, {'and': 'O'}, {'confirmed': 'O'}, {'in': 'O'}, {'30': 'O'}, {'(33.3%)': 'O'}, {'including': 'O'}, {'20': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease:': 'I-Entity'}, {'myositis': 'I-Entity'}, {'(n=6),': 'O'}, {'scleroderma': 'I-Entity'}, {'(n=5),': 'O'}, {'Sjogrens': 'B-Entity'}]"
The coexistence of Sjogrens syndrome (SS) and autoimmune thyroid disease (AITD) has been documented.,"[{'The': 'O'}, {'coexistence': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'thyroid': 'I-Entity'}, {'disease': 'I-Entity'}, {'(AITD)': 'O'}, {'has': 'O'}, {'been': 'O'}, {'documented.': 'O'}]"
All patients had LPR and 60% also had GERD.,"[{'All': 'O'}, {'patients': 'O'}, {'had': 'O'}, {'LPR': 'I-Entity'}, {'and': 'O'}, {'60%': 'O'}, {'also': 'O'}, {'had': 'O'}, {'GERD.': 'I-Entity'}]"
"We investigated the prevalence of anti-GD1b antibodies in acute and chronic immune-mediated neuropathies, and the clinical presentation and outcome in Guillain-Barr‚Äö√†√∂¬¨¬© syndrome (GBS) and Miller Fisher-GBS overlap syndrome (MF-GBS).","[{'We': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'anti-GD1b': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'acute': 'O'}, {'and': 'O'}, {'chronic': 'O'}, {'immune-mediated': 'O'}, {'neuropathies,': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'in': 'O'}, {'Guillain-Barr‚Äö√†√∂¬¨¬©': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(GBS)': 'O'}, {'and': 'O'}, {'Miller': 'B-Entity'}, {'Fisher-GBS': 'I-Entity'}, {'overlap': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(MF-GBS).': 'O'}]"
She was diagnosed with transverse myelitis secondary to varicella zoster infection and was treated with high dose steroids in addition to acyclovir with improvement in her symptoms.,"[{'She': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'transverse': 'B-Entity'}, {'myelitis': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'varicella': 'B-Entity'}, {'zoster': 'I-Entity'}, {'infection': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'high': 'O'}, {'dose': 'O'}, {'steroids': 'I-Entity'}, {'in': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'acyclovir': 'I-Entity'}, {'with': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'her': 'O'}, {'symptoms.': 'O'}]"
The TMH values of dry eyes were significantly smaller than those of normal eyes (p<0.001).,"[{'The': 'O'}, {'TMH': 'O'}, {'values': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'smaller': 'O'}, {'than': 'O'}, {'those': 'O'}, {'of': 'O'}, {'normal': 'O'}, {'eyes': 'O'}, {'(p<0.001).': 'O'}]"
"In the present study, we aimed to investigate differences in the clinical presentation of primary Sjogrens syndrome (pSS) between the sexes and establish whether male sex is associated with a more severe form of long-term pSS.","[{'In': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study,': 'O'}, {'we': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'between': 'O'}, {'the': 'O'}, {'sexes': 'O'}, {'and': 'O'}, {'establish': 'O'}, {'whether': 'O'}, {'male': 'O'}, {'sex': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'more': 'O'}, {'severe': 'O'}, {'form': 'O'}, {'of': 'O'}, {'long-term': 'O'}, {'pSS.': 'I-Entity'}]"
"The methods were implemented in the National Cancer Institutes Early Detection Network Urinary PCA3 Evaluation Trial.Houston Texas 77030, U.S.A.. ntayob@mdanderson.org.Houston Texas 77030, U.S.A.Houston Texas 77030, U.S.A.","[{'The': 'O'}, {'methods': 'O'}, {'were': 'O'}, {'implemented': 'O'}, {'in': 'O'}, {'the': 'O'}, {'National': 'O'}, {'Cancer': 'I-Entity'}, {'Institutes': 'O'}, {'Early': 'O'}, {'Detection': 'O'}, {'Network': 'O'}, {'Urinary': 'O'}, {'PCA3': 'O'}, {'Evaluation': 'O'}, {'Trial.Houston': 'O'}, {'Texas': 'O'}, {'77030,': 'O'}, {'U.S.A..': 'O'}, {'ntayob@mdanderson.org.Houston': 'O'}, {'Texas': 'O'}, {'77030,': 'O'}, {'U.S.A.Houston': 'O'}, {'Texas': 'O'}]"
"Most patients (39%) with Oxford grades III and IV were older, complained of red eye (51.0%), foreign body sensation (47.0%), burning (46.0%), and were using eye drops (67%) and systemic medications (47%).","[{'Most': 'O'}, {'patients': 'O'}, {'(39%)': 'O'}, {'with': 'O'}, {'Oxford': 'O'}, {'grades': 'O'}, {'III': 'O'}, {'and': 'O'}, {'IV': 'O'}, {'were': 'O'}, {'older,': 'O'}, {'complained': 'O'}, {'of': 'O'}, {'red': 'B-Entity'}, {'eye': 'I-Entity'}, {'(51.0%),': 'O'}, {'foreign': 'B-Entity'}, {'body': 'I-Entity'}, {'sensation': 'I-Entity'}, {'(47.0%),': 'O'}, {'burning': 'I-Entity'}, {'(46.0%),': 'O'}, {'and': 'O'}, {'were': 'O'}, {'using': 'O'}, {'eye': 'O'}, {'drops': 'O'}, {'(67%)': 'O'}, {'and': 'O'}, {'systemic': 'O'}, {'medications': 'O'}, {'(47%).': 'O'}]"
"Lactobacilli were isolated from 14 subjects (6 RT, 3 pSS, 5 controls).","[{'Lactobacilli': 'I-Entity'}, {'were': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {'14': 'O'}, {'subjects': 'O'}, {'(6': 'O'}, {'RT,': 'O'}, {'3': 'O'}, {'pSS,': 'O'}, {'5': 'O'}, {'controls).': 'O'}]"
Targeting B-cell candidates as a new therapeutic option in this entity has shown promising results.,"[{'Targeting': 'O'}, {'B-cell': 'O'}, {'candidates': 'O'}, {'as': 'O'}, {'a': 'O'}, {'new': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'in': 'O'}, {'this': 'O'}, {'entity': 'O'}, {'has': 'O'}, {'shown': 'O'}, {'promising': 'O'}, {'results.': 'O'}]"
"Thus, interstitial shadows, which appear during immunotherapy for Crohn's disease, could indicate asymptomatic Sjogrens syndrome; clinicians should consider this rare clinical picture when assessing such a patient.10.11405/nisshoshi.112.1326.histopathology in patients with sicca symptoms.","[{'Thus,': 'O'}, {'interstitial': 'O'}, {'shadows,': 'O'}, {'which': 'O'}, {'appear': 'O'}, {'during': 'O'}, {'immunotherapy': 'O'}, {'for': 'O'}, {""Crohn's"": 'B-Entity'}, {'disease,': 'I-Entity'}, {'could': 'O'}, {'indicate': 'O'}, {'asymptomatic': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome;': 'I-Entity'}, {'clinicians': 'O'}, {'should': 'O'}, {'consider': 'O'}, {'this': 'O'}, {'rare': 'O'}, {'clinical': 'O'}, {'picture': 'O'}, {'when': 'O'}, {'assessing': 'O'}, {'such': 'O'}, {'a': 'O'}, {'patient.10.11405/nisshoshi.112.1326.histopathology': 'O'}]"
"The presumed aetiologies in patients with NP were: chronic spine diseases (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢14), painful diabetic peripheral neuropathy (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢8), Sjogrens syndrome (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1), tarsal tunnel syndrome in rheumatoid arthritis (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1) and bone metastasis (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1).","[{'The': 'O'}, {'presumed': 'O'}, {'aetiologies': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'NP': 'I-Entity'}, {'were:': 'O'}, {'chronic': 'B-Entity'}, {'spine': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢14),': 'O'}, {'painful': 'O'}, {'diabetic': 'B-Entity'}, {'peripheral': 'I-Entity'}, {'neuropathy': 'I-Entity'}]"
"Although hematological abnormalities are usually seen in pSS patients, agranulocytosis and autoimmune hemolytic anemia (AIHA) are rare.","[{'Although': 'O'}, {'hematological': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'are': 'O'}, {'usually': 'O'}, {'seen': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'agranulocytosis': 'I-Entity'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'hemolytic': 'I-Entity'}, {'anemia': 'I-Entity'}, {'(AIHA)': 'O'}, {'are': 'O'}, {'rare.': 'O'}]"
"RTX seems effective in cryoglobulinaemia or vasculitis-related PNS involvement in pSS.de Paris, Universit‚Äö√†√∂¬¨¬© Paris-Sud 13, Bondy, France.Sep 16.malignant lesions in the parotid gland.","[{'RTX': 'I-Entity'}, {'seems': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'cryoglobulinaemia': 'I-Entity'}, {'or': 'O'}, {'vasculitis-related': 'I-Entity'}, {'PNS': 'O'}, {'involvement': 'O'}, {'in': 'O'}, {'pSS.de': 'I-Entity'}, {'Paris,': 'O'}, {'Universit‚Äö√†√∂¬¨¬©': 'O'}, {'Paris-Sud': 'O'}, {'13,': 'O'}, {'Bondy,': 'O'}, {'France.Sep': 'O'}, {'16.malignant': 'O'}, {'lesions': 'I-Entity'}]"
"A 52-year-old woman was hospitalized due to pain in the lumbar region, difficulty in walking, hypoesthesia of the anogenital area and urinary retention.","[{'A': 'O'}, {'52-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'hospitalized': 'O'}, {'due': 'O'}, {'to': 'O'}, {'pain': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'lumbar': 'O'}, {'region,': 'O'}, {'difficulty': 'B-Entity'}, {'in': 'I-Entity'}, {'walking,': 'I-Entity'}, {'hypoesthesia': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'anogenital': 'O'}, {'area': 'O'}, {'and': 'O'}, {'urinary': 'B-Entity'}, {'retention.': 'I-Entity'}]"
"The association of sIBM and Sjogrens syndrome is likely to be due to a common genetic predisposition linked to the MHC and supports the notion that sIBM has an autoimmune basis.Australia, Perth, Western Australia, Australia.","[{'The': 'O'}, {'association': 'O'}, {'of': 'O'}, {'sIBM': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'likely': 'O'}, {'to': 'O'}, {'be': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'common': 'O'}, {'genetic': 'O'}, {'predisposition': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'the': 'O'}, {'MHC': 'O'}, {'and': 'O'}, {'supports': 'O'}, {'the': 'O'}, {'notion': 'O'}, {'that': 'O'}, {'sIBM': 'I-Entity'}, {'has': 'O'}, {'an': 'O'}, {'autoimmune': 'O'}, {'basis.Australia,': 'O'}, {'Perth,': 'O'}, {'Western': 'O'}, {'Australia,': 'O'}, {'Australia.': 'O'}]"
Sjogren's syndrome (SS) is a systemic autoimmune disease that apart from involving the exocrine glands can affect any organ.,"[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'that': 'O'}, {'apart': 'O'}, {'from': 'O'}, {'involving': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'can': 'O'}, {'affect': 'O'}, {'any': 'O'}, {'organ.': 'O'}]"
The management of patients suffering from primary Sjogren syndrome (pSS) has long been mainly symptomatic and demonstration of effectiveness of systemic drugs was lacking.,"[{'The': 'O'}, {'management': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'suffering': 'O'}, {'from': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'has': 'O'}, {'long': 'O'}, {'been': 'O'}, {'mainly': 'O'}, {'symptomatic': 'O'}, {'and': 'O'}, {'demonstration': 'O'}, {'of': 'O'}, {'effectiveness': 'O'}, {'of': 'O'}, {'systemic': 'O'}, {'drugs': 'O'}, {'was': 'O'}, {'lacking.': 'O'}]"
"Light microscopic examination of the renal biopsy specimens showed expansion of mononuclear cell infiltration in the renal interstitium, inflammatory cell infiltration of interstitial areas with edema and mild fibrosis, and tubulitis and mononuclear cell infiltration that included many lymphocytes and plasma cells.","[{'Light': 'O'}, {'microscopic': 'O'}, {'examination': 'O'}, {'of': 'O'}, {'the': 'O'}, {'renal': 'O'}, {'biopsy': 'O'}, {'specimens': 'O'}, {'showed': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'mononuclear': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'the': 'O'}, {'renal': 'O'}, {'interstitium,': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'interstitial': 'O'}, {'areas': 'O'}, {'with': 'O'}, {'edema': 'I-Entity'}, {'and': 'O'}, {'mild': 'O'}, {'fibrosis,': 'I-Entity'}, {'and': 'O'}, {'tubulitis': 'I-Entity'}, {'and': 'O'}, {'mononuclear': 'O'}]"
"Circulating T cells exhibit phenotypes consistent with hyperactivation, cytokine imbalance, and homeostatic alterations; CD4 lymphopenia is recognized as a risk factor for developing lymphoma.","[{'Circulating': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'exhibit': 'O'}, {'phenotypes': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'hyperactivation,': 'O'}, {'cytokine': 'O'}, {'imbalance,': 'O'}, {'and': 'O'}, {'homeostatic': 'O'}, {'alterations;': 'O'}, {'CD4': 'O'}, {'lymphopenia': 'I-Entity'}, {'is': 'O'}, {'recognized': 'O'}, {'as': 'O'}, {'a': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'for': 'O'}, {'developing': 'O'}, {'lymphoma.': 'I-Entity'}]"
"This study aimed to determine the association of C3 and C4 hypocomplementemia at the diagnosis of primary Sjogrens syndrome (pSS) with clinical manifestations, disease activity, and disease damage.","[{'This': 'O'}, {'study': 'O'}, {'aimed': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'C3': 'O'}, {'and': 'O'}, {'C4': 'O'}, {'hypocomplementemia': 'I-Entity'}, {'at': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'manifestations,': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'damage.': 'O'}]"
The female:male ratio was 58:9.,"[{'The': 'O'}, {'female:male': 'O'}, {'ratio': 'O'}, {'was': 'O'}, {'58:9.': 'O'}]"
These patients also seem to have a higher risk of developing hypocomplementemia or lymphadenopathy.,"[{'These': 'O'}, {'patients': 'O'}, {'also': 'O'}, {'seem': 'O'}, {'to': 'O'}, {'have': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'hypocomplementemia': 'I-Entity'}, {'or': 'O'}, {'lymphadenopathy.': 'I-Entity'}]"
"Frequencies of mature naive B cells expressing autoreactive antibodies were also significantly increased in SS patients, thereby illustrating an impaired peripheral B cell tolerance checkpoint in these patients.","[{'Frequencies': 'O'}, {'of': 'O'}, {'mature': 'O'}, {'naive': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'expressing': 'O'}, {'autoreactive': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'also': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients,': 'O'}, {'thereby': 'O'}, {'illustrating': 'O'}, {'an': 'O'}, {'impaired': 'O'}, {'peripheral': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'tolerance': 'O'}, {'checkpoint': 'O'}, {'in': 'O'}, {'these': 'O'}, {'patients.': 'O'}]"
"Recently, striking data implicate Th17 cells in the stimulation of B cells, and a role for the related cytokine IL-21 produced by follicular T helper cells is now appreciated.","[{'Recently,': 'O'}, {'striking': 'O'}, {'data': 'O'}, {'implicate': 'O'}, {'Th17': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'the': 'O'}, {'stimulation': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cells,': 'O'}, {'and': 'O'}, {'a': 'O'}, {'role': 'O'}, {'for': 'O'}, {'the': 'O'}, {'related': 'O'}, {'cytokine': 'O'}, {'IL-21': 'O'}, {'produced': 'O'}, {'by': 'O'}, {'follicular': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'cells': 'O'}, {'is': 'O'}, {'now': 'O'}, {'appreciated.': 'O'}]"
Low MX1 levels were shown to be associated with both a low disease activity score based on the European League Against Rheumatism (EULAR) Sjogrens Syndrome Disease Activity Index (ESSDAI) and hydroxychloroquine use in all patients.,"[{'Low': 'O'}, {'MX1': 'O'}, {'levels': 'O'}, {'were': 'O'}, {'shown': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'both': 'O'}, {'a': 'O'}, {'low': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'score': 'O'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'O'}, {'Rheumatism': 'I-Entity'}, {'(EULAR)': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI)': 'O'}, {'and': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'use': 'O'}, {'in': 'O'}, {'all': 'O'}, {'patients.': 'O'}]"
SUBJECTS AND RT therapy was performed in 13 patients with SD and CGV and in 17 with SD and PC MALT lymphoma.,"[{'SUBJECTS': 'O'}, {'AND': 'O'}, {'RT': 'O'}, {'therapy': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SD': 'I-Entity'}, {'and': 'O'}, {'CGV': 'I-Entity'}, {'and': 'O'}, {'in': 'O'}, {'17': 'O'}, {'with': 'O'}, {'SD': 'I-Entity'}, {'and': 'O'}, {'PC': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma.': 'I-Entity'}]"
"A feared complication is the development of a lymphoma, the risk being especially high in case of positive anti-SSA-(Ro) antibodies, but also in case of a high ESSDAI score, hypocomplementemia, cytopenia or evidence of ectopic germinal centers in salivary gland biopsies.","[{'A': 'O'}, {'feared': 'O'}, {'complication': 'O'}, {'is': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'a': 'O'}, {'lymphoma,': 'I-Entity'}, {'the': 'O'}, {'risk': 'O'}, {'being': 'O'}, {'especially': 'O'}, {'high': 'O'}, {'in': 'O'}, {'case': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-SSA-(Ro)': 'O'}, {'antibodies,': 'O'}, {'but': 'O'}, {'also': 'O'}, {'in': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'high': 'O'}, {'ESSDAI': 'O'}, {'score,': 'O'}, {'hypocomplementemia,': 'I-Entity'}, {'cytopenia': 'I-Entity'}, {'or': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'ectopic': 'I-Entity'}]"
"This article examines the reasons for these failures and proposes future directions.Avenue, Suite 910, La Jolla, CA 92037, USA.","[{'This': 'O'}, {'article': 'O'}, {'examines': 'O'}, {'the': 'O'}, {'reasons': 'O'}, {'for': 'O'}, {'these': 'O'}, {'failures': 'O'}, {'and': 'O'}, {'proposes': 'O'}, {'future': 'O'}, {'directions.Avenue,': 'O'}, {'Suite': 'O'}, {'910,': 'O'}, {'La': 'O'}, {'Jolla,': 'O'}, {'CA': 'O'}, {'92037,': 'O'}, {'USA.': 'O'}]"
"FF cannot replace NH4Cl in testing urinary acidification in pSS, but may be considered as a screening tool, given its reasonable negative predictive value and better tolerability.Society for Rheumatology.","[{'FF': 'O'}, {'cannot': 'O'}, {'replace': 'O'}, {'NH4Cl': 'I-Entity'}, {'in': 'O'}, {'testing': 'O'}, {'urinary': 'O'}, {'acidification': 'O'}, {'in': 'O'}, {'pSS,': 'O'}, {'but': 'O'}, {'may': 'O'}, {'be': 'O'}, {'considered': 'O'}, {'as': 'O'}, {'a': 'O'}, {'screening': 'O'}, {'tool,': 'O'}, {'given': 'O'}, {'its': 'O'}, {'reasonable': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value': 'O'}, {'and': 'O'}, {'better': 'O'}, {'tolerability.Society': 'O'}, {'for': 'O'}, {'Rheumatology.': 'O'}]"
"Despite similarities in the organs damaged in IgG4-related Mikulicz's disease and Sjogrens syndrome, there are marked clinical and pathological differences between the 2 entities.","[{'Despite': 'O'}, {'similarities': 'O'}, {'in': 'O'}, {'the': 'O'}, {'organs': 'O'}, {'damaged': 'O'}, {'in': 'O'}, {'IgG4-related': 'O'}, {""Mikulicz's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'there': 'O'}, {'are': 'O'}, {'marked': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'pathological': 'O'}, {'differences': 'O'}, {'between': 'O'}, {'the': 'O'}, {'2': 'O'}, {'entities.': 'O'}]"
"Positive serum cryoglobulins were detected in 65 (12%) patients, of whom 21 (32%) fulfilled CV classification criteria.","[{'Positive': 'O'}, {'serum': 'O'}, {'cryoglobulins': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'65': 'O'}, {'(12%)': 'O'}, {'patients,': 'O'}, {'of': 'O'}, {'whom': 'O'}, {'21': 'O'}, {'(32%)': 'O'}, {'fulfilled': 'O'}, {'CV': 'O'}, {'classification': 'O'}, {'criteria.': 'O'}]"
Significant conjunctival GC loss occurs in both experimental dry eye models and patients with keratoconjunctivitis sicca due to the induction of interferon (IFN)-‚âà√≠‚Äö√¢‚Ä¢.,"[{'Significant': 'O'}, {'conjunctival': 'O'}, {'GC': 'O'}, {'loss': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'both': 'O'}, {'experimental': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'models': 'O'}, {'and': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'induction': 'O'}, {'of': 'O'}, {'interferon': 'O'}, {'(IFN)-‚âà√≠‚Äö√¢‚Ä¢.': 'O'}]"
The predictors of suboptimal treatment response will be identified.,"[{'The': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'suboptimal': 'O'}, {'treatment': 'O'}, {'response': 'O'}, {'will': 'O'}, {'be': 'O'}, {'identified.': 'O'}]"
"In the 54(th) h, the patient manifested with convulsion, dyspnea and blurred vision.","[{'In': 'O'}, {'the': 'O'}, {'54(th)': 'O'}, {'h,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'manifested': 'O'}, {'with': 'O'}, {'convulsion,': 'I-Entity'}, {'dyspnea': 'I-Entity'}, {'and': 'O'}, {'blurred': 'B-Entity'}, {'vision.': 'I-Entity'}]"
The accurate diagnosis of behavioral disorders in patients with rumination syndrome and supragastric belching using ambulatory multiple intraluminal impedance-pH can lead directly to behavioral interventions in patients with refractory gastroesophageal reflux disease (GERD).,"[{'The': 'O'}, {'accurate': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'behavioral': 'B-Entity'}, {'disorders': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'rumination': 'B-Entity'}, {'syndrome': 'O'}, {'and': 'O'}, {'supragastric': 'O'}, {'belching': 'O'}, {'using': 'O'}, {'ambulatory': 'O'}, {'multiple': 'O'}, {'intraluminal': 'O'}, {'impedance-pH': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'directly': 'O'}, {'to': 'O'}, {'behavioral': 'O'}, {'interventions': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'refractory': 'O'}, {'gastroesophageal': 'B-Entity'}, {'reflux': 'I-Entity'}, {'disease': 'I-Entity'}, {'(GERD).': 'O'}]"
"Oral microbiota composition differed significantly between pSS patients and SLE patients, which could partially be explained by oral dryness in pSS patients.","[{'Oral': 'O'}, {'microbiota': 'O'}, {'composition': 'O'}, {'differed': 'O'}, {'significantly': 'O'}, {'between': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'SLE': 'I-Entity'}, {'patients,': 'O'}, {'which': 'O'}, {'could': 'O'}, {'partially': 'O'}, {'be': 'O'}, {'explained': 'O'}, {'by': 'O'}, {'oral': 'B-Entity'}, {'dryness': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.': 'O'}]"
"This exocrinopathy is frequently associated with extraglandular complications, and the patients are at risk of developing B cell lymphoma.","[{'This': 'O'}, {'exocrinopathy': 'I-Entity'}, {'is': 'O'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'extraglandular': 'O'}, {'complications,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'are': 'O'}, {'at': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'developing': 'O'}, {'B': 'B-Entity'}, {'cell': 'I-Entity'}, {'lymphoma.': 'I-Entity'}]"
The following review summarizes the most common extrahepatic conditions associated with PBC.reported.Tubular Acidosis.,"[{'The': 'O'}, {'following': 'O'}, {'review': 'O'}, {'summarizes': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'extrahepatic': 'O'}, {'conditions': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'PBC.reported.Tubular': 'I-Entity'}, {'Acidosis.': 'I-Entity'}]"
"Pregnancy-revealed AOSD appears to be a specifical subset of the disease with a systemic course, flares on first and second trimester, obstetrical complications such as prematurity and IUGR sometimes leading to life-threatening situations requiring parenteral corticotherapy and intravenous immunoglobulins.","[{'Pregnancy-revealed': 'O'}, {'AOSD': 'I-Entity'}, {'appears': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'specifical': 'O'}, {'subset': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'with': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'course,': 'O'}, {'flares': 'O'}, {'on': 'O'}, {'first': 'O'}, {'and': 'O'}, {'second': 'O'}, {'trimester,': 'O'}, {'obstetrical': 'O'}, {'complications': 'O'}, {'such': 'O'}, {'as': 'O'}, {'prematurity': 'I-Entity'}, {'and': 'O'}, {'IUGR': 'I-Entity'}, {'sometimes': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'life-threatening': 'O'}, {'situations': 'O'}, {'requiring': 'O'}, {'parenteral': 'O'}, {'corticotherapy': 'O'}]"
IgG class switch and plasma cell differentiation were induced in vitro in purified na‚Äö√†√∂‚àö√≤ve B cells of untreated and hydroxychloroquine-treated patients and healthy controls.,"[{'IgG': 'O'}, {'class': 'O'}, {'switch': 'O'}, {'and': 'O'}, {'plasma': 'O'}, {'cell': 'O'}, {'differentiation': 'O'}, {'were': 'O'}, {'induced': 'O'}, {'in': 'O'}, {'vitro': 'O'}, {'in': 'O'}, {'purified': 'O'}, {'na‚Äö√†√∂‚àö√≤ve': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'of': 'O'}, {'untreated': 'O'}, {'and': 'O'}, {'hydroxychloroquine-treated': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'healthy': 'O'}, {'controls.': 'O'}]"
"Treatment with methotrexate and methylprednisolone improved the clinical symptoms and quality of life of this patient and may offer a therapeutic option for some patients with IBM and concomitant Sjogrens syndrome.Borowska Street 213, Wroc‚Äö√¢√†‚àö√°aw, Poland.12.","[{'Treatment': 'O'}, {'with': 'O'}, {'methotrexate': 'I-Entity'}, {'and': 'O'}, {'methylprednisolone': 'I-Entity'}, {'improved': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life': 'O'}, {'of': 'O'}, {'this': 'O'}, {'patient': 'O'}, {'and': 'O'}, {'may': 'O'}, {'offer': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'for': 'O'}, {'some': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'IBM': 'I-Entity'}, {'and': 'O'}, {'concomitant': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.Borowska': 'I-Entity'}, {'Street': 'O'}, {'213,': 'O'}, {'Wroc‚Äö√¢√†‚àö√°aw,': 'O'}]"
To investigate whether the balance of blood follicular helper T (Tfh) cells and T follicular regulatory (Tfr) cells can provide information about ectopic lymphoid neogenesis and disease activity in primary Sjogrens syndrome (SS).,"[{'To': 'O'}, {'investigate': 'O'}, {'whether': 'O'}, {'the': 'O'}, {'balance': 'O'}, {'of': 'O'}, {'blood': 'O'}, {'follicular': 'O'}, {'helper': 'O'}, {'T': 'O'}, {'(Tfh)': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'T': 'O'}, {'follicular': 'O'}, {'regulatory': 'O'}, {'(Tfr)': 'O'}, {'cells': 'O'}, {'can': 'O'}, {'provide': 'O'}, {'information': 'O'}, {'about': 'O'}, {'ectopic': 'O'}, {'lymphoid': 'O'}, {'neogenesis': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"CHB was the only cause of death for offspring of mothers with pSS.Rome, Italy.","[{'CHB': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'only': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'death': 'I-Entity'}, {'for': 'O'}, {'offspring': 'O'}, {'of': 'O'}, {'mothers': 'O'}, {'with': 'O'}, {'pSS.Rome,': 'O'}, {'Italy.': 'O'}]"
"These patients usually have fatigue and pruritus, both of which occur independently of disease severity.","[{'These': 'O'}, {'patients': 'O'}, {'usually': 'O'}, {'have': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'pruritus,': 'I-Entity'}, {'both': 'O'}, {'of': 'O'}, {'which': 'O'}, {'occur': 'O'}, {'independently': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'severity.': 'O'}]"
"We report a case of a female patient with salivary gland dysfunction and pain of several years' duration, who, after numerous tests and hospitalizations, was diagnosed with Sjogrens syndrome.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'dysfunction': 'I-Entity'}, {'and': 'O'}, {'pain': 'I-Entity'}, {'of': 'O'}, {'several': 'O'}, {""years'"": 'O'}, {'duration,': 'O'}, {'who,': 'O'}, {'after': 'O'}, {'numerous': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'hospitalizations,': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"After her second injection cycle, she denied further inflammatory bouts, has not required antibiotics in more than 36¬¨¬®‚Äö√Ñ‚Ä†months, and denied any side effects.","[{'After': 'O'}, {'her': 'O'}, {'second': 'O'}, {'injection': 'O'}, {'cycle,': 'O'}, {'she': 'O'}, {'denied': 'O'}, {'further': 'O'}, {'inflammatory': 'O'}, {'bouts,': 'O'}, {'has': 'O'}, {'not': 'O'}, {'required': 'O'}, {'antibiotics': 'O'}, {'in': 'O'}, {'more': 'O'}, {'than': 'O'}, {'36¬¨¬®‚Äö√Ñ‚Ä†months,': 'O'}, {'and': 'O'}, {'denied': 'O'}, {'any': 'O'}, {'side': 'O'}, {'effects.': 'O'}]"
One hundred and eighty four patients with polyneuropathy associated with limb weakness underwent routine diagnostics including investigations for Sjogrens syndrome.,"[{'One': 'O'}, {'hundred': 'O'}, {'and': 'O'}, {'eighty': 'O'}, {'four': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'polyneuropathy': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'limb': 'B-Entity'}, {'weakness': 'I-Entity'}, {'underwent': 'O'}, {'routine': 'O'}, {'diagnostics': 'O'}, {'including': 'O'}, {'investigations': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"All the 14 patients were received the cerebrospinal fluidcell surface antigen antibody detection, and the results were strong positive 6 cases (6/14), positive 7 cases (7/14), weak positive 1 case (1/14).","[{'All': 'O'}, {'the': 'O'}, {'14': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'received': 'O'}, {'the': 'O'}, {'cerebrospinal': 'O'}, {'fluidcell': 'O'}, {'surface': 'O'}, {'antigen': 'O'}, {'antibody': 'O'}, {'detection,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'results': 'O'}, {'were': 'O'}, {'strong': 'O'}, {'positive': 'O'}, {'6': 'O'}, {'cases': 'O'}, {'(6/14),': 'O'}, {'positive': 'O'}, {'7': 'O'}, {'cases': 'O'}, {'(7/14),': 'O'}, {'weak': 'O'}, {'positive': 'O'}, {'1': 'O'}, {'case': 'O'}, {'(1/14).': 'O'}]"
"An important role also exists for the target tissue (exocrine glands, namely the salivary and lachrymal glands), which promotes local B cell activation.","[{'An': 'O'}, {'important': 'O'}, {'role': 'O'}, {'also': 'O'}, {'exists': 'O'}, {'for': 'O'}, {'the': 'O'}, {'target': 'O'}, {'tissue': 'O'}, {'(exocrine': 'O'}, {'glands,': 'O'}, {'namely': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'and': 'O'}, {'lachrymal': 'O'}, {'glands),': 'O'}, {'which': 'O'}, {'promotes': 'O'}, {'local': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation.': 'O'}]"
Nocturia was frequent but was not associated with fatigue or sleepiness.,"[{'Nocturia': 'I-Entity'}, {'was': 'O'}, {'frequent': 'O'}, {'but': 'O'}, {'was': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fatigue': 'I-Entity'}, {'or': 'O'}, {'sleepiness.': 'I-Entity'}]"
This review provides an overview of the main US findings observed in a wide range of pathological processes that can affect salivary glands.marina.carotti@gmail.com.cases.,"[{'This': 'O'}, {'review': 'O'}, {'provides': 'O'}, {'an': 'O'}, {'overview': 'O'}, {'of': 'O'}, {'the': 'O'}, {'main': 'O'}, {'US': 'O'}, {'findings': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'a': 'O'}, {'wide': 'O'}, {'range': 'O'}, {'of': 'O'}, {'pathological': 'O'}, {'processes': 'O'}, {'that': 'O'}, {'can': 'O'}, {'affect': 'O'}, {'salivary': 'O'}, {'glands.marina.carotti@gmail.com.cases.': 'O'}]"
Histologic data were compared with results from peripheral blood and with changes in saliva secretion.,"[{'Histologic': 'O'}, {'data': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'results': 'O'}, {'from': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'and': 'O'}, {'with': 'O'}, {'changes': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'secretion.': 'O'}]"
The aim of this post hoc analysis was to determine whether epratuzumab had a different clinical efficacy profile in SLE patients with versus those without an associated diagnosis of Sjogrens syndrome (SS).,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'post': 'O'}, {'hoc': 'O'}, {'analysis': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'epratuzumab': 'I-Entity'}, {'had': 'O'}, {'a': 'O'}, {'different': 'O'}, {'clinical': 'O'}, {'efficacy': 'O'}, {'profile': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'versus': 'O'}, {'those': 'O'}, {'without': 'O'}, {'an': 'O'}, {'associated': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
A possible vascular aetiology of SLE myelopathies has been hypothesized and it seems to be much more associated to SLE-associated antiphospholipid syndrome (APS).,"[{'A': 'O'}, {'possible': 'O'}, {'vascular': 'O'}, {'aetiology': 'O'}, {'of': 'O'}, {'SLE': 'B-Entity'}, {'myelopathies': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'hypothesized': 'O'}, {'and': 'O'}, {'it': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'much': 'O'}, {'more': 'O'}, {'associated': 'O'}, {'to': 'O'}, {'SLE-associated': 'I-Entity'}, {'antiphospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS).': 'O'}]"
A pilot study was performed to examine the presence of nerve fibres in minor salivary gland tissue samples obtained by two procedures: punch and linear incisional techniques.,"[{'A': 'O'}, {'pilot': 'O'}, {'study': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'to': 'O'}, {'examine': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'nerve': 'O'}, {'fibres': 'O'}, {'in': 'O'}, {'minor': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'tissue': 'O'}, {'samples': 'O'}, {'obtained': 'O'}, {'by': 'O'}, {'two': 'O'}, {'procedures:': 'O'}, {'punch': 'O'}, {'and': 'O'}, {'linear': 'O'}, {'incisional': 'O'}, {'techniques.': 'O'}]"
"In different bioassays, functional antibodies reacting with the human muscarinic acetylcholine receptor M3(mAchR3) have been detected in sera from patients with Sjogrens syndrome (SS), and there is strong evidence that those antibodies may have pathogenetic relevance.","[{'In': 'O'}, {'different': 'O'}, {'bioassays,': 'O'}, {'functional': 'O'}, {'antibodies': 'O'}, {'reacting': 'O'}, {'with': 'O'}, {'the': 'O'}, {'human': 'O'}, {'muscarinic': 'O'}, {'acetylcholine': 'I-Entity'}, {'receptor': 'O'}, {'M3(mAchR3)': 'O'}, {'have': 'O'}, {'been': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'sera': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'and': 'O'}, {'there': 'O'}, {'is': 'O'}, {'strong': 'O'}, {'evidence': 'O'}, {'that': 'O'}, {'those': 'O'}, {'antibodies': 'O'}, {'may': 'O'}, {'have': 'O'}, {'pathogenetic': 'O'}]"
"In January 2015 the diagnosis of the patients were evaluated and classified in systemic disease connective tissue (systemic lupus erythematosus, Sjogrens syndrome, systemic sclerosis, undifferentiated connective, antiphospholipid syndrome, mixed connective tissue and inflammatory myophaty) or not systemic disease connective tissue.","[{'In': 'O'}, {'January': 'O'}, {'2015': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'and': 'O'}, {'classified': 'O'}, {'in': 'O'}, {'systemic': 'B-Entity'}, {'disease': 'I-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'(systemic': 'O'}, {'lupus': 'I-Entity'}, {'erythematosus,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis,': 'I-Entity'}, {'undifferentiated': 'B-Entity'}, {'connective,': 'I-Entity'}, {'antiphospholipid': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'mixed': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'and': 'I-Entity'}, {'inflammatory': 'I-Entity'}]"
Samples from 4 cohorts of RA patients were examined and compared to normal human subjects and to patients with other inflammatory diseases.,"[{'Samples': 'O'}, {'from': 'O'}, {'4': 'O'}, {'cohorts': 'O'}, {'of': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'and': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'normal': 'O'}, {'human': 'O'}, {'subjects': 'O'}, {'and': 'O'}, {'to': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'other': 'O'}, {'inflammatory': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Significant predictors of greater symptoms than signs were the presence of a chronic pain syndrome, atopic diseases, a known allergy, the use of antihistamines (all P < 0.001), depression (P¬¨¬®‚Äö√Ñ‚Ä†= 0.003), osteoarthritis (P¬¨¬®‚Äö√Ñ‚Ä†= 0.008), and the use of antidepressants (P¬¨¬®‚Äö√Ñ‚Ä†= 0.02).","[{'Significant': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'greater': 'O'}, {'symptoms': 'O'}, {'than': 'O'}, {'signs': 'O'}, {'were': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'chronic': 'B-Entity'}, {'pain': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'atopic': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'a': 'O'}, {'known': 'O'}, {'allergy,': 'I-Entity'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'antihistamines': 'O'}, {'(all': 'O'}, {'P': 'O'}, {'<': 'O'}, {'0.001),': 'O'}, {'depression': 'I-Entity'}, {'(P¬¨¬®‚Äö√Ñ‚Ä†=': 'O'}, {'0.003),': 'O'}]"
"We examined the clinical characteristics, management, and outcomes of Japanese RP patients.","[{'We': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'characteristics,': 'O'}, {'management,': 'O'}, {'and': 'O'}, {'outcomes': 'O'}, {'of': 'O'}, {'Japanese': 'O'}, {'RP': 'I-Entity'}, {'patients.': 'O'}]"
Elevation of acute phase reactants at inclusion was the only parameter associated with progression to erosive RA.,"[{'Elevation': 'O'}, {'of': 'O'}, {'acute': 'O'}, {'phase': 'O'}, {'reactants': 'O'}, {'at': 'O'}, {'inclusion': 'O'}, {'was': 'O'}, {'the': 'O'}, {'only': 'O'}, {'parameter': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'progression': 'O'}, {'to': 'O'}, {'erosive': 'O'}, {'RA.': 'I-Entity'}]"
Serum and synovial fluid CTGF was detected using a direct high sensitivity sandwich ELISA kit.,"[{'Serum': 'O'}, {'and': 'O'}, {'synovial': 'O'}, {'fluid': 'O'}, {'CTGF': 'O'}, {'was': 'O'}, {'detected': 'O'}, {'using': 'O'}, {'a': 'O'}, {'direct': 'O'}, {'high': 'O'}, {'sensitivity': 'O'}, {'sandwich': 'O'}, {'ELISA': 'O'}, {'kit.': 'O'}]"
"According to its variable severity, lubricating tear drops may be sufficient in mild cases, whereas cyclosporine-A ophthalmic solution, glucocorticoids (GCs), methotrexate, and/or other immunosuppressive drugs may be required in the more severe cases.","[{'According': 'O'}, {'to': 'O'}, {'its': 'O'}, {'variable': 'O'}, {'severity,': 'O'}, {'lubricating': 'O'}, {'tear': 'O'}, {'drops': 'O'}, {'may': 'O'}, {'be': 'O'}, {'sufficient': 'O'}, {'in': 'O'}, {'mild': 'O'}, {'cases,': 'O'}, {'whereas': 'O'}, {'cyclosporine-A': 'I-Entity'}, {'ophthalmic': 'O'}, {'solution,': 'O'}, {'glucocorticoids': 'O'}, {'(GCs),': 'O'}, {'methotrexate,': 'I-Entity'}, {'and/or': 'O'}, {'other': 'O'}, {'immunosuppressive': 'O'}, {'drugs': 'O'}, {'may': 'O'}]"
FOT therefore seems to be a sensitive method for detecting obstruction in pSS patients.Jan 7.,"[{'FOT': 'O'}, {'therefore': 'O'}, {'seems': 'O'}, {'to': 'O'}, {'be': 'O'}, {'a': 'O'}, {'sensitive': 'O'}, {'method': 'O'}, {'for': 'O'}, {'detecting': 'O'}, {'obstruction': 'I-Entity'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients.Jan': 'O'}, {'7.': 'O'}]"
"The pathology in most cases is a tubulointerstitial nephritis causing among other things, distal RTA, and, rarely, hypokalemic paralysis.","[{'The': 'O'}, {'pathology': 'O'}, {'in': 'O'}, {'most': 'O'}, {'cases': 'O'}, {'is': 'O'}, {'a': 'O'}, {'tubulointerstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'causing': 'O'}, {'among': 'O'}, {'other': 'O'}, {'things,': 'O'}, {'distal': 'O'}, {'RTA,': 'I-Entity'}, {'and,': 'O'}, {'rarely,': 'O'}, {'hypokalemic': 'I-Entity'}, {'paralysis.': 'I-Entity'}]"
"Compared with clinical assessment, InflammaDry is sensitive and specific in diagnosing dry eye.","[{'Compared': 'O'}, {'with': 'O'}, {'clinical': 'O'}, {'assessment,': 'O'}, {'InflammaDry': 'O'}, {'is': 'O'}, {'sensitive': 'O'}, {'and': 'O'}, {'specific': 'O'}, {'in': 'O'}, {'diagnosing': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"Osteomalacia is a rare association with Sjogrens syndrome, which may result from renal disease.","[{'Osteomalacia': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'association': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'which': 'O'}, {'may': 'O'}, {'result': 'O'}, {'from': 'O'}, {'renal': 'B-Entity'}, {'disease.': 'I-Entity'}]"
"Two patients were rendered homebound, as even the barest graze of outdoor breezes caused intolerable ear pain.","[{'Two': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'rendered': 'O'}, {'homebound,': 'O'}, {'as': 'O'}, {'even': 'O'}, {'the': 'O'}, {'barest': 'O'}, {'graze': 'O'}, {'of': 'O'}, {'outdoor': 'O'}, {'breezes': 'O'}, {'caused': 'O'}, {'intolerable': 'O'}, {'ear': 'B-Entity'}, {'pain.': 'I-Entity'}]"
We here report a case of ILDs associated with dermatomyositis and secondary Sjogrens syndrome.,"[{'We': 'O'}, {'here': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'ILDs': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'dermatomyositis': 'I-Entity'}, {'and': 'O'}, {'secondary': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
Secondary SS (sSS) is diagnosed when symptoms of SS coexist with other systemic connective tissue disease.,"[{'Secondary': 'O'}, {'SS': 'I-Entity'}, {'(sSS)': 'O'}, {'is': 'O'}, {'diagnosed': 'O'}, {'when': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'coexist': 'O'}, {'with': 'O'}, {'other': 'O'}, {'systemic': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"In vivo, SG retrograd instillation of nonobese diabetic mice by the modified U7 cloned into an adeno-associated virus vector significantly decreased BAFF protein expression and lymphocytic infiltrates and improved salivary flow.","[{'In': 'O'}, {'vivo,': 'O'}, {'SG': 'I-Entity'}, {'retrograd': 'O'}, {'instillation': 'O'}, {'of': 'O'}, {'nonobese': 'O'}, {'diabetic': 'I-Entity'}, {'mice': 'O'}, {'by': 'O'}, {'the': 'O'}, {'modified': 'O'}, {'U7': 'I-Entity'}, {'cloned': 'O'}, {'into': 'O'}, {'an': 'O'}, {'adeno-associated': 'O'}, {'virus': 'O'}, {'vector': 'O'}, {'significantly': 'O'}, {'decreased': 'O'}, {'BAFF': 'O'}, {'protein': 'O'}, {'expression': 'O'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltrates': 'O'}, {'and': 'O'}, {'improved': 'O'}, {'salivary': 'O'}, {'flow.': 'O'}]"
"A 40-year-old female presented with cough, exertional dyspnea, abdominal pain with distention, fatigue, dry eyes and dry mouth.","[{'A': 'O'}, {'40-year-old': 'O'}, {'female': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'cough,': 'I-Entity'}, {'exertional': 'B-Entity'}, {'dyspnea,': 'I-Entity'}, {'abdominal': 'B-Entity'}, {'pain': 'I-Entity'}, {'with': 'O'}, {'distention,': 'I-Entity'}, {'fatigue,': 'I-Entity'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth.': 'I-Entity'}]"
"To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjogrens syndrome (pSS) in a double-blind, placebo-controlled, phase II, single-centre study.","[{'To': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'and': 'O'}, {'safety': 'O'}, {'of': 'O'}, {'ianalumab': 'I-Entity'}, {'(VAY736),': 'O'}, {'a': 'O'}, {'B': 'O'}, {'cell-depleting,': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activating': 'O'}, {'factor': 'O'}, {'receptor-blocking,': 'O'}, {'monoclonal': 'O'}, {'antibody,': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'active': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'in': 'O'}, {'a': 'O'}, {'double-blind,': 'O'}]"
Total diffuse keratitis healing occurred after several months of treatment.,"[{'Total': 'O'}, {'diffuse': 'O'}, {'keratitis': 'I-Entity'}, {'healing': 'O'}, {'occurred': 'O'}, {'after': 'O'}, {'several': 'O'}, {'months': 'O'}, {'of': 'O'}, {'treatment.': 'O'}]"
Desiccation of the vocal tract can cause many voice problems.,"[{'Desiccation': 'B-Entity'}, {'of': 'O'}, {'the': 'O'}, {'vocal': 'O'}, {'tract': 'I-Entity'}, {'can': 'O'}, {'cause': 'O'}, {'many': 'O'}, {'voice': 'B-Entity'}, {'problems.': 'I-Entity'}]"
‚Äö√Ñ√∂‚àö√ë¬¨¬¢High umbilical artery pulsatility index in Doppler scans studies has been detected in our anti-Ro/SSA population (basely in SLE patients) demonstrated this measurement as a predictor of SGA and adverse pregnancy outcomes in general population such as cesarean section for fetal distress.,"[{'‚Äö√Ñ√∂‚àö√ë¬¨¬¢High': 'O'}, {'umbilical': 'O'}, {'artery': 'O'}, {'pulsatility': 'O'}, {'index': 'O'}, {'in': 'O'}, {'Doppler': 'O'}, {'scans': 'O'}, {'studies': 'O'}, {'has': 'O'}, {'been': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'our': 'O'}, {'anti-Ro/SSA': 'O'}, {'population': 'O'}, {'(basely': 'O'}, {'in': 'O'}, {'SLE': 'I-Entity'}, {'patients)': 'O'}, {'demonstrated': 'O'}, {'this': 'O'}, {'measurement': 'O'}, {'as': 'O'}, {'a': 'O'}, {'predictor': 'O'}]"
A second goal of researchers is to define the mechanisms by which viruses replicate within glandular tissue where they can then gain access to salivary fluids important for horizontal transmission.,"[{'A': 'O'}, {'second': 'O'}, {'goal': 'O'}, {'of': 'O'}, {'researchers': 'O'}, {'is': 'O'}, {'to': 'O'}, {'define': 'O'}, {'the': 'O'}, {'mechanisms': 'O'}, {'by': 'O'}, {'which': 'O'}, {'viruses': 'O'}, {'replicate': 'O'}, {'within': 'O'}, {'glandular': 'O'}, {'tissue': 'O'}, {'where': 'O'}, {'they': 'O'}, {'can': 'O'}, {'then': 'O'}, {'gain': 'O'}, {'access': 'O'}, {'to': 'O'}, {'salivary': 'O'}, {'fluids': 'O'}, {'important': 'O'}, {'for': 'O'}, {'horizontal': 'O'}, {'transmission.': 'O'}]"
Some cases of AGEP induced by HCQ are reported in literature but only in adults.,"[{'Some': 'O'}, {'cases': 'O'}, {'of': 'O'}, {'AGEP': 'I-Entity'}, {'induced': 'O'}, {'by': 'O'}, {'HCQ': 'I-Entity'}, {'are': 'O'}, {'reported': 'O'}, {'in': 'O'}, {'literature': 'O'}, {'but': 'O'}, {'only': 'O'}, {'in': 'O'}, {'adults.': 'O'}]"
"Identification of the multiple steps that support B cell activation has led to the development of promising targeted therapies that will hopefully lead to the development of an efficient therapeutic strategy for pSS.Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-H‚Äö√†√∂¬¨‚Ä¢pitaux de Paris (AP-HP), H‚Äö√†√∂¬¨‚Ä¢pitaux Universitaires Paris-Sud Bic‚Äö√†√∂‚Äö√ë¬¢tre, Le Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-H‚Äö√†√∂¬¨‚Ä¢pitaux de Paris (AP-HP), H‚Äö√†√∂¬¨‚Ä¢pitaux Universitaires Paris-Sud Bic‚Äö√†√∂‚Äö√ë¬¢tre, Le Kremlin-Bic‚Äö√†√∂‚Äö√ë¬¢tre, France.Feb 8.","[{'Identification': 'O'}, {'of': 'O'}, {'the': 'O'}, {'multiple': 'O'}, {'steps': 'O'}, {'that': 'O'}, {'support': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activation': 'O'}, {'has': 'O'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'promising': 'O'}, {'targeted': 'O'}, {'therapies': 'O'}, {'that': 'O'}, {'will': 'O'}, {'hopefully': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'an': 'O'}, {'efficient': 'O'}, {'therapeutic': 'O'}, {'strategy': 'O'}, {'for': 'O'}, {'pSS.Immunology': 'I-Entity'}, {'of': 'O'}, {'Viral': 'B-Entity'}, {'Infections': 'I-Entity'}, {'and': 'O'}, {'Autoimmune': 'B-Entity'}, {'Diseases,': 'I-Entity'}, {'Assistance': 'O'}, {'Publique-H‚Äö√†√∂¬¨‚Ä¢pitaux': 'O'}]"
"In dermatomyositis patients, Raynaud's phenomenon, anti-Jo-1 positivity, and some capillaroscopy findings were detected more frequently in patients with mechanic hand.","[{'In': 'O'}, {'dermatomyositis': 'I-Entity'}, {'patients,': 'O'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon,': 'I-Entity'}, {'anti-Jo-1': 'O'}, {'positivity,': 'O'}, {'and': 'O'}, {'some': 'O'}, {'capillaroscopy': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'detected': 'O'}, {'more': 'O'}, {'frequently': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'mechanic': 'O'}, {'hand.': 'I-Entity'}]"
"A 68-year-old female patient with Sjogren syndrome was admitted with asthenia, anorexia and weight loss.","[{'A': 'O'}, {'68-year-old': 'O'}, {'female': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'admitted': 'O'}, {'with': 'O'}, {'asthenia,': 'I-Entity'}, {'anorexia': 'I-Entity'}, {'and': 'O'}, {'weight': 'B-Entity'}, {'loss.': 'I-Entity'}]"
There are limited data regarding long-term follow-up and therapeutic outcomes in Sjogren's syndrome (SS)-associated peripheral neuropathy.,"[{'There': 'O'}, {'are': 'O'}, {'limited': 'O'}, {'data': 'O'}, {'regarding': 'O'}, {'long-term': 'O'}, {'follow-up': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'outcomes': 'O'}, {'in': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)-associated': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
"The treatment of pSS warrants an organ based approach, for which local treatment (teardrops, moistures) and systemic therapy (including non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDS) and biologicals) can be considered.","[{'The': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'warrants': 'O'}, {'an': 'O'}, {'organ': 'O'}, {'based': 'O'}, {'approach,': 'O'}, {'for': 'O'}, {'which': 'O'}, {'local': 'O'}, {'treatment': 'O'}, {'(teardrops,': 'O'}, {'moistures)': 'O'}, {'and': 'O'}, {'systemic': 'O'}, {'therapy': 'O'}, {'(including': 'O'}, {'non-steroidal': 'O'}, {'anti-inflammatory': 'O'}, {'drugs': 'O'}, {'(NSAIDs),': 'O'}, {'glucocorticoids,': 'O'}, {'disease-modifying': 'O'}, {'antirheumatic': 'O'}, {'drugs': 'O'}, {'(DMARDS)': 'O'}]"
"are up- or down-regulated in respect to benign, premalignant and malignant conditions in the oral cavity, and several patterns of deregulation are associated with specific disorders.","[{'are': 'O'}, {'up-': 'O'}, {'or': 'O'}, {'down-regulated': 'O'}, {'in': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'benign,': 'O'}, {'premalignant': 'O'}, {'and': 'O'}, {'malignant': 'I-Entity'}, {'conditions': 'O'}, {'in': 'O'}, {'the': 'O'}, {'oral': 'O'}, {'cavity,': 'O'}, {'and': 'O'}, {'several': 'O'}, {'patterns': 'O'}, {'of': 'O'}, {'deregulation': 'O'}, {'are': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'specific': 'O'}, {'disorders.': 'O'}]"
"The objective of this study was to assess if serum FLCs can contribute to classification, mucosa-associated lymphoid tissue (MALT) lymphoma detection, monitoring of disease activity and treatment response in pSS.","[{'The': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'if': 'O'}, {'serum': 'O'}, {'FLCs': 'O'}, {'can': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'classification,': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'O'}, {'tissue': 'O'}, {'(MALT)': 'O'}, {'lymphoma': 'I-Entity'}, {'detection,': 'O'}, {'monitoring': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'response': 'O'}, {'in': 'O'}, {'pSS.': 'I-Entity'}]"
"The study group included 835 patients--197 rheumatoid arthritis (RA), 67 systemic lupus erythematosus (SLE), 119 ankylosing spondylitis (AS), 238 osteoarthritis (OA), 14 familial Mediterranean fever (FMF), 53 Beh‚Äö√†√∂‚àö√ºet's disease (BD), 71 gout, 25 Sjogrens syndrome (SS), 20 vasculitis, 29 polymyalgia rheumatica (PMR), and two polymyositis (PM)--with or without FM.","[{'The': 'O'}, {'study': 'O'}, {'group': 'O'}, {'included': 'O'}, {'835': 'O'}, {'patients--197': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA),': 'O'}, {'67': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'119': 'O'}, {'ankylosing': 'B-Entity'}, {'spondylitis': 'I-Entity'}, {'(AS),': 'O'}, {'238': 'O'}, {'osteoarthritis': 'I-Entity'}, {'(OA),': 'O'}]"
Variants in TNFAIP3 gene have been described as associated with susceptibility to several AIDs.,"[{'Variants': 'O'}, {'in': 'O'}, {'TNFAIP3': 'O'}, {'gene': 'O'}, {'have': 'O'}, {'been': 'O'}, {'described': 'O'}, {'as': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'susceptibility': 'O'}, {'to': 'O'}, {'several': 'O'}, {'AIDs.': 'I-Entity'}]"
"On two previous occasions her cerebrospinal fluid analysis was consistent with meningitis; however, it was normal at this presentation.","[{'On': 'O'}, {'two': 'O'}, {'previous': 'O'}, {'occasions': 'O'}, {'her': 'O'}, {'cerebrospinal': 'O'}, {'fluid': 'O'}, {'analysis': 'O'}, {'was': 'O'}, {'consistent': 'O'}, {'with': 'O'}, {'meningitis;': 'I-Entity'}, {'however,': 'O'}, {'it': 'O'}, {'was': 'O'}, {'normal': 'O'}, {'at': 'O'}, {'this': 'O'}, {'presentation.': 'O'}]"
"Sarcoidosis and Sjogrens syndrome are two different diseases; however, when affecting the salivary glands, both diseases exhibit similar clinical signs and symptoms, which often complicates the diagnosis.","[{'Sarcoidosis': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'are': 'O'}, {'two': 'O'}, {'different': 'O'}, {'diseases;': 'O'}, {'however,': 'O'}, {'when': 'O'}, {'affecting': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'glands,': 'O'}, {'both': 'O'}, {'diseases': 'O'}, {'exhibit': 'O'}, {'similar': 'O'}, {'clinical': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms,': 'O'}, {'which': 'O'}, {'often': 'O'}, {'complicates': 'O'}, {'the': 'O'}, {'diagnosis.': 'O'}]"
"Determining saliva as a credible means of evaluating health status represents a considerable leap forward in health care, one that could lead to enormous translational advantages and significant clinical opportunities.Angeles, Calif., USA.","[{'Determining': 'O'}, {'saliva': 'O'}, {'as': 'O'}, {'a': 'O'}, {'credible': 'O'}, {'means': 'O'}, {'of': 'O'}, {'evaluating': 'O'}, {'health': 'O'}, {'status': 'O'}, {'represents': 'O'}, {'a': 'O'}, {'considerable': 'O'}, {'leap': 'O'}, {'forward': 'O'}, {'in': 'O'}, {'health': 'O'}, {'care,': 'O'}, {'one': 'O'}, {'that': 'O'}, {'could': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'enormous': 'O'}, {'translational': 'O'}, {'advantages': 'O'}, {'and': 'O'}, {'significant': 'O'}, {'clinical': 'O'}, {'opportunities.Angeles,': 'O'}, {'Calif.,': 'O'}, {'USA.': 'O'}]"
Inflammatory conditions of the pleura characterized by a predominantly lymphocytic infiltrate are described in several disorders.,"[{'Inflammatory': 'B-Entity'}, {'conditions': 'I-Entity'}, {'of': 'I-Entity'}, {'the': 'I-Entity'}, {'pleura': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'a': 'O'}, {'predominantly': 'O'}, {'lymphocytic': 'O'}, {'infiltrate': 'O'}, {'are': 'O'}, {'described': 'O'}, {'in': 'O'}, {'several': 'O'}, {'disorders.': 'O'}]"
We report the case of a 31-year-old woman who presented with neuromyelitis optica (NMO) associated with Sjogren syndrome and distal renal tubular acidosis.,"[{'We': 'O'}, {'report': 'O'}, {'the': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'31-year-old': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'neuromyelitis': 'B-Entity'}, {'optica': 'I-Entity'}, {'(NMO)': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'distal': 'O'}, {'renal': 'B-Entity'}, {'tubular': 'I-Entity'}, {'acidosis.': 'I-Entity'}]"
All patients were evaluated with B-mode and elastography by using Hitachi EUB 7500 digital ultrasound equipment.,"[{'All': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'with': 'O'}, {'B-mode': 'O'}, {'and': 'O'}, {'elastography': 'O'}, {'by': 'O'}, {'using': 'O'}, {'Hitachi': 'O'}, {'EUB': 'O'}, {'7500': 'O'}, {'digital': 'O'}, {'ultrasound': 'O'}, {'equipment.': 'O'}]"
"pSS patients also completed EULAR Sjogrens Syndrome patient-reported index (ESSPRI), EULAR Sjogrens syndrome disease activity index (ESSDAI), fatigue impact scale and EURO-QOL 5-dimension (EQ-5D).","[{'pSS': 'O'}, {'patients': 'O'}, {'also': 'O'}, {'completed': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'patient-reported': 'O'}, {'index': 'O'}, {'(ESSPRI),': 'O'}, {'EULAR': 'O'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'O'}, {'activity': 'O'}, {'index': 'O'}, {'(ESSDAI),': 'O'}, {'fatigue': 'I-Entity'}, {'impact': 'O'}, {'scale': 'O'}, {'and': 'O'}, {'EURO-QOL': 'O'}, {'5-dimension': 'O'}, {'(EQ-5D).': 'O'}]"
"We classified 16 (7%) of the 255 patients treated with >20mg GCS and 21/148 (14%) treated with immunosuppressive agents as patients inadequately treated, mainly associated with articular involvement of low/moderate activity.","[{'We': 'O'}, {'classified': 'O'}, {'16': 'O'}, {'(7%)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'255': 'O'}, {'patients': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'>20mg': 'O'}, {'GCS': 'I-Entity'}, {'and': 'O'}, {'21/148': 'O'}, {'(14%)': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'immunosuppressive': 'O'}, {'agents': 'O'}, {'as': 'O'}, {'patients': 'O'}, {'inadequately': 'O'}, {'treated,': 'O'}, {'mainly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'articular': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'low/moderate': 'O'}, {'activity.': 'O'}]"
"We found that the frequency of SS neuropathic pain exceeded the prevalence of peripheral neuropathies, and that painful peripheral neuropathies occurred less frequently than neuropathies not always associated with pain.","[{'We': 'O'}, {'found': 'O'}, {'that': 'O'}, {'the': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'SS': 'B-Entity'}, {'neuropathic': 'B-Entity'}, {'pain': 'I-Entity'}, {'exceeded': 'O'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathies,': 'I-Entity'}, {'and': 'O'}, {'that': 'O'}, {'painful': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathies': 'I-Entity'}, {'occurred': 'O'}, {'less': 'O'}, {'frequently': 'O'}, {'than': 'O'}, {'neuropathies': 'I-Entity'}, {'not': 'O'}, {'always': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pain.': 'I-Entity'}]"
Current focus has increasingly been on genetic and epigenetic markers as candidate predictors.,"[{'Current': 'O'}, {'focus': 'O'}, {'has': 'O'}, {'increasingly': 'O'}, {'been': 'O'}, {'on': 'O'}, {'genetic': 'O'}, {'and': 'O'}, {'epigenetic': 'O'}, {'markers': 'O'}, {'as': 'O'}, {'candidate': 'O'}, {'predictors.': 'O'}]"
Sjogrens syndrome is the second most common rheumatic disease in which autoimmune response targets exocrine glands (salivary and lacrimal glands) result in clinical symptoms of dry mouth and dry eye.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'second': 'O'}, {'most': 'O'}, {'common': 'O'}, {'rheumatic': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'which': 'O'}, {'autoimmune': 'O'}, {'response': 'O'}, {'targets': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'(salivary': 'O'}, {'and': 'O'}, {'lacrimal': 'O'}, {'glands)': 'O'}, {'result': 'O'}, {'in': 'O'}, {'clinical': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye.': 'I-Entity'}]"
"The clinical presentation of CTD in childhood can range from an acute severe illness mimicking a serious infection, to an insidious onset of disease with gradual accumulation of symptoms and signs over wks to months.","[{'The': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'CTD': 'I-Entity'}, {'in': 'O'}, {'childhood': 'O'}, {'can': 'O'}, {'range': 'O'}, {'from': 'O'}, {'an': 'O'}, {'acute': 'O'}, {'severe': 'O'}, {'illness': 'O'}, {'mimicking': 'O'}, {'a': 'O'}, {'serious': 'O'}, {'infection,': 'I-Entity'}, {'to': 'O'}, {'an': 'O'}, {'insidious': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'with': 'O'}, {'gradual': 'O'}, {'accumulation': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'signs': 'O'}, {'over': 'O'}, {'wks': 'O'}, {'to': 'O'}, {'months.': 'O'}]"
"Although uncommon, episcleritis and scleritis can sometimes be detected as an initial finding of SLE and reveal themselves as moderate to intense ocular pain, redness, blurred vision, and lacrimation.","[{'Although': 'O'}, {'uncommon,': 'O'}, {'episcleritis': 'I-Entity'}, {'and': 'O'}, {'scleritis': 'I-Entity'}, {'can': 'O'}, {'sometimes': 'O'}, {'be': 'O'}, {'detected': 'O'}, {'as': 'O'}, {'an': 'O'}, {'initial': 'O'}, {'finding': 'O'}, {'of': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'reveal': 'O'}, {'themselves': 'O'}, {'as': 'O'}, {'moderate': 'O'}, {'to': 'O'}, {'intense': 'O'}, {'ocular': 'B-Entity'}, {'pain,': 'I-Entity'}, {'redness,': 'I-Entity'}, {'blurred': 'B-Entity'}, {'vision,': 'I-Entity'}, {'and': 'O'}, {'lacrimation.': 'O'}]"
"Although there is strong agreement that germinal center (GC)-like structures should be routinely identified, due to their prognostic value, a consensus regarding the best protocol is still lacking.","[{'Although': 'O'}, {'there': 'O'}, {'is': 'O'}, {'strong': 'O'}, {'agreement': 'O'}, {'that': 'O'}, {'germinal': 'O'}, {'center': 'O'}, {'(GC)-like': 'O'}, {'structures': 'O'}, {'should': 'O'}, {'be': 'O'}, {'routinely': 'O'}, {'identified,': 'O'}, {'due': 'O'}, {'to': 'O'}, {'their': 'O'}, {'prognostic': 'O'}, {'value,': 'O'}, {'a': 'O'}, {'consensus': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'best': 'O'}, {'protocol': 'O'}, {'is': 'O'}, {'still': 'O'}, {'lacking.': 'O'}]"
Sjogrens syndrome (SS) is an autoimmune disease most commonly characterized by ocular and oral dryness.,"[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'most': 'O'}, {'commonly': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'ocular': 'B-Entity'}, {'and': 'I-Entity'}, {'oral': 'I-Entity'}, {'dryness.': 'I-Entity'}]"
(18)F-FDG PET plays an important role in the evaluation of patients with lung malignancies but can lead to false-positive and false-negative results.,"[{'(18)F-FDG': 'O'}, {'PET': 'O'}, {'plays': 'O'}, {'an': 'O'}, {'important': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'lung': 'B-Entity'}, {'malignancies': 'I-Entity'}, {'but': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'false-positive': 'O'}, {'and': 'O'}, {'false-negative': 'O'}, {'results.': 'O'}]"
The aim of this study was to find the correlation between severity of dry eye and rheumatoid arthritis (RA) disease activity.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'find': 'O'}, {'the': 'O'}, {'correlation': 'O'}, {'between': 'O'}, {'severity': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA)': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"While arterial dysfunction may be associated with the number of ExRA features and severe ExRA, it does not appear to be associated with other ExRA features.University Medical School, Polwarth Building at Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK.","[{'While': 'O'}, {'arterial': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'ExRA': 'O'}, {'features': 'O'}, {'and': 'O'}, {'severe': 'O'}, {'ExRA,': 'I-Entity'}, {'it': 'O'}, {'does': 'O'}, {'not': 'O'}, {'appear': 'O'}, {'to': 'O'}, {'be': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'ExRA': 'O'}, {'features.University': 'O'}, {'Medical': 'O'}, {'School,': 'O'}, {'Polwarth': 'O'}, {'Building': 'O'}, {'at': 'O'}, {'Foresterhill,': 'O'}, {'Aberdeen,': 'O'}, {'AB25': 'O'}, {'2ZD,': 'O'}, {'Scotland,': 'O'}, {'UK.': 'O'}]"
Primary Sjogrens syndrome (pSS) is a chronic autoimmune disease characterized by lymphoplasmacytic infiltration of the exocrine glands that results in multiple organs and systems damage.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chronic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands': 'O'}, {'that': 'O'}, {'results': 'O'}, {'in': 'O'}, {'multiple': 'O'}, {'organs': 'B-Entity'}, {'and': 'I-Entity'}, {'systems': 'I-Entity'}, {'damage.': 'I-Entity'}]"
We assessed leucocyte infiltration in salivary glands (SGs) from NOD/ShiLtJ mice by immunohistochemistry and examined transcriptomics data of SG tissue from these animals for evidence of a CD40 pathway gene signature.,"[{'We': 'O'}, {'assessed': 'O'}, {'leucocyte': 'O'}, {'infiltration': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'(SGs)': 'O'}, {'from': 'O'}, {'NOD/ShiLtJ': 'O'}, {'mice': 'O'}, {'by': 'O'}, {'immunohistochemistry': 'O'}, {'and': 'O'}, {'examined': 'O'}, {'transcriptomics': 'O'}, {'data': 'O'}, {'of': 'O'}, {'SG': 'O'}, {'tissue': 'O'}, {'from': 'O'}, {'these': 'O'}, {'animals': 'O'}, {'for': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'CD40': 'O'}, {'pathway': 'O'}, {'gene': 'O'}, {'signature.': 'O'}]"
"It classically presents as a mediastinal mass that involves the lymphatic tissue primarily but can also affect extra lymphatic sites including the lungs, larynx, parotid glands, pancreas, meninges, and muscles.","[{'It': 'O'}, {'classically': 'O'}, {'presents': 'O'}, {'as': 'O'}, {'a': 'O'}, {'mediastinal': 'B-Entity'}, {'mass': 'I-Entity'}, {'that': 'O'}, {'involves': 'O'}, {'the': 'O'}, {'lymphatic': 'O'}, {'tissue': 'O'}, {'primarily': 'O'}, {'but': 'O'}, {'can': 'O'}, {'also': 'O'}, {'affect': 'O'}, {'extra': 'O'}, {'lymphatic': 'O'}, {'sites': 'O'}, {'including': 'O'}, {'the': 'O'}, {'lungs,': 'O'}, {'larynx,': 'O'}, {'parotid': 'O'}, {'glands,': 'O'}, {'pancreas,': 'O'}, {'meninges,': 'O'}, {'and': 'O'}, {'muscles.': 'O'}]"
"Evaluation of each subject is composed of lower urinary tract symptoms (LUTS), bladder diary entries, and urodynamic studies, which also included an ice water test (IWT) to detect the presence of a C-fiber mediated micturition pathway.","[{'Evaluation': 'O'}, {'of': 'O'}, {'each': 'O'}, {'subject': 'O'}, {'is': 'O'}, {'composed': 'O'}, {'of': 'O'}, {'lower': 'B-Entity'}, {'urinary': 'I-Entity'}, {'tract': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'(LUTS),': 'O'}, {'bladder': 'O'}, {'diary': 'O'}, {'entries,': 'O'}, {'and': 'O'}, {'urodynamic': 'O'}, {'studies,': 'O'}, {'which': 'O'}, {'also': 'O'}, {'included': 'O'}, {'an': 'O'}, {'ice': 'O'}, {'water': 'O'}, {'test': 'O'}, {'(IWT)': 'O'}, {'to': 'O'}, {'detect': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'C-fiber': 'O'}, {'mediated': 'O'}, {'micturition': 'O'}, {'pathway.': 'O'}]"
"The ScCLs did not change the parameters used to evaluate inflammatory processes, which were measured using conjunctival impression cytology and HLA-DR expression, except in Sjogren syndrome, in which there was an unexpected increase in HLA expression.rights reserved.Sao Paulo, 821 Botucatu St-Vila Clementino, Sao Paulo, SP, 04023-062, Brazil.","[{'The': 'O'}, {'ScCLs': 'O'}, {'did': 'O'}, {'not': 'O'}, {'change': 'O'}, {'the': 'O'}, {'parameters': 'O'}, {'used': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'inflammatory': 'O'}, {'processes,': 'O'}, {'which': 'O'}, {'were': 'O'}, {'measured': 'O'}, {'using': 'O'}, {'conjunctival': 'O'}, {'impression': 'O'}, {'cytology': 'O'}, {'and': 'O'}, {'HLA-DR': 'O'}, {'expression,': 'O'}, {'except': 'O'}, {'in': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'in': 'O'}, {'which': 'O'}, {'there': 'O'}, {'was': 'O'}, {'an': 'O'}, {'unexpected': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'HLA': 'O'}, {'expression.rights': 'O'}, {'reserved.Sao': 'O'}, {'Paulo,': 'O'}, {'821': 'O'}, {'Botucatu': 'O'}]"
The predictive power of the parameter at baseline was examined using receiver operating characteristic (ROC) analysis.,"[{'The': 'O'}, {'predictive': 'O'}, {'power': 'O'}, {'of': 'O'}, {'the': 'O'}, {'parameter': 'O'}, {'at': 'O'}, {'baseline': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'using': 'O'}, {'receiver': 'O'}, {'operating': 'O'}, {'characteristic': 'O'}, {'(ROC)': 'O'}, {'analysis.': 'O'}]"
"The five patients with disseminated disease and systemic immune defects were all men with age at onset of 2 (0.33, 33) years and time from onset of disease until death of 9 (1, 31) years.","[{'The': 'O'}, {'five': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'disseminated': 'O'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'systemic': 'O'}, {'immune': 'B-Entity'}, {'defects': 'I-Entity'}, {'were': 'O'}, {'all': 'O'}, {'men': 'O'}, {'with': 'O'}, {'age': 'O'}, {'at': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'2': 'O'}, {'(0.33,': 'O'}, {'33)': 'O'}, {'years': 'O'}, {'and': 'O'}, {'time': 'O'}, {'from': 'O'}, {'onset': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'until': 'O'}, {'death': 'I-Entity'}, {'of': 'O'}, {'9': 'O'}, {'(1,': 'O'}, {'31)': 'O'}, {'years.': 'O'}]"
"Due to the active renal involvement on the context of systemic lupus erythematosus and Sjogrens syndrome, the patient received immunosuppression with rituximab, resulting in a progressive and complete improvement.of interest with respect to the research, authorship, and/or publication of this article.doi: 10.1177/1179544117722763.","[{'Due': 'O'}, {'to': 'O'}, {'the': 'O'}, {'active': 'O'}, {'renal': 'O'}, {'involvement': 'O'}, {'on': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'the': 'O'}, {'patient': 'O'}, {'received': 'O'}, {'immunosuppression': 'O'}, {'with': 'O'}, {'rituximab,': 'I-Entity'}, {'resulting': 'O'}, {'in': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'and': 'O'}, {'complete': 'O'}, {'improvement.of': 'O'}, {'interest': 'O'}, {'with': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'the': 'O'}, {'research,': 'O'}, {'authorship,': 'O'}]"
The presence of anti-SSA (76.8%) and anti-SSB (53.8%) antibodies was particularly frequent among patients with TIN and was associated with a worse renal prognosis.,"[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-SSA': 'O'}, {'(76.8%)': 'O'}, {'and': 'O'}, {'anti-SSB': 'O'}, {'(53.8%)': 'O'}, {'antibodies': 'O'}, {'was': 'O'}, {'particularly': 'O'}, {'frequent': 'O'}, {'among': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'TIN': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'worse': 'O'}, {'renal': 'O'}, {'prognosis.': 'O'}]"
The aim of the present study was to evaluate predictive factors associated with a worse prognosis in pSS-ILD.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'predictive': 'O'}, {'factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'worse': 'O'}, {'prognosis': 'O'}, {'in': 'O'}, {'pSS-ILD.': 'O'}]"
"PATIENTS AND Peripheral blood mononuclear cells from 34 pSS, 13 nSS patients and 13 healthy controls were stimulated, labeled for cluster of differentiation-4 (CD4), interferon-‚âà√≠‚Äö√¢‚Ä¢ (IFN-‚âà√≠‚Äö√¢‚Ä¢), interleukin-4 (IL-4) and IL-17A and analyzed by flow cytometry.","[{'PATIENTS': 'O'}, {'AND': 'O'}, {'Peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'34': 'O'}, {'pSS,': 'I-Entity'}, {'13': 'O'}, {'nSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'13': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'stimulated,': 'O'}, {'labeled': 'O'}, {'for': 'O'}, {'cluster': 'O'}, {'of': 'O'}, {'differentiation-4': 'O'}, {'(CD4),': 'O'}, {'interferon-‚âà√≠‚Äö√¢‚Ä¢': 'O'}]"
There was neither upper airway nor renal involvement.,"[{'There': 'O'}, {'was': 'O'}, {'neither': 'O'}, {'upper': 'O'}, {'airway': 'I-Entity'}, {'nor': 'O'}, {'renal': 'I-Entity'}, {'involvement.': 'I-Entity'}]"
"FM is often associated with other diseases that act as confounding and aggravating factors, including primary Sjogrens syndrome (pSS), systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).","[{'FM': 'I-Entity'}, {'is': 'O'}, {'often': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'other': 'O'}, {'diseases': 'O'}, {'that': 'O'}, {'act': 'O'}, {'as': 'O'}, {'confounding': 'O'}, {'and': 'O'}, {'aggravating': 'O'}, {'factors,': 'O'}, {'including': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS),': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE)': 'O'}, {'and': 'O'}, {'rheumatoid': 'B-Entity'}, {'arthritis': 'I-Entity'}, {'(RA).': 'O'}]"
"The treatment for each patient was justified by the main manifestations and activity of rheumatic disease: 66.7% received nonsteroidal anti - inflammatory drugs, 80% - glucocorticoids, 46.7% - methotrexate, 20% - azathioprine, 43.3% - hydroxychloroquine, 10% - mycophenolatis mofetilum, 3.4% - cyclophosphamide.","[{'The': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'each': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'justified': 'O'}, {'by': 'O'}, {'the': 'O'}, {'main': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'activity': 'O'}, {'of': 'O'}, {'rheumatic': 'B-Entity'}, {'disease:': 'I-Entity'}, {'66.7%': 'O'}, {'received': 'O'}, {'nonsteroidal': 'O'}, {'anti': 'O'}, {'-': 'O'}, {'inflammatory': 'O'}, {'drugs,': 'O'}, {'80%': 'O'}, {'-': 'O'}, {'glucocorticoids,': 'O'}, {'46.7%': 'O'}, {'-': 'O'}, {'methotrexate,': 'I-Entity'}, {'20%': 'O'}, {'-': 'O'}, {'azathioprine,': 'I-Entity'}]"
Transfer of highly purified FoxP3-negative donor cells demonstrated that accumulation of hLa-specific regulatory T cells (Treg ) was due primarily to expansion of small numbers of donor Treg .,"[{'Transfer': 'O'}, {'of': 'O'}, {'highly': 'O'}, {'purified': 'O'}, {'FoxP3-negative': 'O'}, {'donor': 'O'}, {'cells': 'O'}, {'demonstrated': 'O'}, {'that': 'O'}, {'accumulation': 'O'}, {'of': 'O'}, {'hLa-specific': 'O'}, {'regulatory': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'(Treg': 'O'}, {')': 'O'}, {'was': 'O'}, {'due': 'O'}, {'primarily': 'O'}, {'to': 'O'}, {'expansion': 'O'}, {'of': 'O'}, {'small': 'O'}, {'numbers': 'O'}, {'of': 'O'}, {'donor': 'O'}, {'Treg': 'O'}, {'.': 'O'}]"
The most common subtype developing in parotid glands is marginal zone B-cell mucosa associated lymphoid tissue type lymphoma (MALT) that belongs to a group of low-grade tumours.,"[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'subtype': 'O'}, {'developing': 'O'}, {'in': 'O'}, {'parotid': 'O'}, {'glands': 'O'}, {'is': 'O'}, {'marginal': 'O'}, {'zone': 'O'}, {'B-cell': 'O'}, {'mucosa': 'O'}, {'associated': 'O'}, {'lymphoid': 'I-Entity'}, {'tissue': 'I-Entity'}, {'type': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'(MALT)': 'O'}, {'that': 'O'}, {'belongs': 'O'}, {'to': 'O'}, {'a': 'O'}, {'group': 'O'}, {'of': 'O'}, {'low-grade': 'O'}, {'tumours.': 'I-Entity'}]"
"When assessed using a fluorescence-activated cell sorting (FACS) assay, anti-AQP-4 antibodies were seen exclusively in those SS patients with NMOSD (72.7%), but not in SS patients without NMOSD (P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.01).","[{'When': 'O'}, {'assessed': 'O'}, {'using': 'O'}, {'a': 'O'}, {'fluorescence-activated': 'O'}, {'cell': 'O'}, {'sorting': 'O'}, {'(FACS)': 'O'}, {'assay,': 'O'}, {'anti-AQP-4': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'seen': 'O'}, {'exclusively': 'O'}, {'in': 'O'}, {'those': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'NMOSD': 'I-Entity'}, {'(72.7%),': 'O'}, {'but': 'O'}, {'not': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'without': 'O'}, {'NMOSD': 'I-Entity'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬¢<‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.01).': 'O'}]"
"Despite the absence of overt Sicca syndrome, the evaluation of Sjogrens syndrome (SjS) as a cause of distal RTA was performed.","[{'Despite': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'overt': 'O'}, {'Sicca': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SjS)': 'O'}, {'as': 'O'}, {'a': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'distal': 'O'}, {'RTA': 'O'}, {'was': 'O'}, {'performed.': 'O'}]"
We also review the importance of distinguishing NMOSD from multiple sclerosis in view of the significant implications for treatment and prognosis.permissions.,"[{'We': 'O'}, {'also': 'O'}, {'review': 'O'}, {'the': 'O'}, {'importance': 'O'}, {'of': 'O'}, {'distinguishing': 'O'}, {'NMOSD': 'I-Entity'}, {'from': 'O'}, {'multiple': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'in': 'O'}, {'view': 'O'}, {'of': 'O'}, {'the': 'O'}, {'significant': 'O'}, {'implications': 'O'}, {'for': 'O'}, {'treatment': 'O'}, {'and': 'O'}, {'prognosis.permissions.': 'O'}]"
"Disturbances in fundus perimetry in the SLE group were more prevalent in steroid-na‚Äö√†√∂‚àö√≤ve patients and in SS patients who received a cumulative hydroxychloroquine dose > 1,000 g. Functional eye impairment was demonstrated in SLE patients, possibly associated with kidney involvement.","[{'Disturbances': 'O'}, {'in': 'O'}, {'fundus': 'O'}, {'perimetry': 'O'}, {'in': 'O'}, {'the': 'O'}, {'SLE': 'I-Entity'}, {'group': 'O'}, {'were': 'O'}, {'more': 'O'}, {'prevalent': 'O'}, {'in': 'O'}, {'steroid-na‚Äö√†√∂‚àö√≤ve': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'who': 'O'}, {'received': 'O'}, {'a': 'O'}, {'cumulative': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'dose': 'O'}, {'>': 'O'}, {'1,000': 'O'}, {'g.': 'O'}]"
In patients with chronic inflammatory rheumatic diseases various types of amyloidosis diseases can occur.,"[{'In': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'various': 'O'}, {'types': 'O'}, {'of': 'O'}, {'amyloidosis': 'B-Entity'}, {'diseases': 'I-Entity'}, {'can': 'O'}, {'occur.': 'O'}]"
"On day 28 of hospitalization, the patient was discharged after amelioration of respiratory symptoms and azotemia.","[{'On': 'O'}, {'day': 'O'}, {'28': 'O'}, {'of': 'O'}, {'hospitalization,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'discharged': 'O'}, {'after': 'O'}, {'amelioration': 'O'}, {'of': 'O'}, {'respiratory': 'B-Entity'}, {'symptoms': 'O'}, {'and': 'O'}, {'azotemia.': 'I-Entity'}]"
We assess the potential for novel molecular biomarkers to find a clinical application in disease diagnosis and stratification and in the development of therapeutic agents.,"[{'We': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'for': 'O'}, {'novel': 'O'}, {'molecular': 'O'}, {'biomarkers': 'O'}, {'to': 'O'}, {'find': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'application': 'O'}, {'in': 'O'}, {'disease': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'stratification': 'O'}, {'and': 'O'}, {'in': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'therapeutic': 'O'}, {'agents.': 'O'}]"
"One case was a 32-week pregnant woman with combined liver damage and fever, and her fetus was premature due to bradycardia and pericardial effusion.","[{'One': 'O'}, {'case': 'O'}, {'was': 'O'}, {'a': 'O'}, {'32-week': 'O'}, {'pregnant': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'combined': 'O'}, {'liver': 'B-Entity'}, {'damage': 'I-Entity'}, {'and': 'O'}, {'fever,': 'I-Entity'}, {'and': 'O'}, {'her': 'O'}, {'fetus': 'O'}, {'was': 'O'}, {'premature': 'O'}, {'due': 'O'}, {'to': 'O'}, {'bradycardia': 'I-Entity'}, {'and': 'O'}, {'pericardial': 'B-Entity'}, {'effusion.': 'I-Entity'}]"
mramos@clinic.ub.es.endpoint for assessing treatment efficacy.,"[{'mramos@clinic.ub.es.endpoint': 'O'}, {'for': 'O'}, {'assessing': 'O'}, {'treatment': 'O'}, {'efficacy.': 'O'}]"
"To study the clinical significance of preformed donor-specific human leukocyte antigen antibodies (DSAs) in liver transplantation, we reviewed patients who underwent liver transplantation with a strongly positive flow cytometry crossmatch.","[{'To': 'O'}, {'study': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'significance': 'O'}, {'of': 'O'}, {'preformed': 'O'}, {'donor-specific': 'O'}, {'human': 'B-Entity'}, {'leukocyte': 'I-Entity'}, {'antigen': 'I-Entity'}, {'antibodies': 'O'}, {'(DSAs)': 'O'}, {'in': 'O'}, {'liver': 'O'}, {'transplantation,': 'O'}, {'we': 'O'}, {'reviewed': 'O'}, {'patients': 'O'}, {'who': 'O'}, {'underwent': 'O'}, {'liver': 'O'}, {'transplantation': 'O'}, {'with': 'O'}, {'a': 'O'}, {'strongly': 'O'}, {'positive': 'O'}, {'flow': 'O'}, {'cytometry': 'O'}, {'crossmatch.': 'O'}]"
Patients with higher US scores had more sicca symptoms as well as higher RA activity and poorer oral health.,"[{'Patients': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'US': 'O'}, {'scores': 'O'}, {'had': 'O'}, {'more': 'O'}, {'sicca': 'B-Entity'}, {'symptoms': 'I-Entity'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'higher': 'O'}, {'RA': 'I-Entity'}, {'activity': 'O'}, {'and': 'O'}, {'poorer': 'O'}, {'oral': 'O'}, {'health.': 'O'}]"
"While systemic blockade of adhesion molecules has been used to treat autoimmune diseases, the purpose of this study was to determine the therapeutic efficacy of topical application of an integrin ‚âà√≠¬¨¬±4 adhesion molecule antagonist in a mouse model of dry eye associated with Sjogrens syndrome.","[{'While': 'O'}, {'systemic': 'O'}, {'blockade': 'O'}, {'of': 'O'}, {'adhesion': 'O'}, {'molecules': 'O'}, {'has': 'O'}, {'been': 'O'}, {'used': 'O'}, {'to': 'O'}, {'treat': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'the': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'therapeutic': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'topical': 'O'}, {'application': 'O'}, {'of': 'O'}, {'an': 'O'}, {'integrin': 'O'}, {'‚âà√≠¬¨¬±4': 'O'}, {'adhesion': 'O'}, {'molecule': 'O'}, {'antagonist': 'O'}, {'in': 'O'}, {'a': 'O'}, {'mouse': 'O'}, {'model': 'O'}, {'of': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}]"
"The latter appears to be the most common neuropathy in Sjogrens syndrome and requires skin biopsy for diagnosis to document loss or reduction of nerve fiber density; b) sensorimotor polyneuropathy affecting sensory and motor axons, often associated with severe systemic or pro-lymhomatous manifestations, such as palpable purpura and cryoglobulinemia, and c) rare types that include autoimmune demyelinating neuropathy, mononeuropathy, mononeuropathy multiplex and autonomic neuropathy.","[{'The': 'O'}, {'latter': 'O'}, {'appears': 'O'}, {'to': 'O'}, {'be': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'neuropathy': 'I-Entity'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'requires': 'O'}, {'skin': 'O'}, {'biopsy': 'O'}, {'for': 'O'}, {'diagnosis': 'O'}, {'to': 'O'}, {'document': 'O'}, {'loss': 'O'}, {'or': 'O'}, {'reduction': 'O'}, {'of': 'O'}, {'nerve': 'O'}, {'fiber': 'O'}, {'density;': 'O'}, {'b)': 'O'}, {'sensorimotor': 'O'}, {'polyneuropathy': 'I-Entity'}, {'affecting': 'O'}, {'sensory': 'O'}, {'and': 'I-Entity'}, {'motor': 'I-Entity'}, {'axons,': 'O'}, {'often': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'systemic': 'O'}, {'or': 'O'}, {'pro-lymhomatous': 'O'}]"
"Serum levels of Flt-3L might explain the clinical evolution of primary SS to B cell lymphoma that is observed in some patients, thus opening the possibility of new avenues for therapy.Universit‚Äö√†√∂¬¨¬© Europ‚Äö√†√∂¬¨¬©enne de Bretagne, Brest, France.","[{'Serum': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'Flt-3L': 'O'}, {'might': 'O'}, {'explain': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'evolution': 'O'}, {'of': 'O'}, {'primary': 'O'}, {'SS': 'I-Entity'}, {'to': 'O'}, {'B': 'B-Entity'}, {'cell': 'I-Entity'}, {'lymphoma': 'I-Entity'}, {'that': 'O'}, {'is': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'some': 'O'}, {'patients,': 'O'}, {'thus': 'O'}, {'opening': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'new': 'O'}, {'avenues': 'O'}, {'for': 'O'}, {'therapy.Universit‚Äö√†√∂¬¨¬©': 'O'}, {'Europ‚Äö√†√∂¬¨¬©enne': 'O'}]"
The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'both': 'O'}, {'overall': 'O'}, {'and': 'O'}, {'specific': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'cancer': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'compared': 'O'}, {'to': 'O'}, {'the': 'O'}, {'expected': 'O'}, {'incidence': 'O'}, {'in': 'O'}, {'general': 'O'}, {'population': 'O'}, {'of': 'O'}, {'Argentina.': 'O'}]"
The purpose of the present study was to investigate the differences in salivary flow rates and dry mouth-related subjective symptoms and behaviours in patients with xerostomia according to its aetiology.,"[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rates': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth-related': 'I-Entity'}, {'subjective': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'behaviours': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'xerostomia': 'I-Entity'}, {'according': 'O'}, {'to': 'O'}, {'its': 'O'}, {'aetiology.': 'O'}]"
"Our results indicate the cut-off point for defining a positive test result in the Schirmer's test is worth modified to <10 mm/5 minutes in either eye.General Hospital, National Defense Medical Center, Taipei, Taiwan.University, Taiwan.Defense Medical Center, Taipei, Taiwan.Medical Center, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan.Medical Center, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan; Division of Allergy, Immunology, Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan.General Hospital, National Defense Medical Center, Taipei, Taiwan.","[{'Our': 'O'}, {'results': 'O'}, {'indicate': 'O'}, {'the': 'O'}, {'cut-off': 'O'}, {'point': 'O'}, {'for': 'O'}, {'defining': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'test': 'O'}, {'result': 'O'}, {'in': 'O'}, {'the': 'O'}, {""Schirmer's"": 'O'}, {'test': 'O'}, {'is': 'O'}, {'worth': 'O'}, {'modified': 'O'}, {'to': 'O'}, {'<10': 'O'}, {'mm/5': 'O'}, {'minutes': 'O'}, {'in': 'O'}, {'either': 'O'}, {'eye.General': 'O'}, {'Hospital,': 'O'}, {'National': 'O'}, {'Defense': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'Taipei,': 'O'}, {'Taiwan.University,': 'O'}, {'Taiwan.Defense': 'O'}, {'Medical': 'O'}, {'Center,': 'O'}, {'Taipei,': 'O'}, {'Taiwan.Medical': 'O'}, {'Center,': 'O'}]"
A 52-year-old Caucasian woman with Sjogrens syndrome secondary to autoimmune hepatitis and primary sclerosing cholangitis was admitted to our emergency department owing to bilateral corneal ulcers and corneal perforation in the left eye following exposure keratopathy in an artificially induced coma.,"[{'A': 'O'}, {'52-year-old': 'O'}, {'Caucasian': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {'autoimmune': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'sclerosing': 'I-Entity'}, {'cholangitis': 'I-Entity'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'emergency': 'O'}, {'department': 'O'}, {'owing': 'O'}, {'to': 'O'}, {'bilateral': 'O'}, {'corneal': 'B-Entity'}, {'ulcers': 'I-Entity'}, {'and': 'O'}, {'corneal': 'B-Entity'}, {'perforation': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'left': 'O'}, {'eye': 'O'}, {'following': 'O'}, {'exposure': 'O'}, {'keratopathy': 'I-Entity'}]"
"Sjogrens syndrome (SS) is a systemic autoimmune disease characterized by the infiltration of lymphocytes into exocrine glands, resulting in the typical sicca symptoms.","[{'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic': 'O'}, {'autoimmune': 'I-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'the': 'O'}, {'infiltration': 'O'}, {'of': 'O'}, {'lymphocytes': 'O'}, {'into': 'O'}, {'exocrine': 'O'}, {'glands,': 'O'}, {'resulting': 'O'}, {'in': 'O'}, {'the': 'O'}, {'typical': 'O'}, {'sicca': 'B-Entity'}, {'symptoms.': 'O'}]"
We describe a case of a middle aged woman who presented with ophthalmoplegic symptoms.,"[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'middle': 'O'}, {'aged': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'ophthalmoplegic': 'B-Entity'}, {'symptoms.': 'O'}]"
"Although the levels of KL-6 and SP-D, markers of interstitial pneumonia, decreased after steroid and immunosuppressive therapy, the CT findings of interstitial pneumonia showed no remarkable change.","[{'Although': 'O'}, {'the': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'KL-6': 'O'}, {'and': 'O'}, {'SP-D,': 'O'}, {'markers': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia,': 'I-Entity'}, {'decreased': 'O'}, {'after': 'O'}, {'steroid': 'I-Entity'}, {'and': 'O'}, {'immunosuppressive': 'O'}, {'therapy,': 'O'}, {'the': 'O'}, {'CT': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'interstitial': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'showed': 'O'}, {'no': 'O'}, {'remarkable': 'O'}, {'change.': 'O'}]"
Multiple myeloma (MM) is a bone-marrow-based malignant neoplasm of plasma cells associated with serum/urine monoclonal paraproteins and lytic skeletal lesions.,"[{'Multiple': 'B-Entity'}, {'myeloma': 'I-Entity'}, {'(MM)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'bone-marrow-based': 'O'}, {'malignant': 'B-Entity'}, {'neoplasm': 'I-Entity'}, {'of': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'serum/urine': 'O'}, {'monoclonal': 'O'}, {'paraproteins': 'O'}, {'and': 'O'}, {'lytic': 'O'}, {'skeletal': 'O'}, {'lesions.': 'O'}]"
"This study provides further evidence supporting the use of ESSDAI, EULAR sicca score and ESSPRI measures in the clinic.","[{'This': 'O'}, {'study': 'O'}, {'provides': 'O'}, {'further': 'O'}, {'evidence': 'O'}, {'supporting': 'O'}, {'the': 'O'}, {'use': 'O'}, {'of': 'O'}, {'ESSDAI,': 'O'}, {'EULAR': 'O'}, {'sicca': 'I-Entity'}, {'score': 'O'}, {'and': 'O'}, {'ESSPRI': 'O'}, {'measures': 'O'}, {'in': 'O'}, {'the': 'O'}, {'clinic.': 'O'}]"
"A clinical history was made for each patient, patients were examined clinically, and xerostomia inventory (XI) was performed.","[{'A': 'O'}, {'clinical': 'O'}, {'history': 'O'}, {'was': 'O'}, {'made': 'O'}, {'for': 'O'}, {'each': 'O'}, {'patient,': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'examined': 'O'}, {'clinically,': 'O'}, {'and': 'O'}, {'xerostomia': 'I-Entity'}, {'inventory': 'O'}, {'(XI)': 'O'}, {'was': 'O'}, {'performed.': 'O'}]"
"After 10 years of follow-up, the cumulative incidence of a new EGM or associated AID was 30.7%.","[{'After': 'O'}, {'10': 'O'}, {'years': 'O'}, {'of': 'O'}, {'follow-up,': 'O'}, {'the': 'O'}, {'cumulative': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'new': 'O'}, {'EGM': 'I-Entity'}, {'or': 'O'}, {'associated': 'O'}, {'AID': 'I-Entity'}, {'was': 'O'}, {'30.7%.': 'O'}]"
"We performed immunohistochemical staining for APRIL with Stalk-1 and Aprily-8 antibodies specifically recognizing APRIL-producing cells and secreted APRIL, respectively, in renal and submandibular lesions of IgG4-RD in comparison with those of Sjogrens syndrome and sialolithiasis.","[{'We': 'O'}, {'performed': 'O'}, {'immunohistochemical': 'O'}, {'staining': 'O'}, {'for': 'O'}, {'APRIL': 'O'}, {'with': 'O'}, {'Stalk-1': 'O'}, {'and': 'O'}, {'Aprily-8': 'O'}, {'antibodies': 'O'}, {'specifically': 'O'}, {'recognizing': 'O'}, {'APRIL-producing': 'O'}, {'cells': 'O'}, {'and': 'O'}, {'secreted': 'O'}, {'APRIL,': 'O'}, {'respectively,': 'O'}, {'in': 'O'}, {'renal': 'O'}, {'and': 'O'}, {'submandibular': 'O'}, {'lesions': 'O'}, {'of': 'O'}, {'IgG4-RD': 'B-Entity'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}]"
"Autoimmune extrahepatic conditions may include: rheumatologic, endocrine, pulmonary, gastrointestinal, dermatologic diseases.","[{'Autoimmune': 'B-Entity'}, {'extrahepatic': 'I-Entity'}, {'conditions': 'I-Entity'}, {'may': 'O'}, {'include:': 'O'}, {'rheumatologic,': 'B-Entity'}, {'endocrine,': 'I-Entity'}, {'pulmonary,': 'I-Entity'}, {'gastrointestinal,': 'I-Entity'}, {'dermatologic': 'I-Entity'}, {'diseases.': 'I-Entity'}]"
"For both diseases, comorbidities such as sleep disordered breathing, symptoms of dyspnea, and cough should be evaluated and treated.","[{'For': 'O'}, {'both': 'O'}, {'diseases,': 'O'}, {'comorbidities': 'O'}, {'such': 'O'}, {'as': 'O'}, {'sleep': 'B-Entity'}, {'disordered': 'I-Entity'}, {'breathing,': 'I-Entity'}, {'symptoms': 'O'}, {'of': 'O'}, {'dyspnea,': 'I-Entity'}, {'and': 'O'}, {'cough': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'evaluated': 'O'}, {'and': 'O'}, {'treated.': 'O'}]"
"Recently, many new functions and properties of GRO-‚âà√≠¬¨¬±/CXCR2 system have been discovered and associated with atherosclerosis, angiogenesis, and many inflammatory conditions, such as autoimmune diseases.","[{'Recently,': 'O'}, {'many': 'O'}, {'new': 'O'}, {'functions': 'O'}, {'and': 'O'}, {'properties': 'O'}, {'of': 'O'}, {'GRO-‚âà√≠¬¨¬±/CXCR2': 'O'}, {'system': 'O'}, {'have': 'O'}, {'been': 'O'}, {'discovered': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'atherosclerosis,': 'I-Entity'}, {'angiogenesis,': 'O'}, {'and': 'O'}, {'many': 'O'}, {'inflammatory': 'O'}, {'conditions,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"In those patients receiving monotherapy, all patients were treated with PD-1/PD-L1 inhibitors (nivolumab in 9, pembrolizumab in 7 and durvalumab in 4); no cases associated with CTLA-4 inhibitors were identified.","[{'In': 'O'}, {'those': 'O'}, {'patients': 'O'}, {'receiving': 'O'}, {'monotherapy,': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'PD-1/PD-L1': 'O'}, {'inhibitors': 'O'}, {'(nivolumab': 'O'}, {'in': 'O'}, {'9,': 'O'}, {'pembrolizumab': 'I-Entity'}, {'in': 'O'}, {'7': 'O'}, {'and': 'O'}, {'durvalumab': 'I-Entity'}, {'in': 'O'}, {'4);': 'O'}, {'no': 'O'}, {'cases': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'CTLA-4': 'O'}, {'inhibitors': 'O'}, {'were': 'O'}, {'identified.': 'O'}]"
"Recently, LINE-1 genomic repeat elements have been proposed as potential triggers of type I IFN pathway activation in SS through activation of Toll-like receptor-dependent and -independent pathways.","[{'Recently,': 'O'}, {'LINE-1': 'O'}, {'genomic': 'O'}, {'repeat': 'O'}, {'elements': 'O'}, {'have': 'O'}, {'been': 'O'}, {'proposed': 'O'}, {'as': 'O'}, {'potential': 'O'}, {'triggers': 'O'}, {'of': 'O'}, {'type': 'O'}, {'I': 'O'}, {'IFN': 'O'}, {'pathway': 'O'}, {'activation': 'O'}, {'in': 'O'}, {'SS': 'I-Entity'}, {'through': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'Toll-like': 'O'}, {'receptor-dependent': 'O'}, {'and': 'O'}, {'-independent': 'O'}, {'pathways.': 'O'}]"
"Mean differences were adjusted for age, sex, mean blood pressure, smoking pack-years, fasting cholesterol, Stanford HAQ score and erythrocyte sedimentation rate.","[{'Mean': 'O'}, {'differences': 'O'}, {'were': 'O'}, {'adjusted': 'O'}, {'for': 'O'}, {'age,': 'O'}, {'sex,': 'O'}, {'mean': 'O'}, {'blood': 'O'}, {'pressure,': 'O'}, {'smoking': 'O'}, {'pack-years,': 'O'}, {'fasting': 'O'}, {'cholesterol,': 'I-Entity'}, {'Stanford': 'O'}, {'HAQ': 'O'}, {'score': 'O'}, {'and': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate.': 'O'}]"
Interstitial nephritis and immune complex-mediated glomerulonephritis are the two common renal manifestations of primary Sjogrens syndrome (SS).,"[{'Interstitial': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'and': 'O'}, {'immune': 'O'}, {'complex-mediated': 'O'}, {'glomerulonephritis': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'two': 'O'}, {'common': 'O'}, {'renal': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"IgG4-related MD should be differentiated from similar diseases, such as sarcoidosis, bronchial asthma, Sjogrens syndrome, and malignant lymphoma.Toyama 930-0194, Japan.","[{'IgG4-related': 'O'}, {'MD': 'I-Entity'}, {'should': 'O'}, {'be': 'O'}, {'differentiated': 'O'}, {'from': 'O'}, {'similar': 'O'}, {'diseases,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'sarcoidosis,': 'I-Entity'}, {'bronchial': 'B-Entity'}, {'asthma,': 'I-Entity'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma.Toyama': 'I-Entity'}, {'930-0194,': 'O'}, {'Japan.': 'O'}]"
Primary Sjogrens syndrome is associated with a markedly increased risk of cardiovascular disease and the presence of Ro/SSA and La/SSB autoantibodies identify the subgroup of patients carrying the highest risk.,"[{'Primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'a': 'O'}, {'markedly': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'cardiovascular': 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'Ro/SSA': 'O'}, {'and': 'O'}, {'La/SSB': 'I-Entity'}, {'autoantibodies': 'O'}, {'identify': 'O'}, {'the': 'O'}, {'subgroup': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'carrying': 'O'}, {'the': 'O'}, {'highest': 'O'}, {'risk.': 'O'}]"
"However, there were no statistically significant differences of positive anti-Sjogrens syndrome type B antibodies and anti-Sjogrens syndrome type A antibodies in renal damage, arthritis, malar rash, neuropsychiatric disorders, hematological abnormalities and serositis (p>0.05).","[{'However,': 'O'}, {'there': 'O'}, {'were': 'O'}, {'no': 'O'}, {'statistically': 'O'}, {'significant': 'O'}, {'differences': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'type': 'I-Entity'}, {'B': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'anti-Sjogrens': 'O'}, {'syndrome': 'I-Entity'}, {'type': 'O'}, {'A': 'O'}, {'antibodies': 'O'}, {'in': 'O'}, {'renal': 'B-Entity'}, {'damage,': 'I-Entity'}, {'arthritis,': 'I-Entity'}, {'malar': 'B-Entity'}, {'rash,': 'I-Entity'}, {'neuropsychiatric': 'B-Entity'}, {'disorders,': 'I-Entity'}, {'hematological': 'B-Entity'}, {'abnormalities': 'I-Entity'}, {'and': 'O'}, {'serositis': 'I-Entity'}]"
It was found that patients with pSS show evidence of subclinical atherosclerosis.,"[{'It': 'O'}, {'was': 'O'}, {'found': 'O'}, {'that': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'O'}, {'show': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'subclinical': 'O'}, {'atherosclerosis.': 'I-Entity'}]"
"The most common effects of NLE include cutaneous involvement and congenital heart block (CHB), although it might involve multiple organs, such as the liver, lungs, blood, and nervous or digestive systems.","[{'The': 'O'}, {'most': 'O'}, {'common': 'O'}, {'effects': 'O'}, {'of': 'O'}, {'NLE': 'I-Entity'}, {'include': 'O'}, {'cutaneous': 'O'}, {'involvement': 'O'}, {'and': 'O'}, {'congenital': 'B-Entity'}, {'heart': 'I-Entity'}, {'block': 'I-Entity'}, {'(CHB),': 'O'}, {'although': 'O'}, {'it': 'O'}, {'might': 'O'}, {'involve': 'O'}, {'multiple': 'O'}, {'organs,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'liver,': 'O'}, {'lungs,': 'O'}, {'blood,': 'O'}, {'and': 'O'}, {'nervous': 'O'}, {'or': 'O'}, {'digestive': 'O'}, {'systems.': 'O'}]"
Cell-free nucleic acids isolated from patients' sera competently primed the activation of both NLRP3 and AIM2 inflammasomes in healthy monocytes.,"[{'Cell-free': 'O'}, {'nucleic': 'O'}, {'acids': 'O'}, {'isolated': 'O'}, {'from': 'O'}, {""patients'"": 'O'}, {'sera': 'O'}, {'competently': 'O'}, {'primed': 'O'}, {'the': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'both': 'O'}, {'NLRP3': 'O'}, {'and': 'O'}, {'AIM2': 'O'}, {'inflammasomes': 'O'}, {'in': 'O'}, {'healthy': 'O'}, {'monocytes.': 'O'}]"
Approximately one fifth of a large cohort of pSS patients presented chronic respiratory symptoms.,"[{'Approximately': 'O'}, {'one': 'O'}, {'fifth': 'O'}, {'of': 'O'}, {'a': 'O'}, {'large': 'O'}, {'cohort': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'presented': 'O'}, {'chronic': 'O'}, {'respiratory': 'I-Entity'}, {'symptoms.': 'I-Entity'}]"
A known case of primary Sjogren's syndrome with chronic kidney disease presented with respiratory symptoms and subsequent altered sensorium.,"[{'A': 'O'}, {'known': 'O'}, {'case': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'chronic': 'B-Entity'}, {'kidney': 'I-Entity'}, {'disease': 'I-Entity'}, {'presented': 'O'}, {'with': 'O'}, {'respiratory': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'subsequent': 'O'}, {'altered': 'O'}, {'sensorium.': 'O'}]"
Disease activity in pSS was scored with the European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI).,"[{'Disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'pSS': 'O'}, {'was': 'O'}, {'scored': 'O'}, {'with': 'O'}, {'the': 'O'}, {'European': 'O'}, {'League': 'O'}, {'Against': 'I-Entity'}, {'Rheumatism': 'I-Entity'}, {""Sjogren's"": 'I-Entity'}, {'Syndrome': 'I-Entity'}, {'Disease': 'O'}, {'Activity': 'O'}, {'Index': 'O'}, {'(ESSDAI).': 'O'}]"
"Other forms of primary autonomic neuropathies include acute autonomic and sensory neuropathy and acute autonomic sensory and motor neuropathy, although the nosological relationship of the latter to Guillain-Barr‚Äö√†√∂¬¨¬© syndrome should be discussed.","[{'Other': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'autonomic': 'I-Entity'}, {'neuropathies': 'I-Entity'}, {'include': 'O'}, {'acute': 'O'}, {'autonomic': 'B-Entity'}, {'and': 'I-Entity'}, {'sensory': 'I-Entity'}, {'neuropathy': 'I-Entity'}, {'and': 'O'}, {'acute': 'O'}, {'autonomic': 'B-Entity'}, {'sensory': 'I-Entity'}, {'and': 'I-Entity'}, {'motor': 'I-Entity'}, {'neuropathy,': 'I-Entity'}, {'although': 'O'}, {'the': 'O'}, {'nosological': 'O'}, {'relationship': 'O'}, {'of': 'O'}, {'the': 'O'}, {'latter': 'O'}, {'to': 'O'}, {'Guillain-Barr‚Äö√†√∂¬¨¬©': 'B-Entity'}, {'syndrome': 'O'}, {'should': 'O'}, {'be': 'O'}]"
"The purpose of the current study was to expand the spectrum of proteases identified, to clarify their probable origin as well as to identify the contribution of these changes to disease pathogenesis.","[{'The': 'O'}, {'purpose': 'O'}, {'of': 'O'}, {'the': 'O'}, {'current': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'expand': 'O'}, {'the': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'proteases': 'O'}, {'identified,': 'O'}, {'to': 'O'}, {'clarify': 'O'}, {'their': 'O'}, {'probable': 'O'}, {'origin': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'to': 'O'}, {'identify': 'O'}, {'the': 'O'}, {'contribution': 'O'}, {'of': 'O'}, {'these': 'O'}, {'changes': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'pathogenesis.': 'O'}]"
"In addition to pointing to CD161 as a marker of a pathogenic subset of CD4(+) T cells in pSS patients, our data indicate that even though the ROR‚âà√≠‚Äö√¢‚Ä¢(+) (Th17) CD161(+) subset might contribute to humoral manifestations of the disease, the ROR‚âà√≠‚Äö√¢‚Ä¢(-) (non-Th17) CD161(+) subset is the one associated with disease activity in pSS patients.Society for Rheumatology.","[{'In': 'O'}, {'addition': 'O'}, {'to': 'O'}, {'pointing': 'O'}, {'to': 'O'}, {'CD161': 'O'}, {'as': 'O'}, {'a': 'O'}, {'marker': 'O'}, {'of': 'O'}, {'a': 'O'}, {'pathogenic': 'O'}, {'subset': 'O'}, {'of': 'O'}, {'CD4(+)': 'O'}, {'T': 'O'}, {'cells': 'O'}, {'in': 'O'}, {'pSS': 'I-Entity'}, {'patients,': 'O'}, {'our': 'O'}, {'data': 'O'}, {'indicate': 'O'}, {'that': 'O'}, {'even': 'O'}, {'though': 'O'}, {'the': 'O'}, {'ROR‚âà√≠‚Äö√¢‚Ä¢(+)': 'O'}, {'(Th17)': 'O'}, {'CD161(+)': 'O'}]"
There are rare cases in which these patients developed posterior reversible encephalopathy syndrome (PRES).,"[{'There': 'O'}, {'are': 'O'}, {'rare': 'O'}, {'cases': 'O'}, {'in': 'O'}, {'which': 'O'}, {'these': 'O'}, {'patients': 'O'}, {'developed': 'O'}, {'posterior': 'B-Entity'}, {'reversible': 'O'}, {'encephalopathy': 'I-Entity'}, {'syndrome': 'O'}, {'(PRES).': 'O'}]"
Prompt recognition of sensory neuronopathies may constitute a therapeutic window to intervene before there are irreversible deficits.,"[{'Prompt': 'O'}, {'recognition': 'O'}, {'of': 'O'}, {'sensory': 'B-Entity'}, {'neuronopathies': 'I-Entity'}, {'may': 'O'}, {'constitute': 'O'}, {'a': 'O'}, {'therapeutic': 'O'}, {'window': 'O'}, {'to': 'O'}, {'intervene': 'O'}, {'before': 'O'}, {'there': 'O'}, {'are': 'O'}, {'irreversible': 'O'}, {'deficits.': 'O'}]"
Her menses also resumed and her rheumatological symptoms significantly improved.,"[{'Her': 'O'}, {'menses': 'O'}, {'also': 'O'}, {'resumed': 'O'}, {'and': 'O'}, {'her': 'O'}, {'rheumatological': 'I-Entity'}, {'symptoms': 'O'}, {'significantly': 'O'}, {'improved.': 'O'}]"
"Laboratory data mainly manifested with cytopenia (100%), liver dysfunction (100%), hypofibrinogenemia (62.5%), hypertriglyceridemia (81.8%), serum ferritin > 500 ¬¨¬®¬¨¬µg/L (100%), low NK-cell activity (80%) and hemophagocytosis in bone marrow (100%).","[{'Laboratory': 'O'}, {'data': 'O'}, {'mainly': 'O'}, {'manifested': 'O'}, {'with': 'O'}, {'cytopenia': 'I-Entity'}, {'(100%),': 'O'}, {'liver': 'B-Entity'}, {'dysfunction': 'I-Entity'}, {'(100%),': 'O'}, {'hypofibrinogenemia': 'I-Entity'}, {'(62.5%),': 'O'}, {'hypertriglyceridemia': 'I-Entity'}, {'(81.8%),': 'O'}, {'serum': 'O'}, {'ferritin': 'O'}, {'>': 'O'}, {'500': 'O'}, {'¬¨¬®¬¨¬µg/L': 'O'}]"
"Subjective symptoms were evaluated via visual analogue scales (VAS), and the unstimulated whole salivary flow was measured.","[{'Subjective': 'O'}, {'symptoms': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'via': 'O'}, {'visual': 'O'}, {'analogue': 'O'}, {'scales': 'O'}, {'(VAS),': 'O'}, {'and': 'O'}, {'the': 'O'}, {'unstimulated': 'O'}, {'whole': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'was': 'O'}, {'measured.': 'O'}]"
Our study demonstrates that BR3 is involved in the survival of cultured epithelial cells due to an autocrine effect of BAFF.,"[{'Our': 'O'}, {'study': 'O'}, {'demonstrates': 'O'}, {'that': 'O'}, {'BR3': 'O'}, {'is': 'O'}, {'involved': 'O'}, {'in': 'O'}, {'the': 'O'}, {'survival': 'O'}, {'of': 'O'}, {'cultured': 'O'}, {'epithelial': 'O'}, {'cells': 'O'}, {'due': 'O'}, {'to': 'O'}, {'an': 'O'}, {'autocrine': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'BAFF.': 'O'}]"
"Parotidomegaly, lymphadenopathy, inflammatory neuropathy and vasculitis have been found to be predictive of the development of lymphoma.","[{'Parotidomegaly,': 'I-Entity'}, {'lymphadenopathy,': 'I-Entity'}, {'inflammatory': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'and': 'O'}, {'vasculitis': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'found': 'O'}, {'to': 'O'}, {'be': 'O'}, {'predictive': 'O'}, {'of': 'O'}, {'the': 'O'}, {'development': 'O'}, {'of': 'O'}, {'lymphoma.': 'I-Entity'}]"
"At the same time, the cause or effect is not clear yet because the dysfunction of salivary glands induces alterations in oral and intestinal microbiome which is linked to worsen of symptoms and disease severity.","[{'At': 'O'}, {'the': 'O'}, {'same': 'O'}, {'time,': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'or': 'O'}, {'effect': 'O'}, {'is': 'O'}, {'not': 'O'}, {'clear': 'O'}, {'yet': 'O'}, {'because': 'O'}, {'the': 'O'}, {'dysfunction': 'B-Entity'}, {'of': 'I-Entity'}, {'salivary': 'I-Entity'}, {'glands': 'I-Entity'}, {'induces': 'O'}, {'alterations': 'O'}, {'in': 'O'}, {'oral': 'O'}, {'and': 'O'}, {'intestinal': 'O'}, {'microbiome': 'O'}, {'which': 'O'}, {'is': 'O'}, {'linked': 'O'}, {'to': 'O'}, {'worsen': 'O'}, {'of': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'disease': 'O'}, {'severity.': 'O'}]"
He was also found to have hyperchloremic metabolic acidosis with normal anion gap and preserved ability to acidify urine to a pH of 5.5.,"[{'He': 'O'}, {'was': 'O'}, {'also': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'hyperchloremic': 'I-Entity'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'with': 'O'}, {'normal': 'O'}, {'anion': 'O'}, {'gap': 'O'}, {'and': 'O'}, {'preserved': 'O'}, {'ability': 'O'}, {'to': 'O'}, {'acidify': 'O'}, {'urine': 'O'}, {'to': 'O'}, {'a': 'O'}, {'pH': 'O'}, {'of': 'O'}, {'5.5.': 'O'}]"
"In the past, there were no studies to evaluate the incidence of Sjogren's syndrome and its relationship with sex and age in patients with systemic sclerosis.","[{'In': 'O'}, {'the': 'O'}, {'past,': 'O'}, {'there': 'O'}, {'were': 'O'}, {'no': 'O'}, {'studies': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'the': 'O'}, {'incidence': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'its': 'O'}, {'relationship': 'O'}, {'with': 'O'}, {'sex': 'O'}, {'and': 'O'}, {'age': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis.': 'I-Entity'}]"
It is characterised by an excessive activation of the immune system that leads to a disproportionate and destructive inflammatory response.,"[{'It': 'O'}, {'is': 'O'}, {'characterised': 'O'}, {'by': 'O'}, {'an': 'O'}, {'excessive': 'O'}, {'activation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'immune': 'O'}, {'system': 'O'}, {'that': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'a': 'O'}, {'disproportionate': 'O'}, {'and': 'O'}, {'destructive': 'O'}, {'inflammatory': 'O'}, {'response.': 'O'}]"
"We also compared the hearing thresholds between RA and PSS patients, finding a significant hearing threshold increase in 500-3000¬¨¬®‚Äö√Ñ‚Ä†Hz of the PSS group.","[{'We': 'O'}, {'also': 'O'}, {'compared': 'O'}, {'the': 'O'}, {'hearing': 'O'}, {'thresholds': 'O'}, {'between': 'O'}, {'RA': 'I-Entity'}, {'and': 'O'}, {'PSS': 'I-Entity'}, {'patients,': 'O'}, {'finding': 'O'}, {'a': 'O'}, {'significant': 'O'}, {'hearing': 'O'}, {'threshold': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'500-3000¬¨¬®‚Äö√Ñ‚Ä†Hz': 'O'}, {'of': 'O'}, {'the': 'O'}, {'PSS': 'I-Entity'}, {'group.': 'O'}]"
"The risks of OAB and BPS/IC were significantly increased for pSS patients aged < 65 years (HR: 1.73 and 2.67), female patients (HR: 1.74 and 2.34), and patients requiring treatment for dry eyes and dry mouth (HR: 2.06 and 2.93).","[{'The': 'O'}, {'risks': 'O'}, {'of': 'O'}, {'OAB': 'I-Entity'}, {'and': 'O'}, {'BPS/IC': 'I-Entity'}, {'were': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'for': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'aged': 'O'}, {'<': 'O'}, {'65': 'O'}, {'years': 'O'}, {'(HR:': 'O'}, {'1.73': 'O'}, {'and': 'O'}, {'2.67),': 'O'}, {'female': 'O'}, {'patients': 'O'}, {'(HR:': 'O'}, {'1.74': 'O'}, {'and': 'O'}, {'2.34),': 'O'}, {'and': 'O'}, {'patients': 'O'}, {'requiring': 'O'}, {'treatment': 'O'}, {'for': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'(HR:': 'O'}]"
"Because most non-Hodgkin lymphoma initially involves the neck organs, meticulous imaging studies mainly focused on the cervical regions are recommended in the follow-up of patients with primary Sjogren syndrome.","[{'Because': 'O'}, {'most': 'O'}, {'non-Hodgkin': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'initially': 'O'}, {'involves': 'O'}, {'the': 'O'}, {'neck': 'O'}, {'organs,': 'O'}, {'meticulous': 'O'}, {'imaging': 'O'}, {'studies': 'O'}, {'mainly': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'the': 'O'}, {'cervical': 'O'}, {'regions': 'O'}, {'are': 'O'}, {'recommended': 'O'}, {'in': 'O'}, {'the': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
"All together, these data suggest salivary B cells have unique repertoire characteristics that likely influence autoantigen binding and contribute to Sjogrens syndrome disease in a tissue-specific manner.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA jkramer@buffalo.edu.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.Manhasset, New York, USA; Division of Oral and Maxillofacial Pathology, Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York, USA; Department of Oral Biology, School of Dental Medicine, and Department of Biostatistics, State University of New York at Buffalo, Buffalo, New York, USA; Department of Dental Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Hempstead, New York, USA; and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, Texas, USA.17.in lupus and primary Sjogrens syndrome.","[{'All': 'O'}, {'together,': 'O'}, {'these': 'O'}, {'data': 'O'}, {'suggest': 'O'}, {'salivary': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'have': 'O'}, {'unique': 'O'}, {'repertoire': 'O'}, {'characteristics': 'O'}, {'that': 'O'}, {'likely': 'O'}, {'influence': 'O'}, {'autoantigen': 'O'}, {'binding': 'O'}, {'and': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'tissue-specific': 'O'}, {'manner.Manhasset,': 'O'}, {'New': 'O'}, {'York,': 'O'}, {'USA;': 'O'}, {'Division': 'O'}, {'of': 'O'}, {'Oral': 'O'}, {'and': 'O'}, {'Maxillofacial': 'O'}, {'Pathology,': 'O'}, {'Department': 'O'}, {'of': 'O'}, {'Dental': 'O'}, {'Medicine,': 'O'}]"
Idiopathic LIP is rare; every attempt must be made to diagnose underlying conditions when LIP is diagnosed.,"[{'Idiopathic': 'B-Entity'}, {'LIP': 'I-Entity'}, {'is': 'O'}, {'rare;': 'O'}, {'every': 'O'}, {'attempt': 'O'}, {'must': 'O'}, {'be': 'O'}, {'made': 'O'}, {'to': 'O'}, {'diagnose': 'O'}, {'underlying': 'O'}, {'conditions': 'O'}, {'when': 'O'}, {'LIP': 'I-Entity'}, {'is': 'O'}, {'diagnosed.': 'O'}]"
"In the multivariate analysis, age ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢25 years and anti-Ro/SSA antibodies at SLE diagnosis were identified as predictors of SLE-SS, while the absence of anti-Ro/SSA, anti-La/SSB and RF seems to be protective (LR- 0.14, 95% CI 0.02, 0.95).","[{'In': 'O'}, {'the': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'age': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢25': 'O'}, {'years': 'O'}, {'and': 'O'}, {'anti-Ro/SSA': 'O'}, {'antibodies': 'O'}, {'at': 'O'}, {'SLE': 'I-Entity'}, {'diagnosis': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'as': 'O'}, {'predictors': 'O'}, {'of': 'O'}, {'SLE-SS,': 'B-Entity'}, {'while': 'O'}, {'the': 'O'}, {'absence': 'O'}, {'of': 'O'}, {'anti-Ro/SSA,': 'O'}]"
Anti-CCP antibodies are more specific for RA.Sjogrens syndrome.,"[{'Anti-CCP': 'O'}, {'antibodies': 'O'}, {'are': 'O'}, {'more': 'O'}, {'specific': 'O'}, {'for': 'O'}, {'RA.Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
We report a 62-year-old woman with a history of Basedow's disease and Sjogren's syndrome who presented with slowly progressive limb muscle weakness over the course of ten years.,"[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'62-year-old': 'O'}, {'woman': 'O'}, {'with': 'O'}, {'a': 'O'}, {'history': 'O'}, {'of': 'O'}, {""Basedow's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'and': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'slowly': 'O'}, {'progressive': 'O'}, {'limb': 'O'}, {'muscle': 'B-Entity'}, {'weakness': 'I-Entity'}, {'over': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'ten': 'O'}, {'years.': 'O'}]"
"As a control group, we included 37 consecutive SS patients evaluated by pulmonary CT during the same study period without pulmonary involvement.","[{'As': 'O'}, {'a': 'O'}, {'control': 'O'}, {'group,': 'O'}, {'we': 'O'}, {'included': 'O'}, {'37': 'O'}, {'consecutive': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'pulmonary': 'O'}, {'CT': 'O'}, {'during': 'O'}, {'the': 'O'}, {'same': 'O'}, {'study': 'O'}, {'period': 'O'}, {'without': 'O'}, {'pulmonary': 'O'}, {'involvement.': 'O'}]"
"A biopsy of the quadriceps femoris muscle provided a diagnosis of myositis based on the finding of muscle fibers of unequal size, nuclear centralization, and inflammatory cell infiltration into muscle fibers.","[{'A': 'O'}, {'biopsy': 'O'}, {'of': 'O'}, {'the': 'O'}, {'quadriceps': 'O'}, {'femoris': 'O'}, {'muscle': 'O'}, {'provided': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'myositis': 'I-Entity'}, {'based': 'O'}, {'on': 'O'}, {'the': 'O'}, {'finding': 'O'}, {'of': 'O'}, {'muscle': 'O'}, {'fibers': 'O'}, {'of': 'O'}, {'unequal': 'O'}, {'size,': 'O'}, {'nuclear': 'O'}, {'centralization,': 'O'}, {'and': 'O'}, {'inflammatory': 'O'}, {'cell': 'O'}, {'infiltration': 'O'}, {'into': 'O'}, {'muscle': 'O'}, {'fibers.': 'O'}]"
"We also examined the immunohistochemical staining of salivary glands of SS patients with monoclonal antibodies against fascin, CD11c and human leucocyte antigen DR (HLA-DR).","[{'We': 'O'}, {'also': 'O'}, {'examined': 'O'}, {'the': 'O'}, {'immunohistochemical': 'O'}, {'staining': 'O'}, {'of': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'monoclonal': 'O'}, {'antibodies': 'O'}, {'against': 'O'}, {'fascin,': 'O'}, {'CD11c': 'O'}, {'and': 'O'}, {'human': 'O'}, {'leucocyte': 'O'}, {'antigen': 'O'}, {'DR': 'O'}, {'(HLA-DR).': 'O'}]"
"In pSS, lower total memory B-cells count was associated with longer disease duration (14.3 vs 8.1 years, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.006) and more active disease profile, as evaluated by the¬¨¬®‚Äö√Ñ‚Ä†European League Against Rheumatism (EULAR) Sjogrens Syndrome Disease Activity Index (ESSDAI) (3.1 vs 1.4, p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.043).","[{'In': 'O'}, {'pSS,': 'O'}, {'lower': 'O'}, {'total': 'O'}, {'memory': 'O'}, {'B-cells': 'O'}, {'count': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'longer': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'(14.3': 'O'}, {'vs': 'O'}, {'8.1': 'O'}, {'years,': 'O'}, {'p‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.006)': 'O'}]"
"She had multiple emergency room visits for persistent muscle pain, generalized weakness, and cardiac arrhythmias.","[{'She': 'O'}, {'had': 'O'}, {'multiple': 'O'}, {'emergency': 'O'}, {'room': 'O'}, {'visits': 'O'}, {'for': 'O'}, {'persistent': 'O'}, {'muscle': 'B-Entity'}, {'pain,': 'I-Entity'}, {'generalized': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'and': 'O'}, {'cardiac': 'B-Entity'}, {'arrhythmias.': 'I-Entity'}]"
Sural nerve biopsy specimens reveal predominantly large fiber loss in sensory ataxic neuropathy and predominantly small fiber loss in painful sensory neuropathy.,"[{'Sural': 'O'}, {'nerve': 'O'}, {'biopsy': 'O'}, {'specimens': 'O'}, {'reveal': 'O'}, {'predominantly': 'O'}, {'large': 'O'}, {'fiber': 'O'}, {'loss': 'O'}, {'in': 'O'}, {'sensory': 'O'}, {'ataxic': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'and': 'O'}, {'predominantly': 'O'}, {'small': 'O'}, {'fiber': 'O'}, {'loss': 'O'}, {'in': 'O'}, {'painful': 'B-Entity'}, {'sensory': 'I-Entity'}, {'neuropathy.': 'I-Entity'}]"
Age accounted for all apparent relationships between fatty infiltration and fibrosis or reduced saliva flow.,"[{'Age': 'O'}, {'accounted': 'O'}, {'for': 'O'}, {'all': 'O'}, {'apparent': 'O'}, {'relationships': 'O'}, {'between': 'O'}, {'fatty': 'O'}, {'infiltration': 'O'}, {'and': 'O'}, {'fibrosis': 'I-Entity'}, {'or': 'O'}, {'reduced': 'O'}, {'saliva': 'O'}, {'flow.': 'O'}]"
"The presence of anti-phospholipid syndrome (APS) was associated with fetal loss (P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.018, OR‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢6.41 (95¬¨¬®‚Äö√Ñ‚Ä†% CI‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1.57-26.14)).","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'anti-phospholipid': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(APS)': 'O'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fetal': 'B-Entity'}, {'loss': 'I-Entity'}, {'(P‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢0.018,': 'O'}]"
"Sjogren's syndrome (SS) is a systemic, autoimmune disorder characterized by salivary insufficiency and lymphocytic infiltration of the exocrine glands.","[{""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'systemic,': 'O'}, {'autoimmune': 'I-Entity'}, {'disorder': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'salivary': 'B-Entity'}, {'insufficiency': 'I-Entity'}, {'and': 'O'}, {'lymphocytic': 'O'}, {'infiltration': 'I-Entity'}, {'of': 'O'}, {'the': 'O'}, {'exocrine': 'O'}, {'glands.': 'O'}]"
Relapsing polychondritis (RP) is an unusually rare disease involving multiple organs.,"[{'Relapsing': 'O'}, {'polychondritis': 'I-Entity'}, {'(RP)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'unusually': 'O'}, {'rare': 'O'}, {'disease': 'O'}, {'involving': 'O'}, {'multiple': 'O'}, {'organs.': 'O'}]"
"PATIENTS AND Data for this retrospective, single-center, pilot study were based on a chart review of 48 sequential patients with recalcitrant dry eye who were evaluated for SS via serological analysis.","[{'PATIENTS': 'O'}, {'AND': 'O'}, {'Data': 'O'}, {'for': 'O'}, {'this': 'O'}, {'retrospective,': 'O'}, {'single-center,': 'O'}, {'pilot': 'O'}, {'study': 'O'}, {'were': 'O'}, {'based': 'O'}, {'on': 'O'}, {'a': 'O'}, {'chart': 'O'}, {'review': 'O'}, {'of': 'O'}, {'48': 'O'}, {'sequential': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'recalcitrant': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'who': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'for': 'O'}, {'SS': 'I-Entity'}, {'via': 'O'}, {'serological': 'O'}, {'analysis.': 'O'}]"
We reviewed sIBM cases with Sjogrens syndrome (sIBM/SS) from the Perth Inflammatory Myopathies Database to determine whether they are distinguishable from other sIBM cases.,"[{'We': 'O'}, {'reviewed': 'O'}, {'sIBM': 'I-Entity'}, {'cases': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(sIBM/SS)': 'O'}, {'from': 'O'}, {'the': 'O'}, {'Perth': 'O'}, {'Inflammatory': 'B-Entity'}, {'Myopathies': 'I-Entity'}, {'Database': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'whether': 'O'}, {'they': 'O'}, {'are': 'O'}, {'distinguishable': 'O'}, {'from': 'O'}, {'other': 'O'}, {'sIBM': 'I-Entity'}, {'cases.': 'O'}]"
These results correspond to previous findings on individual samples from patients with these diseases.,"[{'These': 'O'}, {'results': 'O'}, {'correspond': 'O'}, {'to': 'O'}, {'previous': 'O'}, {'findings': 'O'}, {'on': 'O'}, {'individual': 'O'}, {'samples': 'O'}, {'from': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'these': 'O'}, {'diseases.': 'O'}]"
"In the multivariate model identified using backwards selection, four variables (pain catastrophizing, fibromyalgia status, serological status, and the conviction that illness would have severe consequences) predicted 55% of the variance in pain severity.","[{'In': 'O'}, {'the': 'O'}, {'multivariate': 'O'}, {'model': 'O'}, {'identified': 'O'}, {'using': 'O'}, {'backwards': 'O'}, {'selection,': 'O'}, {'four': 'O'}, {'variables': 'O'}, {'(pain': 'O'}, {'catastrophizing,': 'O'}, {'fibromyalgia': 'I-Entity'}, {'status,': 'O'}, {'serological': 'O'}, {'status,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'conviction': 'O'}, {'that': 'O'}, {'illness': 'I-Entity'}, {'would': 'O'}, {'have': 'O'}, {'severe': 'O'}, {'consequences)': 'O'}, {'predicted': 'O'}, {'55%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'variance': 'O'}, {'in': 'O'}, {'pain': 'I-Entity'}, {'severity.': 'O'}]"
"Collectively, the results are suggestive of dysregulation of GILZ playing a role in inflammation and associated Del-1/Il-17 imbalance in SS.","[{'Collectively,': 'O'}, {'the': 'O'}, {'results': 'O'}, {'are': 'O'}, {'suggestive': 'O'}, {'of': 'O'}, {'dysregulation': 'O'}, {'of': 'O'}, {'GILZ': 'O'}, {'playing': 'O'}, {'a': 'O'}, {'role': 'O'}, {'in': 'O'}, {'inflammation': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'Del-1/Il-17': 'O'}, {'imbalance': 'O'}, {'in': 'O'}, {'SS.': 'I-Entity'}]"
The conjunctival inflammation was also accompanied by an increase in local lymphatic vessels.,"[{'The': 'O'}, {'conjunctival': 'B-Entity'}, {'inflammation': 'I-Entity'}, {'was': 'O'}, {'also': 'O'}, {'accompanied': 'O'}, {'by': 'O'}, {'an': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'local': 'O'}, {'lymphatic': 'O'}, {'vessels.': 'O'}]"
"Although extra glandular manifestations are uncommon, they can occur with the musculoskeletal, renal, pulmonary and hematological disease.","[{'Although': 'O'}, {'extra': 'O'}, {'glandular': 'O'}, {'manifestations': 'O'}, {'are': 'O'}, {'uncommon,': 'O'}, {'they': 'O'}, {'can': 'O'}, {'occur': 'O'}, {'with': 'O'}, {'the': 'O'}, {'musculoskeletal,': 'B-Entity'}, {'renal,': 'I-Entity'}, {'pulmonary': 'I-Entity'}, {'and': 'I-Entity'}, {'hematological': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"Regarding characteristic appearances of fat signal, the A/B of parotid gland with homogeneous intensity distribution (3.51 ¬¨¬®¬¨¬± 0.75) was higher than that with heterogeneous intensity distribution (1.56 ¬¨¬®¬¨¬± 0.66, P = 0.001).","[{'Regarding': 'O'}, {'characteristic': 'O'}, {'appearances': 'O'}, {'of': 'O'}, {'fat': 'O'}, {'signal,': 'O'}, {'the': 'O'}, {'A/B': 'O'}, {'of': 'O'}, {'parotid': 'O'}, {'gland': 'O'}, {'with': 'O'}, {'homogeneous': 'O'}, {'intensity': 'O'}, {'distribution': 'O'}, {'(3.51': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'0.75)': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'than': 'O'}, {'that': 'O'}, {'with': 'O'}, {'heterogeneous': 'O'}, {'intensity': 'O'}, {'distribution': 'O'}, {'(1.56': 'O'}, {'¬¨¬®¬¨¬±': 'O'}, {'0.66,': 'O'}]"
Patients with ICD-7-10 codes for Sjogrens syndrome (SS) and a diagnosis of malignant lymphoma before or after SS diagnosis were identified by linking the Swedish Patient Register 1964-2007 with the Cancer Register 1990-2007 (n¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†224).,"[{'Patients': 'O'}, {'with': 'O'}, {'ICD-7-10': 'O'}, {'codes': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'malignant': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'before': 'O'}, {'or': 'O'}, {'after': 'O'}, {'SS': 'I-Entity'}, {'diagnosis': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'by': 'O'}, {'linking': 'O'}, {'the': 'O'}, {'Swedish': 'O'}, {'Patient': 'O'}, {'Register': 'O'}, {'1964-2007': 'O'}, {'with': 'O'}, {'the': 'O'}, {'Cancer': 'I-Entity'}, {'Register': 'O'}, {'1990-2007': 'O'}, {'(n¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†224).': 'O'}]"
"After lymph node biopsy, the patient was proven to have sinus histiocytosis, which is another rare finding in Sjogrens syndrome.","[{'After': 'O'}, {'lymph': 'O'}, {'node': 'O'}, {'biopsy,': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'was': 'O'}, {'proven': 'O'}, {'to': 'O'}, {'have': 'O'}, {'sinus': 'B-Entity'}, {'histiocytosis,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'another': 'O'}, {'rare': 'O'}, {'finding': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"We evaluated the survival impact of MPAP, which is measured using right heart catheterization, on survival of patients with CTD-ILD with various CTD backgrounds.","[{'We': 'O'}, {'evaluated': 'O'}, {'the': 'O'}, {'survival': 'O'}, {'impact': 'O'}, {'of': 'O'}, {'MPAP,': 'I-Entity'}, {'which': 'O'}, {'is': 'O'}, {'measured': 'O'}, {'using': 'O'}, {'right': 'O'}, {'heart': 'O'}, {'catheterization,': 'O'}, {'on': 'O'}, {'survival': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'CTD-ILD': 'O'}, {'with': 'O'}, {'various': 'O'}, {'CTD': 'O'}, {'backgrounds.': 'O'}]"
"One year later she developed severe constitutional symptoms, sicca symptoms, lymphadenopathy, anemia, and interstitial lung disease.","[{'One': 'O'}, {'year': 'O'}, {'later': 'O'}, {'she': 'O'}, {'developed': 'O'}, {'severe': 'O'}, {'constitutional': 'O'}, {'symptoms,': 'O'}, {'sicca': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'lymphadenopathy,': 'I-Entity'}, {'anemia,': 'I-Entity'}, {'and': 'O'}, {'interstitial': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease.': 'I-Entity'}]"
"No significant difference in ANA titer, anti-SSA antibodies, anti-SSB antibodies, C3 concentration or C4 concentration was observed between the two groups.","[{'No': 'O'}, {'significant': 'O'}, {'difference': 'O'}, {'in': 'O'}, {'ANA': 'O'}, {'titer,': 'O'}, {'anti-SSA': 'O'}, {'antibodies,': 'O'}, {'anti-SSB': 'O'}, {'antibodies,': 'O'}, {'C3': 'O'}, {'concentration': 'O'}, {'or': 'O'}, {'C4': 'O'}, {'concentration': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'between': 'O'}, {'the': 'O'}, {'two': 'O'}, {'groups.': 'O'}]"
"Three hundred and seven RA patients responding positive to at least one of the questions in a questionnaire about sicca symptoms, were examined by Schirmer I test for tear production, and unstimulated whole saliva collection (USWC).","[{'Three': 'O'}, {'hundred': 'O'}, {'and': 'O'}, {'seven': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'responding': 'O'}, {'positive': 'O'}, {'to': 'O'}, {'at': 'O'}, {'least': 'O'}, {'one': 'O'}, {'of': 'O'}, {'the': 'O'}, {'questions': 'O'}, {'in': 'O'}, {'a': 'O'}, {'questionnaire': 'O'}, {'about': 'O'}, {'sicca': 'B-Entity'}, {'symptoms,': 'I-Entity'}, {'were': 'O'}, {'examined': 'O'}, {'by': 'O'}, {'Schirmer': 'O'}, {'I': 'O'}, {'test': 'O'}, {'for': 'O'}, {'tear': 'O'}, {'production,': 'O'}, {'and': 'O'}, {'unstimulated': 'O'}, {'whole': 'O'}, {'saliva': 'O'}, {'collection': 'O'}, {'(USWC).': 'O'}]"
The only patient whose biopsy lacked IgG4-positive plasma cells had pathologic evidence of cytomegalovirus infection.,"[{'The': 'O'}, {'only': 'O'}, {'patient': 'O'}, {'whose': 'O'}, {'biopsy': 'O'}, {'lacked': 'O'}, {'IgG4-positive': 'O'}, {'plasma': 'O'}, {'cells': 'O'}, {'had': 'O'}, {'pathologic': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'cytomegalovirus': 'B-Entity'}, {'infection.': 'I-Entity'}]"
"In accordance with other European studies, systemic diseases are the main causes of hepatic granulomas.","[{'In': 'O'}, {'accordance': 'O'}, {'with': 'O'}, {'other': 'O'}, {'European': 'O'}, {'studies,': 'O'}, {'systemic': 'B-Entity'}, {'diseases': 'I-Entity'}, {'are': 'O'}, {'the': 'O'}, {'main': 'O'}, {'causes': 'O'}, {'of': 'O'}, {'hepatic': 'B-Entity'}, {'granulomas.': 'I-Entity'}]"
"The clinical-pathological correlations derived from the study of renal tissues can be useful for differential diagnosis, prognosis assessment and therapeutic decisions.","[{'The': 'O'}, {'clinical-pathological': 'O'}, {'correlations': 'O'}, {'derived': 'O'}, {'from': 'O'}, {'the': 'O'}, {'study': 'O'}, {'of': 'O'}, {'renal': 'O'}, {'tissues': 'O'}, {'can': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'differential': 'O'}, {'diagnosis,': 'O'}, {'prognosis': 'O'}, {'assessment': 'O'}, {'and': 'O'}, {'therapeutic': 'O'}, {'decisions.': 'O'}]"
Presentation of hyposalivation was associated with significant alteration in 22 out of 119 reliably detectable biomarkers.,"[{'Presentation': 'O'}, {'of': 'O'}, {'hyposalivation': 'I-Entity'}, {'was': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'significant': 'O'}, {'alteration': 'O'}, {'in': 'O'}, {'22': 'O'}, {'out': 'O'}, {'of': 'O'}, {'119': 'O'}, {'reliably': 'O'}, {'detectable': 'O'}, {'biomarkers.': 'O'}]"
A 61-year-old woman was admitted to our hospital because of muscle paralysis and was found to have severe hypokalemia.,"[{'A': 'O'}, {'61-year-old': 'O'}, {'woman': 'O'}, {'was': 'O'}, {'admitted': 'O'}, {'to': 'O'}, {'our': 'O'}, {'hospital': 'O'}, {'because': 'O'}, {'of': 'O'}, {'muscle': 'B-Entity'}, {'paralysis': 'I-Entity'}, {'and': 'O'}, {'was': 'O'}, {'found': 'O'}, {'to': 'O'}, {'have': 'O'}, {'severe': 'O'}, {'hypokalemia.': 'I-Entity'}]"
To assess the effect of B cell depletion therapy on effector CD4+ T cell homeostasis and its relation to objective measures of disease activity in patients with primary Sjogren syndrome (pSS).,"[{'To': 'O'}, {'assess': 'O'}, {'the': 'O'}, {'effect': 'O'}, {'of': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'depletion': 'O'}, {'therapy': 'O'}, {'on': 'O'}, {'effector': 'O'}, {'CD4+': 'O'}, {'T': 'O'}, {'cell': 'O'}, {'homeostasis': 'O'}, {'and': 'O'}, {'its': 'O'}, {'relation': 'O'}, {'to': 'O'}, {'objective': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
Nonvasculitic autoimmune meningoencephalitis (NAIM) is a rare condition describing a syndrome of steroid-responsive encephalopathy in patients with similar clinical and pathologic features.,"[{'Nonvasculitic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'meningoencephalitis': 'I-Entity'}, {'(NAIM)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'condition': 'O'}, {'describing': 'O'}, {'a': 'O'}, {'syndrome': 'O'}, {'of': 'O'}, {'steroid-responsive': 'I-Entity'}, {'encephalopathy': 'I-Entity'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'similar': 'O'}, {'clinical': 'O'}, {'and': 'O'}, {'pathologic': 'O'}, {'features.': 'O'}]"
"To study the relationship of the presence of secondary SS with disease activity, duration in RA.","[{'To': 'O'}, {'study': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'of': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'with': 'O'}, {'disease': 'O'}, {'activity,': 'O'}, {'duration': 'O'}, {'in': 'O'}, {'RA.': 'I-Entity'}]"
"A series of 13 patients underwent a comprehensive evaluation for suspected autonomic impairment, including a neurological examination, autonomic testing, and laboratory studies.","[{'A': 'O'}, {'series': 'O'}, {'of': 'O'}, {'13': 'O'}, {'patients': 'O'}, {'underwent': 'O'}, {'a': 'O'}, {'comprehensive': 'O'}, {'evaluation': 'O'}, {'for': 'O'}, {'suspected': 'O'}, {'autonomic': 'B-Entity'}, {'impairment,': 'I-Entity'}, {'including': 'O'}, {'a': 'O'}, {'neurological': 'O'}, {'examination,': 'O'}, {'autonomic': 'O'}, {'testing,': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'studies.': 'O'}]"
"The simultaneous presence of at least three antibodies by BioPlex was found in 35% of patients with SLE, 4% with SSc, 100% with MCTD, 64% with SS, 7% with inflammatory myopathy, 0.7% of CFS and diseased controls, and none of the blood donors.","[{'The': 'O'}, {'simultaneous': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'at': 'O'}, {'least': 'O'}, {'three': 'O'}, {'antibodies': 'O'}, {'by': 'O'}, {'BioPlex': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'35%': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'SLE,': 'I-Entity'}, {'4%': 'O'}, {'with': 'O'}, {'SSc,': 'I-Entity'}, {'100%': 'O'}, {'with': 'O'}, {'MCTD,': 'I-Entity'}, {'64%': 'O'}, {'with': 'O'}, {'SS,': 'I-Entity'}, {'7%': 'O'}, {'with': 'O'}, {'inflammatory': 'B-Entity'}, {'myopathy,': 'I-Entity'}, {'0.7%': 'O'}, {'of': 'O'}, {'CFS': 'I-Entity'}, {'and': 'O'}, {'diseased': 'O'}, {'controls,': 'O'}]"
Systemic autoimmune diseases (SAD) can involve numerous structures and organs.,"[{'Systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(SAD)': 'O'}, {'can': 'O'}, {'involve': 'O'}, {'numerous': 'O'}, {'structures': 'O'}, {'and': 'O'}, {'organs.': 'O'}]"
"Sixteen (6.3%) and seven (2.7%) patients were positive for anti-SS-A and SS-B antibodies, respectively.","[{'Sixteen': 'O'}, {'(6.3%)': 'O'}, {'and': 'O'}, {'seven': 'O'}, {'(2.7%)': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'anti-SS-A': 'O'}, {'and': 'O'}, {'SS-B': 'O'}, {'antibodies,': 'O'}, {'respectively.': 'O'}]"
The total glucosides of paeony (TGP) can inhibit inflammation and alleviate symptoms in autoimmune diseases.,"[{'The': 'O'}, {'total': 'B-Entity'}, {'glucosides': 'I-Entity'}, {'of': 'I-Entity'}, {'paeony': 'I-Entity'}, {'(TGP)': 'O'}, {'can': 'O'}, {'inhibit': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'alleviate': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases.': 'I-Entity'}]"
"Systemic involvement plays a key role in the prognosis of primary Sjogrens syndrome, and recent studies have focused on cutaneous, pulmonary, renal and neurological disease features.","[{'Systemic': 'O'}, {'involvement': 'O'}, {'plays': 'O'}, {'a': 'O'}, {'key': 'O'}, {'role': 'O'}, {'in': 'O'}, {'the': 'O'}, {'prognosis': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'recent': 'O'}, {'studies': 'O'}, {'have': 'O'}, {'focused': 'O'}, {'on': 'O'}, {'cutaneous,': 'B-Entity'}, {'pulmonary,': 'I-Entity'}, {'renal': 'I-Entity'}, {'and': 'I-Entity'}, {'neurological': 'I-Entity'}, {'disease': 'I-Entity'}, {'features.': 'O'}]"
"Modest improvements were observed at week 26 in patient-reported symptoms of fatigue and oral dryness, with no significant improvement in the objective measures of lacrimal and salivary gland function.","[{'Modest': 'O'}, {'improvements': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'at': 'O'}, {'week': 'O'}, {'26': 'O'}, {'in': 'O'}, {'patient-reported': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'fatigue': 'I-Entity'}, {'and': 'O'}, {'oral': 'B-Entity'}, {'dryness,': 'I-Entity'}, {'with': 'O'}, {'no': 'O'}, {'significant': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'the': 'O'}, {'objective': 'O'}, {'measures': 'O'}, {'of': 'O'}, {'lacrimal': 'O'}, {'and': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'function.': 'O'}]"
In this article we discuss two cases of Sjogren's syndrome with diabetes mellitus and renal manifestations.Chennai 600 004.large-scale case-control study.,"[{'In': 'O'}, {'this': 'O'}, {'article': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'two': 'O'}, {'cases': 'O'}, {'of': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'diabetes': 'B-Entity'}, {'mellitus': 'I-Entity'}, {'and': 'O'}, {'renal': 'O'}, {'manifestations.Chennai': 'O'}, {'600': 'O'}, {'004.large-scale': 'O'}, {'case-control': 'O'}, {'study.': 'O'}]"
"Laugier-Hunziker syndrome is a rare benign idiopathic condition characterized by acquired macular pigmentation of lips and buccal mucosa, often accompanied with melanonychia.","[{'Laugier-Hunziker': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'rare': 'O'}, {'benign': 'O'}, {'idiopathic': 'O'}, {'condition': 'O'}, {'characterized': 'O'}, {'by': 'O'}, {'acquired': 'O'}, {'macular': 'O'}, {'pigmentation': 'I-Entity'}, {'of': 'O'}, {'lips': 'O'}, {'and': 'O'}, {'buccal': 'O'}, {'mucosa,': 'O'}, {'often': 'O'}, {'accompanied': 'O'}, {'with': 'O'}, {'melanonychia.': 'I-Entity'}]"
"Glucocorticoids, NSAIDs and/or immunosuppressive drugs may be used for the treatment of extraglandular manifestations or complications.","[{'Glucocorticoids,': 'O'}, {'NSAIDs': 'O'}, {'and/or': 'O'}, {'immunosuppressive': 'O'}, {'drugs': 'O'}, {'may': 'O'}, {'be': 'O'}, {'used': 'O'}, {'for': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'or': 'O'}, {'complications.': 'O'}]"
Measurement of CRP is very useful in the rapid diagnosis of infection as a progressive increase can be shown in the first 48 hours.,"[{'Measurement': 'O'}, {'of': 'O'}, {'CRP': 'O'}, {'is': 'O'}, {'very': 'O'}, {'useful': 'O'}, {'in': 'O'}, {'the': 'O'}, {'rapid': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'infection': 'I-Entity'}, {'as': 'O'}, {'a': 'O'}, {'progressive': 'O'}, {'increase': 'O'}, {'can': 'O'}, {'be': 'O'}, {'shown': 'O'}, {'in': 'O'}, {'the': 'O'}, {'first': 'O'}, {'48': 'O'}, {'hours.': 'O'}]"
Gene expression profiles were analysed and selected enriched genes were further examined using real time PCR and by immunofluorescence.,"[{'Gene': 'O'}, {'expression': 'O'}, {'profiles': 'O'}, {'were': 'O'}, {'analysed': 'O'}, {'and': 'O'}, {'selected': 'O'}, {'enriched': 'O'}, {'genes': 'O'}, {'were': 'O'}, {'further': 'O'}, {'examined': 'O'}, {'using': 'O'}, {'real': 'O'}, {'time': 'O'}, {'PCR': 'O'}, {'and': 'O'}, {'by': 'O'}, {'immunofluorescence.': 'O'}]"
"Central neurological manifestations were infrequent and included seizures (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤3), posterior reversible encephalopathy syndrome (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤2), intracerebral hemorrhage (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤1), vasculitis (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤1), rapidly progressive dementia (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤1), lymphoma (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤1), and myelitis/meningitis (N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤1).","[{'Central': 'O'}, {'neurological': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'infrequent': 'O'}, {'and': 'O'}, {'included': 'O'}, {'seizures': 'I-Entity'}, {'(N‚Äö√Ñ√∂‚àö√ë‚àö√≤=‚Äö√Ñ√∂‚àö√ë‚àö√≤3),': 'O'}, {'posterior': 'O'}, {'reversible': 'O'}, {'encephalopathy': 'I-Entity'}]"
"In Sjogrens syndrome, the utilization of itolizumab as therapeutic option is reinforced by our recent observation that ALCAM, the CD6 ligand, is overexpressed and that CD6-positive T and B cells are detected within salivary glands from Sjogrens syndrome patients.","[{'In': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'the': 'O'}, {'utilization': 'O'}, {'of': 'O'}, {'itolizumab': 'I-Entity'}, {'as': 'O'}, {'therapeutic': 'O'}, {'option': 'O'}, {'is': 'O'}, {'reinforced': 'O'}, {'by': 'O'}, {'our': 'O'}, {'recent': 'O'}, {'observation': 'O'}, {'that': 'O'}, {'ALCAM,': 'O'}, {'the': 'O'}, {'CD6': 'O'}, {'ligand,': 'O'}, {'is': 'O'}, {'overexpressed': 'O'}, {'and': 'O'}, {'that': 'O'}, {'CD6-positive': 'O'}, {'T': 'O'}, {'and': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'are': 'O'}, {'detected': 'O'}, {'within': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'from': 'O'}, {'Sjogrens': 'O'}]"
"Stenting was considered, but the patient died from ventilator-associated pneumonia before the procedure could be performed.","[{'Stenting': 'O'}, {'was': 'O'}, {'considered,': 'O'}, {'but': 'O'}, {'the': 'O'}, {'patient': 'O'}, {'died': 'O'}, {'from': 'O'}, {'ventilator-associated': 'O'}, {'pneumonia': 'I-Entity'}, {'before': 'O'}, {'the': 'O'}, {'procedure': 'O'}, {'could': 'O'}, {'be': 'O'}, {'performed.': 'O'}]"
Similar findings were observed for I‚âà√≠‚Äö√†¬¥K‚âà√≠¬¨¬± and NF-‚âà√≠‚Äö√†¬¥B.,"[{'Similar': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'observed': 'O'}, {'for': 'O'}, {'I‚âà√≠‚Äö√†¬¥K‚âà√≠¬¨¬±': 'O'}, {'and': 'O'}, {'NF-‚âà√≠‚Äö√†¬¥B.': 'O'}]"
MNM is the most common pattern followed by ganglionopathy.,"[{'MNM': 'I-Entity'}, {'is': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'pattern': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'ganglionopathy.': 'I-Entity'}]"
"A 56-year-old HTLV-I-positive woman, initially diagnosed as having Sjogrens syndrome, presented with muscle weakness, myalgia, face erythema and leg edema.","[{'A': 'O'}, {'56-year-old': 'O'}, {'HTLV-I-positive': 'B-Entity'}, {'woman,': 'O'}, {'initially': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'having': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'presented': 'O'}, {'with': 'O'}, {'muscle': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'myalgia,': 'I-Entity'}, {'face': 'B-Entity'}, {'erythema': 'I-Entity'}, {'and': 'O'}, {'leg': 'B-Entity'}, {'edema.': 'I-Entity'}]"
"To analyze the prevalence, characteristics and outcome of cystic lung disease associated with Sjogrens syndrome (SS).","[{'To': 'O'}, {'analyze': 'O'}, {'the': 'O'}, {'prevalence,': 'O'}, {'characteristics': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'cystic': 'B-Entity'}, {'lung': 'I-Entity'}, {'disease': 'I-Entity'}, {'associated': 'O'}, {'with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS).': 'O'}]"
"In contrast, the increased frequency of atypical celiac disease presentations, including anemia and bone disease, is revealed by the widespread availability of serologic testing.","[{'In': 'O'}, {'contrast,': 'O'}, {'the': 'O'}, {'increased': 'O'}, {'frequency': 'O'}, {'of': 'O'}, {'atypical': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'presentations,': 'O'}, {'including': 'O'}, {'anemia': 'I-Entity'}, {'and': 'O'}, {'bone': 'B-Entity'}, {'disease,': 'I-Entity'}, {'is': 'O'}, {'revealed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'widespread': 'O'}, {'availability': 'O'}, {'of': 'O'}, {'serologic': 'O'}, {'testing.': 'O'}]"
"ECS had a 100% sensitivity for Sjogrens syndrome, systemic sclerosis and Sharp syndrome.","[{'ECS': 'O'}, {'had': 'O'}, {'a': 'O'}, {'100%': 'O'}, {'sensitivity': 'O'}, {'for': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'and': 'O'}, {'Sharp': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Our exclusion criteria was a positive history of past head and neck radiation treatment, Hepatitis C infection, acquired immunodeficiency disease (AIDS), pre-existing lymphoma, sarcoidosis, graft versus host disease, use of anticholinergic drugs (including neuroleptics, antidepressants, antihypertensive and parasympatholytics).","[{'Our': 'O'}, {'exclusion': 'O'}, {'criteria': 'O'}, {'was': 'O'}, {'a': 'O'}, {'positive': 'O'}, {'history': 'O'}, {'of': 'O'}, {'past': 'O'}, {'head': 'O'}, {'and': 'O'}, {'neck': 'O'}, {'radiation': 'O'}, {'treatment,': 'O'}, {'Hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'infection,': 'I-Entity'}, {'acquired': 'B-Entity'}, {'immunodeficiency': 'I-Entity'}, {'disease': 'I-Entity'}, {'(AIDS),': 'O'}, {'pre-existing': 'O'}, {'lymphoma,': 'I-Entity'}, {'sarcoidosis,': 'I-Entity'}, {'graft': 'B-Entity'}, {'versus': 'I-Entity'}, {'host': 'I-Entity'}, {'disease,': 'I-Entity'}, {'use': 'O'}, {'of': 'O'}, {'anticholinergic': 'O'}, {'drugs': 'O'}, {'(including': 'O'}, {'neuroleptics,': 'O'}]"
Her rashes responded to oral prednisolone and cyclophosphamide.2012 Feb 2.,"[{'Her': 'O'}, {'rashes': 'I-Entity'}, {'responded': 'O'}, {'to': 'O'}, {'oral': 'O'}, {'prednisolone': 'I-Entity'}, {'and': 'O'}, {'cyclophosphamide.2012': 'I-Entity'}, {'Feb': 'O'}, {'2.': 'O'}]"
"We report a case of a 45-year-old Caucasian woman who developed pneumococcal pneumonia at age 42 years, pneumococcal meningitis at age 44 years and septic shock with Streptococcus agalactiae bacteremia at age 45 years and was subsequently diagnosed with radiological splenic atrophy and functional asplenia, as well as primary Sjogrens syndrome.","[{'We': 'O'}, {'report': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'45-year-old': 'O'}, {'Caucasian': 'O'}, {'woman': 'O'}, {'who': 'O'}, {'developed': 'O'}, {'pneumococcal': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'at': 'O'}, {'age': 'O'}, {'42': 'O'}, {'years,': 'O'}, {'pneumococcal': 'B-Entity'}, {'meningitis': 'I-Entity'}, {'at': 'O'}, {'age': 'O'}, {'44': 'O'}, {'years': 'O'}, {'and': 'O'}, {'septic': 'B-Entity'}, {'shock': 'I-Entity'}, {'with': 'O'}, {'Streptococcus': 'B-Entity'}, {'agalactiae': 'I-Entity'}, {'bacteremia': 'I-Entity'}, {'at': 'O'}, {'age': 'O'}, {'45': 'O'}]"
"We estimated the sensitivity, specificity, positive predictive value, negative predictive value, and likelihood ratio positivity with 95% CI for each criterion.","[{'We': 'O'}, {'estimated': 'O'}, {'the': 'O'}, {'sensitivity,': 'O'}, {'specificity,': 'O'}, {'positive': 'O'}, {'predictive': 'O'}, {'value,': 'O'}, {'negative': 'O'}, {'predictive': 'O'}, {'value,': 'O'}, {'and': 'O'}, {'likelihood': 'O'}, {'ratio': 'O'}, {'positivity': 'O'}, {'with': 'O'}, {'95%': 'O'}, {'CI': 'O'}, {'for': 'O'}, {'each': 'O'}, {'criterion.': 'O'}]"
Results Thirty-five patients (31.8%) had been diagnosed as affected by Sjogren syndrome.,"[{'Results': 'O'}, {'Thirty-five': 'O'}, {'patients': 'O'}, {'(31.8%)': 'O'}, {'had': 'O'}, {'been': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
"Given the high unmet need for efficacious disease-modifying treatment in these diseases, studies are warranted to determine if anti-CD38 antibody-based therapies may delay or prevent the disease progression of systemic autoimmune diseases.60126 Ancona, Italy.60126 Ancona, Italy.pregnancy.","[{'Given': 'O'}, {'the': 'O'}, {'high': 'O'}, {'unmet': 'O'}, {'need': 'O'}, {'for': 'O'}, {'efficacious': 'O'}, {'disease-modifying': 'O'}, {'treatment': 'O'}, {'in': 'O'}, {'these': 'O'}, {'diseases,': 'O'}, {'studies': 'O'}, {'are': 'O'}, {'warranted': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'if': 'O'}, {'anti-CD38': 'O'}, {'antibody-based': 'O'}, {'therapies': 'O'}, {'may': 'O'}, {'delay': 'O'}, {'or': 'O'}, {'prevent': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'progression': 'O'}, {'of': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases.60126': 'I-Entity'}, {'Ancona,': 'O'}, {'Italy.60126': 'O'}]"
Autoimmune diseases included Hashimoto's thyroiditis (n=23); SLE (n=7); Behcet's disease (n=1); Sjogren's syndrome (n=1); ulcerative colitis (n=1); and anti-phospholipid antibody syndrome (n=1).,"[{'Autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'included': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'thyroiditis': 'I-Entity'}, {'(n=23);': 'O'}, {'SLE': 'I-Entity'}, {'(n=7);': 'O'}, {""Behcet's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(n=1);': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(n=1);': 'O'}, {'ulcerative': 'B-Entity'}, {'colitis': 'I-Entity'}, {'(n=1);': 'O'}]"
"In addition, whereas NMOSD was initially thought to spare the brain, it is now recognized that brain lesions occur in a majority of NMOSD patients.","[{'In': 'O'}, {'addition,': 'O'}, {'whereas': 'O'}, {'NMOSD': 'I-Entity'}, {'was': 'O'}, {'initially': 'O'}, {'thought': 'O'}, {'to': 'O'}, {'spare': 'O'}, {'the': 'O'}, {'brain,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'now': 'O'}, {'recognized': 'O'}, {'that': 'O'}, {'brain': 'B-Entity'}, {'lesions': 'I-Entity'}, {'occur': 'O'}, {'in': 'O'}, {'a': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'NMOSD': 'I-Entity'}, {'patients.': 'O'}]"
"Six months after the initial diagnosis, the dry eyes and mouth did not worsen and no masses suggestive of localized amyloidosis were reported.","[{'Six': 'O'}, {'months': 'O'}, {'after': 'O'}, {'the': 'O'}, {'initial': 'O'}, {'diagnosis,': 'O'}, {'the': 'O'}, {'dry': 'B-Entity'}, {'eyes': 'I-Entity'}, {'and': 'I-Entity'}, {'mouth': 'I-Entity'}, {'did': 'O'}, {'not': 'O'}, {'worsen': 'O'}, {'and': 'O'}, {'no': 'O'}, {'masses': 'O'}, {'suggestive': 'O'}, {'of': 'O'}, {'localized': 'O'}, {'amyloidosis': 'I-Entity'}, {'were': 'O'}, {'reported.': 'O'}]"
"To recognize the connective tissue diseases (CTD), which include lupus erythematosus (SLE), Sjogrens syndrome (SS) and Systemic sclerosis (SSc) it is necessary to determine the presence of autoantibodies (Ab).","[{'To': 'O'}, {'recognize': 'O'}, {'the': 'O'}, {'connective': 'B-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(CTD),': 'O'}, {'which': 'O'}, {'include': 'O'}, {'lupus': 'B-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'and': 'O'}, {'Systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'(SSc)': 'O'}, {'it': 'O'}, {'is': 'O'}, {'necessary': 'O'}, {'to': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'autoantibodies': 'O'}, {'(Ab).': 'O'}]"
The majority of patients (86%) were receiving systemic therapy for severe SS.,"[{'The': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'(86%)': 'O'}, {'were': 'O'}, {'receiving': 'O'}, {'systemic': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'severe': 'O'}, {'SS.': 'I-Entity'}]"
"Dispersed calcifications in bilateral parotid glands may strongly suggest Sjogrens syndrome (SS), since the occurrence of bilateral calcifications in other salivary gland diseases is rare.","[{'Dispersed': 'O'}, {'calcifications': 'I-Entity'}, {'in': 'O'}, {'bilateral': 'O'}, {'parotid': 'O'}, {'glands': 'O'}, {'may': 'O'}, {'strongly': 'O'}, {'suggest': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'since': 'O'}, {'the': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'bilateral': 'O'}, {'calcifications': 'I-Entity'}, {'in': 'O'}, {'other': 'O'}, {'salivary': 'B-Entity'}, {'gland': 'I-Entity'}, {'diseases': 'I-Entity'}, {'is': 'O'}, {'rare.': 'O'}]"
"A growing body of evidence links HTLV-1 infection with an increasing spectrum of disease, including uveitis, periodontal disease, arthropathy, sicca syndrome, and neurologic deficits.","[{'A': 'O'}, {'growing': 'O'}, {'body': 'O'}, {'of': 'O'}, {'evidence': 'O'}, {'links': 'O'}, {'HTLV-1': 'B-Entity'}, {'infection': 'I-Entity'}, {'with': 'O'}, {'an': 'O'}, {'increasing': 'O'}, {'spectrum': 'O'}, {'of': 'O'}, {'disease,': 'O'}, {'including': 'O'}, {'uveitis,': 'I-Entity'}, {'periodontal': 'B-Entity'}, {'disease,': 'I-Entity'}, {'arthropathy,': 'I-Entity'}, {'sicca': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'neurologic': 'B-Entity'}, {'deficits.': 'I-Entity'}]"
The aim of this qualitative study was to provide clinicians with insight into how dry mouth can impact on the daily lives of Sjogrens Syndrome patients.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'qualitative': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'provide': 'O'}, {'clinicians': 'O'}, {'with': 'O'}, {'insight': 'O'}, {'into': 'O'}, {'how': 'O'}, {'dry': 'B-Entity'}, {'mouth': 'I-Entity'}, {'can': 'O'}, {'impact': 'O'}, {'on': 'O'}, {'the': 'O'}, {'daily': 'O'}, {'lives': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'Syndrome': 'I-Entity'}, {'patients.': 'O'}]"
"The PFT results were compared with previously studied population-based controls, standardizing results with regard to sex, age, height, weight, and cigarette smoking.","[{'The': 'O'}, {'PFT': 'O'}, {'results': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'previously': 'O'}, {'studied': 'O'}, {'population-based': 'O'}, {'controls,': 'O'}, {'standardizing': 'O'}, {'results': 'O'}, {'with': 'O'}, {'regard': 'O'}, {'to': 'O'}, {'sex,': 'O'}, {'age,': 'O'}, {'height,': 'O'}, {'weight,': 'O'}, {'and': 'O'}, {'cigarette': 'O'}, {'smoking.': 'O'}]"
The autoimmune disease subset included five systemic lupus erythematosus individuals with isolated or combined optic neuritis and myelitis and four primary Sjogrens syndrome (SS) patients with cranial/peripheral neuropathy.,"[{'The': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'subset': 'O'}, {'included': 'O'}, {'five': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'individuals': 'O'}, {'with': 'O'}, {'isolated': 'O'}, {'or': 'O'}, {'combined': 'O'}, {'optic': 'B-Entity'}, {'neuritis': 'I-Entity'}, {'and': 'O'}, {'myelitis': 'I-Entity'}, {'and': 'O'}, {'four': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'cranial/peripheral': 'B-Entity'}, {'neuropathy.': 'I-Entity'}]"
The aim of this study was to assess nailfold capillaroscopic (NC) findings in patients with primary Sjogrens syndrome (PSS) with and without Raynaud's phenomenon (RP) as well as in the presence of positive anti-SSA/Ro and anti-SSB/La antibodies.,"[{'The': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'assess': 'O'}, {'nailfold': 'O'}, {'capillaroscopic': 'O'}, {'(NC)': 'O'}, {'findings': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(PSS)': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {""Raynaud's"": 'B-Entity'}, {'phenomenon': 'I-Entity'}, {'(RP)': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'in': 'O'}, {'the': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'positive': 'O'}, {'anti-SSA/Ro': 'O'}, {'and': 'O'}, {'anti-SSB/La': 'O'}]"
"The PFT results were compared with previously studied population-based controls, standardizing results with regard to gender, age, height, weight and tobacco consumption.","[{'The': 'O'}, {'PFT': 'O'}, {'results': 'O'}, {'were': 'O'}, {'compared': 'O'}, {'with': 'O'}, {'previously': 'O'}, {'studied': 'O'}, {'population-based': 'O'}, {'controls,': 'O'}, {'standardizing': 'O'}, {'results': 'O'}, {'with': 'O'}, {'regard': 'O'}, {'to': 'O'}, {'gender,': 'O'}, {'age,': 'O'}, {'height,': 'O'}, {'weight': 'O'}, {'and': 'O'}, {'tobacco': 'I-Entity'}, {'consumption.': 'O'}]"
"Sixty-nine primary SS patients from a specialist clinical service were assessed for their functional ability (Improved Health Assessment Questionnaire [HAQ]), dryness, pain, and overall primary SS-related symptom burden; systemic disease activity; levels of fatigue, daytime somnolence, anxiety, and depression symptoms; quality of life; and systemic inflammation (erythrocyte sedimentation rate, C-reactive protein [CRP] level).","[{'Sixty-nine': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'from': 'O'}, {'a': 'O'}, {'specialist': 'O'}, {'clinical': 'O'}, {'service': 'O'}, {'were': 'O'}, {'assessed': 'O'}, {'for': 'O'}, {'their': 'O'}, {'functional': 'O'}, {'ability': 'O'}, {'(Improved': 'O'}, {'Health': 'O'}, {'Assessment': 'O'}, {'Questionnaire': 'O'}, {'[HAQ]),': 'O'}, {'dryness,': 'I-Entity'}, {'pain,': 'I-Entity'}, {'and': 'O'}, {'overall': 'O'}, {'primary': 'O'}, {'SS-related': 'I-Entity'}, {'symptom': 'O'}, {'burden;': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'activity;': 'O'}, {'levels': 'O'}, {'of': 'O'}, {'fatigue,': 'I-Entity'}, {'daytime': 'B-Entity'}, {'somnolence,': 'I-Entity'}]"
"As for ESSDAI development, the physician assessment of disease activity (0-10 scale) was used as the 'gold standard' in a multivariate model for weighting domains, after removing the biological domain.","[{'As': 'O'}, {'for': 'O'}, {'ESSDAI': 'O'}, {'development,': 'O'}, {'the': 'O'}, {'physician': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'(0-10': 'O'}, {'scale)': 'O'}, {'was': 'O'}, {'used': 'O'}, {'as': 'O'}, {'the': 'O'}, {""'gold"": 'O'}, {""standard'"": 'O'}, {'in': 'O'}, {'a': 'O'}, {'multivariate': 'O'}, {'model': 'O'}, {'for': 'O'}, {'weighting': 'O'}, {'domains,': 'O'}, {'after': 'O'}, {'removing': 'O'}, {'the': 'O'}, {'biological': 'O'}, {'domain.': 'O'}]"
Rituximab (RTX) is a chimeric antibody anti-CD20 that leads to B cell depletion by diverse mechanisms.,"[{'Rituximab': 'I-Entity'}, {'(RTX)': 'O'}, {'is': 'O'}, {'a': 'O'}, {'chimeric': 'O'}, {'antibody': 'O'}, {'anti-CD20': 'O'}, {'that': 'O'}, {'leads': 'O'}, {'to': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'depletion': 'O'}, {'by': 'O'}, {'diverse': 'O'}, {'mechanisms.': 'O'}]"
"However, performing biopsies of underlying organs is technically difficult.","[{'However,': 'O'}, {'performing': 'O'}, {'biopsies': 'O'}, {'of': 'O'}, {'underlying': 'O'}, {'organs': 'O'}, {'is': 'O'}, {'technically': 'O'}, {'difficult.': 'O'}]"
"Cryoglobulinaemic vasculitis (CV) is often related to hepatitis C virus (HCV) infection, but it can develop in other diseases (e.g.","[{'Cryoglobulinaemic': 'B-Entity'}, {'vasculitis': 'I-Entity'}, {'(CV)': 'O'}, {'is': 'O'}, {'often': 'O'}, {'related': 'O'}, {'to': 'O'}, {'hepatitis': 'B-Entity'}, {'C': 'I-Entity'}, {'virus': 'I-Entity'}, {'(HCV)': 'I-Entity'}, {'infection,': 'I-Entity'}, {'but': 'O'}, {'it': 'O'}, {'can': 'O'}, {'develop': 'O'}, {'in': 'O'}, {'other': 'O'}, {'diseases': 'O'}, {'(e.g.': 'O'}]"
RTA is a recognised but rare complication of Sjogrens syndrome.,"[{'RTA': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'recognised': 'O'}, {'but': 'O'}, {'rare': 'O'}, {'complication': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
MALT lymphoma arises from mucosa-associated lymphoid tissue and is associated with chronic inflammatory disease.,"[{'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'arises': 'O'}, {'from': 'O'}, {'mucosa-associated': 'O'}, {'lymphoid': 'O'}, {'tissue': 'O'}, {'and': 'O'}, {'is': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'chronic': 'O'}, {'inflammatory': 'B-Entity'}, {'disease.': 'I-Entity'}]"
Each Sjogren n syndrome discharge was propensity matched to 4 control discharges.,"[{'Each': 'O'}, {'Sjogren': 'B-Entity'}, {'n': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'discharge': 'O'}, {'was': 'O'}, {'propensity': 'O'}, {'matched': 'O'}, {'to': 'O'}, {'4': 'O'}, {'control': 'O'}, {'discharges.': 'O'}]"
Fifty-two pSS patients and 58 healthy controls were enrolled.,"[{'Fifty-two': 'O'}, {'pSS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'58': 'O'}, {'healthy': 'O'}, {'controls': 'O'}, {'were': 'O'}, {'enrolled.': 'O'}]"
"Most DCLD diseases are rare, although they might resemble common diseases such as emphysema and bronchiectasis.","[{'Most': 'O'}, {'DCLD': 'B-Entity'}, {'diseases': 'O'}, {'are': 'O'}, {'rare,': 'O'}, {'although': 'O'}, {'they': 'O'}, {'might': 'O'}, {'resemble': 'O'}, {'common': 'O'}, {'diseases': 'O'}, {'such': 'O'}, {'as': 'O'}, {'emphysema': 'I-Entity'}, {'and': 'O'}, {'bronchiectasis.': 'I-Entity'}]"
"There was annual increase in the newly diagnosed cases (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.017) reflecting increase in patients' awareness and improvement of medical service, also annual increase in: mean age of onset (P¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001) reflecting changes in health measures, also in cases with monoarticular or oligoarticular patterns at disease onset (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.02, 0.01 respectively) reflecting earlier diagnosis of patients and in patients with small joint involvement (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.001) with a significant decline in: polyarticular pattern (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.001), combined small and large joint affection (P¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001), and number of cases with hand bony erosions (P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.01) denoting earlier diagnosis, tight disease control.","[{'There': 'O'}, {'was': 'O'}, {'annual': 'O'}, {'increase': 'O'}, {'in': 'O'}, {'the': 'O'}, {'newly': 'O'}, {'diagnosed': 'O'}, {'cases': 'O'}, {'(P¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.017)': 'O'}, {'reflecting': 'O'}, {'increase': 'O'}, {'in': 'O'}, {""patients'"": 'O'}, {'awareness': 'O'}, {'and': 'O'}, {'improvement': 'O'}, {'of': 'O'}, {'medical': 'O'}, {'service,': 'O'}, {'also': 'O'}, {'annual': 'O'}, {'increase': 'O'}, {'in:': 'O'}, {'mean': 'O'}, {'age': 'O'}, {'of': 'O'}, {'onset': 'O'}]"
"On the contrary, the inhibition of Kv1.3 channels resulted in a larger decrease of calcium entry in Th2 and CD4 than in Th1 and CD8 cells.","[{'On': 'O'}, {'the': 'O'}, {'contrary,': 'O'}, {'the': 'O'}, {'inhibition': 'O'}, {'of': 'O'}, {'Kv1.3': 'O'}, {'channels': 'O'}, {'resulted': 'O'}, {'in': 'O'}, {'a': 'O'}, {'larger': 'O'}, {'decrease': 'O'}, {'of': 'O'}, {'calcium': 'I-Entity'}, {'entry': 'O'}, {'in': 'O'}, {'Th2': 'O'}, {'and': 'O'}, {'CD4': 'O'}, {'than': 'O'}, {'in': 'O'}, {'Th1': 'O'}, {'and': 'O'}, {'CD8': 'O'}, {'cells.': 'O'}]"
"TAFRO syndrome is a newly proposed disorder that manifests as thrombocytopenia, anasarca, fever, reticulin myelofibrosis, renal dysfunction, and organomegaly.","[{'TAFRO': 'B-Entity'}, {'syndrome': 'O'}, {'is': 'O'}, {'a': 'O'}, {'newly': 'O'}, {'proposed': 'O'}, {'disorder': 'O'}, {'that': 'O'}, {'manifests': 'O'}, {'as': 'O'}, {'thrombocytopenia,': 'I-Entity'}, {'anasarca,': 'I-Entity'}, {'fever,': 'I-Entity'}, {'reticulin': 'O'}, {'myelofibrosis,': 'I-Entity'}, {'renal': 'B-Entity'}, {'dysfunction,': 'I-Entity'}, {'and': 'O'}, {'organomegaly.': 'I-Entity'}]"
"A young male with history of upper respiratory tract symptoms including epistaxis, nasal stuffiness and maxillary sinus pain presented with bilateral lacrimal gland abscess and ptosis.","[{'A': 'O'}, {'young': 'O'}, {'male': 'O'}, {'with': 'O'}, {'history': 'O'}, {'of': 'O'}, {'upper': 'O'}, {'respiratory': 'I-Entity'}, {'tract': 'I-Entity'}, {'symptoms': 'I-Entity'}, {'including': 'O'}, {'epistaxis,': 'I-Entity'}, {'nasal': 'B-Entity'}, {'stuffiness': 'I-Entity'}, {'and': 'O'}, {'maxillary': 'B-Entity'}, {'sinus': 'I-Entity'}, {'pain': 'I-Entity'}, {'presented': 'O'}, {'with': 'O'}, {'bilateral': 'O'}, {'lacrimal': 'B-Entity'}, {'gland': 'I-Entity'}, {'abscess': 'I-Entity'}, {'and': 'O'}, {'ptosis.': 'I-Entity'}]"
Only 1 patient stopped the treatment after 1 dose because of a minor side effect and lack of initial efficacy.,"[{'Only': 'O'}, {'1': 'O'}, {'patient': 'O'}, {'stopped': 'O'}, {'the': 'O'}, {'treatment': 'O'}, {'after': 'O'}, {'1': 'O'}, {'dose': 'O'}, {'because': 'O'}, {'of': 'O'}, {'a': 'O'}, {'minor': 'O'}, {'side': 'O'}, {'effect': 'O'}, {'and': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'initial': 'O'}, {'efficacy.': 'O'}]"
Diagnostic performance of the parotid T1‚âà√¨‚àö√ñ values was evaluated by receiver operating characteristic analysis.,"[{'Diagnostic': 'O'}, {'performance': 'O'}, {'of': 'O'}, {'the': 'O'}, {'parotid': 'O'}, {'T1‚âà√¨‚àö√ñ': 'O'}, {'values': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'by': 'O'}, {'receiver': 'O'}, {'operating': 'O'}, {'characteristic': 'O'}, {'analysis.': 'O'}]"
"We conclude that salivary biomarkers detected by high-resolution mass spectrometry coupled with powerful bioinformatic tools offer the potential to serve as diagnostic/prognostic tools for SjS.MA 02111, USA.","[{'We': 'O'}, {'conclude': 'O'}, {'that': 'O'}, {'salivary': 'O'}, {'biomarkers': 'O'}, {'detected': 'O'}, {'by': 'O'}, {'high-resolution': 'O'}, {'mass': 'O'}, {'spectrometry': 'O'}, {'coupled': 'O'}, {'with': 'O'}, {'powerful': 'O'}, {'bioinformatic': 'O'}, {'tools': 'O'}, {'offer': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'to': 'O'}, {'serve': 'O'}, {'as': 'O'}, {'diagnostic/prognostic': 'O'}, {'tools': 'O'}, {'for': 'O'}, {'SjS.MA': 'I-Entity'}, {'02111,': 'O'}, {'USA.': 'O'}]"
"During the course of disease, one case each was diagnosed as systemic sclerosis + Sjogrens syndrome (SJS) and SJS.","[{'During': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'disease,': 'O'}, {'one': 'O'}, {'case': 'O'}, {'each': 'O'}, {'was': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'systemic': 'B-Entity'}, {'sclerosis': 'I-Entity'}, {'+': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SJS)': 'O'}, {'and': 'O'}, {'SJS.': 'I-Entity'}]"
Phenotypic characterisation of peripheral blood mononuclear cells from SS patients and controls was performed by flow cytometry in freshly isolated and anti-CD3-stimulated cells.,"[{'Phenotypic': 'O'}, {'characterisation': 'O'}, {'of': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}, {'mononuclear': 'O'}, {'cells': 'O'}, {'from': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'and': 'O'}, {'controls': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'by': 'O'}, {'flow': 'O'}, {'cytometry': 'O'}, {'in': 'O'}, {'freshly': 'O'}, {'isolated': 'O'}, {'and': 'O'}, {'anti-CD3-stimulated': 'O'}, {'cells.': 'O'}]"
"Both Schirmer's test and sialoscintigraphy were positive, leading secondary SS as diagnosis.","[{'Both': 'O'}, {""Schirmer's"": 'O'}, {'test': 'O'}, {'and': 'O'}, {'sialoscintigraphy': 'O'}, {'were': 'O'}, {'positive,': 'O'}, {'leading': 'O'}, {'secondary': 'O'}, {'SS': 'I-Entity'}, {'as': 'O'}, {'diagnosis.': 'O'}]"
"When the risk factor of the systemic involvements, was analyzed, two factors were significantly associated with pulmonary interstitial fibrosis: age (OR=1.074, 95% CI=1.031-1.118), and duration (OR=1.075, 95% CI=1.023-1.128).","[{'When': 'O'}, {'the': 'O'}, {'risk': 'O'}, {'factor': 'O'}, {'of': 'O'}, {'the': 'O'}, {'systemic': 'O'}, {'involvements,': 'O'}, {'was': 'O'}, {'analyzed,': 'O'}, {'two': 'O'}, {'factors': 'O'}, {'were': 'O'}, {'significantly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'pulmonary': 'O'}, {'interstitial': 'B-Entity'}, {'fibrosis:': 'I-Entity'}, {'age': 'O'}, {'(OR=1.074,': 'O'}, {'95%': 'O'}, {'CI=1.031-1.118),': 'O'}, {'and': 'O'}, {'duration': 'O'}, {'(OR=1.075,': 'O'}]"
The correlation between CT and X-ray sialography findings was evaluated.,"[{'The': 'O'}, {'correlation': 'O'}, {'between': 'O'}, {'CT': 'O'}, {'and': 'O'}, {'X-ray': 'O'}, {'sialography': 'O'}, {'findings': 'O'}, {'was': 'O'}, {'evaluated.': 'O'}]"
The latter is of particular interest as B cell depletion therapy has been shown a very promising therapy for a subgroup of SS patients.,"[{'The': 'O'}, {'latter': 'O'}, {'is': 'O'}, {'of': 'O'}, {'particular': 'O'}, {'interest': 'O'}, {'as': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'depletion': 'O'}, {'therapy': 'O'}, {'has': 'O'}, {'been': 'O'}, {'shown': 'O'}, {'a': 'O'}, {'very': 'O'}, {'promising': 'O'}, {'therapy': 'O'}, {'for': 'O'}, {'a': 'O'}, {'subgroup': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'patients.': 'O'}]"
"To investigated distinct manifestations of Sjogrens syndrome (SS) patients with neurological complications and the potential risk factors associated with neurological complications in SS, and to produce a disease evaluation and neurological involvement prediction for SS.","[{'To': 'O'}, {'investigated': 'O'}, {'distinct': 'O'}, {'manifestations': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'neurological': 'B-Entity'}, {'complications': 'I-Entity'}, {'and': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'neurological': 'B-Entity'}, {'complications': 'I-Entity'}, {'in': 'O'}, {'SS,': 'I-Entity'}, {'and': 'O'}, {'to': 'O'}, {'produce': 'O'}, {'a': 'O'}, {'disease': 'O'}, {'evaluation': 'O'}, {'and': 'O'}, {'neurological': 'O'}, {'involvement': 'O'}, {'prediction': 'O'}, {'for': 'O'}, {'SS.': 'I-Entity'}]"
"Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by progressive destruction of the intrahepatic bile ducts, leading to cholestasis.","[{'Primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cholangitis': 'I-Entity'}, {'(PBC)': 'O'}, {'is': 'O'}, {'an': 'O'}, {'autoimmune': 'B-Entity'}, {'liver': 'B-Entity'}, {'disease': 'I-Entity'}, {'characterized': 'O'}, {'by': 'O'}, {'progressive': 'O'}, {'destruction': 'O'}, {'of': 'O'}, {'the': 'O'}, {'intrahepatic': 'O'}, {'bile': 'O'}, {'ducts,': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'cholestasis.': 'I-Entity'}]"
Cytopenia and different forms of anemia can be encountered in many rheumatic diseases: they can be related to disease activity or to therapeutic side effects.,"[{'Cytopenia': 'I-Entity'}, {'and': 'O'}, {'different': 'O'}, {'forms': 'O'}, {'of': 'O'}, {'anemia': 'I-Entity'}, {'can': 'O'}, {'be': 'O'}, {'encountered': 'O'}, {'in': 'O'}, {'many': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases:': 'I-Entity'}, {'they': 'O'}, {'can': 'O'}, {'be': 'O'}, {'related': 'O'}, {'to': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'or': 'O'}, {'to': 'O'}, {'therapeutic': 'O'}, {'side': 'O'}, {'effects.': 'O'}]"
"There are many differences and similarities in the pathophysiology, symptomatology, diagnosis, and treatment of fibromyalgia, Sjogren's syndrome, and depression.","[{'There': 'O'}, {'are': 'O'}, {'many': 'O'}, {'differences': 'O'}, {'and': 'O'}, {'similarities': 'O'}, {'in': 'O'}, {'the': 'O'}, {'pathophysiology,': 'O'}, {'symptomatology,': 'O'}, {'diagnosis,': 'O'}, {'and': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'fibromyalgia,': 'I-Entity'}, {""Sjogren's"": 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'and': 'O'}, {'depression.': 'I-Entity'}]"
"Of a total of 210 SSc patients, we identified 30 with AITD (14.3%), including 29 with Hashimoto's disease (13.8%) and one patient with Graves' disease (0.5%), indicating that hypothyroidism was more common among SSc patients with AITD.","[{'Of': 'O'}, {'a': 'O'}, {'total': 'O'}, {'of': 'O'}, {'210': 'O'}, {'SSc': 'I-Entity'}, {'patients,': 'O'}, {'we': 'O'}, {'identified': 'O'}, {'30': 'O'}, {'with': 'O'}, {'AITD': 'I-Entity'}, {'(14.3%),': 'O'}, {'including': 'O'}, {'29': 'O'}, {'with': 'O'}, {""Hashimoto's"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(13.8%)': 'O'}, {'and': 'O'}, {'one': 'O'}, {'patient': 'O'}, {'with': 'O'}, {""Graves'"": 'B-Entity'}, {'disease': 'I-Entity'}, {'(0.5%),': 'O'}, {'indicating': 'O'}, {'that': 'O'}, {'hypothyroidism': 'I-Entity'}, {'was': 'O'}, {'more': 'O'}]"
She was unable to concentrate her urine and so a diagnosis of nephrogenic diabetes insipidus (NDI) was reached.,"[{'She': 'O'}, {'was': 'O'}, {'unable': 'O'}, {'to': 'O'}, {'concentrate': 'O'}, {'her': 'O'}, {'urine': 'O'}, {'and': 'O'}, {'so': 'O'}, {'a': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'nephrogenic': 'B-Entity'}, {'diabetes': 'I-Entity'}, {'insipidus': 'I-Entity'}, {'(NDI)': 'O'}, {'was': 'O'}, {'reached.': 'O'}]"
"In the present paper, the author successively presents the various clinical situations and complementary findings (infectious, vasculitis, NMO or idiopathic) that can lead to a differential diagnosis of MS in a context of ON.Moli‚Äö√†√∂¬¨√Üre, 67098 Strasbourg cedex, France.","[{'In': 'O'}, {'the': 'O'}, {'present': 'O'}, {'paper,': 'O'}, {'the': 'O'}, {'author': 'O'}, {'successively': 'O'}, {'presents': 'O'}, {'the': 'O'}, {'various': 'O'}, {'clinical': 'O'}, {'situations': 'O'}, {'and': 'O'}, {'complementary': 'O'}, {'findings': 'O'}, {'(infectious,': 'O'}, {'vasculitis,': 'I-Entity'}, {'NMO': 'I-Entity'}, {'or': 'O'}, {'idiopathic)': 'I-Entity'}, {'that': 'O'}, {'can': 'O'}, {'lead': 'O'}, {'to': 'O'}, {'a': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'MS': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'context': 'O'}, {'of': 'O'}, {'ON.Moli‚Äö√†√∂¬¨√Üre,': 'I-Entity'}]"
"Considering each EGM individually, the following manifestations were more frequent in the non-treated group: arthritis (p¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001), fatigue (p¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001), purpura (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.01), Raynaud phenomenon (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.003), and hypergammaglobulinemia (p¬¨¬®‚Äö√Ñ‚Ä†=¬¨¬®‚Äö√Ñ‚Ä†0.006).","[{'Considering': 'O'}, {'each': 'O'}, {'EGM': 'I-Entity'}, {'individually,': 'O'}, {'the': 'O'}, {'following': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'more': 'O'}, {'frequent': 'O'}, {'in': 'O'}, {'the': 'O'}, {'non-treated': 'O'}, {'group:': 'O'}, {'arthritis': 'I-Entity'}, {'(p¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001),': 'O'}, {'fatigue': 'I-Entity'}, {'(p¬¨¬®‚Äö√Ñ‚Ä†<¬¨¬®‚Äö√Ñ‚Ä†0.001),': 'O'}]"
"She responded well to intravenous steroids, followed by oral prednisolone and hydroxychloroquine.","[{'She': 'O'}, {'responded': 'O'}, {'well': 'O'}, {'to': 'O'}, {'intravenous': 'O'}, {'steroids,': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'oral': 'O'}, {'prednisolone': 'I-Entity'}, {'and': 'O'}, {'hydroxychloroquine.': 'I-Entity'}]"
"After scoring various findings, diagnosis was made as normal, IgG4-DS or SS, considering all findings for each case.","[{'After': 'O'}, {'scoring': 'O'}, {'various': 'O'}, {'findings,': 'O'}, {'diagnosis': 'O'}, {'was': 'O'}, {'made': 'O'}, {'as': 'O'}, {'normal,': 'O'}, {'IgG4-DS': 'B-Entity'}, {'or': 'O'}, {'SS,': 'I-Entity'}, {'considering': 'O'}, {'all': 'O'}, {'findings': 'O'}, {'for': 'O'}, {'each': 'O'}, {'case.': 'O'}]"
"A presentation of postpartum polydipsia and polyuria followed by periodic weakness led to the diagnosis of nephrogenic diabetes insipidus and hypokalaemic paralysis, both of which are complications of primary Sjogrens syndrome (pSS).","[{'A': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'postpartum': 'O'}, {'polydipsia': 'I-Entity'}, {'and': 'O'}, {'polyuria': 'I-Entity'}, {'followed': 'O'}, {'by': 'O'}, {'periodic': 'O'}, {'weakness': 'I-Entity'}, {'led': 'O'}, {'to': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'nephrogenic': 'B-Entity'}, {'diabetes': 'I-Entity'}, {'insipidus': 'I-Entity'}, {'and': 'O'}, {'hypokalaemic': 'B-Entity'}, {'paralysis,': 'I-Entity'}, {'both': 'O'}, {'of': 'O'}, {'which': 'O'}, {'are': 'O'}, {'complications': 'O'}, {'of': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Although she manifested hypoproteinemia, a possibility of lupus nephritis was denied due to a lack of significant abnormality in kidney function tests and urinalysis.","[{'Although': 'O'}, {'she': 'O'}, {'manifested': 'O'}, {'hypoproteinemia,': 'I-Entity'}, {'a': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'lupus': 'B-Entity'}, {'nephritis': 'I-Entity'}, {'was': 'O'}, {'denied': 'O'}, {'due': 'O'}, {'to': 'O'}, {'a': 'O'}, {'lack': 'O'}, {'of': 'O'}, {'significant': 'O'}, {'abnormality': 'O'}, {'in': 'O'}, {'kidney': 'O'}, {'function': 'O'}, {'tests': 'O'}, {'and': 'O'}, {'urinalysis.': 'O'}]"
"Bell palsy occurs in different rheumatic diseases, causes hemifacial weakness, and targets the motor branch of the 7th cranial nerve.","[{'Bell': 'B-Entity'}, {'palsy': 'I-Entity'}, {'occurs': 'O'}, {'in': 'O'}, {'different': 'O'}, {'rheumatic': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'causes': 'O'}, {'hemifacial': 'B-Entity'}, {'weakness,': 'I-Entity'}, {'and': 'O'}, {'targets': 'O'}, {'the': 'O'}, {'motor': 'O'}, {'branch': 'O'}, {'of': 'O'}, {'the': 'O'}, {'7th': 'O'}, {'cranial': 'O'}, {'nerve.': 'O'}]"
"To study the clinical characteristics of autoimmune rheumatic disease-related organizing pneumonia (AIRD-OP), the clinical presentation, radiological findings, treatment, and outcome of AIRD-OP patients were analyzed, in comparison with patients with cryptogenic organizing pneumonia (COP).","[{'To': 'O'}, {'study': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'characteristics': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'disease-related': 'I-Entity'}, {'organizing': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(AIRD-OP),': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'presentation,': 'O'}, {'radiological': 'O'}, {'findings,': 'O'}, {'treatment,': 'O'}, {'and': 'O'}, {'outcome': 'O'}, {'of': 'O'}, {'AIRD-OP': 'B-Entity'}, {'patients': 'O'}, {'were': 'O'}, {'analyzed,': 'O'}, {'in': 'O'}, {'comparison': 'O'}, {'with': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'cryptogenic': 'O'}, {'organizing': 'B-Entity'}, {'pneumonia': 'I-Entity'}, {'(COP).': 'O'}]"
We describe a case of a 50-year-old lady with newly diagnosed primary Sjogren syndrome who presented with severe pulmonary artery hypertension and pericardial effusion.,"[{'We': 'O'}, {'describe': 'O'}, {'a': 'O'}, {'case': 'O'}, {'of': 'O'}, {'a': 'O'}, {'50-year-old': 'O'}, {'lady': 'O'}, {'with': 'O'}, {'newly': 'O'}, {'diagnosed': 'O'}, {'primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'who': 'O'}, {'presented': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'pulmonary': 'B-Entity'}, {'artery': 'I-Entity'}, {'hypertension': 'I-Entity'}, {'and': 'O'}, {'pericardial': 'B-Entity'}, {'effusion.': 'I-Entity'}]"
"In addition, a majority of the systemic autoimmune diseases showed specific dominant positive patterns or a combination of IIF and LIA results that were disease specific.","[{'In': 'O'}, {'addition,': 'O'}, {'a': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'the': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'I-Entity'}, {'diseases': 'I-Entity'}, {'showed': 'O'}, {'specific': 'O'}, {'dominant': 'O'}, {'positive': 'O'}, {'patterns': 'O'}, {'or': 'O'}, {'a': 'O'}, {'combination': 'O'}, {'of': 'O'}, {'IIF': 'O'}, {'and': 'O'}, {'LIA': 'O'}, {'results': 'O'}, {'that': 'O'}, {'were': 'O'}, {'disease': 'O'}, {'specific.': 'O'}]"
The main objective of the present study was to evaluate various autoimmune activity patterns present in salivary glands by means of immunohistochemistry (IHC) analysis.,"[{'The': 'O'}, {'main': 'O'}, {'objective': 'O'}, {'of': 'O'}, {'the': 'O'}, {'present': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'evaluate': 'O'}, {'various': 'O'}, {'autoimmune': 'I-Entity'}, {'activity': 'O'}, {'patterns': 'O'}, {'present': 'O'}, {'in': 'O'}, {'salivary': 'O'}, {'glands': 'O'}, {'by': 'O'}, {'means': 'O'}, {'of': 'O'}, {'immunohistochemistry': 'O'}, {'(IHC)': 'O'}, {'analysis.': 'O'}]"
"Involvement of the respiratory system, in particular dry airways and chronic obstructive pulmonary disease (COPD), is common in patients with primary Sjogrens syndrome (pSS).","[{'Involvement': 'B-Entity'}, {'of': 'O'}, {'the': 'O'}, {'respiratory': 'I-Entity'}, {'system,': 'I-Entity'}, {'in': 'O'}, {'particular': 'O'}, {'dry': 'B-Entity'}, {'airways': 'I-Entity'}, {'and': 'O'}, {'chronic': 'B-Entity'}, {'obstructive': 'I-Entity'}, {'pulmonary': 'I-Entity'}, {'disease': 'I-Entity'}, {'(COPD),': 'O'}, {'is': 'O'}, {'common': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"Specific questionnaires such as the Profile of Fatigue and Discomfort (PROFAD) and Sicca Symptoms Inventory (SSI) have been proposed as dedicated tools for the evaluation of patients symptoms, whereas different composite indexes have been suggested for the assessment of disease activity and damage.","[{'Specific': 'O'}, {'questionnaires': 'O'}, {'such': 'O'}, {'as': 'O'}, {'the': 'O'}, {'Profile': 'O'}, {'of': 'O'}, {'Fatigue': 'I-Entity'}, {'and': 'O'}, {'Discomfort': 'I-Entity'}, {'(PROFAD)': 'O'}, {'and': 'O'}, {'Sicca': 'O'}, {'Symptoms': 'O'}, {'Inventory': 'O'}, {'(SSI)': 'O'}, {'have': 'O'}, {'been': 'O'}, {'proposed': 'O'}, {'as': 'O'}, {'dedicated': 'O'}, {'tools': 'O'}, {'for': 'O'}, {'the': 'O'}, {'evaluation': 'O'}, {'of': 'O'}, {'patients': 'O'}, {'symptoms,': 'O'}, {'whereas': 'O'}, {'different': 'O'}, {'composite': 'O'}, {'indexes': 'O'}, {'have': 'O'}, {'been': 'O'}, {'suggested': 'O'}, {'for': 'O'}, {'the': 'O'}, {'assessment': 'O'}, {'of': 'O'}]"
Classic histological findings include storiform fibrosis and lymphoplasmacytic infiltrates of immunoglobulin G4 (IgG4)-positive plasma cells.,"[{'Classic': 'O'}, {'histological': 'O'}, {'findings': 'O'}, {'include': 'O'}, {'storiform': 'O'}, {'fibrosis': 'I-Entity'}, {'and': 'O'}, {'lymphoplasmacytic': 'O'}, {'infiltrates': 'O'}, {'of': 'O'}, {'immunoglobulin': 'O'}, {'G4': 'O'}, {'(IgG4)-positive': 'O'}, {'plasma': 'O'}, {'cells.': 'O'}]"
"Although the symptoms of this syndrome are well characterized, patients are not diagnosed until 5-10 years into disease progression; furthermore, the early series of events leading to the initiation of SS are not well understood.","[{'Although': 'O'}, {'the': 'O'}, {'symptoms': 'O'}, {'of': 'O'}, {'this': 'O'}, {'syndrome': 'O'}, {'are': 'O'}, {'well': 'O'}, {'characterized,': 'O'}, {'patients': 'O'}, {'are': 'O'}, {'not': 'O'}, {'diagnosed': 'O'}, {'until': 'O'}, {'5-10': 'O'}, {'years': 'O'}, {'into': 'O'}, {'disease': 'O'}, {'progression;': 'O'}, {'furthermore,': 'O'}, {'the': 'O'}, {'early': 'O'}, {'series': 'O'}, {'of': 'O'}, {'events': 'O'}, {'leading': 'O'}, {'to': 'O'}, {'the': 'O'}, {'initiation': 'O'}, {'of': 'O'}, {'SS': 'I-Entity'}, {'are': 'O'}, {'not': 'O'}, {'well': 'O'}, {'understood.': 'O'}]"
"At diagnosis of PAH, PAH was severe with a mean pulmonary artery pressure of 48.8¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†13.7¬¨¬®‚Äö√Ñ‚Ä†mm¬¨¬®‚Äö√Ñ‚Ä†Hg (range, 27-72¬¨¬®‚Äö√Ñ‚Ä†mm¬¨¬®‚Äö√Ñ‚Ä†Hg) and a mean cardiac index of 2.3¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†0.6¬¨¬®‚Äö√Ñ‚Ä†L/min/m(2) (range, 1.47-3.41¬¨¬®‚Äö√Ñ‚Ä†L/min/m(2) ).","[{'At': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'PAH,': 'I-Entity'}, {'PAH': 'I-Entity'}, {'was': 'O'}, {'severe': 'O'}, {'with': 'O'}, {'a': 'O'}, {'mean': 'O'}, {'pulmonary': 'O'}, {'artery': 'O'}, {'pressure': 'O'}, {'of': 'O'}, {'48.8¬¨¬®‚Äö√Ñ‚Ä†¬¨¬®¬¨¬±¬¨¬®‚Äö√Ñ‚Ä†13.7¬¨¬®‚Äö√Ñ‚Ä†mm¬¨¬®‚Äö√Ñ‚Ä†Hg': 'O'}]"
"Concomitant organic GI disease was found in 14 patients with pSS and included inflammatory bowel disease (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢3), colonic adenoma (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢2) and GI lymphoma (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢1).","[{'Concomitant': 'O'}, {'organic': 'B-Entity'}, {'GI': 'I-Entity'}, {'disease': 'I-Entity'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'14': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'and': 'O'}, {'included': 'O'}, {'inflammatory': 'B-Entity'}, {'bowel': 'I-Entity'}, {'disease': 'I-Entity'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢3),': 'O'}]"
"The presence of the anti-aquaporin4 antibodies, besides anti-Ro and anti-La, in both reported cases, is intriguing and raises the question of whether we are facing two distinct diseases or the NMO is just complicating an unusually less expressive Sjogrens syndrome subtype.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'the': 'O'}, {'anti-aquaporin4': 'O'}, {'antibodies,': 'O'}, {'besides': 'O'}, {'anti-Ro': 'O'}, {'and': 'O'}, {'anti-La,': 'O'}, {'in': 'O'}, {'both': 'O'}, {'reported': 'O'}, {'cases,': 'O'}, {'is': 'O'}, {'intriguing': 'O'}, {'and': 'O'}, {'raises': 'O'}, {'the': 'O'}, {'question': 'O'}, {'of': 'O'}, {'whether': 'O'}, {'we': 'O'}, {'are': 'O'}, {'facing': 'O'}, {'two': 'O'}, {'distinct': 'O'}, {'diseases': 'O'}, {'or': 'O'}, {'the': 'O'}, {'NMO': 'I-Entity'}, {'is': 'O'}, {'just': 'O'}, {'complicating': 'O'}, {'an': 'O'}, {'unusually': 'O'}, {'less': 'O'}, {'expressive': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'subtype.': 'O'}]"
Factors associated with reduced survival were identified by means of log rank test and backward stepwise Cox regression.,"[{'Factors': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'reduced': 'O'}, {'survival': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'by': 'O'}, {'means': 'O'}, {'of': 'O'}, {'log': 'O'}, {'rank': 'O'}, {'test': 'O'}, {'and': 'O'}, {'backward': 'O'}, {'stepwise': 'O'}, {'Cox': 'O'}, {'regression.': 'O'}]"
Our study was performed to explore the potential involvement of microRNA (miRNA) in Chinese patients with pSS.,"[{'Our': 'O'}, {'study': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'the': 'O'}, {'potential': 'O'}, {'involvement': 'O'}, {'of': 'O'}, {'microRNA': 'O'}, {'(miRNA)': 'O'}, {'in': 'O'}, {'Chinese': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'pSS.': 'I-Entity'}]"
"Increased intake of beverages was observed in patients with severe xerostomia and/or low oral health-related quality of life, whereas reduced fat intake was found in hyposmic patients.","[{'Increased': 'O'}, {'intake': 'O'}, {'of': 'O'}, {'beverages': 'O'}, {'was': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'severe': 'O'}, {'xerostomia': 'I-Entity'}, {'and/or': 'O'}, {'low': 'O'}, {'oral': 'O'}, {'health-related': 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life,': 'O'}, {'whereas': 'O'}, {'reduced': 'O'}, {'fat': 'O'}, {'intake': 'O'}, {'was': 'O'}, {'found': 'O'}, {'in': 'O'}, {'hyposmic': 'I-Entity'}, {'patients.': 'O'}]"
"Patients positive for both Ro/SSA and La/SSB autoantibodies had a substantially higher risk of cerebral infarction (HR 1.7, 95% CI 1.0-2.9) and venous thromboembolism (HR 3.1, 95% CI 1.9-4.8) than the general population.","[{'Patients': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'both': 'O'}, {'Ro/SSA': 'I-Entity'}, {'and': 'O'}, {'La/SSB': 'I-Entity'}, {'autoantibodies': 'O'}, {'had': 'O'}, {'a': 'O'}, {'substantially': 'O'}, {'higher': 'O'}, {'risk': 'O'}, {'of': 'O'}, {'cerebral': 'B-Entity'}, {'infarction': 'I-Entity'}, {'(HR': 'O'}, {'1.7,': 'O'}, {'95%': 'O'}, {'CI': 'O'}, {'1.0-2.9)': 'O'}, {'and': 'O'}, {'venous': 'B-Entity'}, {'thromboembolism': 'I-Entity'}, {'(HR': 'O'}, {'3.1,': 'O'}]"
Relevant investigators with highly cited manuscripts in Raynaud's-related research were identified using the Web of Science and invited to participate.,"[{'Relevant': 'O'}, {'investigators': 'O'}, {'with': 'O'}, {'highly': 'O'}, {'cited': 'O'}, {'manuscripts': 'O'}, {'in': 'O'}, {""Raynaud's-related"": 'B-Entity'}, {'research': 'O'}, {'were': 'O'}, {'identified': 'O'}, {'using': 'O'}, {'the': 'O'}, {'Web': 'O'}, {'of': 'O'}, {'Science': 'O'}, {'and': 'O'}, {'invited': 'O'}, {'to': 'O'}, {'participate.': 'O'}]"
"There were no differences in RA patients with and without sSS regarding age, sex, disease duration, disease activity score (DAS-28) and seropositivity for anti-cyclic citrullinated protein.","[{'There': 'O'}, {'were': 'O'}, {'no': 'O'}, {'differences': 'O'}, {'in': 'O'}, {'RA': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'and': 'O'}, {'without': 'O'}, {'sSS': 'O'}, {'regarding': 'O'}, {'age,': 'O'}, {'sex,': 'O'}, {'disease': 'O'}, {'duration,': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'score': 'O'}, {'(DAS-28)': 'O'}, {'and': 'O'}, {'seropositivity': 'O'}, {'for': 'O'}, {'anti-cyclic': 'O'}, {'citrullinated': 'I-Entity'}, {'protein.': 'O'}]"
On the basis of the current report and a review of the literature we suggest investigating the possibility of Sjogren syndrome in all patients with clinically unexplained dRTA.Iran.Jul 1.,"[{'On': 'O'}, {'the': 'O'}, {'basis': 'O'}, {'of': 'O'}, {'the': 'O'}, {'current': 'O'}, {'report': 'O'}, {'and': 'O'}, {'a': 'O'}, {'review': 'O'}, {'of': 'O'}, {'the': 'O'}, {'literature': 'O'}, {'we': 'O'}, {'suggest': 'O'}, {'investigating': 'O'}, {'the': 'O'}, {'possibility': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'all': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'clinically': 'O'}, {'unexplained': 'O'}, {'dRTA.Iran.Jul': 'I-Entity'}, {'1.': 'O'}]"
"It can also present in the form of bronchial hyperresponsiveness, bronchiectasis, bronchiolitis or recurrent respiratory infections.","[{'It': 'O'}, {'can': 'O'}, {'also': 'O'}, {'present': 'O'}, {'in': 'O'}, {'the': 'O'}, {'form': 'O'}, {'of': 'O'}, {'bronchial': 'B-Entity'}, {'hyperresponsiveness,': 'I-Entity'}, {'bronchiectasis,': 'I-Entity'}, {'bronchiolitis': 'I-Entity'}, {'or': 'O'}, {'recurrent': 'O'}, {'respiratory': 'B-Entity'}, {'infections.': 'I-Entity'}]"
"Since mouse models allow the study of disease progression, we investigated the NOD/ShiLtJ mouse to explore temporal changes to the salivary epithelium.","[{'Since': 'O'}, {'mouse': 'O'}, {'models': 'O'}, {'allow': 'O'}, {'the': 'O'}, {'study': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'progression,': 'O'}, {'we': 'O'}, {'investigated': 'O'}, {'the': 'O'}, {'NOD/ShiLtJ': 'O'}, {'mouse': 'O'}, {'to': 'O'}, {'explore': 'O'}, {'temporal': 'O'}, {'changes': 'O'}, {'to': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'epithelium.': 'O'}]"
The course varies widely and prognosis is influenced by both cryoglobulinaemic damage to vital organs and by comorbidities associated with underlying diseases.,"[{'The': 'O'}, {'course': 'O'}, {'varies': 'O'}, {'widely': 'O'}, {'and': 'O'}, {'prognosis': 'O'}, {'is': 'O'}, {'influenced': 'O'}, {'by': 'O'}, {'both': 'O'}, {'cryoglobulinaemic': 'B-Entity'}, {'damage': 'I-Entity'}, {'to': 'O'}, {'vital': 'O'}, {'organs': 'O'}, {'and': 'O'}, {'by': 'O'}, {'comorbidities': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'underlying': 'O'}, {'diseases.': 'O'}]"
"Entropy (information dimension) of the nerve corneal fibers distribution observed by confocal microscopy was evaluated in patients with primary SS (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢30, 6 males, 24 females, 21-81 years), diagnosed by biopsy of salivary gland and blood tests and in sex- age-matched healthy subjects (n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢12).","[{'Entropy': 'O'}, {'(information': 'O'}, {'dimension)': 'O'}, {'of': 'O'}, {'the': 'O'}, {'nerve': 'O'}, {'corneal': 'O'}, {'fibers': 'O'}, {'distribution': 'O'}, {'observed': 'O'}, {'by': 'O'}, {'confocal': 'O'}, {'microscopy': 'O'}, {'was': 'O'}, {'evaluated': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'SS': 'I-Entity'}, {'(n‚Äö√Ñ√∂‚àö√ë‚àö¬¢=‚Äö√Ñ√∂‚àö√ë‚àö¬¢30,': 'O'}]"
"In the majority of patients, it is a late event and frequently associated with systemic disease or risk factors for lymphoma development.10.1136/jnnp.2010.222109.","[{'In': 'O'}, {'the': 'O'}, {'majority': 'O'}, {'of': 'O'}, {'patients,': 'O'}, {'it': 'O'}, {'is': 'O'}, {'a': 'O'}, {'late': 'O'}, {'event': 'O'}, {'and': 'O'}, {'frequently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'systemic': 'O'}, {'disease': 'O'}, {'or': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'for': 'O'}, {'lymphoma': 'I-Entity'}, {'development.10.1136/jnnp.2010.222109.': 'O'}]"
Squamous cell carcinoma is a known complication reported to occur in chronic discoid lupus erythematosus in sun-exposed areas.,"[{'Squamous': 'B-Entity'}, {'cell': 'I-Entity'}, {'carcinoma': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'known': 'O'}, {'complication': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'occur': 'O'}, {'in': 'O'}, {'chronic': 'O'}, {'discoid': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'in': 'O'}, {'sun-exposed': 'O'}, {'areas.': 'O'}]"
"Her manifestations were diagnosed as limbic encephalitis, and she delivered a baby by Cesarean section.","[{'Her': 'O'}, {'manifestations': 'O'}, {'were': 'O'}, {'diagnosed': 'O'}, {'as': 'O'}, {'limbic': 'B-Entity'}, {'encephalitis,': 'I-Entity'}, {'and': 'O'}, {'she': 'O'}, {'delivered': 'O'}, {'a': 'O'}, {'baby': 'O'}, {'by': 'O'}, {'Cesarean': 'O'}, {'section.': 'O'}]"
"Other relevant variables of interest, such as size of glandular tissue harvested and associated signs and symptoms, also were documented.","[{'Other': 'O'}, {'relevant': 'O'}, {'variables': 'O'}, {'of': 'O'}, {'interest,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'size': 'O'}, {'of': 'O'}, {'glandular': 'O'}, {'tissue': 'O'}, {'harvested': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms,': 'O'}, {'also': 'O'}, {'were': 'O'}, {'documented.': 'O'}]"
"According to the literature, about 29% of individuals with pSS can present seronegativity for SS-A (anti-Ro) antibodies and about 33% can present seronegativity for SS-B (anti-La) antibodies.","[{'According': 'O'}, {'to': 'O'}, {'the': 'O'}, {'literature,': 'O'}, {'about': 'O'}, {'29%': 'O'}, {'of': 'O'}, {'individuals': 'O'}, {'with': 'O'}, {'pSS': 'I-Entity'}, {'can': 'O'}, {'present': 'O'}, {'seronegativity': 'O'}, {'for': 'O'}, {'SS-A': 'O'}, {'(anti-Ro)': 'O'}, {'antibodies': 'O'}, {'and': 'O'}, {'about': 'O'}, {'33%': 'O'}, {'can': 'O'}, {'present': 'O'}, {'seronegativity': 'O'}, {'for': 'O'}, {'SS-B': 'O'}, {'(anti-La)': 'O'}, {'antibodies.': 'O'}]"
We researched the findings of musculoskeletal ultrasound sonography (MSUS) on primary Sjogren's syndrome in childhood (pSS-C) with articular manifestations.,"[{'We': 'O'}, {'researched': 'O'}, {'the': 'O'}, {'findings': 'O'}, {'of': 'O'}, {'musculoskeletal': 'O'}, {'ultrasound': 'O'}, {'sonography': 'O'}, {'(MSUS)': 'O'}, {'on': 'O'}, {'primary': 'B-Entity'}, {""Sjogren's"": 'I-Entity'}, {'syndrome': 'I-Entity'}, {'in': 'O'}, {'childhood': 'O'}, {'(pSS-C)': 'O'}, {'with': 'O'}, {'articular': 'O'}, {'manifestations.': 'O'}]"
IMT of pSS with long disease duration is significantly increased with respect to that of OCp.,"[{'IMT': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'with': 'O'}, {'long': 'O'}, {'disease': 'O'}, {'duration': 'O'}, {'is': 'O'}, {'significantly': 'O'}, {'increased': 'O'}, {'with': 'O'}, {'respect': 'O'}, {'to': 'O'}, {'that': 'O'}, {'of': 'O'}, {'OCp.': 'O'}]"
"The prevalence of anti-SMA was higher in PBC, treated patients for Chronic hepatitis C (HCV), and autoimmune hepatitis (AIH) and anti-PCA was higher in biermer anemia patients with vitamin B12 deficiency (BA/Def vit B12).","[{'The': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'anti-SMA': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'PBC,': 'O'}, {'treated': 'O'}, {'patients': 'O'}, {'for': 'O'}, {'Chronic': 'O'}, {'hepatitis': 'I-Entity'}, {'C': 'I-Entity'}, {'(HCV),': 'O'}, {'and': 'O'}, {'autoimmune': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'(AIH)': 'O'}, {'and': 'O'}, {'anti-PCA': 'O'}, {'was': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'biermer': 'B-Entity'}, {'anemia': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'vitamin': 'B-Entity'}, {'B12': 'I-Entity'}, {'deficiency': 'O'}, {'(BA/Def': 'O'}]"
"In 25.7% of the 74 SLE patients, the serum was positive for anti-SSB antibodies, whereas only 3.3% of the 30 control cases were positive.","[{'In': 'O'}, {'25.7%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'74': 'O'}, {'SLE': 'I-Entity'}, {'patients,': 'O'}, {'the': 'O'}, {'serum': 'O'}, {'was': 'O'}, {'positive': 'O'}, {'for': 'O'}, {'anti-SSB': 'O'}, {'antibodies,': 'O'}, {'whereas': 'O'}, {'only': 'O'}, {'3.3%': 'O'}, {'of': 'O'}, {'the': 'O'}, {'30': 'O'}, {'control': 'O'}, {'cases': 'O'}, {'were': 'O'}, {'positive.': 'O'}]"
"Treatment consists in highly active anti-retroviral therapy (HAART), which is usually effective in resolving clinical signs and symptoms.","[{'Treatment': 'O'}, {'consists': 'O'}, {'in': 'O'}, {'highly': 'O'}, {'active': 'O'}, {'anti-retroviral': 'O'}, {'therapy': 'O'}, {'(HAART),': 'O'}, {'which': 'O'}, {'is': 'O'}, {'usually': 'O'}, {'effective': 'O'}, {'in': 'O'}, {'resolving': 'O'}, {'clinical': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'symptoms.': 'O'}]"
"LCDD is recognized as a multisystem disease, in which the kidneys and liver are often affected.","[{'LCDD': 'I-Entity'}, {'is': 'O'}, {'recognized': 'O'}, {'as': 'O'}, {'a': 'O'}, {'multisystem': 'O'}, {'disease,': 'O'}, {'in': 'O'}, {'which': 'O'}, {'the': 'O'}, {'kidneys': 'O'}, {'and': 'O'}, {'liver': 'O'}, {'are': 'O'}, {'often': 'O'}, {'affected.': 'O'}]"
The treatment of SFN is mainly symptomatic and based on antalgic neuropsychotropic drugs and conventional analgesics.,"[{'The': 'O'}, {'treatment': 'O'}, {'of': 'O'}, {'SFN': 'I-Entity'}, {'is': 'O'}, {'mainly': 'O'}, {'symptomatic': 'O'}, {'and': 'O'}, {'based': 'O'}, {'on': 'O'}, {'antalgic': 'O'}, {'neuropsychotropic': 'O'}, {'drugs': 'O'}, {'and': 'O'}, {'conventional': 'O'}, {'analgesics.': 'O'}]"
"In SS patients with localized asymptomatic MALT lymphoma and low SS disease activity, a ""watchful waiting"" strategy seems justified.Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands.elevated miRNA-181a in peripheral blood mononuclear cells.","[{'In': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'localized': 'O'}, {'asymptomatic': 'O'}, {'MALT': 'B-Entity'}, {'lymphoma': 'I-Entity'}, {'and': 'O'}, {'low': 'O'}, {'SS': 'I-Entity'}, {'disease': 'O'}, {'activity,': 'O'}, {'a': 'O'}, {'""watchful': 'O'}, {'waiting""': 'O'}, {'strategy': 'O'}, {'seems': 'O'}, {'justified.Groningen,': 'O'}, {'PO': 'O'}, {'Box': 'O'}, {'30.001,': 'O'}, {'9700': 'O'}, {'RB': 'O'}, {'Groningen,': 'O'}, {'The': 'O'}, {'Netherlands.elevated': 'O'}, {'miRNA-181a': 'O'}, {'in': 'O'}, {'peripheral': 'O'}, {'blood': 'O'}]"
"Coexistence of SSc and another CTD aggravated the clinical course, especially lung, kidney, digestive, vascular and articular involvement.","[{'Coexistence': 'O'}, {'of': 'O'}, {'SSc': 'I-Entity'}, {'and': 'O'}, {'another': 'O'}, {'CTD': 'O'}, {'aggravated': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'course,': 'O'}, {'especially': 'O'}, {'lung,': 'B-Entity'}, {'kidney,': 'I-Entity'}, {'digestive,': 'I-Entity'}, {'vascular': 'I-Entity'}, {'and': 'I-Entity'}, {'articular': 'I-Entity'}, {'involvement.': 'O'}]"
"Subsequently, her serum KL-6 levels gradually decreased after treatment, pulmonary diffuse function improved, and the improvement in the clinical manifestation and HRCT findings were observed.","[{'Subsequently,': 'O'}, {'her': 'O'}, {'serum': 'O'}, {'KL-6': 'O'}, {'levels': 'O'}, {'gradually': 'O'}, {'decreased': 'O'}, {'after': 'O'}, {'treatment,': 'O'}, {'pulmonary': 'O'}, {'diffuse': 'O'}, {'function': 'O'}, {'improved,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'improvement': 'O'}, {'in': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'manifestation': 'O'}, {'and': 'O'}, {'HRCT': 'O'}, {'findings': 'O'}, {'were': 'O'}, {'observed.': 'O'}]"
"The wrist was the most frequently involved joint in our patients, and the most frequently seen extra-articular manifestation was sicca symptom.","[{'The': 'O'}, {'wrist': 'O'}, {'was': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'involved': 'O'}, {'joint': 'O'}, {'in': 'O'}, {'our': 'O'}, {'patients,': 'O'}, {'and': 'O'}, {'the': 'O'}, {'most': 'O'}, {'frequently': 'O'}, {'seen': 'O'}, {'extra-articular': 'O'}, {'manifestation': 'O'}, {'was': 'O'}, {'sicca': 'I-Entity'}, {'symptom.': 'O'}]"
"In multivariate analysis, ESSPRI and HAM-D scale were independently associated with increase of tender point count and symptom severity scale.","[{'In': 'O'}, {'multivariate': 'O'}, {'analysis,': 'O'}, {'ESSPRI': 'O'}, {'and': 'O'}, {'HAM-D': 'O'}, {'scale': 'O'}, {'were': 'O'}, {'independently': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'increase': 'O'}, {'of': 'O'}, {'tender': 'O'}, {'point': 'O'}, {'count': 'O'}, {'and': 'O'}, {'symptom': 'O'}, {'severity': 'O'}, {'scale.': 'O'}]"
"Of the 44 patients, 20 (45%) had OD even though no abnormalities, such as obstructive and inflammatory disease, were detected in their nasal cavities and sinuses.","[{'Of': 'O'}, {'the': 'O'}, {'44': 'O'}, {'patients,': 'O'}, {'20': 'O'}, {'(45%)': 'O'}, {'had': 'O'}, {'OD': 'I-Entity'}, {'even': 'O'}, {'though': 'O'}, {'no': 'O'}, {'abnormalities,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'obstructive': 'B-Entity'}, {'and': 'I-Entity'}, {'inflammatory': 'I-Entity'}, {'disease,': 'I-Entity'}, {'were': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'their': 'O'}, {'nasal': 'O'}, {'cavities': 'O'}, {'and': 'O'}, {'sinuses.': 'O'}]"
Recent progress in understanding the pathogenesis of pSS offers an opportunity to find new biomarkers for the diagnosis and assessment of disease activity.,"[{'Recent': 'O'}, {'progress': 'O'}, {'in': 'O'}, {'understanding': 'O'}, {'the': 'O'}, {'pathogenesis': 'O'}, {'of': 'O'}, {'pSS': 'I-Entity'}, {'offers': 'O'}, {'an': 'O'}, {'opportunity': 'O'}, {'to': 'O'}, {'find': 'O'}, {'new': 'O'}, {'biomarkers': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'assessment': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"Indications included sialolithiasis (47%; 17 of 36), recurrent sialadenitis (44%, 16 of 36), and Sjogrens syndrome (8%; three of 36).","[{'Indications': 'O'}, {'included': 'O'}, {'sialolithiasis': 'I-Entity'}, {'(47%;': 'O'}, {'17': 'O'}, {'of': 'O'}, {'36),': 'O'}, {'recurrent': 'O'}, {'sialadenitis': 'I-Entity'}, {'(44%,': 'O'}, {'16': 'O'}, {'of': 'O'}, {'36),': 'O'}, {'and': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(8%;': 'O'}, {'three': 'O'}, {'of': 'O'}, {'36).': 'O'}]"
"tkoga@nagasaki-u.ac.jp12.indicating expression of disease are not associated with fatigue, well-being and functioning in patients with primary Sjogrens syndrome.","[{'tkoga@nagasaki-u.ac.jp12.indicating': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'disease': 'O'}, {'are': 'O'}, {'not': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'fatigue,': 'I-Entity'}, {'well-being': 'O'}, {'and': 'O'}, {'functioning': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome.': 'I-Entity'}]"
Complement activation occurs in some patients with probable SLE and can be detected with higher frequency by evaluating CB-CAPs and MAP than by assessing traditional serum complement protein levels.,"[{'Complement': 'O'}, {'activation': 'O'}, {'occurs': 'O'}, {'in': 'O'}, {'some': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'probable': 'O'}, {'SLE': 'I-Entity'}, {'and': 'O'}, {'can': 'O'}, {'be': 'O'}, {'detected': 'O'}, {'with': 'O'}, {'higher': 'O'}, {'frequency': 'O'}, {'by': 'O'}, {'evaluating': 'O'}, {'CB-CAPs': 'O'}, {'and': 'O'}, {'MAP': 'O'}, {'than': 'O'}, {'by': 'O'}, {'assessing': 'O'}, {'traditional': 'O'}, {'serum': 'O'}, {'complement': 'O'}, {'protein': 'O'}, {'levels.': 'O'}]"
"In DM and SLE, itch paralleled the course of inflammatory skin manifestations in 83% and 45%, respectively.","[{'In': 'O'}, {'DM': 'I-Entity'}, {'and': 'O'}, {'SLE,': 'I-Entity'}, {'itch': 'I-Entity'}, {'paralleled': 'O'}, {'the': 'O'}, {'course': 'O'}, {'of': 'O'}, {'inflammatory': 'O'}, {'skin': 'O'}, {'manifestations': 'O'}, {'in': 'O'}, {'83%': 'O'}, {'and': 'O'}, {'45%,': 'O'}, {'respectively.': 'O'}]"
"The measurement of cytokines, CgA, and SIgA in saliva is suggested to be useful for the diagnosis of xerostomia and also to reveal disease status.Surgical Sciences, Faculty of Dental Science, Kyushu University, Fukuoka, Japan.Dermatitis on Dry Skin Manifestation.","[{'The': 'O'}, {'measurement': 'O'}, {'of': 'O'}, {'cytokines,': 'O'}, {'CgA,': 'O'}, {'and': 'O'}, {'SIgA': 'O'}, {'in': 'O'}, {'saliva': 'O'}, {'is': 'O'}, {'suggested': 'O'}, {'to': 'O'}, {'be': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'xerostomia': 'I-Entity'}, {'and': 'O'}, {'also': 'O'}, {'to': 'O'}, {'reveal': 'O'}, {'disease': 'O'}, {'status.Surgical': 'O'}, {'Sciences,': 'O'}, {'Faculty': 'O'}, {'of': 'O'}, {'Dental': 'O'}, {'Science,': 'O'}, {'Kyushu': 'O'}, {'University,': 'O'}, {'Fukuoka,': 'O'}, {'Japan.Dermatitis': 'O'}]"
"SGML has a relatively better prognosis with a higher relapse rate than other types of NHLs, dissemination or higher degree of malignant transformation may occur.","[{'SGML': 'I-Entity'}, {'has': 'O'}, {'a': 'O'}, {'relatively': 'O'}, {'better': 'O'}, {'prognosis': 'O'}, {'with': 'O'}, {'a': 'O'}, {'higher': 'O'}, {'relapse': 'O'}, {'rate': 'O'}, {'than': 'O'}, {'other': 'O'}, {'types': 'O'}, {'of': 'O'}, {'NHLs,': 'I-Entity'}, {'dissemination': 'O'}, {'or': 'O'}, {'higher': 'O'}, {'degree': 'O'}, {'of': 'O'}, {'malignant': 'O'}, {'transformation': 'O'}, {'may': 'O'}, {'occur.': 'O'}]"
"In Literature, few studies had investigated oral health status in Sjogrens syndrome and its impact on patients' quality of life, so the aim of this study was to analyse that issue.","[{'In': 'O'}, {'Literature,': 'O'}, {'few': 'O'}, {'studies': 'O'}, {'had': 'O'}, {'investigated': 'O'}, {'oral': 'O'}, {'health': 'O'}, {'status': 'O'}, {'in': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'and': 'O'}, {'its': 'O'}, {'impact': 'O'}, {'on': 'O'}, {""patients'"": 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life,': 'O'}, {'so': 'O'}, {'the': 'O'}, {'aim': 'O'}, {'of': 'O'}, {'this': 'O'}, {'study': 'O'}, {'was': 'O'}, {'to': 'O'}, {'analyse': 'O'}, {'that': 'O'}, {'issue.': 'O'}]"
Isolated lymphocytic hidradenitis is uncommon and its clinical features and associated underlying medical conditions are still undetermined.,"[{'Isolated': 'O'}, {'lymphocytic': 'B-Entity'}, {'hidradenitis': 'I-Entity'}, {'is': 'O'}, {'uncommon': 'O'}, {'and': 'O'}, {'its': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'and': 'O'}, {'associated': 'O'}, {'underlying': 'O'}, {'medical': 'O'}, {'conditions': 'O'}, {'are': 'O'}, {'still': 'O'}, {'undetermined.': 'O'}]"
"Here we discuss a role for B cell activating factor (BAFF), whereby B cell hyperactivity and increased BAFF secretion observed in patients and animal models of the disease can be explained by the altered expression of cell-specific BAFF/BAFF receptor (BAFF-R) variants in several immune cell types.","[{'Here': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'a': 'O'}, {'role': 'O'}, {'for': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'activating': 'O'}, {'factor': 'O'}, {'(BAFF),': 'O'}, {'whereby': 'O'}, {'B': 'O'}, {'cell': 'O'}, {'hyperactivity': 'I-Entity'}, {'and': 'O'}, {'increased': 'O'}, {'BAFF': 'O'}, {'secretion': 'O'}, {'observed': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'animal': 'O'}, {'models': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease': 'O'}, {'can': 'O'}, {'be': 'O'}, {'explained': 'O'}, {'by': 'O'}, {'the': 'O'}, {'altered': 'O'}, {'expression': 'O'}, {'of': 'O'}, {'cell-specific': 'O'}, {'BAFF/BAFF': 'O'}, {'receptor': 'O'}, {'(BAFF-R)': 'O'}, {'variants': 'O'}]"
To identify biomarkers for disease activity in IgG4-related disease (IgG4-RD) and primary Sjogrens syndrome (pSS).,"[{'To': 'O'}, {'identify': 'O'}, {'biomarkers': 'O'}, {'for': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'in': 'O'}, {'IgG4-related': 'B-Entity'}, {'disease': 'I-Entity'}, {'(IgG4-RD)': 'O'}, {'and': 'O'}, {'primary': 'B-Entity'}, {'Sjogrens': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'(pSS).': 'O'}]"
"To determine the demographic data as well as clinical, laboratory and terapeutical features of anti-Jo1 positive patients, followed by the department of the authors.","[{'To': 'O'}, {'determine': 'O'}, {'the': 'O'}, {'demographic': 'O'}, {'data': 'O'}, {'as': 'O'}, {'well': 'O'}, {'as': 'O'}, {'clinical,': 'O'}, {'laboratory': 'O'}, {'and': 'O'}, {'terapeutical': 'O'}, {'features': 'O'}, {'of': 'O'}, {'anti-Jo1': 'O'}, {'positive': 'O'}, {'patients,': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'the': 'O'}, {'department': 'O'}, {'of': 'O'}, {'the': 'O'}, {'authors.': 'O'}]"
Color testing was performed and the fundus was examined to monitor HCQ complications.,"[{'Color': 'O'}, {'testing': 'O'}, {'was': 'O'}, {'performed': 'O'}, {'and': 'O'}, {'the': 'O'}, {'fundus': 'O'}, {'was': 'O'}, {'examined': 'O'}, {'to': 'O'}, {'monitor': 'O'}, {'HCQ': 'I-Entity'}, {'complications.': 'O'}]"
Fatigue also markedly worsens the patients' quality of life.,"[{'Fatigue': 'I-Entity'}, {'also': 'O'}, {'markedly': 'O'}, {'worsens': 'O'}, {'the': 'O'}, {""patients'"": 'O'}, {'quality': 'O'}, {'of': 'O'}, {'life.': 'O'}]"
"Patients with LFS ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢3, ‚Äö√Ñ√∂‚àö¬¢¬¨√ü40% IgA+ or ‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢25% IgM+ plasma cells in salivary gland biopsy specimens had significantly enhanced systemic disease.","[{'Patients': 'O'}, {'with': 'O'}, {'LFS': 'I-Entity'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢3,': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢¬¨√ü40%': 'O'}, {'IgA+': 'O'}, {'or': 'O'}, {'‚Äö√Ñ√∂‚àö¬¢‚Äö√Ñ¬¢25%': 'O'}]"
CXCL13 was the only parameter associated with disease activity on multivariate analysis.,"[{'CXCL13': 'O'}, {'was': 'O'}, {'the': 'O'}, {'only': 'O'}, {'parameter': 'O'}, {'associated': 'O'}, {'with': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'on': 'O'}, {'multivariate': 'O'}, {'analysis.': 'O'}]"
"In conclusion, we provide additional evidence of the existence of a recently defined nonbullous neutrophilic dermatosis in the context of autoimmune connective tissue diseases and propose the term autoimmunity-related neutrophilic dermatosis as an appropriate designation.","[{'In': 'O'}, {'conclusion,': 'O'}, {'we': 'O'}, {'provide': 'O'}, {'additional': 'O'}, {'evidence': 'O'}, {'of': 'O'}, {'the': 'O'}, {'existence': 'O'}, {'of': 'O'}, {'a': 'O'}, {'recently': 'O'}, {'defined': 'O'}, {'nonbullous': 'O'}, {'neutrophilic': 'B-Entity'}, {'dermatosis': 'I-Entity'}, {'in': 'O'}, {'the': 'O'}, {'context': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'connective': 'I-Entity'}, {'tissue': 'I-Entity'}, {'diseases': 'I-Entity'}, {'and': 'O'}, {'propose': 'O'}, {'the': 'O'}, {'term': 'O'}, {'autoimmunity-related': 'I-Entity'}, {'neutrophilic': 'B-Entity'}, {'dermatosis': 'I-Entity'}, {'as': 'O'}, {'an': 'O'}, {'appropriate': 'O'}, {'designation.': 'O'}]"
The occurrence of Sjogren syndrome with RA makes it course worse and increases high morbidity and mortality of RA.,"[{'The': 'O'}, {'occurrence': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'with': 'O'}, {'RA': 'I-Entity'}, {'makes': 'O'}, {'it': 'O'}, {'course': 'O'}, {'worse': 'O'}, {'and': 'O'}, {'increases': 'O'}, {'high': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'mortality': 'O'}, {'of': 'O'}, {'RA.': 'I-Entity'}]"
"Then, to minimize the number of examination items, examinations should be performed in order of anti-SSA antibody, lip biopsy, and parotid gland sialography.Tsurumi-ku, Yokohama , Japan.Jun 12.With and Without Sjogren Syndrome?","[{'Then,': 'O'}, {'to': 'O'}, {'minimize': 'O'}, {'the': 'O'}, {'number': 'O'}, {'of': 'O'}, {'examination': 'O'}, {'items,': 'O'}, {'examinations': 'O'}, {'should': 'O'}, {'be': 'O'}, {'performed': 'O'}, {'in': 'O'}, {'order': 'O'}, {'of': 'O'}, {'anti-SSA': 'O'}, {'antibody,': 'O'}, {'lip': 'O'}, {'biopsy,': 'O'}, {'and': 'O'}, {'parotid': 'O'}, {'gland': 'O'}, {'sialography.Tsurumi-ku,': 'O'}, {'Yokohama': 'O'}, {',': 'O'}, {'Japan.Jun': 'O'}, {'12.With': 'O'}, {'and': 'O'}, {'Without': 'O'}, {'Sjogren': 'B-Entity'}, {'Syndrome?': 'I-Entity'}]"
Current smokers were few making it difficult to draw any firm conclusions about associations to current smoking.Sweden.,"[{'Current': 'O'}, {'smokers': 'I-Entity'}, {'were': 'O'}, {'few': 'O'}, {'making': 'O'}, {'it': 'O'}, {'difficult': 'O'}, {'to': 'O'}, {'draw': 'O'}, {'any': 'O'}, {'firm': 'O'}, {'conclusions': 'O'}, {'about': 'O'}, {'associations': 'O'}, {'to': 'O'}, {'current': 'O'}, {'smoking.Sweden.': 'I-Entity'}]"
"Six months before admission, he developed the lower back pain and numbness in lower limbs, and urinary incontinence.","[{'Six': 'O'}, {'months': 'O'}, {'before': 'O'}, {'admission,': 'O'}, {'he': 'O'}, {'developed': 'O'}, {'the': 'O'}, {'lower': 'O'}, {'back': 'B-Entity'}, {'pain': 'I-Entity'}, {'and': 'O'}, {'numbness': 'I-Entity'}, {'in': 'O'}, {'lower': 'O'}, {'limbs,': 'O'}, {'and': 'O'}, {'urinary': 'B-Entity'}, {'incontinence.': 'I-Entity'}]"
"Immunoelectrophoresis revealed elevated polyclonal immunoglobulin, which was attributed to her known underlying disease.","[{'Immunoelectrophoresis': 'O'}, {'revealed': 'O'}, {'elevated': 'O'}, {'polyclonal': 'O'}, {'immunoglobulin,': 'O'}, {'which': 'O'}, {'was': 'O'}, {'attributed': 'O'}, {'to': 'O'}, {'her': 'O'}, {'known': 'O'}, {'underlying': 'O'}, {'disease.': 'O'}]"
Metformin reduced salivary gland inflammation and restored the salivary flow rate.,"[{'Metformin': 'I-Entity'}, {'reduced': 'O'}, {'salivary': 'O'}, {'gland': 'O'}, {'inflammation': 'I-Entity'}, {'and': 'O'}, {'restored': 'O'}, {'the': 'O'}, {'salivary': 'O'}, {'flow': 'O'}, {'rate.': 'O'}]"
"Laboratory investigations showed profound hypokalemia (1.6 mmol/L) with renal K wasting, hyperchloremic metabolic acidosis with positive urine anion gap, hypophosphatemia with hyperphosphaturia, hypouricemia with hyperuricosuria, normoglycemic glycosuria, and abnormal serum creatinine concentration 2.2 mg/dL.","[{'Laboratory': 'O'}, {'investigations': 'O'}, {'showed': 'O'}, {'profound': 'O'}, {'hypokalemia': 'I-Entity'}, {'(1.6': 'O'}, {'mmol/L)': 'O'}, {'with': 'O'}, {'renal': 'O'}, {'K': 'I-Entity'}, {'wasting,': 'I-Entity'}, {'hyperchloremic': 'I-Entity'}, {'metabolic': 'B-Entity'}, {'acidosis': 'I-Entity'}, {'with': 'O'}, {'positive': 'O'}, {'urine': 'O'}, {'anion': 'O'}, {'gap,': 'O'}, {'hypophosphatemia': 'I-Entity'}, {'with': 'O'}, {'hyperphosphaturia,': 'I-Entity'}, {'hypouricemia': 'I-Entity'}, {'with': 'O'}, {'hyperuricosuria,': 'I-Entity'}]"
All of the patients were affected by pSS.,"[{'All': 'O'}, {'of': 'O'}, {'the': 'O'}, {'patients': 'O'}, {'were': 'O'}, {'affected': 'O'}, {'by': 'O'}, {'pSS.': 'I-Entity'}]"
"The often unnoticed exposure to these conditions during daily life may increase inflammatory activity rapidly, triggering an ocular surface deterioration.Visi‚Äö√†√∂‚Äö√¢‚Ä¢n I+D, SL, Valladolid, Spain.Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Valladolid, Spain.Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Valladolid, Spain.Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine, Valladolid, Spain.","[{'The': 'O'}, {'often': 'O'}, {'unnoticed': 'O'}, {'exposure': 'O'}, {'to': 'O'}, {'these': 'O'}, {'conditions': 'O'}, {'during': 'O'}, {'daily': 'O'}, {'life': 'O'}, {'may': 'O'}, {'increase': 'O'}, {'inflammatory': 'O'}, {'activity': 'O'}, {'rapidly,': 'O'}, {'triggering': 'O'}, {'an': 'O'}, {'ocular': 'B-Entity'}, {'surface': 'I-Entity'}, {'deterioration.Visi‚Äö√†√∂‚Äö√¢‚Ä¢n': 'I-Entity'}, {'I+D,': 'O'}, {'SL,': 'O'}, {'Valladolid,': 'O'}, {'Spain.Biomedical': 'O'}, {'Research': 'O'}]"
"Recently, the association of Th-17 cells or IL-17 with ocular inflammatory diseases such as uveitis, scleritis and dry eye syndrome was discovered.","[{'Recently,': 'O'}, {'the': 'O'}, {'association': 'O'}, {'of': 'O'}, {'Th-17': 'O'}, {'cells': 'O'}, {'or': 'O'}, {'IL-17': 'O'}, {'with': 'O'}, {'ocular': 'B-Entity'}, {'inflammatory': 'I-Entity'}, {'diseases': 'I-Entity'}, {'such': 'O'}, {'as': 'O'}, {'uveitis,': 'I-Entity'}, {'scleritis': 'I-Entity'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'discovered.': 'O'}]"
"Occurence ANCA is mainly associated with Wegener's granulomatosis and vasculitis, but they are also detected in autoimmune diseases (eg.","[{'Occurence': 'O'}, {'ANCA': 'O'}, {'is': 'O'}, {'mainly': 'O'}, {'associated': 'O'}, {'with': 'O'}, {""Wegener's"": 'B-Entity'}, {'granulomatosis': 'I-Entity'}, {'and': 'O'}, {'vasculitis,': 'I-Entity'}, {'but': 'O'}, {'they': 'O'}, {'are': 'O'}, {'also': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'autoimmune': 'B-Entity'}, {'diseases': 'I-Entity'}, {'(eg.': 'O'}]"
Anticardiolipin antibodies were most commonly detected in AIHA; the prevalence of IgG and hypocomplementemia in AIHA was much higher in patients without anemia.,"[{'Anticardiolipin': 'O'}, {'antibodies': 'O'}, {'were': 'O'}, {'most': 'O'}, {'commonly': 'O'}, {'detected': 'O'}, {'in': 'O'}, {'AIHA;': 'I-Entity'}, {'the': 'O'}, {'prevalence': 'O'}, {'of': 'O'}, {'IgG': 'O'}, {'and': 'O'}, {'hypocomplementemia': 'I-Entity'}, {'in': 'O'}, {'AIHA': 'I-Entity'}, {'was': 'O'}, {'much': 'O'}, {'higher': 'O'}, {'in': 'O'}, {'patients': 'O'}, {'without': 'O'}, {'anemia.': 'I-Entity'}]"
In the last few years growing evidence suggests that B-cell depletion by rituximab (RTX) is effective also in pSS.,"[{'In': 'O'}, {'the': 'O'}, {'last': 'O'}, {'few': 'O'}, {'years': 'O'}, {'growing': 'O'}, {'evidence': 'O'}, {'suggests': 'O'}, {'that': 'O'}, {'B-cell': 'O'}, {'depletion': 'O'}, {'by': 'O'}, {'rituximab': 'I-Entity'}, {'(RTX)': 'O'}, {'is': 'O'}, {'effective': 'O'}, {'also': 'O'}, {'in': 'O'}, {'pSS.': 'O'}]"
"For this reason, we discuss the differential diagnosis and management of the most common oral ulcerations in a general section and subsequently address individual conditions that present with oral ulcerations.","[{'For': 'O'}, {'this': 'O'}, {'reason,': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'the': 'O'}, {'differential': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'management': 'O'}, {'of': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common': 'O'}, {'oral': 'O'}, {'ulcerations': 'I-Entity'}, {'in': 'O'}, {'a': 'O'}, {'general': 'O'}, {'section': 'O'}, {'and': 'O'}, {'subsequently': 'O'}, {'address': 'O'}, {'individual': 'O'}, {'conditions': 'O'}, {'that': 'O'}, {'present': 'O'}, {'with': 'O'}, {'oral': 'O'}, {'ulcerations.': 'I-Entity'}]"
The hallucinations resolved while on olanzapine and hydroxychloroquine but recurred when they were stopped.,"[{'The': 'O'}, {'hallucinations': 'I-Entity'}, {'resolved': 'O'}, {'while': 'O'}, {'on': 'O'}, {'olanzapine': 'I-Entity'}, {'and': 'O'}, {'hydroxychloroquine': 'I-Entity'}, {'but': 'O'}, {'recurred': 'O'}, {'when': 'O'}, {'they': 'O'}, {'were': 'O'}, {'stopped.': 'O'}]"
"After a follow-up of years, the serum calcium concentration, renal function, and chest CT scan remained normal after prednisone treatment stopped for more than 18 months.","[{'After': 'O'}, {'a': 'O'}, {'follow-up': 'O'}, {'of': 'O'}, {'years,': 'O'}, {'the': 'O'}, {'serum': 'O'}, {'calcium': 'I-Entity'}, {'concentration,': 'O'}, {'renal': 'O'}, {'function,': 'O'}, {'and': 'O'}, {'chest': 'O'}, {'CT': 'O'}, {'scan': 'O'}, {'remained': 'O'}, {'normal': 'O'}, {'after': 'O'}, {'prednisone': 'I-Entity'}, {'treatment': 'O'}, {'stopped': 'O'}, {'for': 'O'}, {'more': 'O'}, {'than': 'O'}, {'18': 'O'}, {'months.': 'O'}]"
"Thus, measurement of RNAP in SSc patients is useful for the diagnosis and risk stratification of severe manifestation, such as renal crisis and severe skin sclerosis.Gunma, Japan.","[{'Thus,': 'O'}, {'measurement': 'O'}, {'of': 'O'}, {'RNAP': 'O'}, {'in': 'O'}, {'SSc': 'I-Entity'}, {'patients': 'O'}, {'is': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'and': 'O'}, {'risk': 'O'}, {'stratification': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'manifestation,': 'O'}, {'such': 'O'}, {'as': 'O'}, {'renal': 'B-Entity'}, {'crisis': 'I-Entity'}, {'and': 'O'}, {'severe': 'O'}, {'skin': 'B-Entity'}, {'sclerosis.Gunma,': 'I-Entity'}, {'Japan.': 'O'}]"
The patients with peripheral neuropathy had extraglandular manifestations such as palpable purpura and vasculitis.,"[{'The': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'peripheral': 'B-Entity'}, {'neuropathy': 'I-Entity'}, {'had': 'O'}, {'extraglandular': 'O'}, {'manifestations': 'O'}, {'such': 'O'}, {'as': 'O'}, {'palpable': 'O'}, {'purpura': 'I-Entity'}, {'and': 'O'}, {'vasculitis.': 'I-Entity'}]"
Mice were treated with topical formulations containing 0.1% dexamethasone or 30¬¨¬®‚Äö√Ñ‚Ä†mg/ml GW559090 or vehicle control.,"[{'Mice': 'O'}, {'were': 'O'}, {'treated': 'O'}, {'with': 'O'}, {'topical': 'O'}, {'formulations': 'O'}, {'containing': 'O'}, {'0.1%': 'O'}, {'dexamethasone': 'I-Entity'}, {'or': 'O'}, {'30¬¨¬®‚Äö√Ñ‚Ä†mg/ml': 'O'}, {'GW559090': 'I-Entity'}, {'or': 'O'}, {'vehicle': 'O'}, {'control.': 'O'}]"
"Several pathophysiologic processes have been identified including an obliterative vasculopathy, veno-occlusive disease, formation of microthrombi and pulmonary fibrosis.","[{'Several': 'O'}, {'pathophysiologic': 'O'}, {'processes': 'O'}, {'have': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'including': 'O'}, {'an': 'O'}, {'obliterative': 'B-Entity'}, {'vasculopathy,': 'I-Entity'}, {'veno-occlusive': 'B-Entity'}, {'disease,': 'I-Entity'}, {'formation': 'O'}, {'of': 'O'}, {'microthrombi': 'O'}, {'and': 'O'}, {'pulmonary': 'B-Entity'}, {'fibrosis.': 'I-Entity'}]"
"In addition, we discuss future perspectives highlighting pros and cons of utilizing mouse models and current demands for improved models.College of Dentistry, Gainesville, FL32610, USA.","[{'In': 'O'}, {'addition,': 'O'}, {'we': 'O'}, {'discuss': 'O'}, {'future': 'O'}, {'perspectives': 'O'}, {'highlighting': 'O'}, {'pros': 'O'}, {'and': 'O'}, {'cons': 'O'}, {'of': 'O'}, {'utilizing': 'O'}, {'mouse': 'O'}, {'models': 'O'}, {'and': 'O'}, {'current': 'O'}, {'demands': 'O'}, {'for': 'O'}, {'improved': 'O'}, {'models.College': 'O'}, {'of': 'O'}, {'Dentistry,': 'O'}, {'Gainesville,': 'O'}, {'FL32610,': 'O'}, {'USA.': 'O'}]"
"In the eyes with non-Sjogren syndrome, AS(100) and AS(50NS) have similar effects in decreasing symptoms and corneal epitheliopathy.Suwon, Korea South.","[{'In': 'O'}, {'the': 'O'}, {'eyes': 'O'}, {'with': 'O'}, {'non-Sjogren': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'AS(100)': 'I-Entity'}, {'and': 'O'}, {'AS(50NS)': 'I-Entity'}, {'have': 'O'}, {'similar': 'O'}, {'effects': 'O'}, {'in': 'O'}, {'decreasing': 'O'}, {'symptoms': 'O'}, {'and': 'O'}, {'corneal': 'B-Entity'}, {'epitheliopathy.Suwon,': 'I-Entity'}, {'Korea': 'O'}, {'South.': 'O'}]"
"More than 80% of autoimmune disease predominantly affects females, but the mechanism for this female bias is poorly understood.","[{'More': 'O'}, {'than': 'O'}, {'80%': 'O'}, {'of': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'predominantly': 'O'}, {'affects': 'O'}, {'females,': 'O'}, {'but': 'O'}, {'the': 'O'}, {'mechanism': 'O'}, {'for': 'O'}, {'this': 'O'}, {'female': 'O'}, {'bias': 'O'}, {'is': 'O'}, {'poorly': 'O'}, {'understood.': 'O'}]"
"(3) Thirteen of fifteen SS patients with autonomic symptoms (86.7%) were seropositive for anti-gAChR antibodies, and we confirmed sicca complex, orthostatic hypotension, upper and lower gastrointestinal (GI) symptoms, and bladder dysfunction at high rates.","[{'(3)': 'O'}, {'Thirteen': 'O'}, {'of': 'O'}, {'fifteen': 'O'}, {'SS': 'I-Entity'}, {'patients': 'O'}, {'with': 'O'}, {'autonomic': 'O'}, {'symptoms': 'O'}, {'(86.7%)': 'O'}, {'were': 'O'}, {'seropositive': 'O'}, {'for': 'O'}, {'anti-gAChR': 'O'}, {'antibodies,': 'O'}, {'and': 'O'}, {'we': 'O'}, {'confirmed': 'O'}, {'sicca': 'B-Entity'}, {'complex,': 'I-Entity'}, {'orthostatic': 'B-Entity'}, {'hypotension,': 'I-Entity'}, {'upper': 'O'}, {'and': 'O'}, {'lower': 'O'}, {'gastrointestinal': 'I-Entity'}, {'(GI)': 'I-Entity'}]"
"For example, treatment with anti-CD20 Ab has afforded some benefits in this disease, while BAFF blockers are still on the way, but should expand our armamentarium for treating SS.","[{'For': 'O'}, {'example,': 'O'}, {'treatment': 'O'}, {'with': 'O'}, {'anti-CD20': 'O'}, {'Ab': 'O'}, {'has': 'O'}, {'afforded': 'O'}, {'some': 'O'}, {'benefits': 'O'}, {'in': 'O'}, {'this': 'O'}, {'disease,': 'O'}, {'while': 'O'}, {'BAFF': 'O'}, {'blockers': 'O'}, {'are': 'O'}, {'still': 'O'}, {'on': 'O'}, {'the': 'O'}, {'way,': 'O'}, {'but': 'O'}, {'should': 'O'}, {'expand': 'O'}, {'our': 'O'}, {'armamentarium': 'O'}, {'for': 'O'}, {'treating': 'O'}, {'SS.': 'I-Entity'}]"
"Demographic, clinical, and laboratory variables were assessed including disease activity by patient reported outcomes.","[{'Demographic,': 'O'}, {'clinical,': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'variables': 'O'}, {'were': 'O'}, {'assessed': 'O'}, {'including': 'O'}, {'disease': 'O'}, {'activity': 'O'}, {'by': 'O'}, {'patient': 'O'}, {'reported': 'O'}, {'outcomes.': 'O'}]"
"Herein we present a patient with calciphylaxis who had normal kidney function and numerous rheumatologic diseases, namely systemic lupus erythematosus (SLE), Sjogren syndrome (SS), and myasthenia gravis (MG).","[{'Herein': 'O'}, {'we': 'O'}, {'present': 'O'}, {'a': 'O'}, {'patient': 'O'}, {'with': 'O'}, {'calciphylaxis': 'I-Entity'}, {'who': 'O'}, {'had': 'O'}, {'normal': 'O'}, {'kidney': 'O'}, {'function': 'O'}, {'and': 'O'}, {'numerous': 'O'}, {'rheumatologic': 'B-Entity'}, {'diseases,': 'I-Entity'}, {'namely': 'O'}, {'systemic': 'B-Entity'}, {'lupus': 'I-Entity'}, {'erythematosus': 'I-Entity'}, {'(SLE),': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS),': 'O'}, {'and': 'O'}, {'myasthenia': 'B-Entity'}, {'gravis': 'I-Entity'}, {'(MG).': 'O'}]"
Serum CTGF did not vary with symptom duration or disease activity.,"[{'Serum': 'O'}, {'CTGF': 'O'}, {'did': 'O'}, {'not': 'O'}, {'vary': 'O'}, {'with': 'O'}, {'symptom': 'O'}, {'duration': 'O'}, {'or': 'O'}, {'disease': 'O'}, {'activity.': 'O'}]"
"To investigate the relation between visual function, clinical findings, and visual symptoms in Stevens-Johnson syndrome (SJS) and to compare the results with Sjogren syndrome (SS) patients and normal subjects.","[{'To': 'O'}, {'investigate': 'O'}, {'the': 'O'}, {'relation': 'O'}, {'between': 'O'}, {'visual': 'O'}, {'function,': 'O'}, {'clinical': 'O'}, {'findings,': 'O'}, {'and': 'O'}, {'visual': 'O'}, {'symptoms': 'O'}, {'in': 'O'}, {'Stevens-Johnson': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SJS)': 'O'}, {'and': 'O'}, {'to': 'O'}, {'compare': 'O'}, {'the': 'O'}, {'results': 'O'}, {'with': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'patients': 'O'}, {'and': 'O'}, {'normal': 'O'}, {'subjects.': 'O'}]"
"More than one autoimmune disease may be the cause of ocular findings, especially for patients with a complicated presentation.","[{'More': 'O'}, {'than': 'O'}, {'one': 'O'}, {'autoimmune': 'B-Entity'}, {'disease': 'I-Entity'}, {'may': 'O'}, {'be': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'ocular': 'O'}, {'findings,': 'O'}, {'especially': 'O'}, {'for': 'O'}, {'patients': 'O'}, {'with': 'O'}, {'a': 'O'}, {'complicated': 'O'}, {'presentation.': 'O'}]"
"The presence of Sjogren syndrome does not place patients at an increased risk for postoperative complications or in-hospital mortality.‚Äö√Ñ√∂‚àö√ë¬¨‚àûDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio.Fatigue and Oral Dryness in Primary Sjogrens Syndrome.","[{'The': 'O'}, {'presence': 'O'}, {'of': 'O'}, {'Sjogren': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'does': 'O'}, {'not': 'O'}, {'place': 'O'}, {'patients': 'O'}, {'at': 'O'}, {'an': 'O'}, {'increased': 'O'}, {'risk': 'O'}, {'for': 'O'}, {'postoperative': 'O'}, {'complications': 'O'}, {'or': 'O'}, {'in-hospital': 'O'}, {'mortality.‚Äö√Ñ√∂‚àö√ë¬¨‚àûDepartment': 'O'}, {'of': 'O'}, {'Quantitative': 'O'}, {'Health': 'O'}, {'Sciences,': 'O'}, {'Cleveland': 'O'}, {'Clinic,': 'O'}, {'Cleveland,': 'O'}, {'Ohio.Fatigue': 'O'}]"
Projective psychological methods were used for cognitive impairment detection.,"[{'Projective': 'O'}, {'psychological': 'O'}, {'methods': 'O'}, {'were': 'O'}, {'used': 'O'}, {'for': 'O'}, {'cognitive': 'B-Entity'}, {'impairment': 'I-Entity'}, {'detection.': 'O'}]"
"In univariate analyses, serum calprotectin, most traditional cardiovascular (age, male sex, metabolic syndrome, hypertension, hypertriglyceridaemia, and serum creatinine), and some disease-associated risk factors (glucocorticoid or saliva substitute use, constitutional domain of Eular-Sjogrens syndrome disease activity index - EULAR) were associated with a higher risk for plaque.","[{'In': 'O'}, {'univariate': 'O'}, {'analyses,': 'O'}, {'serum': 'O'}, {'calprotectin,': 'O'}, {'most': 'O'}, {'traditional': 'O'}, {'cardiovascular': 'O'}, {'(age,': 'O'}, {'male': 'O'}, {'sex,': 'O'}, {'metabolic': 'B-Entity'}, {'syndrome,': 'I-Entity'}, {'hypertension,': 'I-Entity'}, {'hypertriglyceridaemia,': 'I-Entity'}, {'and': 'O'}, {'serum': 'O'}, {'creatinine),': 'I-Entity'}, {'and': 'O'}, {'some': 'O'}, {'disease-associated': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'(glucocorticoid': 'O'}]"
"Tear lacritin showed equivalent or better diagnostic performance compared to traditional clinical measures for SS (100.00% sensitivity, 85.71% specificity, cutoff = 14.50 ng/100 ng tear protein).","[{'Tear': 'O'}, {'lacritin': 'O'}, {'showed': 'O'}, {'equivalent': 'O'}, {'or': 'O'}, {'better': 'O'}, {'diagnostic': 'O'}, {'performance': 'O'}, {'compared': 'O'}, {'to': 'O'}, {'traditional': 'O'}, {'clinical': 'O'}, {'measures': 'O'}, {'for': 'O'}, {'SS': 'I-Entity'}, {'(100.00%': 'O'}, {'sensitivity,': 'O'}, {'85.71%': 'O'}, {'specificity,': 'O'}, {'cutoff': 'O'}, {'=': 'O'}, {'14.50': 'O'}, {'ng/100': 'O'}, {'ng': 'O'}, {'tear': 'O'}, {'protein).': 'O'}]"
"Although they are not the most common, autoimmunity and inflammation have been identified as possible causes.","[{'Although': 'O'}, {'they': 'O'}, {'are': 'O'}, {'not': 'O'}, {'the': 'O'}, {'most': 'O'}, {'common,': 'O'}, {'autoimmunity': 'I-Entity'}, {'and': 'O'}, {'inflammation': 'I-Entity'}, {'have': 'O'}, {'been': 'O'}, {'identified': 'O'}, {'as': 'O'}, {'possible': 'O'}, {'causes.': 'O'}]"
"Primary biliary cholangitis (PBC) was largely the main cause (n = 67, 4.3%), followed by autoimmune hepatitis (n = 19, 1.2%), and anti-mitochondrial negative PBC (n = 6, 0.4%).","[{'Primary': 'B-Entity'}, {'biliary': 'I-Entity'}, {'cholangitis': 'I-Entity'}, {'(PBC)': 'O'}, {'was': 'O'}, {'largely': 'O'}, {'the': 'O'}, {'main': 'O'}, {'cause': 'O'}, {'(n': 'O'}, {'=': 'O'}, {'67,': 'O'}, {'4.3%),': 'O'}, {'followed': 'O'}, {'by': 'O'}, {'autoimmune': 'B-Entity'}, {'hepatitis': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'19,': 'O'}, {'1.2%),': 'O'}, {'and': 'O'}, {'anti-mitochondrial': 'O'}, {'negative': 'O'}, {'PBC': 'I-Entity'}, {'(n': 'O'}, {'=': 'O'}, {'6,': 'O'}, {'0.4%).': 'O'}]"
"Significant positive correlations of CD4+ T lymphocytopenia with other risk factors (parotid swelling, vasculitis, rheumatoid factors, low complement, cryoglobulinemia) were detected.","[{'Significant': 'O'}, {'positive': 'O'}, {'correlations': 'O'}, {'of': 'O'}, {'CD4+': 'O'}, {'T': 'O'}, {'lymphocytopenia': 'I-Entity'}, {'with': 'O'}, {'other': 'O'}, {'risk': 'O'}, {'factors': 'O'}, {'(parotid': 'O'}, {'swelling,': 'I-Entity'}, {'vasculitis,': 'I-Entity'}, {'rheumatoid': 'B-Entity'}, {'factors,': 'I-Entity'}, {'low': 'O'}, {'complement,': 'O'}, {'cryoglobulinemia)': 'I-Entity'}, {'were': 'O'}, {'detected.': 'O'}]"
"There is no information available regarding the relationship between the respiratory symptoms or lung function and bronchial inflammation, measured by induced sputum.","[{'There': 'O'}, {'is': 'O'}, {'no': 'O'}, {'information': 'O'}, {'available': 'O'}, {'regarding': 'O'}, {'the': 'O'}, {'relationship': 'O'}, {'between': 'O'}, {'the': 'O'}, {'respiratory': 'O'}, {'symptoms': 'O'}, {'or': 'O'}, {'lung': 'O'}, {'function': 'O'}, {'and': 'O'}, {'bronchial': 'B-Entity'}, {'inflammation,': 'I-Entity'}, {'measured': 'O'}, {'by': 'O'}, {'induced': 'O'}, {'sputum.': 'O'}]"
"Also, the subsequent fall in serum CRP concentration on resolution of inflammation is useful for monitoring the efficacy of treatment.","[{'Also,': 'O'}, {'the': 'O'}, {'subsequent': 'O'}, {'fall': 'O'}, {'in': 'O'}, {'serum': 'O'}, {'CRP': 'O'}, {'concentration': 'O'}, {'on': 'O'}, {'resolution': 'O'}, {'of': 'O'}, {'inflammation': 'I-Entity'}, {'is': 'O'}, {'useful': 'O'}, {'for': 'O'}, {'monitoring': 'O'}, {'the': 'O'}, {'efficacy': 'O'}, {'of': 'O'}, {'treatment.': 'O'}]"
It is concluded that topical 0.05 % cyclosporine A is an effective treatment option for keratoconjunctivitis sicca due to SS after a 1-month follow-up period.19.with Established Primary Sjogren Syndrome.,"[{'It': 'O'}, {'is': 'O'}, {'concluded': 'O'}, {'that': 'O'}, {'topical': 'O'}, {'0.05': 'O'}, {'%': 'O'}, {'cyclosporine': 'B-Entity'}, {'A': 'I-Entity'}, {'is': 'O'}, {'an': 'O'}, {'effective': 'O'}, {'treatment': 'O'}, {'option': 'O'}, {'for': 'O'}, {'keratoconjunctivitis': 'B-Entity'}, {'sicca': 'I-Entity'}, {'due': 'O'}, {'to': 'O'}, {'SS': 'I-Entity'}, {'after': 'O'}, {'a': 'O'}, {'1-month': 'O'}, {'follow-up': 'O'}, {'period.19.with': 'O'}, {'Established': 'O'}, {'Primary': 'B-Entity'}, {'Sjogren': 'I-Entity'}, {'Syndrome.': 'I-Entity'}]"
The diagnosis of Sjogrens syndrome (SS) in routine practice is largely a clinical one and requires a high index of suspicion by the treating physician.,"[{'The': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome': 'I-Entity'}, {'(SS)': 'O'}, {'in': 'O'}, {'routine': 'O'}, {'practice': 'O'}, {'is': 'O'}, {'largely': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'one': 'O'}, {'and': 'O'}, {'requires': 'O'}, {'a': 'O'}, {'high': 'O'}, {'index': 'O'}, {'of': 'O'}, {'suspicion': 'O'}, {'by': 'O'}, {'the': 'O'}, {'treating': 'O'}, {'physician.': 'O'}]"
The gold standard for the diagnosis of celiac disease is a small bowel biopsy showing villous atrophy.,"[{'The': 'O'}, {'gold': 'O'}, {'standard': 'O'}, {'for': 'O'}, {'the': 'O'}, {'diagnosis': 'O'}, {'of': 'O'}, {'celiac': 'B-Entity'}, {'disease': 'I-Entity'}, {'is': 'O'}, {'a': 'O'}, {'small': 'O'}, {'bowel': 'O'}, {'biopsy': 'O'}, {'showing': 'O'}, {'villous': 'B-Entity'}, {'atrophy.': 'I-Entity'}]"
"Across multiple systemic autoimmune rheumatic diseases (SARDs), major drivers of lost productivity were generalised items like pain, depression, and fatigue, rather than disease-specific factors.","[{'Across': 'O'}, {'multiple': 'O'}, {'systemic': 'B-Entity'}, {'autoimmune': 'B-Entity'}, {'rheumatic': 'I-Entity'}, {'diseases': 'I-Entity'}, {'(SARDs),': 'O'}, {'major': 'O'}, {'drivers': 'O'}, {'of': 'O'}, {'lost': 'O'}, {'productivity': 'O'}, {'were': 'O'}, {'generalised': 'O'}, {'items': 'O'}, {'like': 'O'}, {'pain,': 'I-Entity'}, {'depression,': 'I-Entity'}, {'and': 'O'}, {'fatigue,': 'I-Entity'}, {'rather': 'O'}, {'than': 'O'}, {'disease-specific': 'O'}, {'factors.': 'O'}]"
Concurrent systemic vasculitis or glomerulonephritis may contribute to higher morbidity and premature mortality.,"[{'Concurrent': 'O'}, {'systemic': 'O'}, {'vasculitis': 'I-Entity'}, {'or': 'O'}, {'glomerulonephritis': 'I-Entity'}, {'may': 'O'}, {'contribute': 'O'}, {'to': 'O'}, {'higher': 'O'}, {'morbidity': 'O'}, {'and': 'O'}, {'premature': 'O'}, {'mortality.': 'O'}]"
The question whether RA causes exocrine pancreatic disfunction remains unclear.,"[{'The': 'O'}, {'question': 'O'}, {'whether': 'O'}, {'RA': 'I-Entity'}, {'causes': 'O'}, {'exocrine': 'B-Entity'}, {'pancreatic': 'I-Entity'}, {'disfunction': 'I-Entity'}, {'remains': 'O'}, {'unclear.': 'O'}]"
Both CCR9+ and CXCR5+ T helper cells induced IgG production by B cells more potently than that induced in the cultures with CCR9-CXCR5- T helper cells.,"[{'Both': 'O'}, {'CCR9+': 'O'}, {'and': 'O'}, {'CXCR5+': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'cells': 'O'}, {'induced': 'O'}, {'IgG': 'O'}, {'production': 'O'}, {'by': 'O'}, {'B': 'O'}, {'cells': 'O'}, {'more': 'O'}, {'potently': 'O'}, {'than': 'O'}, {'that': 'O'}, {'induced': 'O'}, {'in': 'O'}, {'the': 'O'}, {'cultures': 'O'}, {'with': 'O'}, {'CCR9-CXCR5-': 'O'}, {'T': 'O'}, {'helper': 'O'}, {'cells.': 'O'}]"
"The associations between BRAF levels and the clinical features including age, sex, disease duration, swelling joints, tenderness joints, duration of moning stiffness, joint deformity, visual assessment scale (VAS) and extra articular manifestations and laboratory parameters including erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF), disease activity score in 28 joints (DAS28), anti-cyclic citrullinated peptide (CCP) antibody, antikeratin antibody, antnuclear antibody (ANA), immunoglobulin and cytokines, such as TNF-‚âà√≠¬¨¬±, IL-1‚âà√≠‚Äö√¢¬ß, IL-6 and IL-17A in RA patients were evaluated.","[{'The': 'O'}, {'associations': 'O'}, {'between': 'O'}, {'BRAF': 'O'}, {'levels': 'O'}, {'and': 'O'}, {'the': 'O'}, {'clinical': 'O'}, {'features': 'O'}, {'including': 'O'}, {'age,': 'O'}, {'sex,': 'O'}, {'disease': 'O'}, {'duration,': 'O'}, {'swelling': 'I-Entity'}, {'joints,': 'O'}, {'tenderness': 'B-Entity'}, {'joints,': 'O'}, {'duration': 'O'}, {'of': 'O'}, {'moning': 'O'}, {'stiffness,': 'I-Entity'}, {'joint': 'B-Entity'}, {'deformity,': 'I-Entity'}, {'visual': 'O'}, {'assessment': 'O'}, {'scale': 'O'}, {'(VAS)': 'O'}, {'and': 'O'}, {'extra': 'O'}, {'articular': 'O'}, {'manifestations': 'O'}, {'and': 'O'}, {'laboratory': 'O'}, {'parameters': 'O'}, {'including': 'O'}, {'erythrocyte': 'O'}, {'sedimentation': 'O'}, {'rate': 'O'}]"
"Visual acuity, results of slit-lamp examination of the cornea and conjunctiva, and dry eye symptoms, were evaluated before and after CAM insertion.","[{'Visual': 'O'}, {'acuity,': 'O'}, {'results': 'O'}, {'of': 'O'}, {'slit-lamp': 'O'}, {'examination': 'O'}, {'of': 'O'}, {'the': 'O'}, {'cornea': 'O'}, {'and': 'O'}, {'conjunctiva,': 'O'}, {'and': 'O'}, {'dry': 'B-Entity'}, {'eye': 'I-Entity'}, {'symptoms,': 'O'}, {'were': 'O'}, {'evaluated': 'O'}, {'before': 'O'}, {'and': 'O'}, {'after': 'O'}, {'CAM': 'O'}, {'insertion.': 'O'}]"
Lung disease in SjS has been reported to occur early following clinical presentation of the disease.,"[{'Lung': 'B-Entity'}, {'disease': 'I-Entity'}, {'in': 'O'}, {'SjS': 'I-Entity'}, {'has': 'O'}, {'been': 'O'}, {'reported': 'O'}, {'to': 'O'}, {'occur': 'O'}, {'early': 'O'}, {'following': 'O'}, {'clinical': 'O'}, {'presentation': 'O'}, {'of': 'O'}, {'the': 'O'}, {'disease.': 'O'}]"
The results of the study may help to interpret diagnostic signs and follow up their evolution in a clinical course of a disease.with Sjogrens syndrome.,"[{'The': 'O'}, {'results': 'O'}, {'of': 'O'}, {'the': 'O'}, {'study': 'O'}, {'may': 'O'}, {'help': 'O'}, {'to': 'O'}, {'interpret': 'O'}, {'diagnostic': 'O'}, {'signs': 'O'}, {'and': 'O'}, {'follow': 'O'}, {'up': 'O'}, {'their': 'O'}, {'evolution': 'O'}, {'in': 'O'}, {'a': 'O'}, {'clinical': 'O'}, {'course': 'O'}, {'of': 'O'}, {'a': 'O'}, {'disease.with': 'O'}, {'Sjogrens': 'B-Entity'}, {'syndrome.': 'I-Entity'}]"
It was thus concluded that the distal RTA secondary to Sjogren's syndrome was the cause of severe hypokalaemia in our patient.,"[{'It': 'O'}, {'was': 'O'}, {'thus': 'O'}, {'concluded': 'O'}, {'that': 'O'}, {'the': 'O'}, {'distal': 'O'}, {'RTA': 'I-Entity'}, {'secondary': 'O'}, {'to': 'O'}, {""Sjogren's"": 'B-Entity'}, {'syndrome': 'I-Entity'}, {'was': 'O'}, {'the': 'O'}, {'cause': 'O'}, {'of': 'O'}, {'severe': 'O'}, {'hypokalaemia': 'I-Entity'}, {'in': 'O'}, {'our': 'O'}, {'patient.': 'O'}]"
